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LIST OF ABBREVIATIONS 
Abbreviations used in this thesis for amino acids and for the designations of peptides follow 
the rules of the ШРАС-ШВ Joint Commission on Biochemical Nomenclature in Eur J 
Bwchem (1984) 138, 9-37. For numbering of the thrombin amino acid residues, the 
chymotrypsinogen nomenclature introduced by Bode et al. EMBO J (1989) 8, 3467-3475 is 
used Numbering of factor Xa ammo acid residues is based on topological equivalences with 
chymotrypsin J Mol Biol. (1993) 232, 947-966 Pi, P2, Рз and ΡΊ, P'2 designate substrate 
residues amino- and carboxyl-terminal to the scissible peptide bond respectively, and Si, S2, 
S3 and S'l, S'2 the corresponding subsite of the cognate protease introduced by Schechter and 
Berger Biochem. Bwphys Res. Commun (1967)27, 157-162 
Clotting factors are given by roman numerals, the activated clotting factors are designated by 
lowercase a 
The following abbreviations are used-
AA amidolylic activity, AAA amino acid analysis, Alb a-aminoisobutync acid (α-methylalanine), All allyl, 
Aloe allyloxycarbonyl, ANBA 5-amino-2-nitrobenzoic acid, АТ-Ш antithrombin III, Chg cyclohcxylglycine, 
2D two dimensional, DCC N.N'-dicyclohexylcarbodnmide, DCHA dicyclohexylamine, DCU N,N'-
dicyclohexylurea, DEMZ diethylmalonic acid monomethyl ester, DIPCDI N,N' duiopropylcarbodumide, 
DIPEA Ν,Ν-diisopropylethylamine, DMF Ν,Ν-dimethyIformamide, DMMZ dimethylmalonic acid 
monomethyl ester, DMSO dimethyl sulfoxide, EDT 1,2-ethanedithiol, EDTA ethylenediamino-Ν,Ν,Ν ,N -
tetraacetic acid, EtOAc ethylacetate, [Hir50-65] hirudin50-65, HPLC high pressure liquid chromatography, 
ISH international standard heparin, К Nemst-partition coefficient, k
cat catalytic constant (turnover number), 
K! inhibition coefficient, K
m
 Michaelis constant, C12M a2-macroglobulin, MMZ methylmalonic acid 
monomethyl ester, MQPA (2R,4R)-4-methyl-l-[N2-(3-methyl-l,2,3,4-tctrahydro-8-quinolinyl)sulfonyl]-
arginyl]-2-piperidinecarboxylic acid, Msc 2-(methylsulfonylethyl)oxycarbonyl, Mts mcsitylene-2-sulfonyl, 
MZ malonic acid monomethyl ester, pNA para-nitroaniline, NAPAP Na-(2-naphtalenesulfonyl glycyl)-DL-p-
amidinophenylalanyl-pipendine, Nie norleucine, NMM N-methylmorpholine, NMR nuclear magnetic 
resonance, pNS 2-naphtalenesulfonyl, OD optical density, Pd°(PPh3>4 tetrakis(tnphenylphosphine)-
palladium(O), γΡι γ-piperidyl, Pip pipecolic acid (homoproline), PT prothrombin, PTT partial thromboplastin 
time, руг pyridine, SASRIN super acid sensitive resin, SPPS solid phase peptide synthesis, Τ thrombin, 4-
TAPAP Na-(toluenesulfonyl)-DL-p-amidinophenylalanyl-pipendine, TDM 4,4 -telramethyldiaminodiphenyl-
methane, TEA tnethylamine, TF tissue factor, TFA trifluoroacetic acid, THF tetrahydofuran, TLC thin layer 
chromatography, Tris tns(hydroxymethyl)aminomelhane, pTS para-toluenesulfonyl, pTSZ para-
toluenesulfonic acid, UV ultra violet, VIS visible 
GENERAL INTRODUCTION 
In this chapter a short overview of the development- and different types of synthetic substrates, 
a concise introduction of blood coagulation, the basics of enzymology related to the 
determination of the thrombin generation curve, and the principles of peptide synthesis in 
relation to substrate synthesis are given. It will end with a description of the different chapters 
of this thesis. 
SYNTHETIC SUBSTRATES 
To determine the concentration of a particular enzyme of interest, a specific substrate for this 
enzyme has to be used. In most cases, the optimal substrate would be the natural substrate of 
the enzyme. The application of natural substrates is hampered as a consequence of low 
bioavailability and the difficulty of a quantitative determination of enzyme action on the 
substrate. Therefore, intensive research is focussed on the development of synthetic substrates 
that mimic the natural substrate and in which the enzymatic activity can be easily followed by 
titration-, Potentiometrie- or spectrophotometric techniques. In the following, examples of 
synthetic substrates used for hydrolytic enzymes of the serine protease family are given and 
most attention is paid to the serine proteases involved in the blood coagulation cascade, 
especially thrombin. 
Chromogenic substrates: Thrombin (E.C. 3.4.21.5) is a serine protease with trypsin-like 
specificity, i.e., it cleaves behind arginine and lysine residues, with a preference for Arg-Xaa 
bonds. 
The observation that thrombin is capable to hydrolyse ester-like synthetic substrates led to the 
development of Tos-Arg-OMe, Bz-Arg-OMe and H-Arg-OMe as substrates for thrombin1. 
Since the work of Sherry and Troll', many ester-substrates have been proposed and tested for 
their susceptibility for thrombin2. Several drawbacks such as product inhibition (see 
enzymology section) and low sensitivity resulted in the proposal of p-nitrobenzyl alcohol-3 (see 
figure 1) and p-nitrophenyl4 esters as alternatives. Enzymatic hydrolysis liberates p-nitrobenzyl 
alcohol and p-nitrophenol whose generation can be easily followed by spectrophotometric 
techniques. Generally, it can be said that amino acid esters showed very low selectivity towards 
the enzyme of interest, partially due to the high energy content of ester bonds. Furthermore, an 
ester bond is not the bond to be split in the natural substrate, therefore, it would be desirable to 
replace the ester bond by an amide bond which resembles the natural substrate better. 
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Table 1: Some examples of amino acid- and peptide p-nitroanilides as chromogenic 
substrates for serine proteases. 
Substrate 
Bz-DL-Arg-pNA 
Bz-D-Phe-Val-Arg-pNA 
H-D-Val-Leu-Arg-pNA 
Bz-IIe-Glu-Gly-Arg-pNA 
Bz-Pro-Phe-Arg-pNA 
H-D-Va]-Leu-Lys-pNA 
Bz-Gln-Val-Val-Arg-pNA 
<Glu-Gly-Arg-pNA 
H-D-Val-Leu-Arg-pNA 
H-Sar-Pro-Arg-pNA 
Z-Lys-Gly-Arg-pNA 
Sue-Ala-Ala-Pro-Tyr-pNA 
Suc-Ala-Ala-Ala-pNA 
Suc-Ala-Ala-Tyr-pNA 
Suc-Phe-pNA 
Suc-Ala-Tyr-Leu-Val-pNA 
Suc-Ala-Ala-Val-pNA 
Ac-Ala-Ala-Pro-Ala-pNA 
Ac-Ala-Ala-Pro-Val-pNA 
Ac-Ala-Ala-Pro-Phc-pNA 
Bz-Tyr-pNA 
Tos-Arg-pNA 
Suc-Tyr-Leu-Val-pNA 
Ac-Ser-His-Leu-Val-pNA 
H-D-He-Phe-Lys-pNA 
Bz-p-guanidmo-Phe-pNA 
Ac-Tyr-Val-Ala-Asp-pNA 
Enzyme 
trypsin 
trypsin 
trypsin 
human leukocyte elastase 
Reference 
5,6 
7 
factor Xa 
plasma kallikrein 
plasmin 
factor IXa 
urokinase 
activated human protein С 
thrombin 
human lung tryptase 
human skin tryptase 
subtihsin (Bacillus amylohquefaciens) 
pancreatic elastase 
a-chymotrypsin 
chymotrypsin 
human spleen fibrinolytic proteinase 
human leukocyte elastase 
9 
10 
11 
12 
13 
14 
15 
16 
16 
17 
18, 19 
18 
20, 21 
22 
22 
23 
pancreas elastase 
granulocyte elastase 
pancreas chymotrypsin 
chymotrypsin 
trypsin 
human spleen proteinase 
plasmin 
trypsin 
interleukin 1 ß-converting enzyme 
24 
24 
24 
25 
6, 26 
27 
28 
29 
30 
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For this purpose benzoyl-argininep-nitroanilide (Bz-Arg-pNA)5 was introduced to overcome 
these drawbacks. The p-nitroaniline released by enzymatic action of thrombin has a high 
absorption coefficient at a different wave length (380 nm) than the amide (316 nm). Since the 
amide bond is not prone to autohydrolysis, liberation of p-nitroaniline is proportional to 
enzymatic activity on the substrate. 
It was realized that a chromogenic substrate composed of one single amino acid is too simple to 
discriminate between enzymes with similar primary specificities. To obtain substrates that 
would show higher selectivity toward one enzyme, studies to elucidate the role of amino acids 
surrounding the bond to be cleaved in the natural substrate of that particular enzyme were 
attempted. The work in this research area led to the synthesis of a large number of peptides 
which could be used as selective thrombin substrates. Taking the natural substrate of thrombin, 
fibrinogen, as base, Bz-Phe-Val-Arg-pNA7 and Tos-Gly-Val-Arg-pNA31 were synthesized as 
synthetic substrates specific for thrombin. Starting from a systematic variation of the 
composition and configuration of amino acids and α-amino function modifying groups, H-D-
Phe-Pip-Arg-pNA was found to be very specific for thrombin32. Research based on this 
strategy currently continues and has not been restricted to thrombin33'34 or other coagulation 
factors34. Table 1 gives some examples of chromogenic substrates for different serine 
proteases. 
NO, 
pNB 
H,N (\ /) NO, H,N 
COOH 
Figure 1: Chromogenic leaving groups; p-nitrobenzyl alcohol (pNB), p-nitrophenol (pNp), 
p-nitroaniline (pNA) and 5-amino-2-nitrobenzoic acid (ANBA). 
Apart from this, 5-amino-2-nitrobenzoic acid (ANBA) has been described as an analogue of p-
nitroaniline35. This chromophoric leaving group has the same spectroscopic properties as p-
nitroaniline. Its carboxyl function allows the introduction of substituents that increase the 
specificity for thrombin (vide infra). 
Fluorogenic substrates: To enhance sensitivity, substrates with highly fluorescent leaving 
groups (see figure 2) were developed for the assay of coagulation factors. The most widely 
used fluorogenic substrates for thrombin are peptide derivatives of 7-amino-4-methylcoumarin 
3 
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(AMC) as described by Monta et al36a Other examples of fluorogenic leaving groups are, 5-
amino-isophtalic acid dimethyl ester (AIE)37, ß-naphtylamine (ßNA)38, 4-methoxy-2-
naphtylamine (MßNA)39 and rhodamine40 A severe disadvantage of the fluorogenic substrates 
is their poor water solubility Recently, new water soluble fluorogenic substrates, based on 7-
aminocoumann-4-methanesulfonic acid (ACMS) were described41 
Figure 2: Fluorogenic leaving groups; 7-amino-4-methylcoumarin (AMC), 5-amino-
isophtalic acid dimethyl ester (AIE), ß-naphthylamine (ßNA), 4-methoxy-2-naphtylamine 
(MßNA), rhodamine and 7-aminocoumarin-4-methanesulfonic acid (ACMS). 
Thio esters Another type of substrates commonly used in coagulation research are amino acid-
and peptide thio esters In the presence of 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB, 
Ellmann's reagent, figure 3) the cleavage of the thio ester bond can be followed by a 
continuous colorimetrie assay Thio esters combine the ease of detection of chromogenic 
substrates with the high sensitivity of the fluorogenic substrates Z-Lys-SBzl was the first thio 
ester substrate described for trypsm-like proteases42 Arginine-containmg peptide thio esters 
were used for studies to map the active-site region of several coagulation factors including 
thrombin43 Low water solubility, low selectivity and a considerable degree of autohydrolysis 
make thio ester substrates not the compounds of first choice Thio esters can be looked upon as 
weakly activated esters, ι e undergoing SAE-reactions with nucleophiles easily 
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°
2N—\ y~s~s~\ / N°2 
HOOC COOH 
Figure 3: Chromophore used in the analysis of thio esters; 5,5'-dithiobis(2-nitrobenzoic 
acid) (DTNB, Ellmann's reagent). 
Intramolecularly quenched substrates The specificity of enzyme/substrate interactions is a 
complex function of a variety of structural factors which include binding domains in the 
protease for specific amino acid side chains located on both the amino- (Pn-Pl) and carboxyl 
(P'l-Pn) side of the primary specificity pocket in the substrate protein Most studies which 
map the active-site of proteases involved in blood coagulation concentrate on the contributions 
of the aminoacyl residues occurring in the РЗ-Рі positions to optimize a substrate for a 
particular protease Studies to provide additional specificity from subsite interactions (P'l-P'n) 
were almost neglected The principle of intramolecular quenching44 would be a helpful tool to 
exploit subsite interaction to gain more selectivity Intramolecularly quenched fluorogenic 
substrates consist of a peptide chain and bear suitable chromophores at each side of the 
cleavable bond One of the chromophores is a fluorescent group whereas the other is a 
quencher to reduce the fluorescence of the fluorophore Enzymatic cleavage of the substrate is 
followed by a release of fluorescence as the result of cancelling the quenching interaction 
between the chromophores Several examples of fluorophore and quencher combinations 
(figure 4) are mentioned in the literature o-aminobenzoic acid (Abz)/p-nitroanihne (pNA)45, o-
aminobenzoic acid (Abz)/2,4-dinitroanilinoethylamine (Dna)46, o-aminobenzoic acid (Abz)/3-
nitrotyrosine (3-(N02)-Tyr)47, 4-(4-dimethylaminophenylazo)benzoic acid (Dabcyl)/5-[(2-
aminoethyl)amino]naphtalene-l-sulfonic acid (Edans)48 and o-aminobenzoic acid (Abz)/4-
nitrobenzylamine (Nba)49 Only one example of the last mentioned combination is given in the 
literature as substrate for the coagulation enzyme factor IXa49 
Miscellaneous In the development of selective substrates, recent research focusses upon the 
exploration of subsite interaction This resulted in the development of synthetic substrates for 
thrombin, factor Xa, activated protein С and urokinase50, and more recently in substrates for 
factor Vila and factor Vila/tissue factor51 The authors used 6-amino-l-naphtalenesulfonic acid 
(ANSN) as fluorophore (see figure 5) The sulfonyl moiety resulted in higher water solubility 
and permits a large range of chemical modifications with a different degree of interaction with 
subsites of the target enzyme This results in a better discrimination between the specificities of 
thrombin and factor Xa 
All the substrates mentioned thus far, need homogeneous reaction media Daraio de Peunot et 
al52 surpassed this restriction in measuring thrombin electrochemically, as the reporter group, 
p-aminodiphenylamine (pADA) was used After liberation by enzymatic hydrolysis, p-
5 
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aminodiphenylamine is determined amperometrically, the measured oxidation current is herein 
proportional to the enzyme (thrombin) concentration This technique is very sensitive and can 
be carried out m whole blood53 Some other examples of electrochemical determination of 
enzyme activity are mentioned in the literature54, but they found no widespread application 
Q-COOH 
Abz 
'
NH
 /f~\ H 2 N' ^ ^ J N 0 2 
Dna
 л
 / 
0 2N 
N V у N=N V у—COOH 
Η,Ν, 
Dabcyl 
,COOH 
S 0 3 H 
Edans 
H2N-CH2 
Nba 
^ Q b - N O , 
NO, 
OH 
3-(N02)-Tyr 
Figure 4: Structures of quenchers and fluorophores used in intramolecularly quenched 
fluorogenic substrates; o-aminobenzoic acid (Abz), 2,4-dinitroanilinoethylamine (Dna), 4-
(4-dimethylaminophenylazo)benzoic acid (Dabcyl), 5-[(2-aminoethyl)amino]naphtalene-l-
sulfonic acid (Edans), Э-nitrotyrosine (3-(N02)-Tyr) and 4-nitrobenzylamine (Nba). 
H,N 
ANSN 
SO3H 
H,N 
pADA 
Figure 5: Structures of the water soluble fluorogenic leaving group 6-amino- l-
naphtalenesulfonic acid (ANSN), and of p-aminodiphenylamine (pADA). The latter is used 
as leaving group in the electrochemical determination of enzyme activity. 
6 
General Introduction 
BLOOD COAGULATION 
Blood coagulation is the transformation of blood into a solid gel termed a clot or thrombus. 
Blood coagulation is needed as a life saving process when a blood vessel is damaged and blood 
is exposed to the components of damaged endothelial cells. On the other hand blood 
coagulation can be life threatening when a thrombus shuts off essential blood vessels to the 
different organs. Both processes are" the result of the action of thrombin on fibrinogen leading 
to the formation of fibrin, the major component of a blood clot. It is evident that thrombin 
formation must be a strictly controlled process in time and place and only then when necessary. 
In the following, current conceptions on the formation of thrombin are described in general 
terms and the mechanisms which control this process are mentioned. 
Intrinsic pathway: In circulating blood, the coagulation factors are present as inactive 
precursors (zymogens) of serine proteases. These zymogens become activated by minor 
proteolysis. 
More than 25 years ago, two models were proposed to describe the coagulation cascade55·56. 
These models formed the basis of the intrinsic pathway (contact activation)57. This pathway of 
initiation starts with the autoactivation of factor XII upon in vitro contact with negatively 
charged surfaces such as glass, kaolin and ellagic acid. High molecular weight kininogen and 
prekallikrein showed to be critical cofactors in this activation58. Factor Xlla activates factor XI; 
activated factor XI activates factor IX. The complex of factor IXa, factor Villa and Ca2+-ions 
on a negatively charged phospholipid surface (intrinsic tenase) is an efficient activator of the 
formation of factor Xa which, in turn, is responsible for the conversion of prothrombin into 
thrombin (see scheme 1). Generally, patients with a deficiency of one of the contact factors 
appear not to be condemned to have bleeding abnormalities. This observation demanded a new 
interpretation of the intrinsic pathway for in vivo activation. Recent research gave evidence for 
the intrinsic pathway to be a part of the extrinsic pathway (vide infra). The extrinsic pathway 
starts when blood comes into contact with tissue factor, released after vascular injury59. 
Extrinsic pathway: Tissue factor (TF) is a transmembrane glycoprotein and has high affinity for 
factor VII60. In the presence of Ca2+-ions, factor VII and tissue factor form a complex in which 
factor VII is activated to FVIIa, a serine protease. The complex of TF/FVIIa converts factor X 
to factor Xa. This process needs also a negatively charged phospholipid surface in which the 
coagulation factors Vila and X are bound via a Ca2+-ion (extrinsic tenase)61. Once factor X 
becomes activated, it interacts with factor Va, prothrombin and phospholipids in the presence 
of Ca2+-ions, resulting in the formation of the prothrombinase-complex. The final result of this 
interaction is the formation of thrombin (factor IIa), see scheme 2. 
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Feedback reactions Several positive feedback reactions are present in the above mentioned 
activation cascade Factor Xa formed in the initial phase of coagulation activates factor VII to 
factor Vila which, in turn, generates additional factor Xa Furthermore, TF/FVIIa is able to 
activate factor IX62 (intrinsic pathway) resulting in a second reinforcement loop for the 
formation of factor Xa This activation loop is called the Josso-loop63 
F XI 
F XII 
Contact activation by negatively charged surfaces 
e g glass, kaolin and ellagic acid 
High molecular weight kminogen and prekallikrein 
are important cofactors 
FXIIa 
FXIa 
Ca¿ 
FIX FIXa 
F VHIa/Ca2+/PL 
FX -*• F X a 
F Va/Ca2+/PL 
Prothrombin (FII) Thrombin (F Ha) 
Scheme 1: Schematic representation of the intrinsic pathway of coagulation. 
Thrombin stimulates its own formation by activating the protein cofactors V and VIII Factor 
Va and Villa are proteins with no-enzymatic activity but are essential cofactors in the assembly 
of the prothrombinase- and intrinsic tenase-complex, respectively Without these cofactors, the 
catalytic efficiencies of both enzyme complexes are insufficient to account for coagulation In 
tissue factor-activated plasma, thrombin seems to be the only enzyme that activates factor V and 
VIII64, this in contrast to purified systems in which factor Xa is reported also to activate factor 
V« and factor VIII66 
The recently discovered activation of factor XI by thrombin67 could be the link between the 
intrinsic and extrinsic pathways This activation reaction leads to formation of additional factor 
XIa which ultimately causes the formation of factor Xa νια the intrinsic pathway from which 
point both pathways converge This activation loop is proposed as a supplement for the 
General Introduction 
formation of factor IXa formed by TF/FVIIa. This observation is consistent with the 
occurrence of in vivo bleeding disorders in patients with a deficiency of factor XI or in tissues 
with suppressed factor XI levels. 
Control mechanisms: The coagulation cascade needs a tailor-made regulatory system to control 
the different reaction sequences. Most activation processes take place at negatively charged 
phospholipid surfaces i.e. located only at the site of the damaged vessel. Blood flow dilutes the 
activated coagulation factors and transports them away from the lesion site. These mechanisms 
are not complete enough and more sophisticated inhibition processes are needed. 
The action of the complex of tissue factor and factor Vila can only be inhibited when factor Xa 
is present, the reaction product of the former. The ternary complex of factor Vila/tissue 
factor/factor Xa is inhibited by a Kunitz-type protease inhibitor called: lipoprotein-associated 
coagulation inhibitor (LACI)68 or extrinsic pathway inhibitor (EPI)69. 
Plasma also contains other protease inhibitors which have thrombin as target. Antithrombin III 
(AT-III) is one of the best known thrombin inhibitors70. It is a slow-binding inhibitor and 
functions as a pseudo-substrate by forming a non-covalent complex which slowly dissociates. 
Apart from thrombin, antithrombin III inhibits factor IXa, Xa and XIa. The anticoagulant 
capacity of antithrombin III is enormously enhanced by the addition of heparin, a sulfated 
glycosaminoglycan consisting of chains of alternating residues of D-glucosamine and a 
hexuronic acid, either D-glucuronic acid or L-iduronic acid (see figure 6). 
Thrombin is also inhibited by heparin cofactor II (HC-II)71, another heparin-dependent 
inhibitor present in plasma. Several non-specific inhibitors, such as a2-macroglobulin72, Cl-
esterase inhibitor and a]-antitrypsin are present in plasma to retard blood coagulation73. 
Finally, entrapment of thrombin into the fibrin matrix removes it from the plasma milieu. 
ζ^
1
 COOH ζ_ t*°f 
NHR" OH NHSO3H OSO3H NHSO3H 
GlcN GlcA GlcN IdoA GlcN 
Figure 6: Antithrombin III binding region in heparin (acidic form). GlcN: D-glucosamine; 
HexA: hexuronic acid: D-glucuronic acid (GlcA), L-iduronic acid (IdoA). R' = H/SO3H; R" 
= COCH3/SO3H. 
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Vascular injury 
release of tissue factor 
FXI 
Prothrombin (F II) 
Fibrinogen Fibrin matrix 
F Xllla 
Scheme 2: Thrombin is the pivotal enzyme in blood coagulation as can be seen in 
schematic representation of the extrinsic pathway. Inhibition reactions are symbolized 
open arrows. 
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Negative feedback Thrombin not only activates its own formation, it has anticoagulant 
properties too, by activating protein С (PC, activated protein С, APC) which, in turn, 
deactivates the protein cofactors Va and Villa (vide supra)14 By forming a complex with 
thrombomodulin75 (a thrombin-binding protein on endothelial cells), thrombin is able to initiate 
the anticoagulant protein С pathway, thus starting up a negative feedback reaction Scheme 2 
gives a schematic picture of the extrinsic pathway as described in the text 
ENZYMOLOGY76 
Nearly all chemical reactions in biological systems need a catalyst to proceed to some degree 
These catalysts are proteins called enzymes In blood coagulation the reactions to be catalyzed 
are mainly hydrolyses of peptide bonds In the following, some basics about enzyme kinetics, 
mechanism of action of serine proteases, structural features of thrombin and factor Xa, and 
theoretical aspects of the thrombin generation curve are given 
Enzyme kinetics In 1913 L Michaelis and M Menten77 developed a model to describe the 
observations of enzyme-catalyzed reactions according to the reaction sequence 
^on k
c a t 
E + S . ES ·• E + Ρ 
koff 
Scheme 3: Sequence of an enzyme-catalyzed reaction following Michaelis-Menten kinetics. 
This reaction is divided into two distinct steps First, a substrate molecule (S) is bound to the 
enzyme (E), with a rate constant k
on
, leading to an enzyme-substrate complex (ES) This 
complex can dissociate into free enzyme and unaltered substrate with a rate constant koff, or it 
can undergo a chemical reaction forming free enzyme and a product molecule (P) with rate 
constant k
cat The rate of an enzymatic reaction vanes with changes in the concentration of 
substrate, usually as a hyperbolic function according to the Michaelis-Menten equation78, 
(1) v = [E0][S]kca l/(Km + [S]) 
in which [Eo] is the initial enzyme concentration and K
m
, the Michaelis constant (k0ff + 
k
ca()/kon Maximal velocity is obtained at high substrate concentration, when the enzyme is 
saturated by substrate, that is when [S] is much higher than K
m
 so that [S]/([S] + K
m
) 
approaches unity, thus v
max
 = k
cat[Eo], substituting into the Michaelis-Menten equation leads to 
(2) ν = v
m a x
[S]/(K
m
 + [S]) 
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о 
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с 
о 
υ 
л 
α> 
substrate c o n c e n t r a t i o n 
Figure 7: Graphic representation of reaction velocity (v) as a function of substrate 
concentration IS). At K
m
 the reaction velocity is half maximal. Only at an infinite 
substrate concentration the reaction velocity reaches v
m a K : Michaelis-Menten plot (7A). 
(7B): Graphic representation of the inverse of reaction velocity (1/v) as a function of the 
inverse of the substrate concentration (1/S): Lineweaver-Burk plot; adapted from reference 
3 4 . 
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The Michaelis constant is the substrate concentration at which the reaction velocity is its half 
maximal value Substituting K
m
 = [S] into the Michaehs-Menten equation leads to ν = v
max
/2 
Only when k
cat is very small m proportion to k0ff, the Michaelis constant reflects the 
dissociation constant (affinity constant) of the enzyme-substrate complex A high K
m
 indicates 
weak binding, a low K
m
 indicates strong binding The first order rate constant k
ca
i for the 
chemical conversion of the enzyme-substrate complex to the enzyme-product complex is called 
the turnover number the number of substrate molecules converted into product molecules per 
unit time when enzyme is saturated by substrate The Michaehs-Menten equation can be given 
in a graphical representation in which the reaction velocity is plotted against substrate 
concentration (Michaehs-Menten plot), or by a double reciprocal plot of 1/v against 1/[S] 
known as the Lineweaver-Burk plot79, see figure 7 
The Michaehs-Menten equation can be used to describe more complex sequences in which 
additional intermediates are part of the reaction mechanism In serine protease catalyzed 
reactions, the acyl-enzyme is an important covalently bound enzyme-substrate-complex 
intermediate This reaction can be described by the following reaction sequence 
o^n k2 кз E + S . ES — - ^ * - EAc *- E + Ρ 2 
koff
 Ρ ι 
Scheme 4: Reaction sequence of a serine protease catalyzed enzymatic hydrolysis. 
In this reaction sequence, the enzyme-substrate complex undergoes a chemical reaction forming 
the acyl-enzyme (EAc) and a first product molecule The acyl-enzymc undergoes a second 
chemical transformation resulting in free enzyme and a second product molecule The 
Michaehs-Menten equation then changes into 
(3) v = [Eo][S]k*
cat/(K*m + [S]) 
in which k*
cat = k2k3/(k2 + k3) and K*m = к^кз/к^кг + k3) 
An enzyme can be inhibited by a compound which binds to its active-site and prevents substrate 
binding If the inhibitor and substrate compete for the active-site, the inhibitor is called a 
competitive inhibitor The reaction sequence can be given as follows 
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E + S 
^on.S 
K-off.S 
ES E + Ρ 
Ι, к, on,I 
\>ff,l 
ΕΙ 
Scheme 5: Reaction sequence when a substrate (S) and an inhibitor (I) compete for one 
enzyme. 
The Michaelis-Menten equation can be described as 
(4) ν = [Eo][S]kc
at/([S] + K m ( l + [I]/K,)) 
in which К, = k0ffi/koni 
These equations describe enzyme kinetics in purified systems In plasma samples, complex 
mixtures of active enzymes and different substrates (natural as well as synthetic) are present 
This results in complex Michaelis-Menten equations Two examples will be discussed (1) two 
substrates and one enzyme, (2) one substrate and two enzymes. 
Two substrates for one enzyme The reaction sequence can be described as follows 
A, k
on
 д 
E . EA 
k0ff,A 
"•2.A 
•*- E + Ρ 
В, к, 
οη,Β 
^offB 
ЕВ 
"•2 В 
•*• E + Ρ' 
Scheme 6: Reaction sequence when one enzyme can hydrolyse two substrates. 
The reaction velocity is given by 
(5) V = (WKnOtEfneltS] 
In the case of two substrates the ratio of substrate hydrolysis is given by 
(6) VA/VB = ((kc
a
t,A/K
m
,A)[SA])/((kcat,B/Km,B)[SB]) 
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The amount of discrimination between two substrates depends on the ratio of kc
at/Km (the 
specificity constant) and each substrate concentration When a chromogcnic substrate (A) and 
the natural substrate (B) are present, and only the product of A is measured, one can operate as 
if the hydrolysis of A is inhibited by В in a competitive way The process can be described by: 
(4a) V = [Eo][SA]kcat/([SA] + K m , A (l + [SBI/ΚΠ,Β)) 
One substrate for two enzymes. The synthetic substrates used in coagulation assays are not 
specific enough to be hydrolyzed by only one enzyme. Generally, a substrate is hydrolyzed by 
more than one enzyme, how to determine the contribution of the enzyme of interest9 The 
reaction velocity is given by (1), the ratio of velocities is found to be 
(7) V.ntercst/Vtotal = E,/E t = (kcat.i(Km.t + [ S ] ) ) / ( k c a U ( K m , , + [ S ] ) ) 
Serine proteases This class of enzymes is so called because they have a uniquely reactive 
serine residue in the active centre which attacks the bond to be hydrolyzed. The reaction 
sequence is given in scheme 4, the Michaelis Menten equation is given by (3) The reaction 
mechanism is as follows 
Θ 
Î f ï 
J^ + E-OH *- R — C - O - E — ^ - * - À p 
W X | > R O-E 
X HX 
H20 
ОН 
R—С—O-E *- ^ Д ч ^
т т
 + E-OH 
¿ 
О 
χ 
R-^OH 
Scheme 7: Reaction mechanism of a serine proteasc-cataly/ed hydrolysis of an amide- (X = 
NHR') or ester- (X = OR') bond. 
The hydroxy 1 group of Ser 195 (E-OH) of thrombin attacks the carbonyl carbon of the amide-
(X = NHR') or ester- (X = OR') substrate with a simultaneous loss of a proton to a base. A 
tetrahedral intermediate is formed which rearranges to the acyl-enzyme In this step, the proton 
is transferred from the protonated base to the leaving group with liberation of a substrate 
fragment In the next step a water molecule attacks the carbonyl carbon of the acyl-enzyme in a 
same fashion as the senne-hydroxyl did Again a tetrahedral intermediate is formed which 
rearranges to the free enzyme and liberates the other substrate fragment. 
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The hydroxyl function of Ser 195 is highly reactive as a result of the charge relay system of the 
catalytic triad, Aspl02-His57-Serl95 The carboxylate side chain of aspartic acid 102 enhances 
the basicity of the imidazole function of histidine57 which, in turn, results in an increase of the 
nucleophilicity of the hydroxyl function of serine 195 
The catalytic triad of Asp-His-Ser is found in all serine proteases The specificity of these 
enzymes depends on the amino acids forming the primary specificity pocket In thrombin, 
factor Xa and other coagulation factors, Asp 189, with a negatively charged side chain is 
positioned at the bottom of this pocket This results in a preference for binding of substrates 
with a positively charged side chain such as lysine and arginine 
Thrombin generation curves80 The thrombin generation curve (TGC) gives the course of 
appearance and disappearance of thrombin m triggered plasma Concerning the central role of 
thrombin tn thrombosis and hemostasis an adequate formation of thrombin to arrest bleeding is 
essential The thrombin generation curve yields important information about the functioning of 
the coagulation cascade One parameter obtained from the thrombin generation curve is the 
thrombin potential803 the time integral of the free thrombin concentration, a parameter to assess 
the effect of antithrombotic drugs on thrombin generation 
The thrombin generation curve is the result of the activity of the prothrombin activating enzyme 
complex (prothrombinase-complex) and the thrombin mactivation reactions, such as binding to 
antithrombin III and to a2-macroglobulin In figure 8 an example of a thrombin generation 
curve is given It can be seen that the curve shows a short lag phase and a steep rise After the 
maximum has been reached, a gradual decline is observed that approaches a zero level An 
experimental thrombin generation curve obtained with a synthetic substrate shows a steady end 
level due to residual amidolytic activity of oç-macroglobulin complexed thrombin 
The classical thrombin generation curve is obtained by a repeated subsampling from activated 
plasma into a substrate solution81 This method requires intensive experimentation and is not 
suited for routine use 
In order to obtain a method82 in which the thrombin generation curve can be obtained by 
measuring a continuous optical density curve there is a need for substrates with modified 
kinetic parameters The chromogenic substrate present in the plasma sample interferes 
competitively with the physiological substrates of thrombin and thus affects the physiological 
steady state To minimize competitive inhibition processes the Km value of the synthetic 
substrate should be high, and to prevent that this substrate is exhausted long before thrombin 
generation is over a slow reacting substrate has to be used This means that the turnover (kcat) 
of this substrate has to be low The substrate should not interfere but monitor the course of the 
steady state concentration and time 
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Figure 8: Thrombin generation curve. N shows a normal thrombin generation curve, i.e. 
the development of thrombin in time after triggering of coagulation. As soon as it extends 
into area T, the thrombosis risk zone, even people with healthy vessels tend to 
thrombosis. With the increase of age the boundary of the thrombosis danger zone shifts 
downwards (dotted line). Anticoagulant therapy can move the thrombin generation curve 
out of the danger zone (curve A). Anticoagulation should not lead, however, to curves 
entering the bleeding risk zone (B); adapted from reference 80. 
1200 
- SQ6Í 
Figure 9: Continuous optical density curve. This curve is the time integral of a thrombin 
generation curve. The final slope of this curve is the result of the amidolytic activity of 
the a2M-thrombin complex. MZ-Aib-Arg-pNA.HCI (SQ68) is used as substrate; 
constituting one of the lead structures to arrive at more selective thrombin substrates. 
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In figure 9 a continuous optical density curve is shown The thrombin generation curve can be 
calculated from this curve by taking the first derivative The optical density curve is the result of 
the sum of the activity of free thrombin and of the a2-macroglobulin-thrombin complex Via a 
mathematical procedure the contribution of free thrombin can be calculated82 8 3 When the 
subsampling method and the more convenient continuous method were compared a good 
correlation was found between the two methods yielding comparable information about the 
process of thrombin generation 
What are the requirements of the chromogenic substrates to be used in the continuous method9 
First of all, the substrate has to be selective for thrombin with a high K
m
 and low k
cat value 
Secondly, the process of thrombin generation takes place in a plasma sample, thus the 
chromogenic substrate must be free of any inhibitory activity on the coagulation factors, which 
affects the formation of thrombin To minimize additional amidolytic activity by factor Xa, the 
substrate must have a low affinity for factor Xa thus low k
cat and high Km values When 
thrombin is generated in plasma it will be removed by antithrombin III and a2-macroglobuhn 
Antithrombin III is a pseudo-substrate of thrombin and will compete with the substrate for the 
active-site of thrombin For this reason the antithrombin ΠΙ dependent decay of thrombin (ki) 
decreases by a factor K
m
/(K
m
 + [S]) at higher substrate concentrations During the 
measurement the substrate concentration is essentially constant, as is the effect of thrombin 
decay by antithrombin III The influence of the substrate on the a2-macroglobuhn dependent 
decay of thrombin (кг) is not exactly known (probably also competitive inhibition) The 
complex of ci2-macroglobuIin-thrombin has no clotting properties but still has amidolytic 
activity It is evident that the chromogenic substrate should have low affinity to this complex 
From the thrombin generation curve and both decay constants defining the actions of 
antithrombin III and of 02-macroglobuhn the course of the prothrombinase activity (the course 
of the velocity of prothrombin conversion) can be calculated When a substrate has affected the 
coagulation cascade, a change will result in a lowering or shifting of the prothrombinase curve 
Structural features of thrombin and factor Xa The crystal structure of thrombin inhibited by a 
chloromethylketone was resolved in 1989 by Bode and coworkers84 The insight into the three 
dimensional structure of the enzyme was very helpful in the design of selective thrombin 
substrates It was shown that the primary specificity pocket mainly gives access to positively 
charged amino acid side chains Although a preference for basic amino acids as primary 
specificity exists, the Si pocket of thrombin is of hydrophobic character, so neutral, straight 
side chains will be fairly well accommodated The S2 pocket of thrombin has a preference for 
apolar side chains of moderate bulkiness This pocket, sometimes also referred to as the apolar 
binding pocket or the S2 cavity, has a proline residue as preference Another important binding 
pocket in the active-site of thrombin is the aryl binding site in which D-configurated amino 
acids with an aromatic side chain are preferentially bound Crystallization studies of thrombin 
with hirudin85 showed that a positively charged binding cleft (fibrinogen binding exosite) on 
18 
General Introduction 
the thrombin surface is of major importance for recognition and positioning of the physiological 
substrates of thrombin 
The crystal structure of factor Xa was recently resolved86 and showed important differences m 
comparison with the thrombin molecule. Most conspicuous is the narrow S2 cavity of factor Xa 
which is solely compatible with the presence of a glycyl residue, while the amino acyl residues 
of factor Xa forming the S3 and S'3 binding pocket bear positive charges in contrast to 
thrombin where negatively charged residues are present. Additionally, the factor Xa molecule 
lacks a positively charged region for the recognition of fibrinogen. These differences should be 
taken into account in the design of selective thrombin substrates with minimal affinity for factor 
Xa 
PEPTIDE SYNTHESIS87 
Peptide chemistry is the part of organic chemistry that deals with the condensation of amino 
acids to peptides, these can be used as building blocks in the synthesis of protein fragments. 
When two amino acids are coupled to form an amide bond (peptide bond), the carboxyl- and 
amino groups which are not meant to be part of the amide have to be protected The carboxyl 
function which forms the peptide bond requires activation by the introduction of an electron 
withdrawing group 
The classical carboxyl activation is the azide method of Curtius88 This method is extremely 
useful in the coupling of peptide fragments and is accompanied by a minimal degree of 
racemization. Furthermore, the azide process has the possibility to convert a carboxyl-
protecting group into an activating group (see scheme 8). 
О О О 
Il N H 2 - N H 2 II R' ONO/HX и 
г Г ^ О М е *" Γ Γ " Ν Η - Ν Η 2 * " R N 3 
Scheme 8: The carboxyl protection by a methyl ester can be converted to the 
corresponding acid hydrazide by treatment with hydrazine. The hydrazide, in turn, is 
transferred to the reactive azide by treatment with an alkyl nitrite and a mineral acid8 9. 
Activation through anhydrides (mixed or symmetrical) is well known and has found 
widespread application for the activation of suitably protected amino acids (see figure 10) A 
special application of this method is known as activation through active esters, which have a 
long "shelve-life". There are numerous active esters mentioned in the literature, among them the 
most often used are nitrophenyl esters (ONp)93, N-hydroxysuccinimide esters (ONSu)94, N-
hydroxyphthahmide esters (OPth)95 and pentafluorophenyl esters (OPfp)96 (see figure 11) 
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Figure 10: Some examples of mixed anhydrides. A: mixed anhydride of trimethylacetyl 
chloride'' ' (pivaloyl chloride), B: 3-methylbutyryl chloride"! (uovaleryl chloride) and C: 
phosphorus oxychloride9 2. 
RA0U 
ONp 
Figure 11: Some examples of active esters. 
When a peptide bond is formed from a carboxylic component and an amine using condensing 
agents, carboxyl activation occurs in situ This activated carboxylic group is attacked by the 
free amino function The most succesful coupling reagent, dicyclohexylcarbodnmide (DCC) 
was introduced by Sheehan and Hess97 Some variants with water soluble properties such as 1-
(3-dimethylaminopropyl)-3-ethylcarbodnmide hydrochloride (EDO)9 8 or as a soluble urea, 
diiio-propylcarbodnmide (DIPCDI)99 were introduced at a later stage (see figure 12) 
/ \ — N = C = N ( \ \ — N = C = N ί 
\ ' ~„„ \ / ' DIPCDI ^ DCC 
NHC1 
Figure 12: Structural formulas of the coupling reagents mentioned in the text. 
An important consequence of carbodumides as coupling reagents is the introduction of 
racemization at the (highly) activated carboxyl terminal residue The racemization can be 
suppressed by the addition of excesses of 1-hydroxybenzotnazole (HOBt) 1 0 0, N-
hydroxysuccimmide (HONSu)1 0 1·1 0 2 or 3-hydroxy-3,4-dihydro-l,2,3-benzotnazin-4-one 
20 
General Introduction 
(HOOBt),00(see figure 13). These acidic (pKa around 4, and not acylating) nucleophiles 
reduce the life-time of reactive intermediates, by conversion of the overactivated ííouronium 
esters into less reactive and thus more selective active esters. 
О 
HOBt O H HOOBt HONSu О 
Figure 13: Structural formulas of the additives to suppress racemization in DCC-mediated 
coupling reactions. 
A milestone in peptide synthesis was the discovery of the benzyloxycarbonyl (carbobenzoxy, 
Z) group as amino protection by Bergmann and Zervas103. They found that this function could 
be removed by catalytic hydrogénation at neutral conditions, ordinary pressure and room 
temperature. The group can also be removed by acidolysis104. In 1977, Barany and Merrifield 
defined the principle of orthogonality105 to describe how the nature of protective groups should 
be chosen to arrive at the cleanest end-product; one protective function can be removed under 
conditions in which a second is absolutely stable. The pair Z/Boc (removed by 
hydrogenolysis/acidolysis) is the first example of this principle. 
Another important feature of the benzyloxycarbonyl protective function, and all other protective 
functions of the urethane-type, is the ability to protect the chiral integrity of the amino acid to 
which it has been attached. This property stems from the destabilization of the anion generated 
by proton abstraction from the 5(4H)-oxazolone (azlactone) which is formed upon activation of 
the carboxyl component. In general, amino acids protected by urethane-type functions do not 
produce azlactones and hence do not racemize during activation and coupling (see figure 14). 
There are numerous protective groups for the amino- and carboxyl functions. They can be 
divided into different classes based upon the mode of deprotection. In figure 15 some examples 
of protective groups are given. These examples are chosen because they found application in 
this thesis. 
N—OH 
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Protected amino acid 
active ester 
A 4 
•CH 
I 
R' 
Θ 
О 
4 
I 
N 
О  О 
о-«-*- о 
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О / 
-с© 
R' R' 
Figure 14: The most important mechanism of racemization involves the formation of 
azlactones (upper frame). The explanation for the tendency to racemization of azlactones 
lies in the ease by which the acidic proton can be abstracted from the chiral center due to 
resonance stabilization of the carbanion generated in the process as given in the lower 
frame. Azlactones are formed when an acyl amino acid active ester is exposed to the action 
of tertiary amines. Racemization through azlactone intermediates is influenced by several 
factors such as the nature of the amino acid involved, the solvent used in the reaction or 
the presence of tertiary amines. The acyl group on the amine nitrogen, however, plays a 
decisive role in the conservation or loss of chiral purity: the stability of the anion 
produced in proton abstraction by bases is enhanced by electron withdrawing effects in the 
acyl group. Benzyloxycarbonyl, ferf.-butyloxycarbonyl and other alkoxycarbonyl N-
protected amino acids destabilize the anion by electron release and hence are resistant to 
racemization during activation and coupling. 
CARBOXYL PROTECTIVE GROUPS 
-CH 3 
Me methyl"16 
used in the conversion to hydrazides 
-CH 
-o 
Л 
All ally]"*7 
allyl transfer by Pd"(Ph3P)4 
Bzl benzyl"" 
catalytic hydrogénation 
acidolysis 
'Bu ten -butyl"'" 
mild acidolysis 
side chains (Asp/Glu) 
Scr, Thr, Туг"" 
(Figure 15 Continued on the next page) 
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AMINO PROTECTIVE GROUPS 
o-°
x
- -^
1 
Ζ benzyloxycarbonyl'03 
catalytic hydrogénation 
strong acidolysis"14 
Trt tntyl110 
mild acidolysis . . 
side chains Asn/Gln"1 \ // 
His"2,Cys"5 
Boc fert-butyloxycarbonyl"15 
mild acidolysis 
side chain Lys 
о 
X 
Msc 2-(methylsulfonyl)elhyloxycarbonyl' 
ß-elimination, base labile 
Aloe allyloxycarbonyl 
allyl transfer by Pd°(PhiP)4 
Fmoc 9-fluorenylmelhyloxycarbonyl" 
β elimination, base labile 
Figure 15: Amino- and carboxyl protective groups used in the syntheses described in this 
thesis. Deprotection conditions and applications as side chain protections are mentioned. 
In 1963 a new method of peptide synthesis was introduced by Memfield117 In this method a 
protected amino acid derivative is anchored on an insoluble resin After deprotection of the ex­
amino function the next amino acid is coupled When coupling is complete all reactants are 
washed away, leaving a protected dipeptide on the resin Following the required number of 
these cycles the peptide is detached from the resin and purified This principle was an 
enormous step forward since it speeded up the synthesis of large peptide fragments This 
method is called Solid Phase Peptide Synthesis (SPPS) 
In the years following the development of SPPS by Memfield, many improvements of this 
method were made Most striking was the development of more acid sensitive anchoring 
molecules (linkers), resulting in the 4-alkoxybcnzyl alcohol linkers (the Wang resin118) This 
enables a change from Boc/Bzl- (Boc-chemistry, incomplete orthogonality) to Fmoc/fert -Bu-
protected amino acid residues (Fmoc-chemistry, complete orthogonality) A new approach in 
which protected peptide fragments are used in coupling reactions (convergent synthesis) needs 
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highly acid sensitive linkers in which, for example, 2-methoxy-4-alkoxybenzylalcohol 
(SASRIN119) or tntyl-denved linkers120 were applied (see figure 16) 
HOCH, r\ OCH 4 / -RESIN 
CH,Q 
HOCH2 
В 
г\ OCH2 k Ò— RESIN 
HO— " ^ - X - ( C H 2 ) n - •COOH 
Figure 16: Examples of resins/linkers used in SPPS; A: Wang resin11" which makes use 
of 4-alkoxybenzyl alcohol as linker, B: SASRIN 1 1 9 (Super Acid Sensitive Resin) in 
which 2-methoxy-4-aIkoxy benzylalcohol is used as linker, C: trityl linker12", in which 
R and R' can be methoxy groups or hydrogen atoms and X is an oxygen atom or a 
methylene function (X = Ο, η = 4; X = Clb, η = 2) to tune the acid sensitivity of the 
resin. 
For an overview of solid phase peptide synthesis some excellent reviews are given in the 
literature and monographs121 are available Boc-chemistry-SPPS is reviewed by Stewart and 
Young122, Fmoc-chemistry-SPPS by Fields and Noble123 A recent overview of convergent 
peptide synthesis is given by Lloyd-Williams, Albencio and Giralt124 and Benz125 
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OUTLINE OF THE THESIS 
This thesis describes the synthesis of orthogonally protected amino acid p-nitroanilides and 
their conversion into building blocks for peptide synthesis These compounds were used in the 
synthesis of chromogenic substrates for proteolytic enzymes 
The substrates were used to determine the concentration of one particular enzyme in a mixture 
of enzymes This enzyme, the blood coagulation enzyme thrombin, is generated after a series 
of activation reactions by several coagulation factors Unfortunately, these coagulation factors 
possess similar substrate specificities as thrombin 
From studies of the structure-activity relationship with modified substrates and from the results 
of X-ray investigations, the structure of substrates was inferred, which match the specificity of 
thrombin better than the existing and their synthesis was achieved These substrates can be 
used in the continuous registration of thrombin formation in plasma and afford the thrombin 
generation curve, which describes the actual thrombin concentration at each moment 
Chapter 1 describes the synthesis of orthogonally protected amino acid p-nitroanilides 
Phosphorus oxychlonde in pyridine was found to be an excellent activating system to couple 
the poor nucleophile p-nitroaniline to a suitably protected amino acid Through this method, 
Na-Fmoc-protected amino acid p-nitroanilides became available for the first time, leading to 
orthogonally protected amino acid p-nitroanilides, since the p-nitroanihde bond was found to be 
stable under Fmoc-deprotection conditions Th?«t d. compatible with the use of acid-labile 
side chain protective functions, which can be removed after completion of the synthesis under 
mild conditions Application of the Fmoc function in Na-position enables the synthesis of 
peptides containing basic and acidic aminoacyl residues requiring semi-permanent protections 
(Boc, lBu) A most promising compound Boc-Arg-pNA HCl, is readily available and some 
syntheses are given of substrates in which H-Arg-pNA HCl is used 
Chapter 2 describes the synthesis of 25 peptide p-nitroanihdes as substrates fpr thrombin 
This chapter describes the first approach to the design of chromogenic substrates with MZ-Aib-
Arg pNA HCl and 2HC1 H-D-Phe-Pip-Arg-pNA as lead structures 
Chapter 3 deals with the biological screening of the substrates described in chapter 2 to arrive 
at substrates which are predominantly attacked by thrombin and can be used in the continuous 
registration of thrombin formation in plasma One substrate fulfills the requirements, but its 
biological properties are not optimal This substrate has served as a new lead compound in the 
second approach of design described in chapter 4 
Chapter 4 describes the synthesis of a series of 18 peptide p-nitroanihdes in which the 
structure-activity relationships obtained from chapter 3 are incorporated From X-ray studies of 
fibrinopeptide A crystallized with thrombin relevant structural elements were obtained for 
highly specific recognition by thrombin This knowledge led to the synthesis of chromogenic 
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substrates containing up to 6 amino acid residues simultaneously serving another goal, namely 
the exclusion from thrombin's active-site when complexed to a2-macroglobulin 
Chapter 5 describes the biochemical properties of the substrates described in chapter 4 After 
the selection entena, two compounds with optimal biological properties were found which can 
be used as chromogenic substrates in the continuous registration of thrombin formation in 
plasma One of them found application in a commercial test kit made by Baxter Diagnostics 
Unfortunately, longer peptides did not meet the expectations with respect to lower hydrolytic 
activity on thrombin complexed with a2-macroglobulin. This chapter also presents some 
applications of the continuous assay method and a new approach to eliminate the residual 
proteolytic activity of a2-macroglobulm complexed to thrombin is described 
Chapter 6 deals with a new approach to the development of selective thrombin substrates in 
which thrombin acts as an endo-amidase As the chromophoric group, 5-amino-2-nitrobenzoic 
acid was used The carboxyl function can be used to couple peptide segments which enables 
post active-site interactions and thus higher selectivity The synthesis by solid phase and 
solution chemistry and the biochemical properties of these chromogenic substrates are 
described 
Chapter 7 discusses the general conclusions which can be drawn from the investigations 
presented in this thesis 
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CHAPTER 1 
THE SYNTHESIS OF AMINO ACID /7-NITROANILIDES USING 
PHOSPHORUS OXYCHLORIDE AS CONDENSING AGENT; A 
ROUTE TO ORTHOGONALLY PROTECTED 
p-NITROANILIDES 
THEIR USE IN THE SYNTHESIS OF CHROMOGENIC SUBSTRATES FOR 
THROMBIN AND FACTOR Xa 
ABSTRACT 
A method is described for the synthesis of Na-protected bi- and afunctional ammo acid p-
nitroanilides The reaction uses phosphorus oxychlonde as the condensing agent The 
synthesis is simple, rapid, free of racemization and affords yields between 70-90% The 
synthesis can be performed not only with amino acid derivatives of the urethane type including 
acid-labile and base-labile Na-protective functions or allyl-denved protections, but also with 
Na-tntyl amino acids, albeit in lower yield The reaction runs in pyridine and its mechanism 
implies carboxyl activation by formation of a mixed anhydride with phosphorodichlondic acid 
(HOPOCl2) The p-nitroanilides are compatible with the conditions required for N-
deprotection mild acidolysis or treatment with a secondary amine (ß-eliminaüon), affording 
synthons for the synthesis of orthogonally protected peptide p-nitroanihdes As an example, 
the synthesis of free or protected peptide derivatives containing C-terminal arginine p-
nitroanilides will be described They constitute substrates for proteolytic enzymes especially 
thrombin and factor Xa 
INTRODUCTION 
Amino acid p-mtroanilides are compounds of great interest and are widely used as 
chromogenic substrates for the determination of the activity of proteolytic enzymes present in 
body fluids1 
The synthesis of p-nitroanihdes however, is rather troublesome The problem encountered in 
the synthesis of p-nitroanihdes from p-mtroaniline stems from the low nucleophilicity of the 
latter For this reason their synthesis is intensively studied and several methods are mentioned 
in the literature 
33 
Chapter 1 
The common coupling methods used in peptide synthesis are insufficient The use of DCC2, 
DCC/HOBt3 or the mixed anhydride method4 give yields in the range between 30-58% Acid 
chlorides5 or thermal activation6 are recommended to overcome the low nucleophihcity of p-
nitroamline, but in some instances the optical purity of the p-nitroanihdes obtained with these 
methods is questionable 
As an alternative to p-nitroaniline, syntheses using pure p-nitrophenyhsocyanate7, or in situ 
generated from p-nitrobenzoic acid through the modified Curtius reaction with diphenyl 
phosphorazidate8, are found to be general and efficient methods 
In the recent literature some examples are given in which 1,4-diaminobenzene was used to give 
the desired p-nitroanihde after oxidation with ЫаВОз 4НгО in acetic acid Burdick et al9 
described a synthesis of peptide p-nitroanihdes using an urethane-linked p-aminoanilide resin 
in which the peptide is built up by SPPS Reiter10 describes the use of p-(Boc-amino)anihne as 
precursor for p-nitroanihne Besides the moderate yield which can be obtained, the final 
oxidation step limits its practical use when methionine, tryptophan and cysteine are 
incorporated in the peptide 
Another method for synthesizing p-nitroanihdes by SPPS was recently described by Voyer et 
al ' ' They synthesized the desired peptide on a Kaiser-oxim resin12 followed by a nucleophilic 
displacement from the resin by the addition of p-nitroaniline Despite the low nucleophihcity of 
p-nitroaniline the obtained cleavage yield was 30%, after work-up, pure product was obtained 
in only 16% yield 
In the early 1960s, there was an intensive research in the applicability of phosphorus 
compounds as coupling agents in peptide synthesis Among them, the phospho-azo method13 
and the use of phosphorus pentoxide in diethylphosphite14 were the most frequently applied 
methods to synthesize p-nitroanihdes15 However, the obtained yields and the scope of these 
methods were rather limited These syntheses are only succesful when the α-amino function is 
protected with groups which are labile in strongly acidic media (Z-family, Pht etc ) 
The first syntheses of ten -butyloxycarbonyl amino acidp-nitroanilides have been reported by 
Okada et al3 for Boc-Met-pNA and Boc-Lys(Z)-pNA, by Shion et al 8 for Boc-Leu-pNA, 
Boc-Lys(Z)-pNA and Boc-Arg(Mts)-pNA and by Noda et al16 Both Bajusz17 and Oyamada et 
al18 used the phospho-azo method for the synthesis of Boc-Arg-pNA HCl Oyamada et al 
reinvestigated the phospho-azo method and synthesized p-nitroanihdes of Z- and Boc-amino 
acids In contrast to earlier work, they achieved yields in the range between 43-94% 
The recent results of Noda et α/ , 6 and Oyamada et α/1 8 prompted us to publish our results 
obtained using phosphorus oxychlonde as the condensing agent19 We found that phosphorus 
oxychlonde is a versatile condensing agent for the synthesis of protected amino acid p-
nitroanihdes In this chapter a new class of protected amino acid /7-nitroanihdes is described in 
which the α-amino function is protected by a base-labile protective group20 Introduction of a 
base-labile protective function gives access to orthogonally protected p-nitroanihdes which can 
be used as synthons in the synthesis of chromogenic substrates 
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RESULTS A N D D I S C U S S I O N 
The use of phosphorus oxychloride in peptide synthesis was for the first time described by 
Wieland et al.21 We applied this method and found it an excellent and even general way to 
synthesize p-nitroanilides of protected amino acids. The synthesis of a p-nitroanil ide with 
phosphorus oxychloride as condensing agent was carried out for the first time for the synthesis 
of Z-Phe-pNA 2 2 , which was built-in in Z-Gly-Phe-pNA. Earlier attemps to synthesize Z-Gly-
Phe-pNA, in which Z-Gly-Phe-OH was activated by D C C and allowed to react with p -
nitroaniline, gave racemic Z-Gly-Phe-pNA in 4 % yield 2 3 . 
The method implies activation of a protected amino acid with phosphorus oxychloride in 
pyridine at -15°C (see scheme 1). The reaction proved to be complete within 15-30 min as 
described under general method. 
X' 
| POCI3 
X—AA—OH »• 
Pyr 
Scheme 1: Equimolar amounts of amino acid and phosphorus oxychloride are required in 
this method to give in situ a mixed anhydride as the activated species. X is the α-amino 
protective group (Z, Boc, Fmoc, Aloe and Trt) and X' the side chain protection ('Bu, Trt, 
Boc etc.). 
The syntheses started with Z-amino acids since the acid stability of the Z-group precludes the 
occurrence of side reactions in the phosphorus oxychloride/pyridine reaction mixture. The use 
of pyridine as solvent enables the synthesis of p-nitroanilides at low temperature and can also 
be performed when acid-labile protective groups are used, since the solvent acts as a weak 
base. The Boc-amino acid p-nitroanilides synthesized in this study are listed in table 1. The 
values we found give a good correlation with the data cited in the literature. To arrive at 
orthogonality, Boc-protected amino acids require benzyl-derived protections in their side 
chains. Deprotection of the latter evidently cannot be performed by hydrogenolysis, which 
would convert p-nitroanilides into p-aminoanilides and thus removal of benzyl functions 
require rather severe conditions (НВг/AcOH) which are usually unfavorable. When the cl­
amino function is protected by a base-labile group, the side chain can be protected by groups 
which are removable under mildly acidic conditions. This however, requires good stability of 
the p-nitroanilide bond in media, which attack the base-labile protection. 
X' О 
I II 
X—AA—0—P(C1)2 
X' 
H2N-Q-N02 T 
X—AA-^IN-(\ /bN02 
Pyr 4>> 
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Table 1: Physicochemical properties of Na-Boc-protected amino acid p-nitroanilides. 
p-mtroanilide yield % mp °C [a] D c=l MeOH TLC Elemental Analysis (Cale), % 
С Η N S 
Boc-Gly-pNA 80 192 
Boc-Phe-pNA 75 150-151 +69 0 
Boc-Ala-pNA 77 168 -58 6 
Вос-Пе-pNA 82 foam 13 7 
Boc-NlepNA 60 foam -20 8 
Boc-Val-pNA 78 foam -20 0 
Вое-Arg pNA HCl* 91 187 12 8 
Boc-Tyr(Bzl>pNA 89 179-181 +82 0 
Boc-Cys(Bzl)-pNA 90 foam +24 6 
Boc-Lys(Z)-pNA 84 foam -8 1 
BOL His(Bzl)-pNA** 84 138-141 +24 4 
Boc-Glu(OBzl}-pNA 84 foam -7 9 
0 75 b (60 39) (5 95) (9 19) 
4:Η 2 α 2 /ΜεΟΗ 98 2 v/v,
 bCH2Cl2/MeOH 95 5 v/v,
 cBuOH/AcOH/H20 4 1 1 v/v/v,
 dBuOH/pyndine/H20 
1 1 1 v/v/v *EA calculated for Boc-Arg-pNA HCl 0 5AcOH 0 5BuOH, **EA calculated for Boc His(B7l)-
pNA iio-propyl alcohol (СзНаО) 
The acid stability of the p-nitroanilide bond is, however, well documented in the literature The 
p-nitroamlide bond resists 30% HBr in acetic acid2a, saturated HCl in glacial acetic acid24, 
methanesulfonic acid25, 10% HCl in EtOAc25 and HF7 
We tested the base stability of the p-nitroanihde bond in Boc-Ala-pNA in the following media 
10, 25 and 50% pipendine in DMF and 25% pyrrolidine in DMF We found the p-nitroanilide 
bond to be stabile in these media, even on prolonged treatment (24 hrs) with 50% pipendine in 
DMF, no p-nitroanihne was set free and the optical purity was unaffected 
0 18a 
0 49 b 
0 5 1 a 
0 70 b 
031 a 
0 5 1 b 
0 50 a 
0 70 b 
0 53 a 
0 73 b 
0 44 a 
0 68 b 
0 67 е 
0 70е1 
0 57 a 
0 79 b 
0 62 a 
0 8 1 b 
0 18a 
0 53 b 
0 04 a 
0 28 b 
0 46 a 
52 73 
(52 88) 
62 26 
(62 33) 
54 26 
(54 36) 
58 22 
(58 11) 
58 42 
(58 11) 
57 01 
(56 96) 
48 15 
(48 29) 
65 98 
(65 98) 
58 40 
(58 45) 
59 72 
(59 99) 
61 55 
(61 70) 
60 05 
5 66 
(5 80) 
5 86 
(6 01) 
6 13 
(6 19) 
7 01 
(7 17) 
7 19 
(7 17) 
6 89 
(6 87) 
6 62 
(6 79) 
5 79 
(5 95) 
5 75 
(5 84) 
6 32 
(6 44) 
6 01 
(6 71) 
5 77 
13 85 
(14 23) -
10 67 
(10 90) -
13 52 
(13 58) -
11 56 -
(1196) -
11 64 -
(1196) 
12 13 
(12 45) -
16 80 
(16 89) -
8 41 
(8 55) 
9 45 7 55 
(9 74) (7 43) 
10 90 
(1119) -
1391 
(13 32) -
9 03 
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Table 2: Physicochemical properties of Na-Fmoc-protected amino acid p-nitroanilides. 
p-nitroanilide yield % mp °C [Œ]D, с , solv TLC Elemental Analysis (Cale), % 
С Η N S 
Fmoc-Gly-pNA 
Fmoc Val-pNA 
Fmoc-Phe-pNA 
Fmoc-Met-pNA 
Fmoc-Arg-pNA HCl* 
Fmoc-Lys(Boc)-pNA 
Fmoc-Ora(Boc)-pNA 
Fmoc-GKO'BuVpNA 
Fmoc-Ser('Bu)-pNA 
Fmoc-TyK'BuVpNA 
Fmoc-Cys(Trt)-pNA 
Fmoc-His(Trt)-pNA 
Fmoc-Asn(Trt)-pNA 
89 
70 
88 
79 
88 
81 
92 
83 
79 
79 
90 
95 
71 
212-213 
189-191 
197-199 
183 
183 
116-117 
180 
98 
foam 
93-95(dcc) 
foam 
foam 
214-216 
-
-27 1, 
+13 3, 
-39 1, 
-39 1, 
-45 5, 
-23 3, 
-20 5, 
-26 8, 
-36 2, 
+24 1. 
-18 8, 
-6 1, 1 
-25 3, 
l .DMF 
1, DMF 
1,DMF 
l.MeOH 
l.DMF 
l .DMF 
0 94, DMF 
l .DMF 
l.DMF 
, 1, DMF 
l.DMF 
l.DMF 
l .DMF 
0 24 a 
0 14b 
0 67 a 
0 48 b 
0 7 1 a 
0 49 b 
0 68 a 
0 4 1 b 
0 73 e 
0 72 d 
0 24 a 
0 25 b 
0 29 a 
0 24 b 
0 70 a 
0 47 b 
0 76 a 
0 47 b 
0 7 1 a 
0 5 1 b 
0 84a 
0 58 b 
0 16a 
0 10b 
0 7 1 a 
66 02 
(66 18) 
67 47 
(67 96) 
70 95 
(7100) 
63 32 
(63 53) 
57 51 
(57 27) 
63 79 
(64 80) 
65 36 
(65 26) 
65 47 
(66 04) 
66 39 
(66 79) 
68 88 
(68 86) 
69 77 
(69 88) 
72 36 
(72 35) 
73 53 
4 50 
(4 59) 
5 30 
(5 48) 
4 93 
(4 96) 
5 06 
(5 13) 
5 73 
(5 89) 
6 10 
(6 79) 
6 37 
(6 60) 
5 79 
(5 73) 
5 70 
(5 80) 
5 95 
(5 60) 
4 86 
(4 85) 
4 90 
(4 90) 
5 05 
9 89 
(1007) 
8 86 
(9 14) 
8 16 
(8 28) 
8 35 
(8 55) 
13 06 
(12 93) 
8 80 
(8 64) 
9 13 
(8 95) 
6 52 
(7 70) 
8 18 
(8 34) 
6 60 
(7 05) 
5 54 
(5 62) 
8 93 
(9 11) 
7 70 
-
-
-
-
-
-
641 
(6 52) 
-
-
-
-
-
-
-
-
-
-
-
-
4 45 
(4 28) 
-
-
. 
0 49 b 
äCf^Clj/MeOH 98 2 v/v, bElOAc/n-hexane 1 1 v/v, cBuOH/AcOH/H20 
1 1 1 v/v/v *EA calculated for Fmoc-Arg-pNA HCl 0 5BuOH 
(73 73) (5 06) (7 82) -
1 1 v/v/v, dBuOH/pyndine/H20 
Since the Fmoc-group is removed within 10 min in 25% piperidine m DMF, the p-mtroanilide 
bond cannot be expected to undergo damage These observations prompted us to synthesize 
Fmoc-protected p-nitroanilides with acid-labile side chain protections, see table 2 A strategic 
choice of amino acids was made to cover the whole field of properties 
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Table 3: Physicochemical properties of miscellaneous amino acid p-nitroanilides. 
p-nitroanilide yield % mp °C [α]ρ, с , solv TLC Elemental Analysis (Cale), % 
С Η N S 
Msc-Arg-pNA HCl 
Trt-Ala-pNAa 
Aloc-Val-pNAb 
Z-Phe-pNA 
Z-Arg-pNA HCl* 
2HCI H-Arg-pNA" 
HCl H Tyr(Bzl>pNA 
HCl Η-Val pNA 
HCl H-Nle pNA 
HCl H-Lys(Z)-pNA 
H-Lys(Boc)-pNA 
HCl H-Om(Boc>pNA 
65 
26 
78 
86 
96 
-
-
-
-
-
-
-
foam 
foam 
foam 
163 
174 
255 
foam 
264(dec) 
lyophil 
foam 
94-95 
lyophil 
-12 4, l.MeOH 
no data 
-21 1, l.MeOH 
+76 9, 2, DMF 
-10 7, l.MeOH 
-11 9, 1.ЕЮН 
+71 1, 1,H20 
+71 8, 1, 0 IN HCl 
+ 114 9,1, MeOH 
+71 4, 1, DMF 
+64 9,1, MeOH 
+41 1,0 53, MeOH 
+39 3,1, MeOH 
+30 1,0 76, MeOH 
+33 5, 0 37, MeOH 
0 45 e 
0 70 a 
0 33 e 
0 79 f 
0 35 f 
0716 
-
0 69e 
0 7 1 d 
0 38e 
0 6 1 d 
0 80e 
0 73 d 
0 65 e 
0 68d 
0 74 e 
0 8 I d 
0 74e 
0 72d 
0 73 e 
0 82d 
0 74e 
0 80d 
38 33 5 27 
(38 38) (5 48) 
-
56 27 
-
5 77 
(56 07) (5 96) 
-
51 75 
(51 32) 
34 74 
(35 75) 
60 88 
(60 88) 
48 35 
(48 27) 
50 08 
(50 09) 
54 01 
(54 02) 
55 92 
(55 73) 
51 56 
(5171) 
-
6 05 
(5 88) 
5 11 
(6 00) 
5 22 
(5 21) 
5 87 
(5 89) 
6 48 
(6 30) 
5 72 
(5 79) 
7 15 
(7 15) 
6 70 
(6 89) 
16 21 6 39 
(16 78) (6 40) 
-
12 93 -
(13 08) -
-
15 43 -
(15 05) 
19 36 -
(20 84) -
9 04 
(9 43) -
14 98 -
(15 35) -
-
-
11 96 -
(12 00) -
15 15 -
(15 29) -
13 57 -
(13 79) -
aTrt-Ala-pNA could not be obtained in a pure form, ^Aloc-Val-pNA was synthesized from Aloe-Val OH DCHA, 
cBuOH/AcOH/H20 4 1 1 v/v/v,
 dBuOH/pyndine/H20 1 1 1 v/v/v
 e C H 2 C l 2 ,
 fCH2Cl2/MeOH 98 2 v/v. 
8CH2Cl2/Me0H 95 5 v/v *EA calculated for Z-Arg-pNA HCl 0 SAcOH 0 5BuOH, **EA calculated for 
2HC1 H-Arg-pNA 2H 2 0 
In some instances it is desirable to have at hand a third orthogonality in protective groups For 
this purpose, groups of the allyl-family26 would be very useful We found that p-nitroanilides 
resist the allyl-deprotection conditions (catalytic allyl-transfer to morpholine in THF) 
The usefulness of the tntyl function as α-amino protective group was also investigated in these 
syntheses We attempted the preparation of Trt-Ala-pNA, but the anihde was not obtained in a 
pure form Apart from this, the yield was low and the tedious work-up prevented application of 
the tntyl group Noteworthy is the fact that despite the low nucleophilicity of p-nitroaniline and 
the deactivating electron release of the tntyl group into the carboxyl function, phosphorus 
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oxychlonde is capable to activate the carboxyl group sufficiently to convert the acid into 
nitroanihde See table 3 for miscellaneous p-nitroanihdes. In table 4, NMR data of some 
arginine p-nitroanilides are given 
Table 4: NMR data of some arginine p-nitroanilides. 
derivative solvent signals 
Вое-Arg pNA HCl CD3OD δ = 1 45 (s, 9H, Вое), 1 72 (m, 4Н, ß-CH2/y-CH2), 3 22 (m, 2Н, δ-
СН2), 4 23 (m, IH, α-CH), 7 84/7 86-8 20/8 22 (dd, 4H, arom pNA) 
Z-Arg-pNA HCl CD3OD δ = 1 60 (m, 4H, ß-CH2/y-CH2), 3 20 (m, 2H, 6-CH2), 4 25 (m, IH, α-
CH), 5 10 (s, 2Н, CH2-benzyl), 7 34 (m, 5H, arom benzyl), 7 82/7 84-
8 19/821 (dd, 4H, arom pNA) 
Fmoc-Arg-pNA HCl CD3OD δ = 1 64 (m, 4H, β CH2/y-CH2), 3 20 (m, 2H, 6-CH2), 4 22 (t, IH, 
CH Fmoc), 4 26 (m, IH, α-CH), 4 41 (d, 2H, CH2-Fmoc), 7 29/7 38 
(m, 4H, arom Fmoc), 7 68/7 79 (m, 4H, arom Fmoc), 7 82/7 84-
8 19/821 (dd, 4H, arom pNA) 
Msc-Arg pNA HCl CD3OD δ = 1 69/1 81 (dm, 4H, ß-CH2/v-CH2), 3 07 (s, 3H, CH 3 -S0 2 - Msc), 
3 24 (m, 2H, 6-CH2), 3 49 (m, 2H, -S0 2 -CH 2 - Msc), 4 33 (m, IH, a-
CH), 4 49 (m, 2H, -CH2-0-CO- Msc), 7 86/7 88-8 18/8 20 (dd, 4H, 
arom pNA) 
2HC1 Η-Arg pNA CD3OD δ = 1 72 (m, 2H, у-СН2), 2 04 (m, 2H, ß-CH2), 3 24 (m, 2H, 6-CH2), 
4 24 (m, IH, α-CH), 7 65/7 67 8 14/8 16 (dd, 4H, arom pNA) 
Our special interest concerns derivatives of arginine p-nitroanilide as substrates for serme 
proteases involved in the blood clotting cascade These proteases require basic amino acids in 
their primary specificity pocket with a preference for arginine So arginine p-nitroanilide and 
peptides containing this amino acid derivative are valuable tools in this field of research We 
found that Boc-Arg-pNA HCl is obtainable in good yield when Boc-Arg-OH HCl· is activated 
by phosphorus oxychlonde in pyridine in the presence of p-nitroaniline Even in large scale 
experiments (200 mmol) the obtained yield is high At this scale a very good mixing and 
temperature control are strict requirements for optimal yield We performed these experiments 
in 300 mL of dry pyridine in a 500 mL flask, mechanically stirred and cooled on dry 
ice/acetone (-80°C) so that the temperature lies in between -20°C/-15°C during the addition of 
phosphorus oxychlonde The work-up procedure is as described under general method For 
optimal yield, the EtOAc solution obtained after the extractions is not dried on Na2SC>4 to 
prevent premature crystallization of (Boc-Arg-pNA)2S04 Boc-Arg-pNA HCl is purified by 
the following procedure the crude reaction product is rinsed with diethyl ether (only free p-
nitroanihne is the soluble compound) and subjected to counter current distribution with the 
solvent system BuOH/AcOH/H20 4 1 5 v/v/v (see table 5 for partition coefficients of arginine 
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p-nitroanilides in BuOH/AcOH/H20 4· 1 5 v/v/v) After removal of the Boc-group, 2HC1 H-
Arg-pNA is a versatile synthon for further synthesis of chromogenic substrates The α-amino 
function is selectively deprotonated by addition of a base (DIPEA or TEA) and coupling 
reactions can be carried out in which the guanidinium group is protected by protonation. After 
the end of substrate synthesis no deprotection conditions in HF or other harsh media are 
necessary when the N-terminus and side chains are protected by weak acid-labile protective 
groups (Boc respectively tert -Bu esters and/or -ethers) 
Table 5: Partition coefficients of arginine p-nitroanilides in BuOH/AcOH/f^O 4:1:5 
v/v/v. 
p-nitroanilide 
Вое-Arg pNA HCl 
Z-Arg pNA HCl 
Fmoc-Arg-pNA HCl 
Msc-Arg-pNA HCl 
2HC1 Η-Arg pNA 
Ka 
201 
231 
5 97 
1 00 
0 46 
Rfb 
0 67 
0 69 
0 73 
0 45 
0 38 
apartition coefficient К = g = ( r
m a x
 + 0 5)/(n - r
m a x
 + 0 5), r
m a x
 fraction with highest concentration of 
product, η number of transfers, bBuOH/AcOH/H20 4 1 1 v/v/v 
With the obtained amino acid p-nitroanilides we synthesized in good yield (see scheme 2 A-D) 
the thrombin substrate 2HC1 H-D-Phe-Pip-Arg-pNA27 and the factor Xa substrates Bz-Ile-
Glu(7Pi)-Gly-Arg-pNA HCl28 and Bz-Ile-Glu-Gly-Arg-pNA HCl29 For the former, two 
routes were elaborated 
Boc-D-Phe-OH + HCl H-Pip-OMe -i-> Boc-D-Phe-Pip-OMe -«-> Boc-D-Phe-Pip-N2H3 
-i»-> Boc-D-Phe-Pip-Arg-pNA HCl -ÍV-> 2HC1 H-D-Phe-Pip-Arg-pNA 
Scheme 2A: Synthesis scheme of 2HCI.H-D-Phe-Pip-Arg-pNA; i) DCC/HOBt/NMM in 
EtOAc; ii) N2H4.H2O in MeOH; iii) 1. rerr.-BuONO/HCI at -20°C, 2. DIPEA, 3. 
2HCl.H-Arg-pNA/DIPEA in DMF at 0°C; iv) HCl in EtOAc. 
Z-Glu(OlBu)-OH + HCl H-Gly-OMe -i-> Z-Glu(OlBu)-Gly-OMe -u-> 
Z-Glu(OH)-Gly-OMe -m-> Z-Glu(vPi)-Gly-OMe -iv-> HBr H-Glu(7Pi)-Gly-OMe -v-> 
Boc-Ile-Glu(vPi)-GIy-OMe -v«-> HCl H-Ile-Glu(7Pi)-Gly-OMe -vu-> 
Bz-Ile-Glu(vPi)-Gly-OMe - ш-> Bz-Ile-Glu№)-Gly-OH -ix-> 
Bz-Ile-Glu(vPi)-GIy-Arg-pNA HCl 
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Scheme 2B: Synthesis scheme of Bz-Ile-Glu(YPi)-Gly-Arg-pNA.HCI; i) DCC/HOBt/NMM 
in EtOAc; ii) TFA/H 20 7:3 v/v; iii) piperidine/DCC/HOBt in EtOAc; iv) 33% HBr in 
glacial acetic acid; v) Boc-Ile-ONSu, NMM in DMF; vi) HCl in EtOAc; vii) Bz-CI/DIPEA 
in DMF; viii) dioxane/MeOH/4N NaOH 14:5:1 v/v/v; ix) 2HCI.H-Arg-
pNA/DCC/HOBt/NMM in DMF. 
HCl.H-Ile-OMe -i-> Bz-Ile-OMe -»-> Bz-Ile-N2H3 
HCl.H-Glu(OMe)-OMe -iii-> Trt-Glu(OMe)-OMe -iv-> Trt-Glu(OH)-OMe -v-> 
Trt-Glu№)-OMe -vi-> HCl.H-Glu(yPi)-OMe 
Boc-Gly-ONSu + 2HCl.H-Arg-pNA -vii-> Boc-Gly-Arg-pNA.HCI -viii-> 
2HCl.H-Gly-Arg-pNA 
Bz-I]e-N2H3 -«-> Bz-Ile-GlufrPi)-OMe -x-> Bz-Ile-Glu(YPi)-N2H3 -xi-> 
Bz-Ile-Glu(yPi)-Gly-Arg-pNA.HCl 
Scheme 2C: Synthesis scheme of Bz-Ile-GIu(yPi)-Gly-Arg-pNA.HCl; i) Bz-CI/TEA in 
pyridine; ii) N 2 H 4 . H 2 0 in MeOH; iii) Trt-CI/TEA in pyridine; iv) MeOH/dioxane/lN 
NaOH 36:6:11 v/v/v; v) piperidine/DCC/HOBt in EtOAc; vi) HCl in EtOAc/MeOH 1:2 
v/v; vii) DIPEA in DMF; viii) HCl in AcOH/EtOAc 1:1 v/v; ix) 1. ГегЛ-BuONO/HCl at 
-20°C, 2. DIPEA, 3. HCI.H-Glu(YPi)-OMe/DIPEA in DMF at 0°C; χ) N 2 H 4 . H 2 0 in 
MeOH; xi) 1. <erf.-BuONO/HCI at -20°C, 2. DIPEA, 3. 2HCI.H-GIy-Arg-pNA/DIPEA in 
DMF at 0°C. 
Fmoc-Gly-O-SASRIN -<-> Bz-Ile-Glu(0'Bu)-Gly-0-SASRIN -ii-> 
Bz-Ile-Glu(0'Bu)-Gly-OH -iii-> Bz-Ile-Glu(OtBu)-Gly-Arg-pNA.HCl -iv-> 
Bz-Ue-Glu-Gly-Arg-pNA.HCl 
Scheme 2D: Synthesis scheme of Bz-Ile-Glu-Gly-Arg-pNA.HCl; i) 1. 2 0 % 
piperidine/DMF, 2. Fmoc-Glu(0'Bu)-OH/DIPCDI/HOBt in DMF, 3. 20% piperidine/DMF, 
4. Fmoc-Ile-OPfp in DMF, 5. 20% piperidine/DMF, 6. Bz-CI/DIPEA in DMF; ii) 1% 
TFA in С Н 2 С І 2 ! iii) 2HCl.H-Arg-pNA/DCC/HOBt/DIPEA in DMF; iv) HCl in 
AcOH/EtOAc 1:1 v/v. 
CONCLUSION 
Phosphorus oxychloride in pyridine is a powerful reagent to synthesize orthogonally protected 
amino acidp-nitroanilides. After selective deprotection, the anilides can serve as synthons in 
the synthesis of nearly every chromogenic substrate. 
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EXPERIMENTAL PROCEDURES 
General 
Ή NMR spectra were recorded on Braker AM 100 and AM 400 spectrometers. As an internal 
standard the residual solvent peak was used. Chemical shifts are given in part per million 
(ppm). Optical rotations were measured on a Perkin Elmer 241 Polarimeter in a 10 cm cuvette 
at room temperature. Melting points were determined with a Buchi melting point apparatus 
(Tottoli). Elemental analyses were performed on a Carlo Erba Strumentazione EA MOD 1106. 
TLC was performed on Merck Silicagel 6OF254 plates, and column chromatography on Merck 
Kieselgel 60 70-230 Mesh ASTM. Spots were detected by UV-fluorescence quenching, 
ninhydrine (free amino functions), chlorine/TDM (NH groups), Barton (hydrazides), 
Sakaguchi (arginine residues), Pauly (histidine residues) and sulfuric acid (trityl groups). 
Pyridine was distilled over KOH pellets and stored on 4Â molsieves. p-Nitroaniline was 
purified by dissolution in hot EtOAc, treatment with active carbon, filtration and dilution with 
three volumes of toluene. The crystals formed on cooling were filtered off. 
Z-amino acids were synthesized with benzyloxycarbonyl chloride (Z-CI)30. Boc-amino acids 
were synthesized by the method of Schnabel31. Fmoc-amino acids were synthesized by 
acylation with 9-fluorenylmethyloxycarbonylhydroxysuccinimide (Fmoc-ONSu)32. Trityl 
(Trt)-Ala-OH was synthesized by the method of Barlos33. 2-(Methylsulfonyl)ethyloxycarbonyl 
(Msc)-Arg-OH.HCl was synthesized with Msc-Cl34. The synthesis of allyloxycarbonyl 
(Aloc)-Val-OH was carried out with Aloc-ONSu. 
Phosphorus oxychloride was from Merck. DL-Pipecolic acid was from Janssen, D(-)-tartaric 
acid was from Aldrich. D-Phenylalanine was a generous gift of Dr. J. Kamphuis (DSM 
Research, Geleen, The Netherlands). Z-GIu(OlBu)-OH, Fmoc-Gly-O-SASRIN, Boc-
derivatives of He, Cys(Bzl), GIu(OBzl), His(Bzl) and Fmoc-derivatives of Met, Lys(Boc), 
Glu(O'Bu), Ser(lBu), Tyr('Bu), Cys(Trt), His(Trt) and Asn(Trt) were from Bachern. All other 
chemicals were of reagent grade. 
Syntheses 
General method 
Ρ rotected amino acid (10 mmol) and p-nitroaniline (10 mmol) were dissolved in dry pyridine 
(30 mL). The clear yellowish solution was cooled to -15°C and phosphorus oxychloride (11 
mmol) was added dropwise with vigorous stirring. During the addition the reaction mixture 
coloured deeply red and became turbid in the course of 5 to 20 min. The colour of the 
suspension slowly changed to orange, the reaction being complete after a total of 10 to 30 min 
(monitored by TLC). The reaction mixture was then quenched with crushed ice/water (100 mL) 
and the nitroanilide was extracted into EtOAc (once 50 mL and three times 30 mL). The 
combined EtOAc layers were washed with saturated NaHC03 and NaCl (three times 30 mL 
each). After drying on Na 2 S0 4 (except the arginine derivatives; this is to prevent co-
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crystallization), the EtOAc solution was filtered and evaporated in vacuo. The residue was 
coevaporated successively with toluene, EtOAc and MeOH. 
The p-nitroanilides of: Boc-Gly-OH, Boc-Phe-OH, Boc-Ala-OH, Boc-Tyr(Bzl)-OH, Boc-
His(Bzl)-OH, Z-Phe-OH, Fmoc-Gly-OH, Fmoc-Phe-OH and Fmoc-Met-OH were purified by 
recrystallization from /jo-propyl alcohol. The following p-nitroanilides were purified by 
column chromatography (eluens: СНгС^/МеОН mixtures): Boc-Ile-pNA, Boc-Val-pNA, Boc-
Cys(Bzl)-pNA, Boc-Lys(Z)-pNA, Boc-Glu(OBzl)-pNA, Fmoc-Val-pNA, Fmoc-Lys(Boc)-
pNA, Fmoc-Glu(0'Bu)-pNA, Fmoc-Ser('Bu)-pNA, Fmoc-Tyr('Bu)-pNA, Fmoc-Cys(Trt)-
pNA, Fmoc-His(Trt)-pNA, Fmoc-Asn(Trt)-pNA, Trt-Ala-pNA, and Aloc-Val-pNA. Boe-, Z-
and Fmoc-Arg-pNA.HCl were purified by counter current distribution with BuOH/AcOH/H20 
4:1:5 v/v/v as solvent combination. The water solubility of Msc-Arg-pNA.HCl requires a 
modified work-up procedure. After quenching, the reaction mixture was evaporated in vacuo 
and the oily residue was purified by counter current distribution with the above mentioned 
solvent combination. 
'HNMR data of amino acid p-nitroanilides 
Boc-Gly-pNA (DMSO-d6): δ = 1.33 (s, 9H, Вое); 3.70 (d, 2Н, СН2 (J = 6 Hz)); 7.11 (t, IH, 
NH (J = 6 Hz)); 7.72/7.81-8.12/8.22 (dd, 4H, arom pNA); 10.54 (s, IH, NH). 
Boc-Phe-pNA (CDCI3): δ = 1.43 (s, 9H, Boc); 3.17 (d, 2H, ß-CH2); 4.50 (m, IH, ot-CH); 
7.26 (m, 5H, arom Phe); 7.56/7.58-8.16/8.18 (dd, 4H, arom pNA). 
Boc-Ala-pNA (CDCI3): δ = 1.41 (d, 3H, CH3); 1.48 (s, 9H, Boc); 4.35 (m, IH, a-CH); 
7.64/7.70-8.13/8.21 (dd, 4H, arom pNA). 
Boc-Ile-pNA (CDCI3): δ = 0.96 (t, 3H, 6-CH3); 1.05 (m, 2H, y-CH2); 1.47 (s, 9H, Boc); 
0.93/1.68 (d, 3H, γ-СНз); 1.24/1.97 (dm, IH, ß-CH); 4.14 (m, IH, a-CH); 7.55/7.64-
8.04/8.12 (dd, 4H, arom pNA). 
Boc-Nle-pNA (CDC13): δ = 0.91 (t, 3H, e-CH3); 1.41 (m, 4H, y-CH2/6-CH2); 1.47 (s, 9H, 
Boc); 1.87 (bm, 2H, ß-CH2); 4.22 (m, IH, a-CH); 5.05 (d, IH, NH); 7.57/7.66-8.07/8.16 
(dd, 4H, arom pNA); 9.17 (bs, IH, NH). 
Boc-Val-pNA (CDCI3): δ = 1.01/1.08 (d, 6H, CH3); 1.47 (s, 9H, Boc); 2.24 (m, IH, ß-CH); 
4.08 (m, Ш, a-CH); 7.58/7.65-8.06/8.15 (dd, 4H, arom pNA). 
Boc-Tyr(Bzl)-pNA (CD3OD): δ = 1.40 (s, 9H, Boc); 2.89/3.03 (dm, 2H, ß-CH2); 4.38 (m, 
IH, a-CH); 5.03 (s, 2H, CH2-benzyl); 6.87/6.90-7.15/7.17 (dd, 4H, arom Туг); 7.26-7.40 
(m, 5H, arom benzyl); 7.73/7.75-8.17/8.19 (dd, 4H, arom pNA). 
Boc-Cys(Bzl)-pNA (CD3OD): δ = 1.45 (s, 9H, Boc); 2.72/2.88 (dm, 2H, ß-CH2); 3.77 (s, 
2H, CH2-benzyl); 4.43 (m, IH, a-CH); 7.19-7.31 (m, 5H, arom benzyl); 7.81/7.83-
8.17/8.19 (dd, 4H, arom pNA). 
Boc-Lys(Z)-pNA (CD3OD): δ = 1.44 (s, 9H, Boc); 1.56 (m, 4H, y-CH2/6-CH2); 1.72 (m, 
2H, ß-CH2); 3.13 (m, 2H, e-CH2); 4.16 (m, IH, a-CH); 5.04 (s, 2H, CH2-benzyl); 7.27-
7.35 (m, 5H, arom benzyl); 7.81/7.83-8.18/8.20 (dd, 4H, arom pNA). 
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Boc-His(Bzl)-pNA (CDCI3): δ = 1.45 (s, 9Η, Вое); 3.08 (dd, 2Н, ß-CH2); 4.57 (m, IH, α-
CH); 5.05 (s, 2Н, CH2-benzyl); 6.82 (s, IH, arom His (H5)); 7.05/7.4 (m, 5Н, arom benzyl); 
7.53 (s, IH, arom His (НЗ)); 7.73/8.20 (dd, 4Н, arom pNA). 
Boc-Glu(OBzl)-pNA (CD3OD): δ = 1.44 (s, 9H, Вое); 2.02/2.15 (dm, 2Н, ß-CH2); 2.53 (m, 
2Н, 7-CH2); 4.24 (m, IH, ct-CH); 5.10 (s, 2H, CH2-benzyl); 7.27-7.34 (m, 5H, arom 
benzyl); 7.79/7.81-8.17/8.19 (dd, 4H, arom pNA). 
Fmoc-Gly-pNA (DMSO-d6): δ = 3.86 (d, 2H, CH2 (J = 5.8 Hz)); 4.26 (m, 3H, CH-
Fmoc/CH2-Fmoc); 7.23-7.47 (m, 3H, NH/arom pNA (2H)); 7.69-7.90 (m, 8H, arom Fmoc); 
8.17/8.26 (d, 2H, arom pNA); 10.63 (s, IH, NH). 
Fmoc-Val-pNA (CDCI3): δ = 0.97/1.04 (dd, 6H, r-CH3/y-CH3); 1.68 (m, IH, ß-CH); 4.02 
(m, IH, ct-CH); 4.24 (t, IH, CH-Fmoc); 4.45 (d, 2H, CH2-Fmoc); 5.41 (d, IH, NH); 7.32-
7.79 (2 χ dd/2 χ dt, 8H, arom Fmoc); 7.58/7.67-8.09/8.18 (dd, 4H, arom pNA). 
Fmoc-Phe-pNA (CDCI3/CD3OD 1:1 ν/ν): δ = 3.08 (d, 2H, ß-CH2); 4.20 (t, IH, CH-Fmoc); 
4.38 (d, 2H, CH2-Fmoc); 4.49 (m, IH, ct-CH); 7.23-7.33 (m, 5H, arom Phe); 7.40/7.49-
8.11/8.20 (dd, 4H, arom pNA); 7.58-7.79 (m, 8H, arom Fmoc). 
Fmoc-Met-pNA (CD3OD): δ = 1.98 (m, 2H, ß-CH2); 2.10 (s, 3H, 6-CH3); 2.55 (m, 2H, γ-
CH2); 4.23 (t, IH, CH-Fmoc); 4.38 (m, IH, CH); 4.42 (d, 2H, CH2-Fmoc); 7.29/7.39 (dm, 
4H, arom Fmoc); 7.66/7.79 (dm, 4H, arom Fmoc); 7.82/7.85-8.21/8.23 (dd, 4H, arom 
pNA). 
Fmoc-Lys(Boc)-pNA (CDCI3/CD3OD 1:1 ν/ν): δ = 1.43 (s, 9H, Boc); 1.56 (m, 5H, β-
CH2(lH)/y-CH2/ô-CH2); 1.80 (m, IH, ß-CH2(lH)); 3.07 (m, 2H, e-CH2); 4.29 (t, IH, CH-
Fmoc); 4.40 (d, 2H, CH2-Fmoc); 4.46 (m, IH, ct-CH); 7.35-7.47 (m, 4H, arom Fmoc); 
7.61-7.80 (m, 4H, arom Fmoc); 7.77/7.86-8.16/8.25 (dd, 4H, arom pNA). 
Fmoc-Om(Boc)-pNA (CDCI3/CD3OD 1:1 ν/ν): δ = 0.95 (s, 9H, Boc); 1.01-1.38 (bm, 4H, β-
CH2/y-CH2); 2.83 (m, 2H, Ô-CH2); 3.74 (t, IH, CH-Fmoc); 3.92 (d, 2H, CH2-Fmoc); 3.98 
(m, IH, ct-CH); 6.86 (m, 4H, arom Fmoc); 7.13 (m, 4H, arom Fmoc); 7.27/7.37-7.68/7.77 
(dd, 4H, arom pNA). 
Fmoc-Gtu(0'Bu)-pNA (CDCI3): δ = 1.48 (s, 9H, O'Bu); 2.07 (m, 2H, ß-CH2); 2.46 (m, 2H, 
y-CH2); 4.10 (m, IH, ct-CH); 4.27 (t, IH, CH-Fmoc); 4.40 (d, 2H, CH2-Fmoc); 5.95 (d, 
IH, NH); 7.33-7.80 (m, 8H, arom Fmoc); 7.66/7.75-8.15/8.24 (dd, 4H, arom pNA); 9.41 (s, 
<1H, NH). 
Fmoc-Ser('Bu)-pNA (CD3OD): δ = 1.16 (s, 9H, 'Bu); 3.63 (m, 2H, ß-CH2); 4.23 (t, IH, CH-
Fmoc); 4.41 (m, 3H, ct-CH/CH2-Fmoc); 7.29/7.38 (dm, 4H, arom Fmoc); 7.66/7.79 (dm, 
4H, arom Fmoc); 7.81/7.83-8.20/8.22 (dd, 4H, arom pNA). 
Fmoc-Tyr('Bu)-pNA (CDCI3): δ = 1.25 (s, 9H, 'Bu); 3.05 (d, 2H, ß-CH2); 4.24 (t, IH, CH-
Fmoc); 4.36 (d, 2H, CH2-Fmoc); 4.41 (m, IH, ct-CH); 5.65 (d, IH, NH); 6.81/6.89 (d, 2H, 
arom Tyr); 7.00-7.76 (bm, 12H, arom Tyr(2H)/arom Fmoc(8H)/arom pNA(2H)); 8.01/8.10 
(d, 2H, arom pNA); 8.56 (s, <1H, NH). 
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Fmoc-Cys(Trt)-pNA (CDC13): δ = 2.72 (d, 2H, CH2); 3.88 (m, IH, a-CH); 4.18 (t, IH, CH-
Fmoc); 4.43 (m, 2H, CH2-Fmoc); 7.19 (m, 11H, arom Fmoc(2H)/arom Trt(9H)); 7.39 (m, 
8H, arom Fmoc(2H)/arom Trt(6H)) 7.51 (t, 4H, arom Fmoc); 7.54 (d, 2H, arom pNA); 8.11 
(d, 2H, arom pNA). 
Fmoc-His(Trt)-pNA (CD3OD): δ = 2.94/3.06 (m, 2H, ß-CH2); 4.14 (t, IH, CH-Fmoc); 4.30 
(d, 2H, CH2-Fmoc); 4.54 (m, IH, α-CH); 6.76 (s, IH, arom His(H5)); 7.07 (m, 6H, arom 
Trt); 7.24-7.34 (m, 14H, arom Trt(9H)/arom Fmoc(4H)/arom His(H3)); 7.61 (m, 2H, arom 
Fmoc); 7.76 (m, 4H, arom Fmoc(2H)/arom pNA(2H)); 8.18 (d, 2H, arom pNA). 
Fmoc-Asn(Trt)-pNA (CDCI3/CD3OD 1:1 ν/ν): δ = 2.46 (m, 2H, ß-CH2); 3.83 (t, IH, CH-
Fmoc); 4.01 (d, 2H, CH2-Fmoc); 4.21 (m, IH, a-CH); 6.81-7.05 (m, 19H, arom 
Fmoc(4H)/arom trityl(15H)); 7.11-7.42 (m, 4H, arom Fmoc); 7.28/7.37-7.75/7.84 (dd, 4H, 
arom pNA). 
Trt-Ala-pNA (CDCI3): δ= 1.43 (d, 3H, CH3 (J = 9 Hz)); 3.14 (d, IH, NH (J = 10 Hz)); 3.53 
(q, IH, a-CH); 7.20-7.40 (m, arom trityl/arom pNA (contaminated with Trt-OH)); 8.03/8.13 
(d, 2H, arom pNA); 9.04 (s, IH, NH). 
Aloc-Val-pNA (CDCI3): δ= 1.02/1.09 (dd, 6H, Y-CH3/Y'-CH3); 2.17 (m, IH, ß-CH); 4.22 
(dd, IH, a-CH); 4.60 (d, 2H, -CH2-0-CO- allyl (J = 7.39 Hz)); 5.30 (m, 2H, CH2=C-
allyl); 5.70 (d, <1H, NH (J = 8.3 Hz)); 5.95 (m, IH, =CH~ allyl); 7.58/7.68-8.04/8.13 (dd, 
4H, arom pNA); 9.22 (s, <1H, arom NH). 
HCl.H-Tyr(Bzl)-pNA (CD3OD): δ = 3.12 (dd, 2H, ß-CH2); 4.13 (t, IH, a-CH); 5.00 (s, 2H, 
CH2-benzyl); 6.85/6.94-7.11/7.20 (dd, 4H, arom Tyr); 7.24-7.31 (m, 5H, arom benzyl); 
7.66/7.75-8.12/8.20 (dd, 4H, arom pNA). 
HCl.H-Val-pNA (D20): δ = 0.97/1.03 (dd, 6H, у-СН3/у-СН3); 2.33 (m, IH, ß-CH); 4.45 
(d, IH, a-CH); 7.64/8.19 (dd, 4H, arom pNA). 
HCl.H-Lys(Z)-pNA (CD3OD): δ = 1.46 (m, 4H, у-СН2/6-СН2); 1.88 (m, 2H, ß-CH2); 3.04 
(m, 2H, e-CH2); 3.99 (m, IH, a-CH); 4.90 (s, 2H, CH2-benzyl); 7.19 (m, 5H, arom benzyl); 
7.73/7.82-8.06/8.15 (dd, 4H, arom pNA). 
The synthesis of a thrombin substrate: 2HCl.H-D-Phe-Pip-Arg-pNA (scheme 2A) 
The resolution of DL-pipecolic acid was carried out according to the method of Mende and 
Lukes et al.35 The complex of D(-)tartaric acid/L(-)pipecolic acid ([α]ρ = -20.0° с = 1 H20, mp: 
187°C; Lit: [a]D = -20.2° с = 1 H20, mp: 182°C) was eluted over a Dowex 50WX2 strongly 
acidic (H+-form) ion exchange resin. Pipecolic acid was removed from the resin by elution 
with 2M NH4OH and subsequently lyophilized. Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.18, [a]D 
= -27.1° с = 1 H 2 0 (Lit: [a]D = -26.1° с = 5 H20) mp: 264°C (dec). 
L(-) Pipecolic acid was converted into its methyl ester hydrochloride by the method of Brenner 
and Huber36. Yield: 91%, R[<BuOH/AcOH/H20 4:1:1 v/v/v): 0.20, [a]D = -8.8° с =1 MeOH, 
mp: 164-165°C, "H NMR (D20): δ = 1.33-1.96 (bm, 6H, CH2 (3 χ 2H)); 2.76-3.28 (bm, 
2H, N-CH2); 3.56 (s, 3H, OCH3); 3.75 (m, IH, a-CH). 
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Boc-D-Phe-Pip-OMe 
To a solution of Boc-D-Phe-OH (18 65 g, 70 31 mmol) in EtOAc (250 mL) was added 
HCl H-Pip-OMe (12 68 g, 70 64 mmol, 1 00 eq ), HOBt (10 78 g, 70 38 mmol, 1 00 eq ) 
and NMM (7 73 mL, 70 31 mmol, 1 00 eq ) The reaction mixture was cooled on ice and 
DCC (15 25 g, 73 91 mmol, 1 05 eq ) was added The obtained reaction mixture was stirred 1 
hr at 0°C and 16 hrs at room temperature DCU was filtered off and the filtrate was washed 
with 10% citric acid, saturated NaHC03 and saturated NaCI (three times 75 mL each) After 
drying on Na 2 S0 4 and filtration, the EtOAc solution was evaporated in vacuo The crude 
dipeptide methylester was obtained in 85% yield as an oil and directly used for further 
synthesis R,(CHCl3/MeOH/AcOH 95 20 3 v/v/v) 0 88, Ή NMR (CDCI3) δ = 1 36 (m, 6H, 
CH2-Pip (3 χ 2Η)), 1 42 (s, 9H, Вое), 2 99 (m, 2Н, ß-CH2-Phe), 3 14 (m, 2H, N-CH2-Pip), 
3 60 (bd, IH, NH), 3 71 (s, 3H, OCH3), 4 98 (m, IH, ct-CH-Pip), 5 25 (m, IH, a-CH-Phe), 
7 19-7 28 (m, 5H, arom Phe) 
Boc-D-Phe-Pip-N2H3 
То a solution of Boc-D-Phe-Pip-OMe (16 18 g, 41 19 mmol) m MeOH (200 mL), N2H4 H 20 
(50 mL, 1 03 mol, 24 8 eq ) was added and this reaction mixture was left for three days at 
room temperature The white precipitate was filtered off, dried and recrystallized from iso-
propyl alcohol Yield 10 5 g (65%), Rf(CH2Cl2/MeOH 9 1 v/v) 0 55, [a]D = -78 9° с = 0 54 
DMF, mp 209-212°C, Ή NMR (CD3OD) δ = 1 15-1 38 (m, 6H, CH2-Pip (3 χ 2Η)), 1 44 
(s, 9H, Вое), 2 89-3 04 (m, 2Н, ß-CH2-Phe), 3 26 (m, 2H, N-CH2-Pip), 4 58 (m, IH, α-
CH-Pip), 4 74 (m, IH, α-CH-Phe), 7 20-7 33 (m, 5H, arom Phe) 
Boc-D-Phe Pip-Arg-pNA HCl 
Boc-D-Phe-Pip-N2H3 (7 8 g, 20 51 mmol) was suspended in DMF (150 mL) and cooled to 
-30°C The suspension was acidified with 2 6 M HCl in EtOAc (22 mL, 57 2 mmol, 2 79 eq ) 
and the reaction mixture became clear Then tert -BuONO (2 5 mL, 21 01 mmol, 1 02 eq ) 
was added and the reaction mixture was stirred for 20 min at -25°C The azide-containing 
solution was neutralized by DIPEA (9 mL) and 2HC1 H-Arg-pNA (7 60 g, 20 76 mmol) 
followed by DIPEA (6 mL) were added This reaction mixture was allowed to stand overnight 
at 4°C After evaporation of DMF the residue was diluted with EtOAc/BuOH 1 1 v/v (250 mL) 
and subsequently washed with 10% citric acid, H20, saturated NaHC03 and saturated NaCI (4 
times 100 mL each) The solvent was evaporated in vacuo, the oily residue was crystallized 
from diethyl ether and purified by counter current distribution with the solvent system 
BuOH/AcOH/H20 4 1 5 v/v/v (K = 10 52) Yield 12 61 g (89%), Rf(BuOH/AcOH/H20 4 1 1 
v/v/v) 0 75, [ct]D = -90 0° с = 1 MeOH, mp 110°C (dec ), Ή NMR (CD3OD) δ = 1 33 (s, 
9H, Вое), 1 41 (m, 6Н, СН2-Рір (3 χ 2Н)), 1 67 (m, 2Н, Y-CH2-Arg), 1 86/2 04 (dm, 2H, 
P-CH2-Arg), 2 93-3 04 (bm, 4H, ß-CH2-Phe/N-CH2-Pip), 3 21 (m, 2H, 6-CH2-Arg), 4 54 
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(m, IH, α-CH-Pip); 4.78 (m, IH, cc-CH-Arg); 4.96 (m, IH, α-CH-Phe); 7.21-7.35 (bm, 5H, 
arom Phe); 7.90/7.92-8.20/8.23 (dd, 4H, arom pNA). 
2HCI. H-D-Phe-Pip-Arg-pNA: 
The protected tripeptide was suspended in 2.6 M HCl in EtOAc (200 mL). After stirring for 2 
hours the suspension was filtered and the solid was washed with EtOAc and diethyl ether. 
After drying 2HCl.H-D-Phe-Pip-Arg-pNA was obtained as a pale yellow powder in 96% 
yield. (Purification by counter current distribution with the solvent combination: 
BuOH/AcOH/H20 4:1:5 ν/ν/ν, К = 0.92.) R,(BuOH/AcOH/H20 4:1:1 v/v/v): 0.52, [a]D = 
-128.7°c = 1 H 20, mp: 174°C (dec), Ή NMR (D20): δ = 1.18 (m, 2H, CH2-Pip); 1.44 (m, 
2H, Y-CH2-Arg); 1.63 (m, 4H, CH2-Pip (2 χ 2Н)); 1.88 (m, 2Н, ß-CH2-Arg); 3.13 (m, 2Н, 
ß-CH2-Phe); 3.19 (m, 2H, N-CH2-Pip); 3.21 (m, 2H, 8-CH2-Arg); 4.31 (m, IH, a-CH-Pip); 
4.40 (m, IH, a-CH-Arg); 4.81 (m, IH, a-CH-Phe); 7.26-7.40 (m, 5H, arom Phe); 
7.63/7.65-8.18/8.20 (dd, 4H, arom pNA). 
The synthesis of a factor Xa substrate: Bz-Ile-Glu(yPi)-Gly-Arg-pNA.HCl (scheme 2B) 
Z-Glu(0'Bu)-Gly-OMe: 
To a suspension of Z-Glu(0'Bu)-OH (6.75 g, 20 mmol), HCl.H-Gly-OMe36 (2.79 g, 22 
mmol, 1.1 eq.), HOBt (3.4 g, 22 mmol, 1.1 eq.) and NMM (2.2 mL, 20 mmol) in EtOAc (50 
mL) DCC (4.3 g, 21 mmol, 1.05 eq.) was added at 0°C. This reaction mixture was stirred for 
45 min at 0°C and 2 hrs at room temperature. The white precipitate was filtered off and the 
EtOAc solution was washed successively with 10% citric acid, saturated NaHC03, H20 and 
saturated NaCl (three times 40 mL each). The EtOAc solution was dried on Na2S04, filtered 
and evaporated in vacuo. The resulting oil was diluted with diethyl ether, the precipitate was 
filtered off and the filtrate was evaporated in vacuo. The resulting oil slowly crystallizes. Yield: 
7.71 g (94%), R^CHClj/MeOH/AcOH 95:20:3 v/v/v): 0.78, [a]D = -16.4° с = 1 MeOH, mp: 
59-61°C, Ή NMR (CD3OD): δ= 1.44 (s, 9H, O'Bu); 1.88/2.08 (dm, 4H, ß-CH2/y-CH2-
Glu); 3.71 (s, 3H, OCH3); 3.92 (dd, 2H, CH2-Gly); 4.19 (dd, IH, a-CH-Glu); 5.08 (m, 2H, 
CH2-benzyl); 7.32 (m, 5H, arom benzyl). 
Z-Glu(OH)-Gly-OMe: 
The selective removal of the ten.-butyl ester was carried out following the method described by 
Schnabel et α/.37 
Z-Glu(0'Bu)-Gly-OMe (5.21 g, 12.77 mmol) was dissolved in TFA/H20 7:3 v/v (100 mL) 
and stirred for 4 hrs at room temperature. The reaction mixture was evaporated in vacuo and 
coevaporated with toluene, EtOAc and MeOH. The oily residue was solidified in diethyl ether 
and the crystals were collected. Yield: 4.23 g (94%), Rf(CHCl3/MeOH/AcOH 95:20:3 v/v/v): 
0.57, [a]D= -23.0° с = 1 MeOH, mp: 91°C, Ή NMR (CDCI3): δ= 2.05 (m, 2H, ß-CH2-
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Glu), 2 51 (m, 2H, y-CH2-Glu), 3 72 (s, 3H, OCH3), 4 00 (dd, 2H, CH2-GIy), 4 44 (m, IH, 
ct-CH-Glu), 5 09 (s, 2H, CH2-benzyl), 5 86 (d, IH, NH), 7 33 (m, 5H, arom benzyl) 
Z-Glu(yPi)-Gly-OMe 
Z-Glu(OH)-Gly-OMe (2 16 g, 6 15 mmol) was dissolved in EtOAc (50 mL), HOBt (1 08 g, 
6 64 mmol, 1 08 eq ) and pipendine (0 70 mL, 7 10 mmol, 1 15 eq ) were added After 
cooling at 0°C, DCC (1 37 g, 6 72 mmol, 1 09 eq ) was added and the reaction mixture was 
stirred for 1 hr at 0°C and 16 hrs at room temperature DCU was filtered off and the EtOAc 
solution was successively washed with saturated NaHC03, H20, 2N KHS04, H20, saturated 
NaHC03 and saturated NaCl (three times 20 mL each) After drying on Na2S04, the EtOAc 
solution was filtered and evaporated in vacuo The resulting oil was crystallized from diethyl 
ether Yield 2 39 g (92%), R^CHCl3/MeOH/AcOH 95 20 3 v/v/v) 0 66, [a]D = -12 Io с = 1 
MeOH, mp 75°C, 'H NMR (CD3OD) δ = 1 52-1 65 (bm, 6H, CH2-pipendyl (3 χ 2H)), 
1 95/2 10 (dm, 2H, ß-CH2-Glu), 2 50 (m, 2H, y-CH2-Glu), 3 44/3 51 (dm, 4H, N-CH2-
pipendyl (2 χ 2H)), 3 71 (s, ЗН, OCH3), 3 92 (dd, 2Н, CH2-Gly), 4 21 (m, IH, a-CH-Glu), 
5 10 (m, 2H, CH2-benzyl), 7 34 (m, 5H, arom benzyl) 
Boc-1le-Glu(yPi)-Gly-OMe 
Z-Glu№)-Gly-OMe (18 92 g, 51 7 mmol) was dissolved in AcOH (100 mL) and 33% HBr 
in glacial acetic acid (300 mL) was added The clear yellowish solution was stirred for 35 min 
and then poured into diethyl ether (1800 mL) at -15°C The hygroscopic precipitate was filtered 
off under an atmosphere of N2, washed with diethyl ether and dried over P 2 0 5 The resulting 
foamy hydrobromide was dissolved in DMF (100 mL), neutralized with NMM, and acylated 
by adding Boc-Ile-ONSu^» (18 65 g, 56 86 mmol, 1 10 eq ) and NMM (12 05 mL, 108 6 
mmol, 2 10 eq ) After stirring for 16 hrs at room temperature, the reaction mixture was 
evaporated in vacuo at 40°C and the resulting oil was dissolved in EtOAc (200 mL) The 
EtOAc solution was washed respectively with saturated NaHC03, H20, 10% citric acid, H20 
and saturated NaCl (four times 50 mL each) The clear yellowish EtOAc solution was dried on 
Na2S04, filtered and evaporated in vacuo The residue was solidified in diethyl ether The 
crystals were collected, washed with diethyl ether and dried Yield 20 75 g (80%), 
Rf(CH2Cl2/MeOH 9 1 v/v) 0 55, [a]D = -29 8° с = 0 76 MeOH, mp 91°C, Ή NMR 
(CD3OD) δ = 0 92 (m, 6H, 5-СН3/у-СН3-ІІе), 1 20 (m, 2Н, у-СН2-І1е), 1 45 (s, 9Н, Вое), 
1 56 (bm, 6Н, CH2-piperidyl (3 χ 2Η)), 1 81 (m, IH, ß-CH-Ile), 2 10/2 14 (dm, 2H, ß-CH2-
Glu), 2 56 (m, 2H, Y-CH2-GIU), 3 49 (bm, 4H, N-CH2-pipcridyl (2 χ 2H)), 3 72 (s, ЗН, 
ОСН3), 3 93 (m, IH, a-CH-Ile), 4 06 (m, 2H, CH2-Gly), 4 46 (m, IH, a-CH-Glu) 
Bz-Ile-GluirPi)-Gly-OMe 
Boc-Ile-Glu(YPi)-Gly-OMe (5 0 g, 10 04 mmol) was dissolved in AcOH (10 mL) and 2 3 M 
HCl in EtOAc (50 mL) The solution was stirred for 1 hr in which the deprotection was 
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complete The acid was quenched with tert -BuOH and the solvent was evaporated in vacuo 
The residue was coevaporated with tert -BuOH and MeOH (two times each) The resulting 
hygroscopic foam was dried on NaOH pellets (R,<BuOH/AcOH/H20 4 1 1 v/v/v) 0 51) The 
obtained product was dissolved in DMF (100 mL), neutralized with DIPEA and stirred for 30 
min with Bz-Cl (1 30 mL, 11 2 mmol, 1 12 eq ) and DIPEA (3 90 mL, 22 4 mmol, 2 24 eq ) 
at room temperature The reaction mixture was evaporated in vacuo and the oily residue was 
dissolved in EtOAc (75 mL) The EtÖAc solution was subsequently washed with 2N KHS04, 
H20, saturated NaHC03 and saturated NaCl (three times 20 mL each) The organic phase was 
dried on Na2S04, filtered and evaporated in vacuo The residue was precipitated in diethyl 
ether The resulting solid was filtered off, washed and dried Yield 4 58 g (91%), Rf 
(СНСуМеОН/АсОН 95 20 3 v/v/v) 0 82, Ή NMR (CD3OD) δ = 0 95 (m, 6H, б-СН/,-
СНз-Пе), 1 25 (m, IH, у-СН2-І1е(1Н)), 1 55 (bm, 7H, γ-ΟΗ2-Ι1ε(1Η)/ CH2-piperidyl (3 χ 
2Η)), 1 95 (m, 2H, ß-CH2-Glu(lH)/ß-CH-Ile), 2 10 (m, IH, ß-CH2-Glu(lH)), 2 50 (m, 2H, 
7-CH2-Glu), 3 45/3 55 (dm, 4H, N-CH2-pipendyl (2 χ 2H)), 3 71 (s, 3H, OCH3), 4 00 (dd, 
2H, CH2-Gly), 4 22 (d, IH, a-CH-Ile), 4 50 (m, IH, a-CH-Glu), 7 44-7 56 (m, 3H, arom 
benzoyl), 7 83-7 87 (m, 2H, arom benzoyl) 
Bz-Ile Glu(yPi)-Gly-Arg-pNA HCl 
The foregoing methyl ester was deprotected by the method of Tesser and Balvert-Geers34 Bz-
Ile-Glu(YPi)-Gly-OMe (1 033 g, 2 06 mmol) was dissolved in dioxane (29 mL) and MeOH 
(10 mL) 4N NaOH (2 mL) was added in one portion with vigorous stirring After 63 s the 
reaction mixture was acidified with 3N HCl (3 5 mL) which resulted in a pale white 
suspension The reaction mixture was neutralized with saturated NaHC03 and evaporated in 
vacuo The residue was dissolved in 5% NaHCO3 (10 mL) and washed with EtOAc (three 
times 5 mL) The obtained aqueous layer was acidified with 3N HCl to pH = 3 and the formed 
precipitate was extracted into EtOAc (5 mL) The aqueous phase was extracted with EtOAc 
(two times 5 mL) and the combined organic phases were washed with 2N KHS04 (two times 
5 mL) and saturated NaCl (three times 5 mL) followed by drying on Na2S04 After filtration 
and evaporation in vacuo, Bz-Ile-Glu(7Pi)-GIy-OH could be obtained in 65% yield (0 648 g, 
R,(CHCl3/MeOH/AcOH 95 20 3 v/v/v) 0 48) This product was coupled to H-Arg-pNA HCl 
with DCC/HOBt giving the tetrapeptide nitroanihde as follows 
Bz-Ile-Glu(yPi)-Gly-OH (108 7 mg, 222 7 μπιοί) was dissolved in DMF (5 mL) and 2HC1 H-
Arg-pNA (85 8 mg, 233 8 цтоі, 1 05 eq ), HOBt (37 5 mg, 245 μηιοί, 1 10 eq ) and NMM 
(26 y¡L, 233 8 μπιοί, 1 05 eq) were added The reaction mixture was cooled on ice, DCC (48 2 
mg, 233 8 μπιοί, 1 05 eq ) was added, and stirred for 1 hr at 0°C and 16 hrs at room 
temperature When the reaction was complete, the precipitate was filtered off and the solvent 
was evaporated in vacuo The residue was purified by counter current distribution with 
BuOH/AcOH/H20 4 1 5 v/v/v as solvent combination (K = 5 88) After lyophilization the 
product obtained was a fluffy pale yellow powder Yield 155 2 mg (87%), 
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R,(BuOH/AcOH/H20 4 1 1 v/v/v) 0 69, Ή NMR (CD3OD) δ = О 93 (m, 6H, 6-СН3/т-СН3-
Ile), 1 19 (m, 2H, y-CH2-Ue), 1 47/1 63 (bm, ЮН, ß-CH2-Arg(lH)/Y-CH2-Arg/ß-CH-
Ile/CH2-pipendyl (3 χ 2H», 1 95 (m, 2Н, ß-CH2-Glu(lH)/ß-CH2-Arg(lH)), 2 12 (m, IH, ß-
CHrGlu(lH)), 2 51 (m, 2H, Y-CH2-G1U), 3 22 (m, 2H, 5-CH2-Arg), 3 43/3 52 (dm, 4H, N-
CH2-piperidyl (2 χ 2H)), 3 92 (dd, 2H, CH2-Gly), 4 20 (d, IH, α-CH-Ile), 4 35 (m, IH, α-
CH-Glu), 4 57 (m, IH, α-CH-Arg), 7 34 (bm, 5H, arem benzoyl), 7 87/7 89-8 20/8 22 (dd, 
4H, arom pNA) 
The synthesis of a factor Xa substrate Bz-Ile-Glu(yPi)-Gly-Arg-pNA HCl, an alternative route 
(scheme 2C) 
Boc-Gly-Arg-pNA HCl 
Boc-Gly-ONSu38 (8 30 g, 30 2 mmol) and 2HC1 H-Arg-pNA (11 2 g, 30 5 mmol, 1 01 eq ) 
were dissolved m DMF (250 mL), the reaction was started by the addition of DIPEA (110 
mL, 61 4 mmol, 2 03 eq ) After 2 5 hrs of stirring at room temperature, the solvent was 
removed under reduced pressure The residue was diluted with BuOH (200 mL) and 
subsequently washed with H 20, saturated NaHC03, H 2 0 and saturated NaCl (three times 50 
mL each) After these washings the BuOH phase was evaporated in vacuo and the residue was 
crystallized from diethyl ether Yield 11 1 g (75%), R,<BuOH/AcOH/H20 4 1 1 v/v/v) 0 71, 
second spot Rf 0 52 (HONSu) This crude material was used in the deprotection of the Boc-
function 
2HCI H-Gly-Arg pNA 
Boc-Gly-Arg-pNA HCl (11 1 g, 22 8 mmol) was dissolved in AcOH (100 mL) and 3 5 M 
HCl in EtOAc (100 mL) was added The obtained reaction mixture was stirred for 2 hrs at 
room temperature After acid quenching with tert -BuOH (50 mL), the solvent was removed in 
vacuo The residue was coevaporated with tert -BuOH (once 50 mL) and MeOH (twice 50 mL) 
and was subsequently dissolved in H 2 0 (350 mL) The aqueous solution was washed with 
CH2C12 (three times 50 mL) and diethyl ether (50 mL) and lyophilized This product was 
purified by counter current distribution with BuOH/AcOH/H20 4 1 5 v/v/v as solvent system 
(K = 0 62) Yield 8 19 g (84%), R,(BuOH/AcOH/H20 4 1 1 v/v/v) 0 20, [ct]D = -16 7° с = 
0 71 MeOH, Ή NMR (D20) δ = 1 58 (m, 4H, y-CH2/ß-CH2-Arg), 2 92 (m, 2H, 6-СН2-
Arg), 3 62 (s, 2Н, СНг-Gly), 4 21 (m, IH, α-CH-Arg), 7 27/7 37-7 80/7 89 (dd, 4H, arom 
pNA) 
Bz-Ue-OMe 
H-Ile-OH was converted to the methyl ester hydrochloride by the method of Brenner and 
Huber36 (HCl H-Ile-OMe, Yield quant, R,<BuOH/AcOH/H20 4 1 I v/v/v) 0 65, [a]D = 
+26 3° с = 1 30 H 20, mp 83°C, Lit
39
 [a]D = +26 6° с = 2 H20, mp 100 5-101°C) HCl H-
Ile-OMe (18 2 g, 100 mmol) was dissolved in dry pyridine (250 mL) and cooled on ice To 
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this solution, TEA (31 3 mL, 225 mmol, 2 25 eq ) and Bz-Cl (12 8 mL, 110 mmol, 1 10 eq ) 
were added During the addition of TEA the solution became turbid When the addition of Bz-
CI was complete, the cooling bath was removed and stirring continued for 1 hr The formed 
precipitate was filtered off and pyridine was removed under reduced pressure, and by 
coevaporation with toluene (twice) and MeOH (once) The residue was dissolved in EtOAc 
(300 mL) and subsequently washed with 2N KHS04, H 20, saturated NaHC03 and saturated 
NaCI (three times 75 mL each), dried on Na 2S0 4, filtered and evaporated in vacuo The 
residue was recrystallized from pet ether 60-80 to yield pale yellow crystals Yield 21 1 g 
(85%), Rf(CH2Cl2/MeOH 95 5 v/v) 0 83 (only visible under UV-Iight), [a]D = -2 9° с = 1 04 
MeOH, mp 89°C, Ή NMR (CDC13) 6 = 0 94/1 04 (d, 3H, γ-СНз), 0 89/1 08 (t, 3H, 8-
CH3), 1 26-1 32 (bm, 2H, y-CH2), 2 04 (m, IH, p-CH), 3 76 (s, 3H, OCH3), 4 81 (m, IH, 
a-CH), 6 70 (m, IH, NH), 7 48 (m, 3H, arom benzoyl), 7 78 (m, 2H, arom benzoyl) 
Bz-Ile-N2H3 
Bz-Ile-OMe (10 0 g, 40 2 mmol) was dissolved in MeOH (100 mL) and N2H4 H 2 0 (10 mL, 
200 mmol, 5 eq ) was added This mixture was left for three days at room temperature After 
evaporating in vacuo the residue was crystallized from diwo-propyl ether Yield 9 54 g, 
(95%), R(<CH2Cl2/MeOH 95 5 v/v) 0 25, [a]D = -16 8° с = 1 25 MeOH, mp 195-197°C, 
•H NMR (CDCI3) δ = 0 92 (m, 6H,
 Y-CH3/Ô-CH3), 1 28 (m, 2H, y-CH2), 1 62 (m, IH, β-
СН), 4 43 (m, IH, a-CH), 7 49 (m, 3H, arom benzoyl), 7 79 (m, 2H, arom benzoyl) 
Trt-Glu(OMe)-OMe 
H-Glu(OH)-OH was converted into its dimethyl ester hydrochloride by the method of Brenner 
and Huber36 (HCl H-Glu(OMe) OMe, Yield quant, Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 044, 
[a]D = +25 8° с = 1 83 MeOH) HCl H-Glu(OMe)-OMe (21 2 g, 100 mmol) was dissolved in 
dry pyridine (450 mL) in the presence of TEA (31 3 mL, 225 mmol, 2 25 eq ) which resulted 
in a viscous turbid reaction mixture Trt-Cl (34 8 g, 125 mmol, 1 25 eq ) was added 
portionwise and stirred for additional 2 hrs at room temperature After this period the 
precipitate was filtered off and pyridine was removed under reduced pressure The residue was 
coevaporated with toluene (twice) and MeOH (once) The oily residue was diluted with EtOAc 
(250 mL) and washed with H20, saturated NaHC03 and saturated NaCI (four times 50 mL 
each) After drying on Na2S04 the solvent was evaporated in vacuo leaving a brown-yellow oil 
containing still some solvent A sample (5 g) of the crude reaction product was purified by 
column chromatography on silica gel with CH2C12 as eluens The pure product was a pale 
yellow oil which slowly crystallizes Yield 2 85 g (64%), R,<CH2C12) 0 39, [a]D = +38 6° с 
= 1 66 MeOH, mp 77°C, Ή NMR (CDCI3) δ = 2 12 (m, 2H, ß-CH2), 2 36 (m, 2H, γ-
СН2), 2 62/2 72 (d, IH, NH (J = 10 Hz)), 3 14 (s, 3H, a-OCH3), 3 36 (m, IH, a-CH (J = 
10 Hz)), 3 68 (s, 3H, r-OCH3), 7 15-7 54 (m, 15H, arom tntyl) 
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Trt-Glu(OH)-OMe: 
The hydrolysis of the γ-ester was carried out by a modification of the method described by 
Amiard et al.40 Trt-Glu(OMe)-OMe (37.2 g, 89.2 mmol) was dissolved in MeOH (360 mL) 
and dioxane (60 mL). To the clear solution, IN NaOH (110 mL, 110 mmol, 1.23 eq.) was 
added portionwise, causing a transient turbidity. When the total amount of base was added the 
turbidity remained. After 16 hrs of stirring at room temperature, the reaction mixture was 
neutralized with 1.5N HCl and poured into CH2C12 (500 mL). The organic phase was 
extracted with H 2 0 (twice 75 mL). The aqueous layers were pooled and acidified with 10% 
citric acid to pH = 4. The precipitating oil was extracted into EtOAc (three times 100 mL) and 
subsequently washed with H 2 0 and saturated NaCl (four times 75 mL each). The EtOAc layer 
was dried on Na2S04, filtered and evaporated in vacuo. The residue was a slowly crystallizing 
oil. Yield: 28.5 g (78%), Rf(CH2CI2/MeOH 95:5 v/v): 0.26 (one spot), [ot]D = +41.1° с = 
1.14 MeOH, mp: 120-124°C (lit40: [a]D = +45° с = 2 MeOH, mp: I40-141°C), Ή NMR 
(CDCI3): δ = 2.04 (m, 2H, CH2); 2.46 (m, 2Н, СН2); 3.18 (s, ЗН, ОСН3); 3.45 (t, IH, a-
СН (J = 6.7 Hz)); 7.19-7.53 (m, 15H, arom trityl). 
Trt-Glu(yPi)-OMe: 
Trt-Glu(OH)-OMe (28.0 g, 69.5 mmol), HOBt (11.7 g, 76.4 mmol, 1.10 eq.) and piperidine 
(6.95 mL, 70.2 mmol, 1.01 eq.) were dissolved in EtOAc (400 mL). This mixture was cooled 
on ice and DCC (15.0 g, 72.8 mmol, 1.05 eq.) was added. After stirring of one hour at 0°C 
and 16 hrs at room temperature, DCU was filtered off. The EtOAc solution was subsequently 
washed with H 20, 5% citric acid, H 20, saturated NaHC03, H 2 0 and saturated NaCl (three 
times 75 mL each) and dried on Na2S04. After evaporation in vacuo the obtained residue was 
purified by column chromatography on silica gel with CH2Cl2/Me0H 98:2 v/v as eluens. 
Yield: 27.4 g (84%), R,<CH2Cl2/MeOH 98:2 v/v): 0.52, [ct]D = +56.5° с = 0.84 MeOH, >H 
NMR (CDCI3): δ = 1.61 (m, 6H, CH2-piperidyl (3 χ 2H)); 2.12 (m, 2Н, CH2-Glu); 2.32 (m, 
2H, CH2-Glu); 2.72 (m, IH, NH); 3.15 (s, 3H, OCH3); 3.38-3.57 (bm, 5H, a-CH/N-CH2-
piperidyl (2 χ 2H)); 7.18-7.46 (m, 15H, arom trityl). 
HCl.H-Glu(yPi)-OMe: 
Trt-Glu(yPi)-OMe (25.0 g, 53.2 mmol) was dissolved in MeOH (100 mL) and 3.5 M HCl in 
EtOAc (50 mL, 175 mmol, 3.3 eq.) was added. This reaction mixture was stirred for 40 min at 
room temperature and subsequently evaporated in vacuo. The residue was dissolved in H 20 
(130 mL) and washed with diethyl ether (three times 40 mL). The aqueous solution was 
lyophilized which results in an oil. Yield: 13.1 g (93%), R,<BuOH/AcOH/H20 4:1:1 v/v/v): 
0.46, Rf(CH2Cl2/MeOH 8:2 v/v): 0.52, [a]D = +16.2° с = 3.23 MeOH, Ή NMR (D20): δ = 
1.25 (m, 6H, CH2-piperidyl (3 χ 2Η)); 1.87 (m, 2H, ß-CH2 (J = 6.57 Hz)); 2.29 (m, 2H, γ-
СН2); 3.11 (m, 4Н, N-CH2-piperidyl (2 χ 2Η)); 3.47 (s, ЗН, OCH3); 3.81 (t, IH, o-CH (J = 
6.57 Hz)). 
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Bz-Ile-Glu(yPi)-OMe: 
Bz-Ile-N2H3 (1.99 g, 8.0 mmol) was dissolved in DMF (80 mL). This solution was cooled to 
-20°C and 3.5 M HCl in EtOAc (6.3 mL, 22.1 mmol, 2.75 eq.) followed by terf.-BuONO 
(1.34 mL, 9.6 mmol, 1.2 eq.) were added. After 10 min the azide formation was complete, 
and the reaction mixture was neutralized by the addition of DIPEA (3.78 mL, 22 mmol). To 
this solution, HCl.H-Glu(YPi)-OMe (2.14 g, 8.09 mmol, 1.01 eq.) followed by DIPEA (1.38 
mL, 8.0 mmol) were added. The obtained reaction mixture was allowed to react at 0°C at pH = 
7 to 8 (DIPEA was added during several time intervals to adjust the pH value). After 16 hrs, 
DMF was removed under reduced pressure and the residue was dissolved in EtOAc (100 mL). 
This solution was subsequently washed with H 20, 2N KHS04, H 2 0, saturated NaHC03, 
H20 and saturated NaCl (three times 30 mL each). The EtOAc solution was dried on Na2S04, 
filtered and evaporated in vacuo. The residue was recrystallized from diiio-propyl ether. Yield: 
2.70 g (76%), R,<CH2Cl2/MeOH 95:5 v/v): 0.25, R[(CH2Cl2/MeOH 92:8 v/v): 0.40, [a]D = 
-21.9° с = 1.25 MeOH, mp: 78-82°C, 'H NMR (CD3OD): δ = 0.53 (t, 3H, 5-CH3-Ile); 0.65 
(d, 3H, 7-CH3-Ile); 0.88 (m, IH, у-СН2-І1е); 1.04/1.14 (dm, 6H, CH2-piperidyl (3 χ 2H)); 
1.23 (m, IH, Y-CH2-Ile); 1.59 (m, 2H, ß-CH-Ile/ß-CH2-Glu(lH)); 1.83 (m, IH, ß-CH2-
Glu(lH)); 2.06 (m, 2H, y-CH2-Glu); 2.94/3.07 (dm, 4H, N-CH2-piperidyl (2 χ 2Η)); 3.32 
(s, ЗН, OCH3); 4.03 (d, IH, a-CH-Ue); 4.12 (dd, IH, a-CH-Glu); 7.06 (m, 2H, arom 
benzoyl); 7.13 (m, IH, arom benzoyl); 7.46 (m, 2H, arom benzoyl). 
Bz-Ile-Glu(-fPi)-N2H3 : 
Bz-Ile-Glu(yPi)-OMe (1.50 g, 3.37 mmol) was dissolved in MeOH (40 mL) and N2H4.H2'0 
(0.84 mL, 16.9 mmol, 5.0 eq.) was added; the obtained reaction mixture stands for three days 
at room temperature. After this period, the reaction mixture was evaporated to dryness and the 
residue was recrystallized from diwo-propyl ether. Yield: 1.23 g (82%), R((CH2Cl2/MeOH 
92:8 v/v): 0.23, [a]D = -24.1° с = 0.71 MeOH, mp: 171°C, Ή NMR (CD3OD): δ = 0.64 (t, 
ЗН, δ-СНз-Пе); 0.70 (d, ЗН,
 Y-CH3-Ile); 0.99 (m, IH, γ-Οί2-Ι1ε); 1.17/1.29 (dm, 6Η, СН2-
piperidyl (3 χ 2Н)); 1.36 (m, IH, у-СН2-І1е); 1.69 (m, 2H, ß-CH-Ile/ß-CH2-Glu(lH)); 1.78 
(m, IH, ß-CH2-Glu(lH)); 2.16 (m, 2H, y-CH2-Glu); 3.06/3.18 (dm, 4H, N-CH2-piperidyl 
(2 χ 2H)); 4.13 (m, 2H, a-CH-Ile/a-CH-GIu); 7.18 (m, 2H, arom benzoyl); 7.26 (m, IH, 
arom benzoyl); 7.61 (m, 2H, arom benzoyl). 
Bz-lle-Glu(yPi)-Gly-Arg-pNA.HCl: 
Bz-Ile-Glu(yPi)-N2H3 (1.0 g, 2.25 mmol) was dissolved in DMF (25 mL) and cooled to 
-20°C. At this temperature 3.5 M HCl in EtOAc (1.78 mL, 6.23 mmol, 2.77 eq.) followed by 
/erf.-BuONO (0.32 mL, 2.70 mmol, 1.20 eq.) were added. After 10 min azide formation was 
complete and the reaction mixture was neutralized by the addition of DIPEA (1.06 mL). To this 
neutral solution, 2HCl.H-Gly-Arg-pNA (0.954 g, 2.25 mmol, 1.0 eq.) and DIPEA (0.39 mL, 
2.23 mmol, 1.0 eq.) were added and the obtained reaction mixture was allowed to react at 0°C 
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for 16 hrs When coupling was complete, the reaction mixture was evaporated in vacuo and the 
residue was purified by counter current distribution with the solvent system BuOH/AcOH/H20 
4 1 5 v/v/v (K = 4 18) Yield 1 69 g (94%) R,<BuOH/AcOH/H20 4 1 1 v/v/v) 0 54, [a]D = 
-31 7" с = 0 56 MeOH, Ή NMR (CD3OD) 8 = 0 93 (t, 3H, 5-CH3-Ile), 0 99 (d, 3H, y-CH3-
Ile), 1 28/1 71 (dm, 2H, у-СН2-І1е), 1 45/1 56 (dm, 6H, CH2-pipendyl (3 χ 2H)), 1 63 (m, 
3H, ß-CH-Ile(lH)/Y-CH2-Arg), 1 87/2 15 (dm, 2H, ß-CH2-Arg), 2 03 (m, 2H, ß-CH2-Glu), 
2 52 (m, 2H,
 Y-CH2-Glu), 3 21 (m, 2H, 5-CH2-Arg), 3 36/3 43 (m, 4H, N-CH2-pipendyl (2 
χ 2H)), 3 94 (s, 2H, CH2-Gly), 4 35 (m, 2H, a-CH-Ile/a-CH-Glu), 4 55 (m, IH, a-CH-
Arg), 7 43-7 53 (m, 3H, arom benzoyl), 7 84-7 89 (m, 4H, arom benzoyl(2H)/arom 
pNA(2H)), 8 16/819 (d, 2H, arom pNA) 
The nnthesis of a factor Xa substrate Bz-Jle-Glu-Gly-Arg pNA HCl (scheme 2D) 
Bz-Ile-Glu(0'Bu)-Gly-OH 
Starting from Fmoc-Gly-O-SASRINKi, Bz-Ile-Glu(OtBu)-Gly-0-SASRIN was synthesized 
following the Fmoc/tert -Bu protocol Fmoc deprotection was carried out in 25% 
pipendine/DMF (three times 6 mm) Fmoc-Glu(OlBu)-OH was coupled with N,N'-di(jo-
propylcarbodnmide/HOBt, Fmoc-Ile was coupled as the corresponding HOPfp42 ester and the 
benzoyl group was introduced via Bz-Cl/DIPEA The resulting protected tripeptide was split 
off in 1% TFA/CH2C12, TFA was neutralized with 5% DIPEA/CH2CI2 (The treatment with 
acid was carried out 6 times for 10 min ) The resulting CH2C12 solution was evaporated in 
vacuo The obtained residue was acidified with 2N KHS04 to pH = 3 and extracted into 
EtOAc The obtained EtOAc solution was washed with 2N KHS04 and saturated NaCl The 
EtOAc solution was dried on Na 2S0 4, filtered and evaporated m vacuo The protected 
tnpeptide was obtained as a white foam Yield 62%, Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 85, 
[<x]D = -27 8° с = 0 49 MeOH, Ή NMR (CD3OD) 5 = 0 92/1 01 (m, 6H, у-СН3/6-СН3-Пе), 
1 30 (m, IH, ß-CH-Ile), 1 39 (s, 9H, O'Bu), 1 63 (m, IH, 7-CH2-Ile), 1 95 (m, 2H, ß-CH2-
Glu), 2 12 (m, IH, Y-CH2-Ile), 2 37 (t, 2H, y-CH2-Glu), 3 85/4 01 (dd, 2H, CH2-Gly), 4 42 
(d, IH, α-CH-Ile), 4 48 (m, IH, ct-CH-Glu), 7 44/7 53 (m, 3H, arom benzoyl), 7 84 (m, 2H, 
arom benzoyl) 
Bz-lle-Glu-Gly-Arg-pNA HCl 
Bz-Ile-Glu(0'Bu)-Gly-OH (0 4491 g, 0 942 mmol) was dissolved in DMF (10 mL) To this 
solution was added 2HC1 H-Arg-pNA (0 349 g, 0 951 mmol, 1 01 eq), HOBt (0 158 g, 1 04 
mmol, 1 10 eq ), DIPEA (0 172 mL, 0989 mmol, 1 05 eq ) and finally, to the ice cooled 
solution, DCC (0 204 g, 0 989 mmol, 1 05 eq ) This reaction mixture was stirred for one 
hour at 0°C and 16 hrs at room temperature The formed white precipitate was filtered off, the 
filtrate was evaporated in vacuo at 40°C The oily residue was dissolved in EtOAc/AcOH (10 
mL 1 1 v/v) followed by the addition of 2 3 M HCl in EtOAc (10 mL) This reaction mixture 
was stirred for 3 hrs The deprotection was followed with TLC, and was found to be complete 
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after this time The acidic reaction mixture was quenched by the addition of ten -BuOH (5 
mL), evaporated in vacuo, coevaporated with tert -BuOH (once 5 mL) and with toluene (twice 
5 mL) The crude reaction product was purified by counter current distribution (solvent 
combination BuOH/AcOH/H20 4 1 5 v/v/v (K = 2 97)) After work up the product was 
lyophihzed Yield 0 53 g, (77%), R,(BuOH/AcOH/H20 4 1 1 v/v/v) 0 70, [a]D = -27 6° с = 
0 145 MeOH, Ή NMR (CD,OD) δ = 0 94 (t, 3H, 5-CH3-Ile), 1 00 (d, 3H, -j-CHj-Ile), 1 29 
(m, 2H, y-CH2-Ile), 1 64 (m, 4H, ß-CH2/y-CH2-Arg), 1 96 (m, 2H, ß-CH2-Glu), 2 04 (dm, 
IH, p-CH-Ile), 2 36 (t, 2H, Y-CH2-G1U), 3 20 (m, 2H, o-CH2-Arg), 3 92 (dd, 2H, CH2-Gly), 
4 29 (t, IH, a-CH-Glu), 4 38 (d, IH, a-CH-Ile), 4 54 (m, IH, a-CH-Arg); 7 41/7 53 (m, 
3H, arom benzoyl), 7 82 (m, 4H, arom benzoyl(2H)/arom pNA(2H)), 8 16 (dd, 2H, arom 
pNA) 
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CHAPTER 2 
THE SYNTHESIS OF CHROMOGENIC SUBSTRATES DERIVED 
FROM MZ-Aib-Arg-pNA.HCl AND 2HCl.H-D-Phe-Pip-Arg-pNA 
ABSTRACT 
A series of 25 peptide p-mlroanihdes was synthesized by classical solution methods As lead 
structures SQ68 (MZ-Aib-Arg-pNA HCl) and S2238 (2HCl.H-D-Phe-Pip-Arg-pNA) were 
used These thrombin substrates were used as a starting point to arrive at selective thrombin 
substrates with modified kinetic parameters In our method for the continuous registration of 
thrombin formation in plasma', we need selective thrombin substrates which show moderate 
binding affinities (high Km) and low turnover numbers (low kcal) With the introduction of 
specific structure modifications we tried to alter the kinetic data in the required direction. From 
specific thrombin inhibitors, crystal structures of thrombin-complexes with active-site-directed 
inhibitors, and homology model-building-studies of thrombin and thrombin-like serine 
proteases, insight was obtained concerning the nature of the structure modifications leading to 
the before mentioned criteria This chapter describes the synthesis of these substrates, their 
biochemical properties are discussed in chapter 3. 
INTRODUCTION 
Several serine proteases, e.g thrombin, factor Xa and other coagulation factors, hydrolyse 
peptide bonds at the carboxyl group of basic amino acids, preferentially arginine. To meet the 
high specificity of a peptide sequence for the target enzyme, the amino acid sequence 
surrounding the bond cleaved m the natural substrate constitutes an important lead structure 
Fibrinogen is the natural substrate of thrombin. Thrombin hydrolyses only four Arg/Lys-Xaa 
bonds of the 376 Arg/Lys-Xaa bonds present2 This remarkable specificity has been localized 
in the first 51 amino acids of the Aoc-chain3 In this region the amino acids 1-23 are most 
important4 Structure-activity relationship-studies showed that the tripeptide Phe-Val-Arg, 
corresponding to amino acids Phe8, Val 15 and Arg 16, contains the high affinity sequence 
towards thrombin5 This sequence was used as lead structure to obtain highly specific thrombin 
substrates which resulted in the synthesis of Bz-Phe-Val-Arg-pNA6 Replacing Bz-Phe by Bz-
D-Phe or H-Phe in this substrate at position P37 resulted in a dramatical drop in hydrolysis rate 
However, when H-D-Phe is incorporated in this position no significant reduction in hydrolysis 
rate was observed8 In many thrombin susceptible substrates, the sequence Pro-Arg is present, 
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what means that Pro-Arg seems to be an important specificity sequence9. These two 
observations resulted in the development of the highly specific thrombin substrate H-D-Phe-
Pip-Arg-pNA (S2238)10, see scheme 1 
H-Ala-Asp-Ser-Gly-Glu5-Gly-Asp-/7ii?-Leu-Ala10-
-GIu-Gly-Gly-Gly-Va/15-Arg-Gly-Pro-Arg-Val20-
-Val-Glu-Arg-OH 
Bz-Phe-Val-Arg-pNA Tos-Gly-Pro-Arg-pNA 
H-D-Phe-Pip-Arg-pNA 
Pro 
D-Phe analogues 
- Arg analogues 
- neutral side chains: 
ketomethylene 
chloromethylketone 
aminoboronic acid 
aldehyde 
aminophosphonic acid 
Scheme 1: Design scheme of highly selective thrombin substrates/inhibitors derived from 
fibrinogen Aol-23 as lead structure. 
This structure was used as lead structure for the development of several highly specific 
thrombin inhibitors Derivatives of this structure containing aldehyde-1 ', chloromethylketone-
12
, aminoboronic acid-n, ketomethylene-14 and aminophosphonic acid15 functions at the Pi 
residue were described as potent and specific transition-state analogue inhibitors of thrombin 
All these inhibitors contain an arginine in the Pi position corresponding to the primary 
specificity of thrombin 
Recent research shows that inhibitors derived from H-D-Phe-Pip-Arg containing an amino acid 
at position Pi with a neutral side chain, are fairly good inhibitors that show enhanced 
selectivity towards thrombin. Thrombin inhibitors in which the positively charged side chain of 
arginine is replaced by a neutral side chain, containing aldehyde-16, aminoboronic acid-17 and 
aminophosphonic acid l8 functions have been described 
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This result is somewhat surprising, because it was believed that electrostatic interaction 
between the positively charged guanidino group of inhibitors and substrates, and the negatively 
charged Asp 189 side chain in the primary specificity pocket of thrombin is essential for 
complex formation19 The crystal structure of human α-thrombin complexed with H-D-Phe-
Pro-Arg-CH2Cl showed that the active-site consists of two important binding regions the 
hydrophobic binding pocket, S2 subsite, which interacts preferentially with proline residues, 
and the aryl-binding pocket (S3) in which aromatic stacking interactions (D-phenylalanine) are 
of major importance for strong binding affinity20 The fact that inhibitors containing the H-D-
Phe-Pro sequence with a modified Pi residue still bind to thrombin can be attributed to these 
binding interactions Also, the inhibitors with neutral side chains at the Pi position show 
enhanced selectivity towards thrombin compared to other serine proteases with an arginine as 
primary specificity Comparison of the Si binding pockets of thrombin, trypsin and plasmin 
showed that the S l binding pocket of thrombin is the most hydrophobic one This explains 
why a neutral side chain at Pi would be better accommodated by thrombin than by trypsin or 
plasmin The improvement of selectivity is paid by a decrease of potency as a result of a loss in 
electrostatic binding interactions with Aspl8917c 
These findings motivated us to synthesize pNA-substrates with maintenance of the H-D-Phe-
Pip(Pro)~ sequence in which the Pi amino acid residue is varied, see table 1 
Another starting point was MZ-Aib-Arg-pNA (SQ68) synthesized by Serbio Laboratories, to 
arrive at selective substrates for the assay of coagulation enzymes21 
This substrate has not the optimal structural elements at position P2 and P3 for interaction with 
thrombin We started an investigation into a structure-activity relationship to obtain substrates 
selective for thrombin, in which occur the optimal structural elements of dipeptides, N-
terminally modified as an eventuality 
In this study the amino acid at Pi was always an arginine residue to ensure optimal interaction 
with the Si specificity pocket The amino acid residue at P2 was systematically changed, 
incorporating glycine, alanine and valine with observation of the unnatural antipodes of the 
latter two This results in a gradual increasing occupancy of the hydrophobic binding pocket, 
leading to more important interaction and thus expectedly higher suitability for thrombin The 
Рз modification was either omitted (a free N-terrrunus) or modified by a malonic acid derivative 
in which the methylene protons were exchanged against methyl- or ethyl groups This resulted 
in fairly apolar aliphatic side chains which have not the optimal interaction with the aryl-binding 
site of thrombin To achieve better interaction possibilities with the aryl-binding site, the N-
terminus was modified by the introduction of an aromatic function For this purpose the p-
toluenesulfonyl- and ß-naphtalenesulfonyl group were chosen (see table 1) From modeling 
studies22 and homology model-building23 it has been concluded that the ß-naphtalenesulfonyl 
function interacts with thrombin in a highly specific manner, whereas interaction with other 
senne proteases is minimal The /?-toluenesulfonyl group showed the same binding interactions 
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as the ß-naphtalenesulfonyl moiety, albeit to a somewhat lesser extent24. These findings were 
confirmed by X-ray studies of thrombm-complexes formed with active-site-directed inhibitors 
containing these structural elements25. 
Table 1: Substrates of the type H-D-Phe-Y-X-pNA and Y-X-Arg-pNA with S2238 
respectively SQ68 as lead structures. 
H-D-Phe-Y-X-pNA 
MZ 
MMZ 
DMMZ 
DEMZ 
PNS 
pTS 
MZ 
MMZ 
DMMZ 
MZ 
MZ 
MZ 
D-Ala 
Val 
D-Val 
Code 
Pip Lys 
Pip Om 
Pip Glu 
Pip Nie 
Pro Lys 
Pro Nie 
Y-X-Arg-pNA 
l a 
l b 
l c 
Id 
2a 
2b 
Code 
Gly 
Gly 
Gly 
Gly 
Gly 
Gly 
Ala 
Ala 
Ala 
3a 
3b 
3c 
3d 
3e 
3f 
4a 
4b 
4c 
5a 
6a 
7a 
Derived from 
H-D-Phe-Pip-Arg-pNA 
H-D-Phe-Pro-Arg-pNA 
Derived from 
H-Gly-Arg-pNA 
H-Ala-Arg-pNA 
H-D-Ala-Arg-pNA 
H-Val-Arg-pNA 
H-D-Val-Arg-pNA 
Code 
1 
Code 
3 
Unprotected amino functions are suitably protonated (HCl) to give neutral solutions in plain water 
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METHODS OF SYNTHESIS 
52238 derived substrates (scheme 2) The dipeptide ester Boc-D-Phe-Pip-OMe was prepared 
from Boc-D-Phe-OH and HCl Η-Ρφ-ОМе using DCC/HOBt in EtOAc as solvent in the 
presence of 1 eq DIPEA as described by König and Geiger26 
In this strategy the α-amino function was protected by a Boc-group, this enables a single 
deprotection step of the protected tnpeptide p-nitroanilide (vide infra) for conversion into the 
desired substrate As carboxyl protection, a methyl ester was used The methyl ester can be 
easily converted into the corresponding hydrazide 
After work-up the dipeptide methyl ester was obtained as a colourless oil in 74% yield and 
directly used for further synthesis Its conversion into the protected dipeptide hydrazide was 
carried out by treatment with 5 eq of N2H4 H2O in MeOH for three days at room temperature 
The product was obtained as white crystals after recrystallization from wo-propyl alcohol in 
70% yield 
Hydrazide derivatives give access to azides which can be coupled to amino components via the 
azide method as described by Curtius27 This is one of the earliest peptide coupling methods 
described in the literature Its value has been found in the fact that acylpeptides can be coupled 
without or with a minimal degree of racemization 
The conversion of Boc-D-Phe-Pip-N2H3 to its corresponding azide was performed by tert -
butyl nitrite in the presence of a strong mineral acid (HCl in EtOAc) in DMF as solvent at 
-20°C as described by Honzl and Rudinger28 They studied the conditions in which the 
unwanted Curtius rearrangement is largely suppressed and the desired coupling reaction is 
favoured 
Boc-D-Phe-OH + HCl H-Pip-OMe -i-> Boc-D-Phe-Pip-OMe -n-> Boc-D-Phe-Pip-N2H3 
-ш-> Boc-D-Phe-Pip-Arg-pNA HCl -iv-> 2HC1 H-D-Phe-Pip-Arg-pNA (1) 
Boc-D-Phe-Pip-Lys(Boc)-pNA 2HC1 H-D-Phe-Pip-Lys-pNA (la) 
Boc-D-Phe-Pip-Orn(Boc)-pNA 2HC1 H-D-Phe-Pip-Om-pNA (lb) 
Boc-D-Phe-Pip-Glu(0'Bu)-pNA HCl H-D-Phe-Pip-Glu-pNA (lc) 
Boc-D-Phe-Pip-Nle-pNA HCl H-D-Phe-Pip-Nle-pNA (Id) 
(Scheme 2 Continued on the next page) 
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Boc-D-Phe-ONSu + H-Pro-OH -v-> Boc-D-Phe-Pro-OH -vi-> 
Boc-D-Phe-Pro-Arg-pNA HCl -iv-> 2HC1 H-D-Phe-Pro-Arg-pNA (2) 
Boc-D-Phe-Pro-Lys(Boc)-pNA 2HC1 H-D-Phe-Pro-Lys-pNA (2a) 
Boc-D-Phe-Pro-NIe-pNA HCl H-D-Phe-Pro-NIe-pNA (2b) 
Scheme 2: Synthesis scheme of substrates derived from S2238 as lead structure; i) 
DCC/HOBt/DIPEA in EtOAc; ii) N 2 H 4 . H 2 0 in MeOH; iii) 1. /er/.-BuONO/HCI at -20°C, 
2. DIPEA, 3. H-Xaa-pNA/DIPEA in DMF at 0°C; iv) HCl in AcOH/EtOAc 1:1 v/v; v) 
N a H C 0 3 in H2O/CH3CN 1:1 v/v; vi) DCC/HOBt/DIPEA/H-Xaa-pNA. 
This coupling procedure was used to come to five fully protected tnpeptides The side chain 
functionalities were protected with acid-labile protective groups The ω-amino function of 
lysine and ornithine was protected by a Boc-group The carboxyl side chain of glutamic acid 
was protected as a tert -butyl ester The guanidino function of arginine was protected by 
protonation only, to avoid harsh deprotection conditions when the usual protective groups 
would be used The α-ammo function is selectively liberated from the dihydrochlonde by 
addition of DIPEA due to its lower pK
a
 value, the guanidino function is the stonger base 
Boc-D-Phe-Pip-N3 was synthesized in situ and coupled to the amino acid p-nitroanilide in 
DMF at 0°C during 16 hrs at neutral pH The amino components were added as hydrochlorides 
(2HCI H-Arg-pNA, HCl H-Nle-pNA) or as free amines (H-Lys(Boc)-pNA, H-Orn(Boc)-
pNA and H-Glu(O'Bu)-pNA) The latter three were obtained from their corresponding Fmoc-
protected derivatives Fmoc-removal was carried out with 20% pipendine in DMF for 30 min 
at room temperature After removal of the solvent and coevaporation with DMF to remove 
excess pipendine, the p-nitroanilides were used for synthesis without further purification 
When the acylation was complete, DMF was evaporated in vacuo and the product was purified 
by column chromatography Arginine derivatives were purified by counter current distribution 
after Craig 2 9 · 3 0 The protected tnpeptides were obtained as amorphous products in yields of 
62-95% 
Final deprotection was with HCl in EtOAc Purification by counter current distribution and 
lyophilization from H 2 0 gave the products as off-white fluffy powders in 46-94% yield 
The derivatives in which pipecolic acid is replaced by a proline residue were synthesized as 
follows H-Pro-OH was acylated by Boc-D-Phe-ONSu in H20/CH3CN 1 1 v/v in the presence 
of 2 25 eq NaHCC<3 The dipeptide acid was obtained as a white solid in 72% yield Since 
acylpeptides with a carboxy-terminal proline can be coupled without racemization, the amino 
acid p-nitroanilides were acylated directly with Boc-D-Phe-Pro-OH using DCC/HOBt The 
coupling reactions were carried out in EtOAc as solvent (DMF was used for arginine p-
nitroamhde, work-up was performed in BuOH after evaporation of DMF) After work-up by 
aqueous extraction, the product was purified by column chromatography The arginine 
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derivative was purified by counter current distribution. Drying of compounds with protonated 
guanidino functions is not recommended: premature crystallization of sulphate salts can occur 
and appears as a source of unnecessary product loss. 
The protected tripeptides were obtained as amorphous products in 55-90% yield. After 
deprotection, the unprotected compounds were purified by counter current distribution, the 
lyophilized products were off-white fluffy materials and were obtained in 75-91% yield. 
SQ68-derived substrates: (scheme 3): Boc-Xaa-Arg-pNA.HCl dipeptides were synthesized 
from 2HCl.H-Arg-pNA by acylation with Boc-Xaa-ONSu in DMF as the solvent in the 
presence of 1 eq. DIPEA during 16 hrs at room temperature. Boc-Gly-OH was coupled using 
DCC/HOBt to H-Arg-pNA.HCl. When the reactions were complete, DMF was evaporated in 
vacuo and the residue was dissolved in BuOH and subsequently washed with aqueous acid and 
-base. The BuOH solution was not dried but directly evaporated to dryness. The obtained 
products were purified by counter current distribution in 70-89% yield. The work-up and 
purification of Boc-Gly-Arg-pNA.HCl was slightly different due to the substantial water 
solubility. The reaction mixture was concentrated and the crude dipcptide was directly purified 
by counter current distribution, yield: 88%. The five dipeptides were lyophilized from AcOH to 
obtain amorphous powders. 
After Boc-removal and subsequent purification, the α-amino function was modified by a 
malonic acid derivative. These couplings were carried out by DCC/HOBt (or the ONSu ester of 
MZ) in DMF in the presence of 1 eq. DIPEA. The products were purified by counter current 
distribution and lyophilized from H2O which resulted in off-white fluffy powders, yield: 34-
74%. The ß-naphtalenesulfonyl- and p-toluenesulfonyl modifications were performed with the 
acid chlorides using dry pyridine in the presence of 2 eq. DIPEA during 16 hrs at room 
temperature. After removal of the solvent, the products were purified by counter current 
distribution and lyophilized from AcOH, yield: 59 respectively 63%. 
Boc-Gly-OH + 2HCl.H-Arg-pNA -i-> Boc-Gly-Arg-pNA.HCl -/<-> 2HCl.H-Gly-Arg-pNA(3) 
-ш-> MZ-Gly-Arg-pNA.HCl (3a) 
MMZ-Gly-Arg-pNA.HCl (3b) 
DMMZ-Gly-Arg-pNA.HCl (3c) 
DEMZ-Gly-Arg-pNA.HCl (3d) 
-iv-> ßNS-Gly-Arg-pNA.HCl (3e) 
pTS-Gly-Arg-pNA.HCl (3f) 
(Scheme 3: Continued on the next page) 
65 
Chapter 2 
Boc-Xaa-ONSu + 2HC1 H-Arg-pNA -v-> Boc-Xaa-Arg-pNAHCl -ÍÍ-> 2HC1 H-Xaa-Arg-pNA 
--> 2HC1 H-AIa-Arg-pNA(4) -ш-> MZ-Ala-Arg-pNA HCl (4a) 
MMZ-Ala-Arg-pNA HCl (4b) 
DMMZ-Ala-Arg-pNA HCl (4c) 
--> 2HC1 H-D-Ala-Arg-pNA(5)-Hi-> MZ-D-Ala-Arg-pNA HCl (Sa) 
-> 2HC1 H-Val-Arg-pNA(ó) -ш-> MZ-Val-Arg-pNA HCl (6a) 
-> 2HC1 H-D-Val-Arg-pNA(7)-iii-> MZ-D-Val-Arg-pNA HCl (7a) 
Scheme 3: Synthesis scheme of substrates with SQ68 as lead structure; i) 
DCC/HOBt/NMM in DMF, ii) HCl in EtOAc/AcOH 1:1 v/v, iii) malonic acid 
monomethyl ester/DCC/HOBt/DIPEA (or MZ-ONSu/DIPEA) in DMF, iv) arylsulfonyl 
chloride/DIPEA in dry pyridine, v) DIPEA in DMF. 
CONCLUSION 
A series of 25 peptide p-nitroanihdes with 2HC1 H-D-Phe-Pip-Arg-pNA (S2238) and MZ-Aib-
Arg-pNA HCl (SQ68) as lead structures was synthesized by classical solution methods in 
good yields 
It was shown that orthogonally protected amino acid p-nitroanilides are well suited for 
fragment condensations in DCC/HOBt- or azide-mediated coupling procedures Protonation of 
the guanidino side function of arginine has the advantage of evading harsh deprotection 
conditions However, its highly polar character necessitates modified work-up and purification 
methods. 
Since the substrates described in this chapter are to be used in the continuous registration of 
thrombin formation in plasma, and some of them cannot be used due to the low water 
solubility, we were looking tor new lead structures These structures mimic the binding 
characteristics of the natural substrates/inhibitors of thrombin to a better extent Full selectivity 
and optimal physicochemical properties will be incorporated in these structural elements 
EXPERIMENTAL PROCEDURES 
General 
Ή NMR spectra were recorded on Bruker AM 100 and Bruker AM 400 spectrometers As an 
internal standard the residual solvent peak was used Chemical shifts are given in part per 
million (ppm) Optical rotations were measured on a Perkin Elmer 241 polanmeter in a 10 cm 
cuvette at room temperature Melting points were determined with a Buchi melting point 
apparatus (Tottoli) TLC was performed on Merck Silicagel 6OF254 plates, and column 
chromatography on Merck Kieselgel 60, 70-230 Mesh ASTM Spots were detected by UV-
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fluorescence quenching, ninhydrinc (free amino functions), chlorine/TDM (NH groups), 
Barton's- (hydrazides) and Sakaguchi's (arginine residues) reagent. 
Methanol was refluxed on magnesium turnings for two hours, distilled and stored on 3Â 
molsieves. Pyridine was distilled over KOH pellets and stored on 4À molsieves. 
Boc-amino acids were synthesized by the method of Schnabel31. Their hydroxysuccinimide 
esters were prepared according to Anderson et al.32 Amino acidp-nitroanilides were prepared 
as described in chapter 1. The resolution of DL-pipecolic acid was carried out according to the 
method of Mende and Lukes et al.33 Malonic acid and dimethylmalonic acid were converted to 
their corresponding dimethyl esters by heating the dicarboxylic acid with an excess of methanol 
in the presence of concentrated sulfuric acid34. Dimethyl methylmalonate was prepared by 
generating the mono-sodio derivative of dimethyl malonate which reacts with methyl iodide via 
a SN2 mechanism34. The corresponding half esters were prepared by controlled partial 
hydrolysis of the diester with one equivalent of potassium hydroxide35. The monomethyl ester 
of diethylmalonic acid was obtained in a direct way by refluxing the acid in an excess of 
methanol with sulfuric acid as catalyst. 
Dimethylmalonic acid and DL-pipecolic acid were from Janssen, diethylmalonic acid and D(-)-
tartaric acid were from Aldrich. Naphtalene-2-sulfonyl chloride, toluene-4-sulfonyl chloride 
and D-alanine were obtained from Fluka. Boc-Nle-OH, Boc-D-Val-ONSu and Fmoc-
Orn(Boc)-OH were from Bachern. D-Phenylalanine was a generous gift of Dr. J. Kamphuis 
(DSM Research, Geleen, The Netherlands). 
Syntheses 
Boc-D-Phe-Pip-N2H3 : 
To a solution of Boc-D-Phe-OH (19.88 g, 75 mmol) in EtOAc (350 mL) was added HC1.H-
Pip-OMe33 (13.46 g, 75 mmol, 1.0 eq.), HOBt (12.62 g, 82.5 mmol, 1.10 eq.) and NMM 
(8.75 mL, 78.7 mmol, 1.05 eq.). The obtained suspension was cooled on ice and DCC (16.22 
g, 78.7 mmol, 1.05 eq.) was added. After stirring for two hrs at 0°C and 16 hrs at room 
temperature, DCU was filtered off. The pale yellow EtOAc solution was successively washed 
with 2N KHSO4, H20, saturated NaHC03 and saturated NaCl (four times 50 mL each). The 
obtained organic solution was dried on Na2S04, filtered and evaporated in vacuo. The residual 
oil contained some DCU, so diethyl ether was added and the suspension was filtered. The 
filtrate was evaporated in vacuo; the obtained residue was a clear yellowish oil, yield: 21.52 g 
(74%). This product was checked by TLC on purity and directly used for further synthesis 
(R|{CH2Cl2/MeOH 9:1 v/v): 0.87). The protected dipeptide methyl ester was dissolved in 
MeOH (150 mL) and N2H4.H20 (13.5 mL, 278 mmol, 5.0 eq.) was added. This reaction 
mixture was left for three days at room temperature. The formed precipitate was filtered off and 
dried, yield: 12.48 g (58%). The filtrate was evaporated to 25 mL and dropped out into H20 
(500 mL), to give another crop of 2.53 g. Total yield: 15.01 g (70%, overall: 52%), 
Rf(CH2Cl2/McOH 9:1 v/v): 0.54, [<x]D = -77.1° с = 0.98 DMF, mp: 202-204°C, Ή NMR 
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(CD3OD): δ = 1.15-1.38 (m, 6H, CH2-Pip (3 χ 2Н)); 1.44 (s, 9Н, Вое); 3.08/3.18 (dm, 2H, 
ß-CH2-Phe); 3.28 (m, 2H, N-CH2-Pip); 4.58 (m, IH, α-CH-Pip); 4.74 (m, IH, α-CH-Phe); 
7.20-7.33 (m, 5H, arom Phe). 
Boc-D-Phe-Pip-X-pNA 
a)X = Arg.HCl: 
Boc-D-Phe-Pip-N2H3 (0.39 g, 1.0 mmol) was dissolved in DMF (10 mL) and cooled to -20°C 
with dry ice/aceton. To this solution was added 2.3 M HCl/EtOAc (1.20 mL, 2.75 mmol, 2.75 
eq.) followed by feri.-BuONO(0.114 mL, 1.20 mmol, 1.20 eq.). This reaction mixture was 
stirred for 15 min at -20°C. (After this period the azide-formation was complete.) The acid 
solution was neutralized by adding DIPEA (0.48 mL, 2.77 mmol). 2HCl.H-Arg-pNA (0.367 
g, 1.0 mmol, 1.0 eq.) was added followed by 1.0 eq. DIPEA. This reaction mixture was kept 
on neutrality by adding DIPEA at regular time intervals. The obtained reaction medium was 
allowed to react during 16 hrs at 0°C. After this period, DMF was removed in vacuo and the 
oily residue was dissolved in BuOH (10 mL). The BuOH solution was washed with H 20, 
saturated NaHC03 and saturated NaCl (three times 5 mL each) and evaporated in vacuo. Boc-
D-Phe-Pip-Arg-pNA.HCl was purified by counter current distribution with BuOH/AcOH/H20 
4:1:5 v/v/v as solvent system (K = 10.52) and lyophilized from AcOH. Yield: 0.613 g (89%), 
Rf<BuOH/AcOH/H20 4:1:1 v/v/v): 0.75, [a]D = -90.0» с = 1 MeOH, Ή NMR (CD3OD): δ = 
1.33 (s, 9H, Вое); 1.41 (m, 6Н, CH2-Pip (3 χ 2Η)); 1.67 (m, 2H, y-CH2-Arg); 1.86/2.04 
(dm, 2H, p-CH2-Arg); 2.93-3.04 (bm, 4H, ß-CH2-Phe/N-CH2-Pip); 3.21 (m, 2H, 6-CH2-
Arg); 4.54 (m, IH, a-CH-Pip); 4.78 (m, IH, a-CH-Arg); 4.96 (m, IH, a-CH-Phe); 7.21-
7.35 (bm, 5H, arom Phe); 7.90/7.92-8.20/8.23 (dd, 4H, arom pNA). 
h) X = Lys(Boc): 
In general as described for a). 
Quantities used: Boc-D-Phe-Pip-N2H3: 0.398 g (1.019 mmol), H-Lys(Boc)-pNA: 0.373 g 
(1.022 mmol). Extractions were performed with EtOAc, after drying on Na2SC>4, the solvent 
was removed under reduced pressure. The obtained foam was purified by column 
chromatography with CH2Cl2/MeOH 98:2 v/v as eluens. Yield: 0.69 g (95%), 
R(<CH2Cl2/MeOH 98:2 v/v): 0.30, [ct]D = -61.8° с = 0.44 MeOH, Ή NMR (CD3OD): δ = 
1.18-1.56 (bm, 10H, Y-CH2/6-CH2-Lys/CH2-Pip (3 χ 2H)); 1.34 (s, 9H, Вое); 1.41 (s, 9Н, 
Вое); 1.93 (m, 2Н, ß-CH2-Lys); 3.02 (m, 6Н, N-CH2-Pip/E-CH2-Lys/ß-CH2-Phe); 4.45 (m, 
IH, α-CH-Pip); 4.78 (m, IH, α-CH-Lys); 5.11 (m, IH, α-CH-Phe); 7.21-7.34 (m, 5H, 
arom Phe); 7.85/7.87-8.16/8.18 (dd, 4H, arom pNA). 
c) X = Om(Boc): 
Obtained as described for b). 
Quantities used: Fmoc-Orn(Boc)-pNA: 0.625 g ( 1.089 mmol). The Fmoc-protection was 
removed by treatment with 20% piperidine in DMF ( 15 mL) during 35 min. After this period, 
the reaction mixture was evaporated to dryness and coevaporated with DMF to remove any 
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residual piperidine. Yield: 0.525 g (74%), R,<CH2Cl2/MeOH 98:2 v/v): 0.22, [ct]D = -64.8° с 
= 0.13 МеОН, Ή NMR (CD3OD): δ = 1.26-1.48 (bm, 6H, CH2-Pip (3 χ 2Η)); 1.34 (s, 9H, 
Вое); 1.41 (s, 9Н, Вое); 1.56/1.65 (dm, 2Н, у-СН2-Огп); 1.78/1.99 (dm, 2Н, ß-CH2-Orn); 
2.97 (m, 2Н, ß-CH2-Phe); 3.07 (m, 4Н, 5-CH2-Orn/N-CH2-Pip); 4.48 (m, 2H, a-CH-Orn/α-
CH-Pip); 4.79 (m, IH, a-CH-Phe); 7.25-7.32 (m, 5H, arem Phe); 7.86/7.88-8.18/8.20 (dd, 
4H, arom pNA). 
d)X = Glu(OlBu): 
Obtained as described for b). 
Quantities used: Fmoc-Glu(0'Bu)-pNA: 0.577 g ( 1.06 mmol). The Fmoc-protection was 
removed as described above. Yield: 0.422 g (62%), Rf(CH2Cl2/MeOH 98:2 v/v): 0.44, [a] D 
= -78.5° с = 0.33 МеОН, Ή NMR (CD3OD): δ = 1.26-1.54 (bm, 8H, ß-CH2-GIu/CH2-Pip 
(3 χ 2H)); 1.33 (s, 9Н, O'Bu); 1.43 (s, 9H, Вое); 2.38 (m, 2Н, y-CH2-Glu); 2.96 (m, 2H, β-
CH2-Phe); 3.08 (m, 2H, N-CH2-Pip); 4.53 (dd, IH, a-CH-Glu); 4.59 (m, IH, a-CH-Pip); 
4.82 (m, IH, a-CH-Phe); 7.26-7.33 (m. 5H, arom Phe); 7.89/7.91-8.20/8.22 (dd, 4H, arom 
pNA). 
e)X = Nle: 
Obtained as described for b). 
Quantities used: HCl.H-Nle-pNA: 0.288 g (1.0 mmol), DIPEA: 0.173 mL (1.0 mmol). Yield: 
0.512 g (84%), Rf(CH2Cl2/MeOH 98:2 v/v): 0.42, [a] D = -93.9° с = 0.23 МеОН. 
пНа.Н-D-Phe-Pip-X-pNA 
The protected tripeptide was dissolved in EtOAc or AcOH (1 mmol in 5 mL). To the solution 
2.3 M HCl/EtOAc (10 mL for 1 mmol) was added and the reaction mixture was stirred until 
deprotection was complete. The acid was quenched with ierf.-BuOH (10 mL) and evaporated 
in vacuo. The residue was coevaporated with fert.-BuOH (twice) and with MeOH (once). The 
residue was dissolved in H 2 0 and lyophilized. Crude tripeptides were purified by counter 
current distribution with BuOH/AcOH/H20 4:1:5 v/v/v as solvent system. 
a)n = 2,X = Arg (1): 
Yield: 0.436 g (96%), Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.52 (K = 0.92), [a] D = -128.7° с = 
1 МеОН, Ή NMR (D 2 0) : δ = 1.18 (m, 2H, CH2-Pip); 1.44 (m, 2H, >-CH2-Arg); 1.63 (m, 
4H, СН2-Рір (2 χ 2Н)); 1.88 (m, 2Н, ß-CH2-Arg); 3.13 (m, 2Н, ß-CH2-Phe); 3.21 (m, 4H, 
6-CH2-Arg/N-CH2-Pip); 4.40 (m, IH, a-CH-Arg); 4.69 (bs, IH, a-CH-Pip); 4.81 (m, IH, 
a-CH-Phe); 7.26 (m, 2H, arom Phe); 7.38 (m, 3H, arom Phe); 7.63/7.65-8.18/8.20 (dd, 4H, 
arom pNA). 
b)n = 2,X = Lys (la): 
Yield: 0.297 g (72%), Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.60, [a]D = -115.3° с = 0.15 
МеОН, >H NMR (CD3OD): δ = 1.17-1.60 (bm, 8H, Y-CH2-Lys/CH2-Pip (3 χ 2H)); 1.71 (m, 
2H, 6-CH2-Lys); 1.94 (m, 2H, ß-CH2-Lys); 2.94 (t, 2H, e-CH2-Lys); 3.08/3.18 (dm, 2H, ß-
CH2-Phe); 3.28 (bs, 2H, N-CH2-Pip); 4.48 (m, IH, a-CH-Lys); 4.58 (m, IH, a-CH-Pip); 
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4 72 (m, IH, α-CH-Phe), 7 29-7 41 (m, 5H, arom Phe), 7 85/7 88-8 20/8 22 (dd, 4H, arom 
pNA) 
c) η = 2, X = От (lb) 
Yield 0 315g (96%), Rf<BuOH/AcOH/H20 4 1 1 ν/ν/ν) 0 42 (К = 0 71), [cc]D = -96 7° с = 
0 18 МеОН, Ή NMR (CD3OD) δ = 1 29-1 49 (m, 6Η, CH2-Pip (3 χ 2Η)), 1 62-1 77 (dm, 
2H, y-CH2-Orn), 2 00-2 15 (dm, 2H, ß-CH2-Om), 2 98 (m, 6H, ß-CH2-Phe/N-CH2-Pip/6-
CH2-Orn), 4 34 (m, IH, a-CH-Pip), 4 46 (m, Ш, a-CH-Orn), 4 57 (m, IH, a-CH-Phe), 
7 23-7 35 (m, 5H, arom Phe), 7 85/7 87-8 20/8 22 (dd, 4H, arom pNA) 
d)n = 1,X = Glu (le) 
Yield 0 158 g (64%), Rf<BuOH/AcOH/H20 4 1 1 v/v/v) 0 67 (K = 5 15), [a]D = -107 4° с = 
0 22 МеОН, ·Η NMR (CD3OD) δ = 1 11-1 35 (m, 6H, CH 2 Pip (3 χ 2H), 2 03 (m, 2H, β-
CH2-Glu), 2 26/2 42 (dm, 2H, y-CH2-Glu), 2 82/3 55 (dm, 2H, N-CH2-Pip), 3 11/3 24 
(dm, 2H, ß-CH2-Phe), 4 17 (m, IH, α-CH-Glu), 4 52 (m, IH, a-CH-Pip), 4 82 (m, IH, a-
CH-Phe), 7 26-7 41 (m, 5H, arom Phe), 7 84/7 86-8 19/8 22 (dd, 4H, arom pNA) 
e) η = 1, X = Nie (ld) 
Yield 0 124 g (46%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 82, [ a ] D = -117 I o с = 0 17 
МеОН, 'H NMR (CD3OD) δ = 0 93 (t, 3H, E-CH3-Nle), 1 29-1 48 (bm, 10H, 7-CH2-Nle/ö-
CH2-Nle/CH2-Pip (3 χ 2H)), 1 78/1 87 (dm, 2H, ß-CH2-Nle), 3 00 (m, 4H, N-CH2-Pip/ß-
CH2-Phe), 4 45 (m, 2H, cc-CH-Nle/a-CH-Pip), 5 07 (m, IH, a-CH-Phe), 7 24-7 37 (m, 5H, 
arom Phe), 7 82/7 84-8 19/8 21 (dd, 4H, arom pNA) 
Boc-D-Phe-Pro-OH 
To a solution of H-Pro-OH (1 00 g, 8 70 mmol, 1 09 eq ) and NaHC03 (1 40 g, 16 7 mmol, 
2 09 eq ) in H 2 0 (10 mL) a solution of Boc-D-Phe-ONSu (2 90 g, 8 01 mmol) in CH3CN (30 
mL) was added dropwise The obtained reaction mixture was stirred at room temperature for 
16 hrs After this period of stirring the reaction mixture was evaporated in vacuo, the resulting 
syrup was diluted with water and the solution was acidified with 2N KHS04 to pH = 3 and 
extracted into EtOAc (50 mL) The EtOAc solution was washed with saturated NaCI (three 
times 20 mL), dried on Na 2 S0 4 , filtered and evaporated to dryness The residue was 
precipitated in diethyl ether, filtered and dried Yield 2 12 g (73%), R(<CH2Cl2/MeOH 8 2 
v/v) 0 45, [a]D = -56 5° с = 0 78 МеОН, mp 168°C, Ή NMR (CDCI3) δ = 1 43 (s, 9H, 
Вое), 2 24 (m, 2H, СН2-Рго), 2 51 (m, 2Н, СН 2 Pro), 3 02 (d, 2Н, ß-CH2-Phe), 3 55 (m, 
2H, N-CH2-Pro), 4 34 (m, IH, a-CH-Pro), 4 61 (m, IH, a-CH-Phe), 5 33 (d, IH, NH), 
7 26 (bs, 5H, arom Phe) 
Boc-D-Phe Pro-Arg-pNA HCl 
То a solution of Boc-D-Phe-Pro-OH (0 362 g, 1 00 mmol), 2HC1 H-Arg-pNA (0 365 g, 
0 995 mmol, 0 995 eq ), HOBt (0 172 g, 1 12 mmol, 1 12 eq ) and DIPEA (0 18 mL, 1 05 
mmol, 1 05 eq ) in DMF (10 mL), DCC (0 221 g, 1 07 mmol, 1 07 eq ) was added The 
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obtained reaction mixture was stirred for one hour on ice and 17 hrs at room temperature The 
formed DCU was filtered off and DMF was evaporated in vacuo The oily residue was 
dissolved in BuOH (20 mL) and subsequently washed with H 2 0, saturated NaHC03 and 
saturated NaCl (four times 10 mL each) The clear organic solution was evaporated in vacuo 
and the residue was purified by counter distribution with the solvent system 
BuOH/AcOH/H20 4 1 5 v/v/v The pure product was lyophilized from AcOH Yield 0 51 g 
(76%), R,<BuOH/AcOH/H20 4 1 1 v/v/v) 0 65 (K = 6 48), [a]D = -31 3° с = 0 22 MeOH, 
•H NMR (CD3OD) δ = 1 20 (s, 9H, Вое), 1 58-2 18 (bm, 8Н, ß-CH2-Arg/Y-CH2-Arg/CH2-
Pro (2 χ 2Η)), 2 77/3 69 (dm, 2H, N-CH2-Pro), 3 02 (m, 2H, ß-CH2-Phe), 3 22 (m, 2H, δ-
СНг-Arg), 4 27 (m, IH, a-CH-Pro), 4 49 (m, IH, a-CH-Arg), 4 55 (m, IH, a-CH-Phe), 
7 28-7 36 (m, 5H, arom Phe), 8 12/8 15-8 23/8 26 (dd, 4H, arom pNA) 
Boc-D Phe-Pro-X-pNA 
a)X = Lys(Boc) 
Boc-D-Phe-Pro-OH (0 1975 g, 0 546 mmol, 1 01 eq ) was coupled in EtOAc (10 mL) with H-
Lys(Boc)-pNA (0 1982 g, 0 543 mmol) using DCC (0 113 g, 0 55 mmol, 1 01 eq ) in the 
presence of HOBt (0 077 g, 0 55 mmol, 1 01 eq ) After one hour of stirring at 0°C the 
reaction mixture was stirred overnight at room temperature DCU was filtered off, and the 
organic solution was washed with saturated NaHC03, H 20, 2N KHSO4 and saturated NaCl 
(three times 10 mL each) The clear yellowish EtOAc solution was dried on Na2S04, filtered 
and evaporated in vacuo The resulting foam was purified by column chromatography on silica 
gel with CH2Cl2/MeOH 98 2 v/v as eluens Yield 0 212 g (55%), R((CH2Cl2/MeOH 98 2 
v/v) 0 21, Rf(CH2Cl2/MeOH 95 5 v/v) 0 62, [cx]D = -52 9° с = 0 18 MeOH, Ή NMR 
(CD3OD) δ = 1 20 (s, 9H, Вое), 1 33-1 60 (bm, 6Н, y-CH2-Lys/CH2-Pro (2 χ 2Η)), 1 42 
(s, 9H, Вое), 1 77-2 10 (bm, 4Н, |ì-CH2-Lys/6-CH2-Lys), 2 73/3 70 (dm, 2H, N-CH2-Pro), 
3 03 (m, 4H, E-CH2-Lys/p-CH2-Phe), 4 26 (m, IH, α-CH-Pro), 4 48 (m, 2H, cc-CH-Lys/α-
CH-Phe), 7 26-7 35 (m, 5H, arom Phe), 8 12/8 14-8 22/8 24 (dd, 4H, arom pNA) 
b) X = Nie 
Obtained as described for a) 
Quantities used Boc-D-Phe-Pro-OH 0 202 g (0 558 mmol), HCl H-Nle-pNA 0 162 g (0 562 
mmol, 1 01 eq ), HOBt 95 4 mg (0 624 mmol, 1 12 eq ), DIPEA 100 μι (0 575 mmol, 1 03 
eq ) and DCC 0 132 g (0 641 mmol, 1 15 eq ) in 10 mL EtOAc Yield 0 299 g (90%), 
Rf(CH2Cl2/MeOH 98 2 v/v) 0 38, [a]D = -72 0° с = 0 15 MeOH 
nHCl H D-Phe-Pro-X-pNA 
The protected tripeptide was dissolved in EtOAc or AcOH (1 mmol in 5 mL) To this solution, 
2 3 M HCl/EtOAc (5 mL for 1 mmol) was added and stirred for a period until deprotection was 
complete After completion, the acid was quenched with tert -BuOH (10 mL) and the mixture 
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was evaporated in vacuo. After coevaporation with ferr.-BuOH (twice 10 mL) and MeOH 
(once 10 mL) the residue was dissolved in H 20 and lyophilized. 
a) η = 2, X = Arg (2): 
Yield: 0.330 g (91%), R,{BuOH/AcOH/H20 4:1:1 v/v/v): 0.48, [a]D = -102.0° с = 0.10 
MeOH, Ή NMR (CD3OD): δ = 1.51-2.04 (bm, 8H, ß-CH2/y-CH2-Arg/CH2-Pro (2 χ 2H)); 
2.64/3.65 (dm, 2Н, N-CH2-Pro); 3.14 (m, 2H, ß-CH2-Phe); 3.23 (m, 2H, Ö-CH2-Arg); 4.34 
(m, IH, a-CH-Pro); 4.43 (m, 2H, a-CH-Arg/a-CH-Phe); 7.30-7.42 (m, 5H, arom Phe); 
7.94/7.96-8.21/8.23 (dd, 4H, arom pNA). 
b)n = 2,X = Lys (2a): 
Yield: 0.110 g (75%), R,{BuOH/AcOH/H20 4:1:1 v/v/v): 0.44, [a]D = -138.9° с = 0.27 
MeOH, 'H NMR (CD3OD): δ = 1.50-2.00 (bm, 10H, ß-CH2/Y-CH2/e-CH2-Lys/CH2-Pro (2 χ 
2H)); 2.63-3.63 (dm, 2H, N-CH2-Pro); 2.96 (m, 2H, e-CH2-Lys); 3.17 (m, 2H, ß-CH2-
Phe); 4.33 (m, IH, a-CH-Pro); 4.43 (m, 2H, a-CH-Lys/a-CH-Phe); 7.30-7.39 (m, 5H, arom 
Phe); 7.93/7.95-8.21/8.23 (dd, 4H, arom pNA). 
c)n = 1,X = Nie (2b): 
Yield: 0.167 g (75%), Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.80, [a]D = -125.0° с = 0.16 
MeOH, 'H NMR (CD3OD): δ = 0.94 (t, 3H, e-CH3-Nle); 1.36-1.51 (bm, 8H, y-CH2/6-CH2-
Nle/CH2-Pro (2 χ 2H)); 1.75-1.94 (bm, 2H, ß-CH2-Nle); 2.68/3.51 (dm, 2H, N-CH2-Pro); 
3.01 (m, 2H, ß-CH2-Phe); 4.09 (m, IH, a-CH-Pro); 4.31 (m, IH, a-CH-Nle); 4.41 (m, IH, 
a-CH-Phe); 7.25-7.36 (m, 5H, arom Phe); 7.88/7.91-8.20/8.23 (dd, 4H, arom pNA). 
Boc-X-Arg-pNA.HCl 
a)X = Gly: 
Boc-Gly-OH (1.75 g, 10 mmol), 2HCl.H-Arg-pNA (3.67 g, 10 mmol, 1.0 eq.), HOBt (1.60 
g, 10.1 mmol, 1.01 eq.) and NMM (1.10 mL, 10.0 mmol, 1.0 eq.) were dissolved in DMF 
(75 mL). This reaction mixture was cooled on ice and DCC (2.16 g, 10.5 mmol, 1.05 eq.) was 
added. After stirring for one hr at 0°C and 16 hrs at room temperature, DCU was filtered off 
and DMF was removed under reduced pressure. The residue was purified by counter current 
distribution with BuOH/AcOH/H20 4:1:5 v/v/v (K = 1.84) as the solvent system. After work-
up the pure product was lyophilized from AcOH. Yield: 4.29 g (88%), R,{BuOH/AcOH/H20 
4:1:1 v/v/v): 0.64, [a]D = -36.8° с = 0.63 MeOH. 
b)X = Ala: 
Boc-Ala-ONSu (2.91 g, 10.14 mmol, 1.01 eq.) was coupled to 2HCl.H-Arg-pNA (3.69 g, 
10.05 mmol) in the presence of DIPEA (1.83 mL, 10.5 mmol, 1.04 eq.) in 75 mL DMF. After 
16 hrs of stirring at room temperature, DMF was removed under reduced pressure and the 
residue was diluted with BuOH (75 mL). The BuOH solution was washed with H20, saturated 
NaHC03, H 20 and saturated NaCl (four times 20 mL each). The organic layer was evaporated 
in vacuo. The residue was purified by counter current distribution with the solvent system 
BuOH/AcOH/ H 2 0 4:1:5 v/v/v. The pure product was lyophilized from AcOH. Yield: 4.06 g 
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(81%), Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.62, [ct]D = -44.5° с = 0.72 MeOH, >H NMR 
(D2O/CD3OD 3:1 ν/ν): δ = 0.83 (d, 3H, ß-CH3-Ala (J = 7.14 Hz)); 0.92 (s, 9H, Boc); 1.29 
(m, 4H, Y-CH2-Arg/ß-CH2-Arg); 2.78 (m, 2H, 6-CH2-Arg); 3.60 (q, IH, α-CH-Ala); 4.04 
(m, IH, α-CH-Arg); 7.20/7.30-7.72/7.82 (dd, 4H, arom pNA). 
c)X = D-Ala: 
Obtained as described for b). 
Quantities used: Boc-D-Ala-ONSu: 1.43 g (5.0 mmol), 2HCl.H-Arg-pNA: 1.84 g (5.0 mmol), 
DIPEA: 1.92 mL (11.0 mmol, 2.2 eq.) in 30 mL DMF. Yield: 1.76 g (70%), 
R(<BuOH/AcOH/H20 4:1:1 v/v/v): 0.59 (K = 1.93), [a]D = -47.0° с = 0.77 MeOH, >H NMR 
(CD3OD): δ = 1.33 (d, ЗН, ß-СНз-АІа (J = 7.12 Hz)); 1.43 (s, 9H, Boc); 1.71 (m, 2H, γ-
CH2-Arg); 1.80/2.06 (dm, 2H, ß-CH2-Arg); 3.22 (m, 2H, Ô-CH2-Arg); 4.07 (q, IH, a-CH-
Ala (J = 7.12 Hz)); 4.56 (m, IH, a-CH-Arg); 7.92/7.94-8.20/8.22 (dd, 4H, arom pNA). 
d)X= Val: 
Obtained as described for b). 
Quantities used: Boc-Val-ONSu: 1.57 g (5.0 mmol), 2HCl.H-Arg-pNA: 1.80 g (5.0 mmol), 
DIPEA: 1.92 mL in 30 mL DMF. Yield: 2.36 g (89%), R,<BuOH/AcOH/H20 4:1:1 v/v/v): 
0.69 (K = 2.11), [a]D = -44.4° с = 0.59 MeOH, 'H NMR (CD3OD): δ = 0.94-0.98 (dd, 6H, 
γ-СНз/У-СНз- аІ); 1.44 (s, 9H, Boc); 1.70 (m, IH, ß-CH-Val); 1.82 (m, 2H, y-CH2-Arg); 
2.03 (m, 2H, ß-CH2-Arg); 3.23 (m, 2H, 6-CH2-Arg); 3.88 (d, IH, a-CH-Val); 4.56 (m, IH, 
a-CH-Arg); 7.84/7.86-8.20/8.22 (dd, 4H, arom pNA). 
e)X = D-Val: 
Obtained as described for b). 
Quantities used: Boc-D-Val-ONSu: 1.57 g (5.0 mmol), 2HCl.H-Arg-pNA: 1.80 g (5.0 mmol), 
DIPEA: 1.92 mL in 30 mL DMF. Yield: 1.93 g (73%), Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 
0.68 (K = 2.59), [a]D = -50.6° с = 0.88 MeOH, 'H NMR (CD3OD): δ = 0.98-1.01 (dd, 6H, 
Y-CH3/y-CH3-Val); 1.42 (s, 9H, Boc); 1.66-1.80 (bm, 3H, ß-CH2-Arg(lH)/Y-CH2-Arg); 
1.99-2.09 (bm, 2H, ß-CH2-Arg(lH)/ß-CH-Val); 3.23 (m, 2H, 6-CH2-Arg); 3.79 (d, IH, a-
CH-Val); 4.56 (m, IH, a-CH-Arg); 7.93/7.95-8.20/8.22 (dd, 4H, arom pNA). 
2HCl.H-X-Arg-pNA 
Protected dipeptides were dissolved in AcOH (1 mmol in 2 mL) and to this solution 2.3 M HCl 
in EtOAc (5 mL for 1 mmol) was added. The resulting solution was stirred for 2.5 hrs at room 
temperature. After acid quenching with terf.-BuOH (10 mL for 1 mmol) the solution was 
evaporated in vacuo and residual solvents were removed by coevaporation with íerí.-BuOH 
(two times 10 mL) and with MeOH. The residue was dissolved in H20 (10 mL for 1 mmol) 
and washed with EtOAc (three times). The resulting aqueous solution was lyophilized. When 
necessary the product was purified by counter current distribution with the solvent system: 
BuOH/AcOH/H20 4:1:5 v/v/v. 
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a)X= Gly (3) 
Yield 0 360 g (85%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 29 (K = 0 62), [ct]D = -14 1« с = 
0 75 MeOH, Ή NMR (D 2 0) δ = 1 58 (m, 4H, ß-CH2/Y-CH2-Arg), 2 92 (m, 2H, б-СН2-
Arg), 3 63 (s, 2H, CH2-Gly), 4 21 (m, IH, α-CH-Arg), 7 27/7 37-7 80/7 89 (dd, 4H, arom 
pNA) 
b) X = Ala (4) 
Yield 0 407 g (93%), R,<BuOH/AcOH/H20 4 1 1 v/v/v) 0 33 (K = 0 36), [a] D = -5 5° с = 
0 24 MeOH, 'H NMR (D 2 0) δ = 1 32 (d, 3H, ß-CH3-Ala (J = 7 1 Hz)), 1 62 (m, 4H, p-
CH2/Y-CH2-Arg), 2 99 (m, 2H, 6-CH2-Arg), 3 89 (q, Ш, a-CH-Ala (J = 7 1 Hz)), 4 31 (m, 
IH, ct-CH-Arg), 7 44/7 54-8 01/8 10 (dd, 4H, arom pNA) 
c)X = D-Ala(5) 
Yield 0 385 g (88%), R f (BuOH/AcOH/H 2 0 4 1 1 v/v/v) 0 33, [ a ] D = -26 8° с = 0 40 
MeOH, 1H NMR (D 2 0) δ = 1 29 (d, 3H, CH3-Ala (J = 7 1 Hz)), 1 54 (m, 4H, ß-CH2/y-
CH2-Arg), 2 96 (m, 2H, 8-CH2-Arg), 3 91 (q, IH, a-CH-Ala (J = 7 1 Hz)), 4 24 (m, IH, a-
CH-Arg), 7 33/7 42-7 85/7 94 (dd, 4H, arom pNA) 
d) X = Val (6) 
Yield 0 401 g (86%), R,<BuOH/AcOH/H20 4 1 1 v/v/v) 0 40, [o]D = -5 7° с = 0 21 MeOH, 
'H NMR (CD3OD) δ = 1 05/1 07-1 08/1 10 (dd, 6H, у-СН3/у'-СН3- а1), 1 70-1 89 (m, 
3H, Y-CH2-Arg/ß-CH-Val), 1 96/2 25 (dm, 2H, ß-CH2-Arg), 3 26 (m, 2H, 6-CH2 Arg), 3 82 
(d, IH, a-CH-Val), 4 58 (m, IH, ct-CH-Arg), 7 85/7 87-8 20/8 22 (dd, 4H, arom pNA) 
e)X = D-Val(7) 
Yield 0 447 g (96%), Rf{BuOH/AcOH/H20 4 1 I v/v/v) 0 40, [ct]D = -40 8° с = 0 25 
MeOH, 'H NMR ( D 2 0 ) δ = 0 69/0 76 (dd, 6H, 7-CH3/y-CH3-Val), 1 44-1 51 (m, 4H, γ-
CH2/ß-CH2-Arg), 1 90 (m, IH, ß-CH-Val), 2 91 (m, 2H, 6-CH2-Arg), 3 60 (d, IH, ct-CH-
Val), 4 22 (m, IH, o-CH-Arg), 7 26/7 35-7 76/7 86 (dd, 4H, arom pNA) 
R-X-Arg-pNA HCl 
The monomethyl ester of the malonic acid derivative was coupled with DCC/HOBt with 
2HC1 H-X-Arg-pNA in the presence of DIPEA for one hour at 0°C and 16 hrs at room 
temperature (or as ONSu active ester in the presence of 1 eq DIPEA) After filtration, the clear 
DMF solution was evaporated in vacuo The residue was purified by counter current 
distribution with the solvent system BuOH/AcOH/H20 4 1 5 v/v/v The pure product was 
lyophihzed from H 2 0 
a)R = MZ.X= Gly (3a) 
Quantities used 2HC1 H-Gly-Arg-pNA 0 557 g (1 31 mmol), malonic acid monomethyl ester 
0 31 g (2 62 mmol, 2 0 eq ), HOBt 0 235 g (1 54 mmol, 1 17 eq ), DIPEA 0 24 mL (1 38 
mmol, 1 05 eq ) and DCC 0 289 g (1 40 mmol, 1 07 eq ) in 10 mL DMF Yield 0 319 g 
(50%), Rr(BuOH/AcOH/H20 4 1 1 v/v/v) 0 45 (K = 0 85), [cc]D = -16 2° с = 0 29 MeOH, 
•H NMR (D 2 0) δ = 1 63 (m, 2H, y-CH2-Arg), 1 85 (m, 2H, ß-CH2-Arg), 3 16 (m, 2H, δ-
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CH2-Arg), 3 47 (s, 2H, CH2-malonic acid), 3 67 (s, 3H, OCH3), 3 96 (s, 2Н, CH2-Gly), 
4 42 (m, IH, α-CH-Arg), 7 55/7 57-8 07/8 09 (dd, 4H, arom pNA) 
b)R = MZ,X = Ala (4a) 
Quantities used 2HCI H-Ala-Arg-pNA О 438 g ( 1 0 mmol), malonic acid monomethyl ester 
0 158 g (1 34 mmol, 1 34 eq ), HOBt 0 171 g (1 08 mmol, 1 08 eq ), DIPEA 0 19 mL 
(1 05 mmol, 1 05 eq ) and DCC 0 216 g (1 05 mmol, 1 05 eq ) in 10 mL DMF Yield 0 201 
g (40%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 40 ( К = 0 91), [ot]D = -28 I o с = 0 26 МеОН, 
Ή NMR (D20) δ = 1 35 (d, 3Η, ß-CH3-Ala (J = 7 2 Hz)), 1 65 (m, 2H, y-CH2-Arg), 
1 79/1 90 (dm, 2H, ß-CH2-Arg), 3 17 (m, 2H, 6-CH2-Arg), 3 43 (s, 2H, CH2-malonic acid), 
3 66 (s, 3H, OCH3), 4 28 (q, IH, a-CH-Ala (J = 7 2 Hz)), 4 42 (m, IH, cc-CH-Arg), 
7 57/7 59-8 09/8 11 (dd, 4H, arom pNA) 
c)R = MZ.X= D-Ala (5a) 
Quantities used 2HC1 H-D-Ala-Arg-pNA 0 183 g (0 419 mmol), О 87 mL of О 5 M MZ-
ONSu in CH3CN (0 435 mmol, 1 04 eq ), DIPEA 0 144 mL (0 838 mmol, 2 0 eq ) in 2 mL 
DMF Yield 0 101 g (48%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 45 (K = 1 60), [a]D = 
-18 3° с = 0 18 МеОН, 'H NMR (D20) δ = 1 26/1 33 (d, 3H, ß-CH3-Ala (J = 7 2 Hz)), 1 60 
(m, 4H, y-CH2/ß-CH2-Arg), 1 80 (s, 2H, CH2-malonic acid), 3 10 (m, 2H, 6-CH2-Arg), 3 58 
(s, 3H, OCH3), 4 23 (q, IH, a-CH-Ala (J = 7 2 Hz)), 4 32 (m, IH, a-CH-Arg), 7 50/7 59-
8 03/8 13 (dd, 4H, arom pNA) 
d)R = MZ,X= Val (6a) 
Quantities used 2HC1 H-Val-Arg-pNA 0 172 g (0 368 mmol), 0 76 mL of 0 5 M MZ-ONSu 
in CH3CN (0 38 mmol, 1 03 eq ), DIPEA 0 126 mL (0 733 mmol, 1 99 eq ) in 2 mL DMF 
Yield 79 9 mg (41%), Rt<BuOH/AcOH/H20 4 1 1 v/v/v) 0 57 (K = 1 99), [a]D = -27 6° с = 
0 21 МеОН, 'H NMR (D20) δ = 079 (dd, 6H, у-СН3/уСН3- а1), 1 54 (m, 2H, y-CH2-
Arg), 1 70 (m, IH, ß-CH-Val), 1 80/1 94 (dm, 2H, ß-CH2-Arg), 3 06 (m, 2H, Ô-CH2-Arg), 
3 34 (s, 2H, CH2-malomc acid), 3 57 (s, 3H, OCH3), 3 99 (d, IH, ct-CH-Val), 4 34 (m, IH, 
a-CH-Arg), 7 52/8 07 (dd, 4H, arom pNA) 
e) R = MZ, X = D-Val (7a) 
Quantities used 2HC1 H-D-Val-Arg-pNA 0 183 g (0 393 mmol), 0 82 mL of 0 5 M MZ-
ONSu m CH3CN (0 41 mmol, 1 04 eq ), DIPEA 0 134 mL (0 78 mmol, 1 98 eq ) in 2 mL 
DMF Yield 70 8 mg (34%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 59 (K = 2 10), [a]D = 
-35 3° с = 0 10 МеОН, 'H NMR (D20) δ = 0 91/0 96 (dd, 6H, y-CH3/y-CH3-Val), 1 62-
2 11 (m, 5Н, ß-CH-Val/ß-CH2-Arg/y-CH2-Arg), 1 86 (s, 2H, CH2-malonic acid), 3 19 (m, 
2H, 6-CH2-Arg), 3 62 (s, 3H, OCH3), 4 07 (d, IH, a-CH-Val), 4 43 (m, IH, a-CH-Arg), 
7 59/7 69-8 14/8 23 (dd, 4H, arom pNA) 
f) R = MMZ, X = G/v (3b) 
Quantities used 2HC1 H-Gly-Arg-pNA 0 557 g (131 mmol), methylmalonic acid 
monomethyl ester 0 31 g (2 34 mmol, 1 79 eq ), HOBt 0 228 g, (1 49 mmol, 1 14 eq ), 
DIPEA 0 24 mL (1 38 mmol, 1 05 eq ) and DCC 0 316 g (1 54 mmol, 1 17 eq ) in 10 mL 
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DMF Yield 0 407 g (62%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 48 (K = 1 18), [a] D = 
-16 9° с = 0 29 MeOH, Ή NMR (D 2 0) 6 = 1 30-1 32 (d, 3H, CH3-methylmalonic acid (J = 
7 0 Hz)), 1 63 (m, 2H, y-CH2-Arg), 1 80/1 91 (dm, 2H, ß-CH2-Arg), 3 16 (m, 2H, 5-CH2-
Arg), 3 58/3 61 (dq, IH, CH-methylmalonic acid (J = 7 0 Hz)), 3 65 (s, ЗН, OCH3), 3 95 (s, 
2Н, CH2-Gly), 4 45 (m, IH, α-CH-Arg), 7 55/7 57-8 06/8 08 (dd, 4H, arom pNA) 
g) R = MMZ, X = Ala (4b) 
Quantities used 2HC1 H-Ala-Arg-pNA 0 431 g (0 98 mmol), methylmalonic acid 
monomethylester 0 22 g (1 67 mmol, 1 70 eq ), HOBt 0 193 g, (1 26 mmol, 1 29 eq ), 
DIPEA 0 19 mL (1 05 mmol, 1 07 eq ) and DCC 0 243 g (1 18 mmol, 1 21 eq ) in 10 mL 
DMF Yield 0 283 g (56%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 46 (K = 1 18), [cc]D = 
-39 3° с = 0 29 MeOH, ·Η NMR ( D 2 0 ) 8 = 1 28-1 40 (3 χ d, 6H, ß-CH3-Ala/CH3-
methylmalonic acid), 1 63 (m, 2H,
 Y-CH3-Arg), 1 85/1 91 (dm, 2H, ß-CH2-Arg), 3 18 (m, 
2H, 5-CH2-Arg), 3 54 (dq, IH, CH-methylmalonic acid), 3 60-3 68 (ds, ЗН, ОСН3), 4 26 
(q, IH, α-CH-Ala), 4 42 (m, IH, α-CH-Arg), 7 59/7 62-8 13/8 15 (dd, 4H, arom pNA) 
h) R = DMMZ, X = Gly (3c) 
Quantities used 2HC1 H-Gly-Arg-pNA 0 557 g (1 31 mmol), dimethylmalonic acid 
monomethyl ester 0 52 g (3 57 mmol, 2 72 eq ), HOBt 0 225 g, (1 47 mmol, 1 12 eq ), 
DIPEA 0 24 mL (1 38 mmol, 1 05 eq ) and DCC 0 291 g (1 41 mmol, 1 08 eq ) in 10 mL 
DMF Yield 0 492 g (73%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 49 (K = 1 40), [ a ] D = 
-30 3° с = 0 45 MeOH, 'H NMR (D 2 0) 5 = 1 4 1 (s, 6H, (CH3)2-C-dimethylmalonic acid (2 
χ ЗН)), 1 64 (m, 2H,
 Y-CH2-Arg), 1 78/1 91 (dm, 2H, ß-CH2-Arg), 3 17 (m, 2H, 5-CH2-
Arg), 3 66 (s, 3H, OCH3), 3 92 (s, 2H, CH2 Gly), 4 45 (m, IH, α-CH-Arg), 7 58/7 60-
8 10/812 (dd, 4H, arom pNA) 
ι) R = DMMZ, X = Ala (4c) 
Quantities used 2HC1 H-Ald-Arg-pNA 0 435 g (0 99 mmol), dimethylmalonic acid 
monomethyl ester 0 22 g (1 51 mmol, 1 53 eq ), HOBt 0 182 g, (1 19 mmol, 1 20 eq ), 
DIPEA 0 19 mL (1 05 mmol, 1 06 eq ) and DCC 0 245 g (1 19 mmol, 1 20 eq ) in 10 mL 
DMF Yield 0 283 g (54%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 52 (K = 1 40). [ a ] D = 
-35 2" с = 0 28 MeOH, ·Η NMR (D 2 0) δ = 1 36 (d, 3H, ß-CH3-Ala (J = 7 3 Hz)), 1 39 (s, 
6H, (CH3)2-C-dimethylmalomc acid (2 χ ЗН)), 1 67 (m, 2H, y-CH2-Arg), 1 81/1 92 (dm, 
2H, ß-CH2-Arg), 3 18 (m, 2H, 5-CH2-Arg), 3 66 (s, 3H, OCH3), 4 28 (q, α-CH-Ala (J = 7 3 
Hz)), 4 42 (m, IH, α-CH-Arg), 7 59/7 62-8 12/8 14 (dd, 4H, arom pNA) 
j) R = DEMZ, X = Gly (3d) 
Quantities used 2HC1 H-Gly-Arg-pNA 0 419 g (0 99 mmol), diethylmalonic acid 
monomethyl ester 0 30 g (1 72 mmol, 1 74 eq ), HOBt 0 153 g, (1 0 mmol, 101 eq ), 
DIPEA 0 182 mL (1 Ol mmol, 1 02 eq ) and DCC 0 206 g (1 0 mmol, 1 01 eq ) m 10 mL 
DMF Yield 0 398 g (74%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 57 (K = 2 31), [ a ] D = 
-29 8° с = 0 27 MeOH, 'H NMR (D 2 0) δ = 0 85 (t, 6H, C H 3 - diethylmalonic acid (2 χ ЗН)), 
1 59 (m, 4Н, ß-CH2/7-CH2-Arg), 1 92 (q, 4H, ~CH2~ diethylmalonic acid (2 χ 2H)), 3 19 
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(m, 2H, 6-CH2-Arg), 3 79 (s, 3H, OCH3), 3 92 (s, 2Н, CH2-Gly), 4 24 (m, IH, α-CH-Arg), 
7 25/7 32-7 64/7 73 (dd, 4H, arom pNA) 
ßNS-Gly-Arg-pNA HCl (Зе) 
2HC1 H-Gly-Arg-pNA (0 2632 g, 0 621 mmol) was dissolved in dry pyridine (IO mL) To 
this solution were added DIPEA (120 μι, 0 689 mmol, 1 11 eq ) and ß-naphtalenesulfonyl 
chloride (0 1588 g, 0 701 mmol, 1 13 eq ) The obtained reaction mixture was stirred 
overnight at room temperature After completion of the reaction, pyridine was removed under 
reduced pressure and the oily residue was coevaporated with toluene (twice) and MeOH 
(once) The foamy residue was purified by counter current distribution with the solvent system 
BuOH/AcOH/H20 4 1 5 v/v/v The pure product was lyophilized from AcOH Yield. 0 211 g 
(59%), R,{BuOH/AcOH/H20 4 1 1 v/v/v) 0 67 (K = 7 13), [cc]D = -39 5° с = 0 19 MeOH, 
Ή NMR (CD3OD) δ = 1 59 (m, 2H, Y-CH2-Arg), 1 74/1 95 (dm, 2H, ß-CH2-Arg), 3 16 (m, 
2H, 8-CH2-Arg), 3 66 (dd, 2H, CH2-Gly), 4 47 (m, IH, ct-CH-Arg), 7 58-7 66 (m, 2H, 
arom ßNS), 7 78/7 80 (d, 2H, arom pNA), 7 84-8 03 (m, 4H, arom ßNS), 8 16/818 (d, 2H, 
arom pNA), 8 45 (s, IH, arom ßNS) 
pTS-Gly-Arg-pNA HCl (3f) 
Obtained as described for ßNS-Gly-Arg-pNA HCl 
Quantities used 2HC1 H-Gly-Arg-pNA 0 2717g (0 641 mmol), DIPEA 124 μ ι (0 712 
mmol, 1 11 eq ), /?-toluencsulfonyl chloride 0 1352 g (0 709 mmol, 1 11 eq ) in 10 mL 
pyridine Yield 0 211g (63%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 71 ( К = 4 38), [a]D = 
-34 0« с = 0 15 MeOH, Ή NMR (CD3OD) δ = 1 65 (m, 2H, γ-CHrArg), 1 78/1 96 (dm, 
2H, ß-CH2-Arg), 2 36 (s, ЗН, СН3), 3 21 (m, 2Н, Ô-CH2-Arg), 3 59 (dd, 2Н, CH2-Gly), 
4 55 (m, IH, α-CH-Arg), 7 37/7 39-7 74/7 77 (dd, 4H, arom tosyl), 7 84/7 87-8 20/8 22 
(dd, 4H, arom pNA) 
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CHAPTER 3 
THE APPLICATION OF PEPTIDE p-NITROANILIDES IN THE 
CONTINUOUS REGISTRATION OF THROMBIN GENERATION 
IN PLASMA 
ABSTRACT 
We previously described the use of SQ68 (CH30-CO-CH2-CO-Aib-Arg-pNA HCl) for the 
continuous registration of thrombin generation in activated plasma1 This chapter describes a 
study to obtain other chromogenic substrates which can be used in this technique A series of 
25 peptide p-nitroanihdes was synthesized (chapter 2) and screened for their application in the 
continuous assay As lead substrates we chose SQ68, S2238 (2HC1 H-D-Phe-Pip-Arg-pNA) 
and fibrinogen Act -like fragments With the introduction of a selective modification we tried to 
alter the kinetic behaviour of the substrate in such a way that it is slowly, but still selectively, 
hydrolyzed by thrombin Besides this, the hydrolysis of the substrate by factor Xa and other 
coagulation factors must be restricted to a minimum and no inhibition may occur When these 
requirements would be met, the substrate could be used in the continuous registration of 
thrombin generation in plasma From the experimental thrombin generation curve and with the 
decay constants of thrombin, the prothrombinase activity was calculated On the basis of these 
data we decided a substrate to be suitable for the continuous registration or not We present 
here the kinetic data of hydrolysis of 28 chromogenic substrates by thrombin and factor Xa In 
the first selection, we found four substrates suitable for the continuous registration of thrombin 
formation, from these the most promising being 2HC1 H-Val-Arg-pNA With respect to the 
decay constants of thrombin in the presence of this substrate and its effect on the 
prothrombinase activity, we concluded that this compound will be a successful candidate to 
replace SQ68 
INTRODUCTION 
The chromogenic substrates mentioned in the literature at present time were synthesized to 
achieve higher activity, selectivity or sensitivity for the enzyme studied2 In the case of 
thrombin3, substrates which have basic amino acids, preferentially arginine, at the Pi 
position4, small hydrophobic amino acids at position P2 (proline, glycine) and bulky or 
aromatic amino acids of the D-configuration at the Рз position (preferentially D-phenylilaninei 
are good substrates5 An example is 2HC1 H-D-Phe-Pip-Arg-pNA (S2238) 
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In literature most chromogenic substrates are tested in purified enzyme systems From these 
tests, substrates are selected which have high binding affinities, and high turnover numbers 
This means that the substrate has a low K
m
 and a high kc
a
t The susceptibility to other enzymes 
are in most cases not tested and the possibility for optimal kinetic parameters for more than one 
enzyme is real 
Our goal is, to measure the concentration of one particular enzyme (thrombin) in a mixture of 
enzymes which unfortunately have the same primary specificity Besides this, the enzymes are 
present as zymogens and will be activated during the measurement This means that the 
substrate may neither have any inhibitory activities on the activation cascade nor be prone to 
hydrolysis by an enzyme which is not thrombin 
Thrombin is the pivotal enzyme in thrombosis and hemostasis Its concentration in plasma 
must be maintained between narrow ranges The thrombin generation curve gives the course of 
appearance and disappearance of thrombin in triggered plasma, and gives much information 
about its achievable concentration In our search for selective thrombin substrates we found 
CH30-CO-CH2-CO-Aib-Arg-pNA HCl (SQ68) a good candidate We used this substrate in 
the continuous registration of thrombin generation in plasma1 
The current thrombin substrates cannot be used in this method because the substrate will be 
exhausted long before thrombin generation is over, even at high substrate concentration For 
this reason we need a substrate which is slowly hydrolyzed by thrombin, so k
cat has to be low 
Additionally, the K
m
 value should be high for two reasons The occupancy of the enzyme by 
substrate must be low to minimize inhibition effects Since the K
m
 value represents the 
substrate concentration at which half of the enzyme is saturated, the substrate concentration 
during the experiment must be below K
m
 Secondly, the total amount of converted substrate 
must be minimal to exclude lower conversion rates due to declining substrate concentration 
These two requirements are met at a high K
m
 value With respect to our before mentioned goal 
we need a thrombin substrate which is selective and possesses a high K
m
 and a low k
cat value 
SQ68 fulfills these requirements, but its properties are not optimal The ideal substrate would 
be a highly specific thrombin substrate, which has no interaction with factor Xa, which will not 
act as a competitive inhibitor of АТ-Ш, which is not hydrolyzed by the cçM-thrombin complex 
(which has no clotting properties but still remains amidolytic activity) and is stable in plasma 
This chapter describes the biochemical evaluation of a set of substrates which could be used in 
the continuous registration of thrombin formation in plasma 
MATERIALS AND METHODS 
Materials 
Chromogenic substrates The syntheses of the substrates are described in chapter 2 The 
preparation of Boc-Gly-Val-Arg-pNA HCl and 2HC1 H-Gly-Val-Arg-pNA is described in 
chapter 4 The substrates were dissolved in distilled water to obtain 10 mM stock solutions 
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The concentration was determined at 316 nm using a molar extinction coefficient of 12,500 
Stock solutions were stored in the dark at 4°C 
Factor Xa substrate methyloxycarbonyl-D-cyclohexylglycyl-glycyl-arginine p-nitroanilide 
acetate (CH30-CO-D-Chg-Gly-Arg-pNA AcOH) was obtained from Pentapharm (Basel, 
Switzerland) Thrombin substrate SQ68 (malonyl-a-aminoijobutyryl-arginine p-nitroanilide 
methyl ester monohydrochlonde, CH30-CO-CH2-CO-Aib-Arg-pNA HCl) was purchased 
from Serbio Laboratories, France 
Phospholipids Phospholipids required were 80 mol-% dioleoyl phosphatidyl choline and 20 
mol-% dioleoyl phosphatidyl serine solutions in chloroform, they were obtained from Avanti 
Polar Lipids They were used to prepare vesicles as described by Rosing et al6 
Buffers Buffer A 0 05 M Tris-HCl, 0 1 M NaCl pH = 7 35 containing 0 5 g/L bovine serum 
albumin (Sigma) Buffer В buffer A containing additional EDTA (20 mM), pH = 7 90 
Enzyme preparations Pure human α-thrombin and human factor Xa samples were generous 
gifts of Dr Τ Lindhout (University of Limburg, Maastricht, The Netherlands) The euglobulin 
thrombin fraction was prepared from defibnnated human plasma by acid precipitation at low 
ionic strength as described by Josso and Prou-Wartelle7 The precipitate was dissolved in half 
the original volume of buffer A, containing 0 02 M tnsodium citrate 
Plasma Plasma was prepared by collecting 9 parts of blood (from 10 healthy donors) on 1 part 
of 0 13 M tnsodium citrate Following centrifugation at 900g (15°C, 15 min) and 10,000g 
(15°C, 15 min) the obtained plasma was pooled and centnfuged at 4°C for 1 hour at 23,000g, 
this plasma was stored at -80°C Plasma was defibnnated by mixing an aliquot of plasma with 
1/50 volume of reptilase (Laboratories Stago, Asnières, France, the solution was made as 
instructed by the manufacturer), letting a clot form for 10 min at 37°C followed by 10 min on 
ice The fibnn clot was removed by winding it on a plastic spatula 
Tissue factor Recombinant tissue factor (Recomplastin S, Dade, Baxter Diagnostics Ine , 
Deerfield II, USA) was used as a trigger for coagulation The solution was prepared according 
to the instructions of the manufacturer The intrinsic pathway was triggered by Actin FS, 
activated PTT reagent from soy phosphatides, containing 1 10 4 M ellagic acid and was 
obtained from Baxter 
Methods 
Kinetic parameters The hydrolysis experiments were run in buffer A at 37°C The liberation of 
p-nitroaniline was monitored at 405 nm in a dual wavelength (405-546 nm) spectrophotometer 
made in our workshop, using a personal computer for data recording In a polystyrene 
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microcuvette (total volume 500 μι), buffer A and substrate solution were added to obtain a 
final substrate concentration between 1 to 2000 μΜ After 5 min of incubation at 37°C, enzyme 
solution was added to achieve a final concentration between 0 5 to 100 nM The measurement 
was earned out at 37°C in a thermostated cuvette-holder The Michaelis constant (K
m
) and the 
catalytic constant (k
cat) were obtained by measuring initial reaction velocities at different 
substrate concentrations The data obtained were fitted by linear regression on the Michaelis-
Menten equation 
Factor Xa inhibition experiments8 In a polystyrene microcuvette were added buffer A (the 
substrate to be tested on inhibitory effects on factor Xa in the concentration range between 0 to 
1000 μΜ), the chromogenic substrate CH30-CO-D-Chg-Gly-Arg-pNA AcOH at a 
concentration of 100 μΜ and factor Xa at a concentration of 1 0 nM In an other fashion the 
inhibitor (the substrate to be tested) concentration was kept at 250 μΜ and the chromogenic 
substrate concentration (CH30-CO-D-Chg-GIy-Arg-pNA AcOH) was varied between 25 to 
1000 μΜ at the same enzyme concentration Both measurements were carried out in a total 
volume of 500 μι at 37°C Optical density was measured as above 
Continuous registration of the thrombin generation curve Extrinsic pathway In a polystyrene 
microcuvette were added 400 uL defibrinated plasma, 20 pL of a 45 μΜ phospholipid solution 
(final concentration 1 5 μΜ), 140 μι of buffer A which contains the substrate at the desired 
final concentration (100-2000 μΜ) After 4 min of incubation at 37°C, 20 μL· tissue factor 
(undiluted) was added Thrombin generation was started by adding 20 μι of a 0 5 M CaCl2 
solution (final concentration 16 67 mM), dunng the measurement the temperature was kept at 
37°C The optical density was monitored at 405 nm From the obtained optical density curve, 
the first derivative was calculated This gives the enzyme concentration during the 
measurement Intrinsic pathway 400 μι defibrinated plasma, 110 μ ι buffer A (eventually 
containing the substances to be tested) and 40 \iL Actin FS (undiluted) were added in a plastic 
microcuvette, intensively mixed and incubated at 37°C during 4 min Then 30 μ ι of a 10 mM 
substrate solution (final concentration 500 μΜ), followed by 20 μι of a 0 5 M СаСІг solution 
(final concentration 16 7 mM) were added (both solutions were prewarmed at 37°C for 4 
mm) The optical density was measured at 37°C at 405 nm during 20 mm 
Decay constants of thrombin m plasma To 120 μΙ_. defibrinated plasma was added 50 \¡L of 
buffer A which contained the substrate at a concentration range between 0 to 2000 μΜ To this 
mixture was added 10 μ!, of a thrombin preparation to achieve a final concentration of 100 nM 
At regular time intervals (5-10 s) 10 μι samples were subsampled into 490 μι buffer В which 
contained 200 μΜ of S2238 to determine thrombin activity After 2 min the reaction was 
stopped by adding 300 \iL IM citnc acid The moment of sampling and stopping were recorded 
on a personal computer with pushbutton-equipped pipettes The optical density was then read 
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at 405 nm and the obtained amidolytic activities were used to calculate the decay constants The 
obtained decay constant is the sum of the decay constants of the reaction of thrombin with 
antithrombin III (k^ and a2-macroglobulin (k2) 
Manual determination of thrombin generation in plasma Extrinsic pathway To 480 μ ι 
defibnnated plasma were added 172 uL buffer A which contains the substrate at concentrations 
between 0 to 2000 μΜ and 20 pL of a 54 μΜ phospholipid solution (final concentration 1 5 
μΜ) After incubation of 4 mm at 37°C, 24 μι tissue factor (undiluted) was added Thrombin 
formation started at zero time by adding 24 μι of a 0 5 M CaCl2 solution (final concentration 
16 67 mM) At regular time intervals of 12 s samples of 10 μι were subsampled as described 
above From the amidolytic activities thus obtained, the thrombin generation curve can be 
drawn The decay constant k2 can be calculated from these data in an alternatively way, see 
reference 9 for further details Intrinsic pathway To 480 μι defibnnated plasma were added 
168 μ ι buffer A which contains the substrate at concentrations between 0 to 1000 μΜ and 48 
μι Actin FS (undiluted) This mixture was intensively mixed and incubated for 4 min at 37°C 
Thrombin generation was started at zero time by adding 24 pL of a 0 5 M CaCl2 solution (final 
concentration 16 67 mM) 
Influence of the substrate on the prothrombinase-complex With the obtained decay constants 
and from the curves obtained by the subsampling method we calculated the course of 
prothrombin conversion and the course of prothrombinase concentration 
RESULTS 
Kinetic parameters In a preliminary experiment, the substrate was hydrolyzed under the 
following conditions enzyme concentration 10 to 20 nM, substrate concentration 200 μΜ in 
buffer A to get an impression of the initial velocity From these data (not shown) the conditions 
at which the substrate was hydrolyzed to obtain the kinetic parameters K
m
 and k
cal were 
selected The results are given in table 1 and 2 for thrombin and factor Xa respectively The K
m 
and k
cat for each substrate were determined from the initial velocities measured for at least six 
substrate concentrations in the concentration range as given The enzyme concentration used 
gives a good signal to noise ratio The data given are obtained from one or two experiments 
The data from table 1 and 2 were only used as the first selection criterion to get a rough 
impression of the hydrolysis behaviour Notwithstanding the preliminary character of the 
measurement it was helpful in the design of the substrates of our interest The narrow substrate 
concentration range used in entries 6, 7 and 25 is due to the restricted water solubility of the 
substrates 
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Factor Xa inhibition experiments With the substrates of interest (entries 5, 8 and 12) no 
detectable initial velocities or very bad signal to noise ratios were observed when hydrolyzed 
by factor Xa This can be a result of substrate inhibition or factor Xa shows no proteolytic 
activity on these substrates From these data our experiments give reason to exclude inhibition 
of factor Xa We found that the initial velocity of substrate hydrolysis remains unaltered by 
changing "inhibitor" concentration In addition, the Lineweavcr-Burk plots obtained at different 
"inhibitor" concentrations show no difference with that obtained from a control experiment. 
Continuous registration of the thrombin generation curve After application of the first two 
selection criteria only four substrates (entries 5, 8, 12 and 22) were selected for evaluation in 
the continuous registration of thrombin formation in plasma, see figure 1-5 and compared to 
SQ68, our reference All of them show the characteristic thrombin generation curve, but the 
signal to noise ratio and the degree of substrate conversion is strongly substrate dependent On 
basis of a low degree of substrate conversion when thrombin formation is over and a 
reasonable signal to noise ratio only one substrate (entry 12 2HC1 H-Val-Arg-pNA) remained 
The continuous thrombin generation curves triggered by Actin FS are given for SQ68 
(reference) and 2HC1 H-Val-Arg-pNA, see figure 8 
Decay constants of thrombin in plasma The decay of thrombin in a plasma sample gives 
information about the influence of the substrate on the efficiency of antithrombin III AT-III as 
well as substrate compete for the active-site of thrombin In the presence of substrate, thrombin 
decay must be minimally influenced by substrate, that means thrombin decay in the presence of 
substrate should be approximately the same as in the control experiment In table 3 the data of 
thrombin decay in the presence of substrate 2HC1 H-Val-Arg-pNA are given Compared to the 
decay constants of SQ68 (given in reference 1 ) it can be concluded that 2HCI H-Val-Arg-pNA 
interferes to a lesser extent with AT-III This is in agreement with a higher Km value which is 
inversely proportional to competitive interaction with AT-III 
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Table 1: Kinetics of hydrolysis of a number of defined substrates by human α-thrombin in 
buffer A at 37° С 
No Substrate 
1 2HC1 H-D-Phe-Pip-Arg-pNA 
2 2HC1 H-D-Phe-Pro-Arg-pNA 
3 2HC1 H-D-Phe-Pip-Lys-pNA 
4 2HC1 H-D-Phe-Pro-Lys-pNA 
5 2HC1 H-D-Phe-Pip-Om-pNA 
6 HCl H-D-Phe-Pip-NIe-pNA 
7 HCl H-D-Phe-Pro-Nle-pNA 
8 HCl H-D-Phc-Pip-Glu-pNA 
9 2HC1 H-Gly-Arg-pNA 
10 2HC1 H-Ala-Arg-pNA 
11 2HC1 H-D-Ala-Arg-pNA 
12 2HC1 H-Val-Arg-pNA 
13 2HC1 H-D-Val-Arg-pNA 
14 MZ-Gly-Arg-pNA HCl 
15 MZ-Ala-Arg-pNA HCl 
16 MZ-D-Ala-Arg-pNA HCl 
17 MZ-Aib-Arg-pNA HCla 
18 MZ-Val-Arg-pNA HCl 
19 MZ-D-Val-Arg-pNA HCl 
20 MMZ-Gly-Arg-pNA HCl 
21 MMZ-Ala-Arg-pNA HCl 
22 DMMZ-Gly-Arg-pNA HCl 
23 DMMZ-Ala-Arg-pNA HCl 
24 DEMZ-Gly-Arg-pNA HCl 
25 ßNS-Gly-Arg-pNA HCl 
26 pTS Gly-Arg-pNA HCl 
27 2HC1 H-Gly-Val-Arg-pNAb 
28 Boc-Gly-Val Arg-pNA HCIb 
NH not hydrolyzed by thrombin, afrom 
described in chapter 4 
[S] 
μΜ 
2-200 
1 200 
1 500 
1-200 
10-1000 
10-200 
20-500 
25-2000 
250-2000 
250-2000 
250-2000 
250-2000 
250-2000 
250-4000 
125-2000 
250-2000 
250-2000 
125-2000 
250-2000 
250-2000 
250-2000 
250-2000 
250-2000 
250-2000 
250-750 
250-2000 
50-1000 
5-1000 
reference 1, bused as 
IE) 
nM 
0 5 
0 5 
0 5 
0 5 
25 
50 
25 
50 
50 
50 
100 
50 
50 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
50 
50 
50 
1 
1 
K
m 
μΜ 
5 62 
3 16 
65 11 
35 04 
4199 
943 3 
87 9 
473 8 
2282 
1140 
4083 
1239 
4247 
2537 
1539 
1330 
830 
1007 
1312 
1737 
666 
902 
565 
866 5 
-
-
1638 
244 
lead structure in 
^cat 
s"' 
236 5 
28 4 
1183 
90 4 
4 64 
11 4 
6 66 
0 35 
0 107 
0 074 
0 096 
0 23 
0 28 
123 
107 5 
0 059 
0 46 
14 4 
0 146 
6 60 
16 5 
6 44 
4 08 
1 73 
NH 
NH 
16 54 
11 2 
Ксаг*тп 
(Ms)"1 
4 21E7 
8 99E6 
1 82E6 
2 58E6 
1 11E4 
1 21E4 
7 54E4 
7 39E2 
4 69E1 
6 49E1 
2 35E1 
1 86E2 
6 59E1 
4 85E3 
6 99E4 
4 44E1 
5 54E2 
1 43E4 
1 11E2 
3 80E3 
2 48E4 
7 14E3 
7 22E3 
1 99E3 
-
-
101E4 
4 59E4 
the design of substrates as 
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Table 2: Kinetics of hydrolysis of a defined number of substrates by human factor Xa in 
buffer A at 37°C. 
No 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
NH not 
Substrate 
2HC1 H-D-Phe-Pip-Arg-pNA 
2HC1 H-D-Phe-Pro-Arg-pNA 
2HC1 H-D-Phe-Pip-Lys-pNA 
2HC1 H-D-Phe-Pro-Lys pNA 
2HC1 H-D-Phe-Pip Om-pNA 
HCl H-D-Phe Pip Nle-pNA 
HCl H-D-Phe-Pro-Nlc-pNA 
HCl H-D-Phe Pip-Glu-pNA 
2HC1 H-Gly Arg pNA 
2HC1 H-Ala-Arg-pNA 
2HC1 H-D-Ala-Arg-pNA 
2HC1 H-Val-Arg-pNA 
2HC1 H-D-Val-Arg pNA 
MZ-Gly-Arg pNA HCl 
MZ-Ala-Arg-pNA HCl 
MZ-D-Ala Arg-pNA HCl 
MZ-Aib-Arg-pNA HCla 
MZ-Val-Arg-pNA HCl 
MZ-D-Val Arg pNA HCl 
MMZ-Gly-Arg pNA HCl 
MMZ-Ala-Arg-pNA HCl 
DMMZ-Gly-Arg-pNA HCl 
DMMZ-Ala-Arg-pNA HCl 
DEMZ-Gly-Arg-pNA HCl 
ßNS-Gly-Arg-pNA HCl 
pTS-Gly-Arg-pNA HCl 
2HC1 H-Gly-Val-Arg-pNA 
Boc-Gly-Val-Arg-pNA HCl 
[S] 
μΜ 
50-1500 
50-2000 
250 1500 
ND 
ND 
5-500 
ND 
250-1500 
ND 
ND 
ND 
250 2000 
ND 
250-3000 
250-3000 
250-2000 
250-2000 
250-2000 
250-2000 
250-3000 
250-3000 
250 3000 
250-3000 
250-2000 
50-1500 
25-1500 
250-1500 
250 1500 
[E] 
nM 
10 
10 
25 
-
-
25 
-
50 
-
-
50 
-
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
10 
10 
25 
25 
K
m 
μΜ 
174 4 
693 
963 
-
-
-
-
-
-
-
-
-
-
4700 
5593 
3084 
3940 
2569 
1821 
6402 
7054 
2838 
22422 
2321 
116 
233 
2679 
959 
*cat 
S"· 
7 49 
187 
061 
-
NH 
-
NH 
-
-
-
NH 
-
55 0 
51 7 
0 088 
2 9 
6 42 
0 13 
43 9 
40 6 
136 
11 04 
4 54 
200 
9 26 
3 51 
1 90 
^cat^n 
(Ms) ' 
4 29E4 
2 69E4 
6 31Ь2 
-
-
-
-
-
-
-
-
1 17E4 
9 25E3 
2 85E1 
7 38E2 
2 50E3 
6 95E1 
6 86E3 
5 75E3 
4 79E3 
4 93E3 
1 96E3 
1 73E4 
3 98E4 
1 31E3 
1 98E3 
hydrolyzed by factor Xa, ND not determined, afrom reference 1 
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250 
200 400 600 
time (s) 
800 1000 
— H-V«l-Arg-pNA — H-D-Pbe-Pip^îlu-pNA 
2500 
400 600 
time (s) 
1000 
DEMZ-Gly-Arg-pNA — H-D-Phe-Pip-Om-pNA 
Figure 1: Continuous optical density curves obtained from tissue factor triggered plasma 
using the substrates (upper frame): 2HCI.H-Val-Arg-pNA and HCl.H-D-Phe-Pip-Glu-pNA; 
(lower frame): DEMZ-Gly-Arg-pNA.HCl and 2HCl.H-D-Phe-Pip-Orn-pNA at 500 μΜ. 
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1000 
— - 300 μΜ — 400 μΜ — 500 μΜ - — 600 μΜ Ι 
Figure 2: Continuous optical density curves obtained from tissue factor triggered plasma 
using HCl.H-D-Phe-Pip-Glu-pNA as substrate. P 
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250 
400 
time (s) 
800 
25 μΜ —- 50цм| 
2000 
400 
time (s) 
ΙΟΟ μΜ — 250 μΜ —- 500 μΜ 
Figure 3: Continuous optical density curves obtained from tissue factor triggered plasma 
using 2HCI.H-D-Phe-Pip-Orn-pNA as substrate. 
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200 400 
time (s) 
600 800 
I —— 25 μΜ -~- 50 μΜ 
1200 
400 
time (s) 
800 
250 μΜ —*- 500 μ.Μ , 
Figure 4: Continuous optical density curves obtained from tissue factor triggered plasma 
using DEMZ-Gly-Arg-pNA.HCI as substrate. 
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300 
1200 
— 100 μΜ — 200 μΜ - — 500 μΜ 
1000 
200 400 600 
time (s) 
800 1000 1200 
I — 1000 μΜ -— 1500 μΜ - — 2000 μΜ Ι 
Figure 5: Continuous optical density curves obtained from tissue factor trieeered nlasma 
using 2HCI.H-Val-Arg-pNA as substrate. 
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Manual determination of thrombin formation m plasma and the influence of substrate on the 
prothrombinase-complex The thrombin generation curves obtained by the subsampling method 
are given in figure 6 As can be seen the peak of the curve is shifted to the right at increasing 
substrate concentration This unfortunately means that the maximum of thrombin concentration 
is at a later point of time The maximum of the curve increases at increasing substrate 
concentration due to the diminished action of antithrombin ΠΊ in the presence of substrate The 
a2-macroglobulin concentration is in each of the four cases the same, from these data k2 can be 
determined in an alternative way, the obtained decay constants are shown in table 3 
From the velocity of thrombin formation and the decay constants, the activity of the 
prothrombinase-complex can be calculated, the results are shown in figure 7 As can be seen 
these curves have a lower maximum The thrombin generation curves obtained by activating 
the intrinsic pathway are given in figure 9 and 10 
Table 3: Decay constants of euglobuhn thrombin in plasma in the presence of different 
substrate concentrations (2HCI.H-Val-Arg-pNA). 
IS] koverall k l k 2 4/2 k 2 M k l corr ( k l corr> 
μΜ min ' min ' min ' s min ' min ' min ' 
0 2 520 2 137 0 383 16 51 0 298 2 052 1508 
100 2 317 2 064 0 253 17 95 ND ND ND 
200 2 154 1751 0 402 19 31 0 234 1750 1286 
500 1898 1509 0 389 2191 0 207 1521 1118 
1000 1879 1676 0 204 27 12 0 199 1510 1110 
1500 1 217 1 087 0 130 34 17 ND ND ND 
2000 1005 0 877 0 128 41 37 ND ND ND 
k
overall = k i + k 2 + 0 170, kj AT III dependent decay of thrombin, k2 α2Μ dependent decay of thrombin, 
k
overall' k l a n c* k 2 " * determined in a decay experiment k2 м
 k 2 determined by the subsampling method, 
k l corr k l a f t e r correcting for k2 M and 0 170, k, c o r r c o n t r o l / l 508 = 2 052/1 508 = 1 361 μΜ AT III, 
( k l (,οιτ) = k l corr" 361, ND not determined 
DISCUSSION 
As mentioned earlier the kinetic data of hydrolysis m tables 1 and 2 are despite their preliminary 
character valuable tools in the design of substrates 
Entries 1-8 are derived from S2238 The sequence H-D-Phe-Pip(Pro)-R is so optimal for 
thrombin that even neutral or acidic side chain-containing amino acids in position Pi are prone 
to hydrolysis As expected the k
cat is low but the Km value is still too low for our purpose, this 
is somewhat disappointing R was chosen on the basis of known inhibitors of thrombin10 13, 
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300 
— control - — 200 μΜ — 500 μΜ — - 1000 μΜ 
Figure 6: Thrombin generation curves from tissue factor triggered plasma obtained by the 
subsampling method. The influence of additional 2HCl.H-Val-Arg-pNA at different 
concentrations on thrombin generation. 
700 
100 200 300 400 500 
time (s) 
600 700 
— control — 200 μΜ I 
(Figure 7 Continued on the next page) 
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700 
300 400 
time (s) 
, -«— control — 500 μ.Μ 1000 μΜ ¡ 
Figure 7: The influence of 2HCI.H-Val-Arg-pNA on the prothrombinase activity in tissue 
factor triggered plasma, upper frame (previous page): control and 200 μΜ; lower frame: 
control, 500 and 1000 μΜ 2HCI.H-Val-Arg-pNA 
they mostly were poorer inhibitors due to insufficient interaction with respect to the 
corresponding arginine derivatives; this means that such substrates have higher K
m
 values. As 
can be seen from table 2, factor Xa is more restricted in the variation of the amino acids at the 
Pi position. This can be used to enhance the selectivity to the advantage of thrombin. 
Entries 9-24 are designed as a variation of SQ68 (entry 17). All these substrates contain an 
arginine residue at the Pi position. The P2 residue mainly determines the hydrolysis behaviour. 
A free N-terminus reduces the hydrolysis rate drastically and results in fairly high K
m
 values 
(entries 9-13). Substituting an apolar group at the N-terminus (which can be seen as а Рз 
amino acid) results in better substrates. Enhancing hydrophobicity at this position reduces both 
kCM and Km (entries 14-24). At the same time, the bulkiness and position of the amino acid side 
chain is very important, too small (glycine) or too sterically demanding (valine) reduces the 
hydrolysis rate. When the configuration is not correct, the hydrolysis rate is drastically 
reduced. Noteworthy is the fact that substrates with valine at position P2 are better hydrolysed 
by thrombin than the corresponding glycine containing derivatives. From structure-activity 
relationships14 and X-ray studies15 it was found that amino acids in the P2 position should be 
small hydrophobic residues, preferentially proline. The loose fit of a glycine residue results in 
reduced interaction and thus in a higher K
m
 value. A valine residue at this position offers 
stronger binding but less than found with proline. This results in a moderate increase in K
m 
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value and helps designipg a substrate with an optimal K
m
 value for the enhancement of the 
selectivity for thrombin, factor Xa favors glycine residues at this position16 This can be 
explained on a molecular basis from the crystal structure of factor Xa which was recently 
resolved17 The three dimensional space of the S2 subsite is dramatically reduced by insertion 
of the side chain of Tyr99, since only glycine or a residue with a small side chain can be 
accommodated This is confirmed by entries 25 and 26 No detectable hydrolysis occurs when 
thrombin is used whereas factor Xa splits these substrates at considerable rates From 
crystallographic studies of trypsin-18 and thrombin-complexes19 with small active-site-directed 
inhibitors the hydrolysis behaviour of the substrates from entries 25 and 26 may be understood 
by the following explanation In the crystal structure of NAPAP (Na-(2-naphtalenesulfonyl-
glycyl)-DL-p-amidinophenylalanyl-pipendine) with bovine ε-thrombin20, the ß-naphtalene 
group is almost perpendicular to the indole moiety of Trp215 and interacts with the aryl-
binding site of thrombin The carboxy-terminal pipendine ring has an optimal interaction with 
the characteristic hydrophobic S2 binding site of thrombin This results in a binding mode in 
which the carboxyl group connecting the pipendine ring points away from the Seri95 side 
chain Thrombin complexed with 4-TAPAP (Na-(toluenesulfonyl)-DL-/?-amidinophenylalanyl-
pipendine) is somewhat different in comparison with the thrombin/NAPAP complex The 
toluene group interacts less efficiently with the aryl-bmding site of thrombin which results in a 
looser fit of the pipendine ring into the hydrophobic S2 binding pocket This maybe give some 
space for interactions with Ser 195 Translating this knowledge to the observations we made, 
we can understand why pNS-Gly-Arg-pNA HCl (entry 25) is not attacked by thrombin The p-
mtroaniline ring interacts in a similar way as the pipendine nng in NAPAP with the thrombin 
hydrophobic binding pocket due to the steering effect of the ß-naphtalene ring This way of 
binding results that a nucleophilic attack of Ser 195 on the p-nitroanihde bond cannot take place 
preventing hydrolysis The tosyl function of pTS-Gly-Arg-pNA HCl (entry 26) causes more 
space to the p-nitroanihne ring so some interactions with the Seri 95 side chain may occur 
which results in substrate hydrolysis Indeed we found that the initial velocity of hydrolysis of 
pTS-Gly-Arg-pNA HCl is very slow in contrast to (JNS-Gly-Arg-pNA HCl which shows no 
hydrolysis at all This is confirmed by inhibition constants of the different inhibitors Indeed 
the K, value of NAPAP21 is two orders of magnitude lower than the value of Na-
(toluenesulfonyl-g/ycv/)-DL-/?-amidinophenylalanyl-pipendine22 (0 0066 respectively 0 64 
μΜ) 
Entries 27 and 28 are fibrinogen Aa-hke fragments A free N-terminus enhances the K
m
 value, 
but in this substrate (2HC1 H-Gly-Val-Arg-pNA, entry 27) k
cat is still too high Further 
research focusses on this substrate in which arginine is replaced by lysine, ornithine or 
norleucine to reduce kLat with maintenance of the high Km value Further, this substrate 
contains a valine residue at position P2 which probably enhances selectivity to thrombin 
Together with the modifications at position Pi and additional polar or small neutral amino acid 
residues at the N-terminus will result in an optimal substrate suitable in the continuous 
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registration of thrombin formation in plasma. These modifications are based on the interactions 
with the active-site of thrombin15 and from data obtained from the interactions of fibrinogen 
fragments on thrombin by structure-activity relationships2326, NMR data2 7 - 2 9 and X-ray 
data30-31 (see chapter 4 and 5). 
On basis of the kinetic constants, four substrates were submitted to test in the continuous 
registration of thrombin generation in plasma (figure 1). Each substrate gives the characteristic 
thrombin generation curve. The substrate HCl.H-D-Phe-Pip-Glu-pNA (entry 8; figure 2) gives 
a bad signal to noise ratio and measurement at higher concentrations is difficult due to the 
restricted water solubility. This is in contrast to the substrates 2HCl.H-D-Phe-Pip-Orn-pNA 
(entry 5; figure 3) and DEMZ-Gly-Arg-pNA.HCl (entry 22; figure 4) which show very good 
signal to noise ratios but these substrates are still too good for thrombin (20 to 50% of the 
initial substrate is consumed during the thrombin generation). Additionally, DEMZ-Gly-Arg-
pNA.HCl shows too much activity on factor Xa so competitive inhibition with the 
endogeneous factor Xa substrate can not be excluded during the thrombin generation process. 
The substrate 2HCl.H-Val-Arg-pNA (entry 12; figure 5) shows a good signal to noise ratio 
and at highest substrate concentration the conversion is below 10%. The interaction of this 
substrate with factor Xa is neglectable whilst SQ68 shows a considerable interaction. Based on 
these results 2HCl.H-Val-Arg-pNA could be a better substrate than SQ68 for the continuous 
registration of thrombin formation in plasma, but this conclusion will only be valid if 2HC1.H-
Val-Arg-pNA does not affect the prothrombinase-complex. 
The decay constants of thrombin in plasma in the presence of the substrate 2HC1.H-Val-Arg-
pNA show a slighter drop than in the case of SQ68 (see reference 1). This means that 2HCI.H-
Val-Arg-pNA competes at a lesser degree with АТ-Ш for the active-site of thrombin than SQ68 
does. 
In the manual determination of the thrombin generation curve the peak value increases with 
increasing substrate concentration, due to the interaction of the substrate with the active-site of 
thrombin (figure 6). As a consequence, AT-III acts less efficiently in the deactivation of 
thrombin. Additionally, the peak value appears at a later point of time even at low substrate 
concentrations. Both effects were also seen in the case of SQ68 but the delaying effect only 
occurs at high substrate concentration. 
Finally, when the influence of 2HCl.H-Val-Arg-pNA on the prothrombinase-complex is 
calculated, the substrate clearly decreases its concentration (figure 7). This was also seen in the 
case of SQ68 but now it starts at a remarkebly lower substrate concentration. These results 
make clear that 2HCl.H-Val-Arg-pNA possesses an unexpected inhibitory effect. This means 
that 2HCl.H-Val-Arg-pNA is at best equal to SQ68 in the continuous registration of thrombin 
formation in plasma. 
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How can the lower prothrombinase concentration be explained? The substrate 2HC1.H-Val-
Arg-pNA may be a competitor of i) factor Vila, ii) factor Xa in the prothrombinase-complex or 
iii) the feedback-loop activation of factor V and/or factor Ш by thrombin. 
Factor Vila plays a key role in the extrinsic pathway of coagulation. It forms a complex with 
tissue factor (TF) which activates factor X and factor IX, thereby leading to the initiation of the 
coagulation cascade32. Recent research shows the rate enhancing effect of TF on factor Vlla-
catalyzed hydrolysis of synthetic substrates33. It remains unclear what the molecular basis is of 
this altered substrate specificity. It is postulated that complex formation with TF results in a 
conformational change in factor Vila serine protease domain. In the presence of TF, factor Па 
is inhibited by H-Ile-Glu-Gly-Arg-CH2C134, a highly specific factor Xa inhibitor35. It 
hydrolyses different chromogenic- and fluorogenic substrates which are consistent with 
structural requirements resembling thrombin specificity33e. Additionally, thrombin-specific 
substrates show the largest TF-enhanced rate factors36. For full activity, factor Vila needs 
phospholipids, Ca2+ and tissue factor. In our test-system all these requirements are met, so it 
may be possible that the factor Vila-affinity for 2HCl.H-Val-Arg-pNA is substantially 
enhanced by TF, so that the hydrolysis of the natural substrates (factor X and factor IX) will be 
inhibited resulting in a lower prothrombinase concentration. To check this assumption we 
performed the following experiment. Factor X was activated by TF/r-FVIIa in the presence of 
phospholipids and Ca2+ in an aqueous buffer (Tris-HCl, pH = 7.9). The amount of factor Xa 
was measured with СНзО-CO-D-Chg-Gly-Arg-pNA.AcOH. To this reaction medium different 
concentrations of 2HCl.H-Val-Arg-pNA were added. Even at 1000 μΜ of 2HC1.H-Val-Arg-
pNA the amount of factor Xa was not significantly lowered what means that the dipeptide 
substrate has no inhibitor activity on TF/r-FVIIa37. In a second control experiment, thrombin 
generation triggered by Actin FS leading to the activation of the intrinsic pathway (see figure 8 
and 9) was carried out and the influence on the prothrombinase-complex was studied. After 
calculating the prothrombinase concentration it seems that the prothrombinase concentration is 
not lowered at higher substrate concentration (see figure 10). This means that, in the absence of 
factor Vila, factor Xa assembled on the prothrombinase-complex is not inhibited by 2HC1.H-
Val-Arg-pNA. 
In both activation pathways the peak of the prothrombinase concentration is shifted to a later 
point of time (see table 4). This means that the feedback-loop activation of factor V and factor 
ІП by thrombin is inhibited in the presence of 2HCl.H-Val-Arg-pNA. The K
m
 value and the 
high substrate concentration result in a substantial decrease of thrombin which is available for 
the activation of factor V and factor VIII with a lag-phase in prothrombinase concentration as 
the result. 
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Table 4: Time-point at which the maximum of the amidolytic activity, prothrombinase 
activity and thrombin concentration occur at different substrate concentrations. 
Extrinsic 
[S] 
0 
200 
500 
1000 
pathway 
AA 
250 80 
248 28 
269 33 
298 74 
Intrinsic pathway 
[S] 
0 
200 
500 
AA 
360 65 
402 54 
399 87 
t 
72 
84 
85 
96 
t 
96 
106 
120 
PT 
676 20 
613 14 
606 58 
649 40 
PT 
1722 
1787 
1733 
t 
24 
24 
36 
48 
t 
72 
94 
107 
Τ 
234 75 
229 64 
248 88 
278 03 
Τ 
348,58 
399 50 
397 60 
t 
60 
72 
85 
96 
t 
84 
106 
120 
1000 448 98 180 1636 168 440 76 180 
AA amidolytic activity (mOD/min), PT prothrombinase concentration (mOD/min), Τ thrombin concentration 
(mOD/min), t time-point at which maximum of concentration (amidolytic activity) is achieved (s), [S] 
substrate concentration, 2HC1 H Val-Arg-pNA (μΜ) 
1000 
, — - MZ-Aib-Arg-pNA — - H-Val-Arg-pNA 
Figure 8: Continuous optical density curves from intrinsic triggered plasma (Actin FS) 
using SQ68 and 2HCl.H-Val-Arg-pNA as substrates at a concentration of 500 μ Μ . 
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Figure 9: Thrombin generation curves from intrinsic triggered plasma (Actin FS) obtained 
by the subsampling method. The influence of additional 2HCl.H-Val-Arg-pNA at different 
concentrations on thrombin generation. 
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Figure 10: The influence of 2HCl.H-Val-Arg-pNA on the prothrombinase activity in 
intrinsically triggered plasma. 
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CONCLUSION 
From the 28 peptide p-nitroamlides we screened in this study, only one fulfills the entena for 
the use in the continuous registration of thrombin formation in activated plasma 
This substrate, 2HC1 H-Val-Arg-pNA shows low k
cat and high Km values on thrombin, but is 
still selective to this enzyme Furthermore, it is proteolytically stable to factor Xa and gives no 
inhibition on factor Xa In the continuous registration of thrombin formation it gives a good 
signal to noise ratio and the substrate conversion is below 10% what means that substrate 
inhibition is constant during the thrombin generation Comparing these results with SQ68 we 
conclude that 2HC1 H-Val-Arg-pNA is a good candidate to replace SQ68 in the continuous 
determination of thrombin formation in plasma 
Further research is in progress with 2HCI H-Val-Arg-pNA as lead structure to come to more 
selective substrates which fulfill our requirements to a better extent 
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CHAPTER 4 
THE SYNTHESIS OF CHROMOGENIC SUBSTRATES FITTING 
THROMBIN LIKE FIBRINOGEN Act 
ABSTRACT 
A series of 18 peptide p-nitroanilides was synthesized. The lead structure was derived from 
human fibrinogen Aa(7-16) decapeptide since this fragment constitutes the minimal sequence 
which binds to thrombin with high affinity. In this sequence Glul 1 participates in an important 
salt-bridge to Arg 173 of thrombin; Gly 12 is involved in a type II ß-tum enabling the fold-back 
of the side chains of Phe8 and Leu9 for interaction with the active-site. This chapter deals with 
the synthesis of substrates to be used in an investigation into the structure-activity relationship 
of the substrates and thrombin. To this end the role of the guanidinium group in Arg 16 was 
considered by the exchange of this residue against Lys, Om or Nie in the C-terminal tripeptide 
p-nitroanilides. We similarly considered the glycyl-spacer by extension of the fragment Glu-
(Gly)n-Val-Argl6-pNA to three units and stepwise shortening to zero, respectively by 
replacement of Gly 12 or Gly 13 of the extended chain by Pro, to mimic a ß-tum. Finally, the N-
terminus of the substrate Val-Arg-pNA was substituted with the polar 2-
(methylsulfonylethyl)oxycarbonyl group (Msc) whilst the arginine residue was substituted for 
Lys, Orn or Nie. 
INTRODUCTION 
Fibrinogen is the natural substrate of thrombin. It is a covalently linked dimer of three peptide 
chains: Αα, Bß and γ. The general structure can be given by (ΑαΒβγ^1. 
Thrombin catalyzes the hydrolysis of peptide bonds involving the carboxyl group of arginine; 
in fibrinogen Arg 16 (Act-chain) and Arg 14 (Bß-chain) are attacked, releasing the 
fibrinopeptides A and В respectively and leaving the fibrin monomer (αβγ)2· This monomer 
polymerizes which results in the formation of the blood clot. 
The cleavage of fibrinogen by thrombin is highly specific since only four Arg-Xaa or Lys-Xaa 
bonds of the 376 present will be hydrolyzed2. This remarkable specificity is confined to the N-
terminal henpentacontapeptide fragment of the Aa-chain3. In this region, fragment 1 -23 (see 
figure 1) which also contains these combinations, interacts with the active-site and is most 
important for the observed specificity4. Additional specificity is introduced by fragment 30-44, 
which interacts with the fibrinogen recognition exosite; this site is of major importance for 
binding of thrombin to other proteins5 (see chapter 6). 
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H-Ala-Asp-Ser-Gly-GIu5-Gly-Asp-P/ie-Leu-Ala10-
-Glu-Gly-Gly-Gly-Va/15-Arg-Gly-Pro-Arg-Val20-
-Val-Glu-Arg-OH 
Figure 1: Sequence of human fibrinogen Aot(l-23) tricosapeptide (I). 
By active-site mapping studies insight was obtained into the contribution of each of the 
individual ammoacyl residues to the hydrolysis rate and demands of specificity It was found 
that the aminoacyl residues located at the C-terminal of Pro 18 do not contribute substantially in 
binding to thrombin6 
van Nispen demonstrated earlier7 that the presence of residues Phe8 and Leu9 greatly enhances 
the rate of catalytic hydrolysis of the Arg 16-Gly 17 bond by thrombin This has been confirmed 
by NMR measurements of complexes of the fibrinogen fragments (1-23)8 and (7-16)9 and 
thrombin These experiments explained why Asp7, Phe8 and Gly 12 had to be conserved in 
mammelian fibrinogens and also that a mutation Asp7 -» Asn and Gly 12 -» Val resulted in 
human bleeding disorders10 When bound to thrombin, the peptide chain undergoes a 
direction-reversal between Asp7 and Arg 16, enabling the side chain of Phe8 to fold back into 
the aryl-binding site of the active-site Similarly, the side chains of Leu9 and Val 15 are bound 
into the apolar binding pocket of thrombin11, resulting in the occupation of both binding 
pockets as demonstrated with the inhibitor H-D-Phe-Pro-Arg-CH2Cl and congeners The 
reversal of the chain-direction demands a conformation of the aminoacyl residue at position 12, 
which is incompatible with the presence of other residues than glycyl Recently, the crystal 
structure was determined of thrombin complexed with an analogue of fibnnopeptide A12 This 
investigation confirmed the reversal of the chain-direction, and the mentioned hydrophobic 
interactions It was also found that Glul 1 of the peptide forms a salt-bridge with Argl73 in 
thrombin, thus stabilizing the peptide within the active-site cleft of the enzyme In contrast to 
earlier work13, no interactions of Asp7 and thrombin were observed The reason of a bleeding 
disorder characterized by the occurrence of fibrinogen Lille (Asp7 -» Asn) remains unclear14 
The N-terminal hexapeptidyl part of the substrate points away from the enzyme and extends 
freely into solution These experiments lead to the conclusion that the sequence Phe8-Argl6 
enables the highly specific binding interactions of compound I and congeners with thrombin15 
We decided to synthesize small peptide p-nitroanilides derived from compound I in which Phe8 
and Leu9 were omitted to arrive at substrates, which are attacked by thrombin, with modified 
kinetic parameters Fitting our continuous assay16 
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The approach was based on a report17 in which chloromethylketones of peptide fragments 
related to fibrinopeptide A were found to be recognized differently by thrombin when the 
positions 8, 9 and 12 were substituted with residues other than Phe, Leu and Gly respectively. 
The lead structures employed in this study were valylarginine p-nitroanilide and 
glycylvalylarginine p-nitroanilide Using the methods described in chapter 1 and 2, a general 
racemization-free synthesis was developed for compounds of the type Y-Val-X-pNA. The 
compounds synthesized in this study are given in table 1 
Table 1: Substrates of the type Y-Val-X-pNA fitting the active-site of thrombin like 
fibrinogen. 
Code Derived from Code 
H 
Msc 
Msc 
Msc 
Msc 
H Gly 
H-Gly 
H-Gly 
H-Glu 
H-Glu-Gly 
H-Glu-Gly-Gly 
H-Glu-Gly-Gly Gly 
H-Glu-Gly-Pro-Gly 
H-Glu-Pro-Gly-Gly 
Lys 
Arg 
Lys 
Om 
Nie 
Lys 
Om 
Nie 
Arg 
Arg 
Arg 
Arg 
Arg 
Arg 
l a 
2a 
2b 
2c 
2d 
3a 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
Η-Val Arg-pNA (Ch 2) 
MZ-Val-Arg-pNA (Ch 2) 
Compound I 
Boc-Gly-Val-Arg-pNA (Ch 3) 
H-Gly-Val-Arg pNA (Ch 3) 
1 
2 
3 
3 
Unprotected amino functions are suitably protonated (HCl) to give neutral solutions in plain water 
The substrates are defined herein as valine derivatives, since this aminoacyl residue, occurring 
in the P2 position and fits the S2 pocket of thrombin fairly well In the series studied, the ammo 
group of valine is either protonated or substituted either with a slim, polar aminoprotective 
function (Msc)18, or with acyl(peptidyl) groups of variable bulkiness, length and polarity 
The structure of these substrates is incompatible with the S2 pocket of factor Xa which is so 
narrow that only glycyl in position P2 will fit19 
The importance of the conspicuous glycyl-spacer (positions 12-14) in the substrate, which can 
attain a ß-turn, was studied As the second approach to affect the Km by modification of the 
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linker length and its flexibility (compounds 3a-g); the peptide chain was changed by insertion 
of Pro as a constraint either in position 13 (P4, 3h) or in position 12 (P5, 3i), cf. Kahn20. 
Variation of the length of the glycyl-spacer, affects the ability to form the salt-bridge between 
Glul 1 and Arg 173 in thrombin and this would be revealed by the value of the Km. Proline is 
known to facilitate the formation of a ß-turn and might thus replace the hydrophobic binding 
exerted by the residues Phe8 and Leu9, which causes the reversal of the peptide backbone and 
the formation of the salt-bridge. 
METHODS OF SYNTHESIS 
Syntheses with nitroanilides are incompatible with conditions which attack or remove the 
nitroanilide function; these are: treatment with strong bases for hydrolysis or ß-elimination, 
hydrazinolysis and catalytic hydrogenolysis. The necessary protective functions should be 
removable using conditions compatible with the conservation of the nitroanilide moiety. 
Excluded are thus the use of OMe and OEt for carboxyl protection, Msc for amino protection, 
preactivation of carboxylic functions with hydrazine hydrate and finally, application of most of 
the members of the benzyl "family". Acidolysis is compatible with the conservation of the 
nitroanilide function. 
Strict conservation of the chirality of aminoacyl residues excludes the activation of N-protected 
peptides with C-termini other than Gly or Pro. It is therefore risky to convert an existing 
peptide into a nitroanilide. The approaches which are compatible with this condition are 
stepwise elongation of the chain using activated N-protected amino acids and/or fragment 
condensation using azides to acylate an existing amino acid p-nitroanilide. Azides are often 
used to evade racemization during fragment condensations, on condition that neutral conditions 
are maintained and use is made of sterically hindered bases (DIPEA) to effect this. 
Compounds of the type 1 and 2 (see table 1) were obtained by acylation of the α-amino 
function of the partially protected nitroanilide X with the active ester Boc-Val-ONSu, removal 
of the N-protection by acidolysis (la), subsequent acylation with monomethyl malonate (2) or 
by acylation with Msc-Val-ONp (2a), respectively Msc-Val-ONSu (2b-d). 
Compounds of type 3 were obtained by acylation of the α-amino group of the nitroanilide X 
with acylated valine azides and subsequent treatment with acid (3, 3a-c), see scheme 1. 
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Boc-Val-ONSu + 2HCl.H-Arg-pNA -i-> Boc-Val-Arg-pNA.HCl -ii-> 
2HCI.H-Val-Arg-pNA (1) -iii-> MZ-Val-Arg-pNA.HCl (2) 
Boc-Val-ONSu + H-Lys(Boc)-pNA -i-> Boc-VaI-Lys(Boc)-pNA -«'-> 
2HCl.H-Val-Lys-pNA (la) 
Scheme 1A: i) DIPEA in DMF; ii) HCl in EtOAc/AcOH 1:1 v/v; Hi) malonic acid 
monomethyl ester, DCC/HOBt/DIPEA in DMF. 
Msc-ONSu + H-Val-OH -i-> Msc-Val-OH -н->/-ш-> Msc-Val-ONSu/Msc-Val-ONp 
Msc-Val-ONp + 2HCl.H-Arg-pNA -iv-> Msc-Val-Arg-pNA.HCl (2a) 
Msc-Val-ONSu + H-Lys(Boc)-pNA -i'v-> Msc-Val-Lys(Boc)-pNA -v-> 
Msc-Val-Lys-pNA.HCl (2b) 
Msc-Val-ONSu + HCl.H-Orn(Boc)-pNA -i'v-> Msc-Val-Om(Boc)-pNA -v-> 
Msc-Val-Om-pNA.HCl (2c) 
Msc-Val-ONSu + HCl.H-Nle-pNA -iv-> Msc-Val-Nle-pNA (2d) 
Scheme IB: i) TEA in C H 3 C N / H 2 0 4:1 v/v; ii) DCC/HONSu; iii) DCC/HONp; iv) TEA 
in DMF; v) HCl in EtOAc/AcOH 1:1 v/v. 
Compounds representing a modified glycyl-spacer were obtained by acylation of compound 1 
and 3 respectively (see scheme 2) with Boc-Glu(OlBu)-ONSu and subsequent acidolysis 
(3d,e). Similarly, the introduction of Boc-Glu(OlBu)-Gly-ONSu into compound 3 afforded 
the substrate with the shortened glycyl-spacer (3f). The introduction of the complete glycyl-
spacer was performed by acylation of 3 with Boc-Gly-Gly-ONSu, removal of the Boc-group 
and acylation with Boc-Glu(OlBu)-ONSu (3g). The modified spacers were inserted using the 
same route, replacing Boc-Gly-Gly-ONSu by Boc-Gly-Pro-ONSu (3h) or Boc-Pro-Gly-
ONSu (3i). 
Deprotection of compounds containing the Boc-Glu(O'Bu) moiety (3d-i) was performed using 
Sieber's method21, to evade ineomplete reactions as a consequence of the induced field effect 
by N a . 
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Boc-Gly-OH + HCl.H-Val-OMe -i-> Boc-Gly-Val-OMe -ÍÍ-> Boc-Gly-Va]-N2H3 
-iii-> Boc-Gly-Val-Arg-pNA.HCl (3') -iv-> 2HCl.H-Gly-Val-Arg-pNA (3) 
-iii-> Boc-Gly-Val-Lys(Boc)-pNA -iv-> 2HCl.H-Gly-Val-Lys-pNA (3a) 
-iii-> Boc-Gly-Val-Om(Boc)-pNA -i'v-> 2HCl.H-Gly-Val-Om-pNA (3b) 
-iii-> Boc-Gly-Val-Nle-pNA -/v-> HCl.H-Gly-Val-Nle-pNA (3c) 
Scheme 1С: i) DCC/HOBt/DIPEA in EtOAc; ii) N 2 H 4 . H 2 0 in MeOH; iii) 1. tert.-
BuONO/HCI at -20°C, 2. DIPEA, 3. H-Xaa-pNA/DIPEA in DMF at 0°C; iv) HCl in 
EtOAc/AcOH 1:1 v/v. 
2HCl.H-Val-Arg-pNA -i-> Boc-Glu(0'Bu)-Val-Arg-pNA.HCl -ii-> 
2HCI.H-Glu-Val-Arg-pNA (3d) 
Scheme 2A: i) Boc-Glu(0'Bu)-ONSu, DIPEA in DMF; ii) 37% HCl at 0°C. 
2HCl.H-Gly-Val-Arg-pNA -/"-> Boc-Glu(OlBu)-Gly-Val-Arg-pNA.HC] -ii-> 
2HCl.H-Glu-Gly-Val-Arg-pNA (3e) 
-üi-> Boc-Glu(OiBu)-Gly-Gly-Val-Arg-pNA.HCl -ii-> 
2HCl.H-Glu-Gly-Gly-Val-Arg-pNA(3f) 
-JV> Boc-Glu(0'Bu)-Giy-Gly-Gly-Val-Arg-pNA.HCl -ii-> 
2HCl.H-Glu-Gly-Gly-Gly-Val-Arg-pNA(3g) 
-v-> Boc-Glu(OlBu)-Gly-Pro-Gly-Val-Arg-pNA.HCl -ii-> 
2HCl.H-Glu-Gly-Pro-Gly-Val-Arg-pNA(3h) 
-vi-> Boc-GluiO'Bui-Pro-Gly-Gly-Val-Arg-pNA.HCl -ii-> 
2HCl.H-Glu-Pro-Gly-GIy-Val-Arg-pNA(3i) 
Scheme 2B: i) Boc-Glu(0'Bu)-ONSu, DIPEA in DMF; ii) 37% HCl at 0°C; iii) Boc-
Glu(O tBu)-Gly-ONSu, 2HCI.H-Gly-VaI-Arg-pNA, DIPEA in DMF; iv) Boc-Glu(O'Bu)-
ONSu, 2HCI.H-Gly-Gly-Gly-Val-Arg-pNA, DIPEA in DMF; v) Boc-Glu(0'Bu)-ONSu, 
2HCl.H-Gly-Pro-Gly-Val-Arg-pNA, DIPEA in DMF; vi) Boc-Glu(0«Bu)-ONSu, 2HC1.H-
Pro-Gly-Gly-Val-Arg-pNA, DIPEA in DMF. 
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CONCLUSION 
The chromogenic substrates described in this chapter were synthesized by classical solution 
methods and were obtained in good yields. 
The N-terminal stepwise elongation of the peptide chain proved to be an efficient strategy for 
the rapid synthesis of tri-, tetra-, penta- and hexapeptides. Pentapeptides were synthesized by 
coupling of protected activated dipeptides to N-terminal deprotected tripeptides. The C-terminal 
glycine- or proline residues in the dipeptides were not prone to racemization during activation. 
The deprotection of the N-terminal Boc-Glu(0'Bu)~ residue was performed in concentrated 
hydrochloric acid in a very efficient way. 
EXPERIMENTAL PROCEDURES 
General 
Ή NMR spectra were recorded on Bruker AM 100 and AM 400 spectrometers. As an internal 
standard the residual solvent peak was used. Chemical shifts are given in part per million 
(ppm). Optical rotations were measured on a Perkin Elmer 241 Polarimeter in a 10 cm cuvette 
at room temperature. Melting points were determined with a Buchi melting point apparatus 
(Tottoli). Peptides (1 μπιοί) were hydrolysed in 5.7 M HCl (Merck Suprapur 30% HCl) for 24 
hrs at 120°C and analysed on a Varían Star amino acid analyser. 
TLC was performed on Merck Silicagel 60F254 plates, and column chromotography on Merck 
Kieselgel 60 70-230 Mesh ASTM. Spots were detected by UV-fluorescence quenching, 
ninhydrine (free amino functions), chlorine/TDM (NH groups), Barton's- (hydrazides) and 
Sakaguchi's (arginine residues) reagent. 
Boc-amino acids were synthesized by the method of Schnabel22. Amino acid methyl esters 
were prepared as their hydrochlorides by the method of Brenner and Huber23. Amino acid p-
nitroanilides were synthesized as described in chapter 1. Arginine nitroanilide derivatives were 
never dried with anhydrous sulfates to prevent their crystallization as sulfates. 
Boc-Val-ONSu was from Bachern. 
Syntheses 
Boc-Val-Arg-pNA.HCl: 
Boc-Val-ONSu (3.40 g, 10.0 mmol) was allowed to react with 2HCl.H-Arg-pNA (3.67 g 
10.0 mmol, 1.0 eq.) in the presence of 1.05 eq DIPEA (1.36 g, 1.83 mL, 10.5 mmol) in DMF 
(75 mL) at room temperature for 16 hrs. After this period of stirring, DMF was evaporated in 
vacuo and the residue was diluted with BuOH (100 mL). The organic solution was washed 
with H20, saturated NaHC03, H20 and saturated NaCl (four times 30 mL each). The 
obtained organic solution was directly evaporated in vacuo. The residue was purified by 
counter current distribution with the solvent system BuOH/AcOH/H20 4:1:5 v/v/v. The 
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product fractions were collected, evaporated in vacuo and lyophihzed from AcOH Yield 4 71 
g (89%), Rf (BuOH/AcOH/H20 4 1 1 v/v/v) 0 69 (K = 2 11), [ct]D = -44 4° с = 0 59 MeOH, 
Ή NMR (CD3OD) δ = 0 94-0 98 (dd, 6Н, у-СН3/У-СН3- а1, J = 6 91 Hz), 1 44 (s, 9H, 
Вое), 1 70 (m, IH, ß-CH-Val (J = 6 82 Hz)), 1 82 (m, 2H, Y-CH2-Arg), 2 03 (m, 2H, ß-
CHj-Arg), 3 23 (m, 2H, 6-CH2-Arg), 3 88 (d, IH, α-CH-Val (J = 6 86 Hz)), 4 56 (m, IH, 
α-CH-Arg), 7 84/7 86-8 20/8 22 (dd, 4H, arom pNA) 
2HCI H-Val-Arg-pNA (1) 
Boc-Val-Arg-pNA HCl (2 50 g, 4 72 mmol) was dissolved in AcOH (10 mL) and 2 3 M HCl 
in EtOAc (10 mL) The reaction mixture was stirred for 2 5 hrs at room temperature The 
excess of hydrochloric acid was quenched with tert -BuOH (50 mL) and the solution was 
evaporated in vacuo, and coevaporated with tert -BuOH (twice 20 mL) and MeOH (three times 
20 mL) The residue was dissolved in H 2 0 (50 mL) and washed with CH2C12 (twice 10 mL) 
and EtOAc (once 10 mL) The resulting aqueous phase was lyophihzed Yield 1 89 g (86%), 
Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 40, [o]D = -5 7° с = 0 21 MeOH, Ή NMR (CD3OD) δ 
= 1 05/1 07-1 08/1 10 (dd, 6H, 7-СН,/7-СН3- а1), 1 70-1 89 (m, ЗН, Y-CH2-Arg/ß-CH-
Val), 1 96-2 25 (dm, 2H, ß-CH2-Arg), 3 26 (m, 2H, 6-CH2-Arg), 3 82 (d, IH, α-CH-Val), 
4 58 (m, IH, α-CH-Arg), 7 85/7 87-8 20/8 22 (dd, 4H, arom pNA) 
Boc- Val-Lys(Boc)-pNA 
Boc-Val-OH (0 217 g, 1 0 mmol), H-Lys(Boc)-pNA (0 367 g, 1 0 mmol) and HOBt (0 168 
g, I 10 mmol, 1 10 eq ) were dissolved in EtOAc (10 mL) and cooled on ice DCC (0 219 g, 
1 06 mmol, 1 06 eq ) was added and the reaction mixture was stirred for one hour at 0°C and 
then for 16 hrs at room temperature DCU was filtered off and the organic layer was 
subsequently washed with H 20, 2N KHS04, H 20, saturated NaHCOj and saturated NaCl 
(three times each) The EtOAc layer was dried on Na2S04, filtered and evaporated in vacuo 
The resulting foam was purified by column chromatography on silica gel, eluens 
CH2Cl2/MeOH 98 2 v/v Yield 0 441 g (78%), R,(CH2CI2/MeOH 95 5 v/v) 0 35, [cc]D = 
-42 40 с = 0 67 MeOH, Ή NMR (CDC13) δ = 0 96/1 02 (dd, 6H, у-СН3/У-СН3- а1). 1 44 
(s, 18H, Вое (2 χ 9Н)), 1 52 (m, 4Н, y-CH2/6-CH2-Lys), 1 76 (m, IH, ß-CH-Val), 
2 04/2 22 (dm, 2H, ß-CH2-Lys), 3 15 (m, 2H, e-CH2-Lys), 4 04 (m, IH, α-CH-Val), 4 52 
(m, IH, α-CH-Lys), 7 84/8 17 (dd, 4H, arom pNA) 
2HCI H-Val-Lys-pNA (la) 
Boc-Val-Lys(Boc)-pNA (0 400 g, 0 71 mmol) was dissolved in AcOH (10 mL) and 3 5 M 
HCl in EtOAc (10 mL) was added After stirring for 4 hrs at room temperature, the acid was 
quenched by the addition of tert -BuOH (20 mL) and the mixture was evaporated in vacuo The 
residue was coevaporated with tert -BuOH (once 10 mL) and MeOH (twice 10 mL) The crude 
deprotected product was purified by counter current distribution with BuOH/AcOH/H20 4 1 5 
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v/v/v as the solvent system Fractions containing the pure product were collected and 
evaporated in vacuo The residue was dissolved in H 2 0 and lyophilized Yield 0 233 g (75%), 
R,<BuOH/AcOH/H20 4 1 1 v/v/v) 0 34 (K = 0 34), [a]D = -10 7° с = 0 36 MeOH, 4i NMR 
(D20) δ = 0 87 (dd, 6H, у-СН3/у-СН3- а1), 1 37 (m, 2H, Y-CH2-Lys), 1 57 (m, 2H, δ-
CH2-Lys), 1 77 (m, 2H, ß-CH-Val/ß-CH2-Lys(lH)), 2 11 (m, IH, ß-CH2-Lys(lH)), 2 86 
(m, 2H, e-CH2-Lys), 3 75 (d, IH, a-СН- аІ), 4 35 (m, IH, a-CH-Lys), 7 51/8 04 (dd, 4H, 
arom pNA) 
MZ-Val-Arg-pNA HCl (2) 
2HC1 H-Val-Arg-pNA (0 1716 g, 0 368 mmol) was dissolved in DMF (2 mL) which 
contained DIPEA (126 μι, 0 723 mmol, 2 0 eq ) To this solution was added MZ-ONSu (0 76 
mL of a 0 5 M solution in CH3CN, 0 38 mmol, 1 03 eq ) and the reaction mixture was stirred 
for two days at room temperature DMF was evaporated in vacuo and the oily residue was 
purified by counter current distribution using the solvent combination BuOH/AcOH/H20 4 1 5 
v/v/v The pure product fractions were collected, evaporated in vacuo, dissolved in H 2 0 and 
lyophilized Yield 80 mg (41%), R[<BuOH/AcOH/H20 4 1 1 v/v/v) 0 57 (K = 1 99), [a]D = 
-27 6° с = 0 21 MeOH, >H NMR (D20) δ = 0 79 (dd, 6H, y-CH3/y-CH3-Val), 1 54 (m, 
2H, Y-CH2-Arg), 1 70 (m, IH, ß-CH- аІ), 1 80/1 94 (dm, 2H, ß-CH2-Arg), 3 06 (m, 2H, δ-
CH2-Arg), 3 34 (s, 2H, CH2-malonic acid), 3 57 (s, 3H, OCH3), 3 99 (d, IH, a-CH-Val), 
4 34 (m, IH, α-СН Arg), 7 52/8 07 (dd, 4H, arom pNA) 
Msc-Val-OH 
This compound was synthesized according to the method of Tesser and Balvert-Geers18 
H-Val-OH (5 7 g, 48 7 mmol, 1 09 eq ) was suspended into CH3CN/H20 4 1 v/v (50 mL) 
Msc-ONp (11 8 g, 44 5 mmol) was added followed by TEA (6 2 mL, 44 5 mmol, 1 0 eq ) 
The obtained turbid reaction mixture was stirred for 3 hrs at room temperature After this 
period of stirring, the reaction mixture was filtered and evaporated in vacuo to remove the co-
solvent CH3CN The aqueous phase was turbid and was acidified to pH = 3 with 3N HCl The 
clear solution was stored at 0°C for several days The crystals were filtered off, washed with 
ice-cold H 2 0 and dried over P 2 0 5 Yield 3 60 g (30%, first crop, 2 5 g (21%, second crop), 
total 6 10 g (51%), ht 66%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 65, [oc]D = -0 95u с = 1 16 
AcOH, mp 128°C (lit [a]D = -2 2° с = 1 AcOH, mp 128°C), Ή NMR (D20) δ = 
0 67/0 71-0 73/0 78 (dd, 6H, у-СН3/У-СН3- а1), 1 94 (m, IH, ß-CH- аІ), 2 93 (s, ЗН, 
CH 3 -S0 2 - Msc), 3 39 (t, 2H, -S02-CH2~ Msc), 3 82 (d, IH, a-CH-Val), 4 26 (t, 2H, 
-CH2-0-CO~ Msc) 
Msc-Val-ONSu 
Msc-Val-OH (1 08 g, 4 04 mmol) and HONSu (0 47 g, 4 09 mmol, 1 01 eq ) were dissolved 
in CH3CN (40 mL) The solution was cooled on ice, DCC (0 88 g, 4 27 mmol, 1 06 eq ) was 
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added and the reaction mixture was stirred for 16 hrs at room temperature. DCU was filtered 
off and the CH3CN phase was evaporated to dryness. The residue was recrystallized from iso-
propyl alcohol. Yield: 1.10 g (75%), [ct]D = -31.8° с = 1 dioxane, mp: 129°C, Ή NMR 
(CDCI3): δ = 1.03/1.06-1.09/1.13 (dd, 6H, y-CH3/y-CH3-Val); 2.31 (m, IH, ß-CH-Val); 
2.86 (s, 4H, CH2-ONSu (2 χ 2H)); 2.97 (s, ЗН, CH3-S02~ Msc); 3.37 (t, 2H, ~S02-CH2~ 
Msc); 4.53-4.63 (m, 3H, a-CH-Val/-CH2-OCO~ Msc); 5.35 (bd, IH, NH). 
Msc-Val-ONp: 
Msc-Val-OH (2.0 g, 7.49 mmol) and p-nitrophenol (1.3 g, 9.75 mmol, 1.25 eq.) were 
dissolved in CH3CN (50 mL). The solution was cooled on ice and DCC (1.62 g, 7.86 mmol, 
1.05 eq.) was added. After stirring of 16 hrs at room temperature, DCU was filtered off and 
the solution was evaporated in vacuo. The residual oil was solidified in diethyl ether and 
recrystallized from /jo-propyl alcohol. Yield: 2.0 g (69%), [a]D = -39.9° с = 1 dioxane, mp: 
114°C, Ή NMR (CDC13): δ = 1.06 (dd, 6H, у-СН3/У-СН3- а1); 2.40 (m, IH, ß-CH-Val); 
2.99 (s, ЗН, CH3-S02~ Msc); 3.37 (t, 2H, -S02-CH2- Msc); 4.56 (m, 3H, a-CH-Val/~CH2-
0-CO- Msc); 5.31 (d, IH, NH); 7.26/7.34-8.25/8.36 (dd, 4H, arom ONp). 
Msc-Val-Arg-pNA. HCl (2a): 
Msc-Val-ONp (116 mg, 0.30 mmol), 2HCl.H-Arg-pNA (120 mg, 0.33 mmol, 1.10 eq.) were 
dissolved in DMF (3 mL) and TEA (51 μι, 0.37 mmol, 1.23 eq.) was added. The suspension 
was stirred for 16 hrs at room temperature, and DMF was removed under reduced pressure. 
The oily residue was dissolved in H 2 0 (20 mL) and washed with diethyl ether (three times 5 
mL). The aqueous phase was lyophilized. The product was purified by counter current 
distribution with the solvent system BuOH/AcOH/H20 4:1:5 v/v/v. The pure product fractions 
were collected , evaporated in vacuo, dissolved in H 2 0 and lyophilized. Yield: 147 mg, (85%), 
R,(BuOH/AcOH/H20 4:1:1 v/v/v): 0.48 (K = 1.50), [a]D = -37.6° с = 0.29 MeOH, Ή NMR 
(D20): δ = 0.76 (dd, 6H, у-СН3/у-СН3- а1); 1.50 (m, 2H, y-CH2-Arg); 1.62-1.94 (bm, 
ЗН, ß-CH-Val/ß-CH2-Arg); 2.94 (s, ЗН, CH3-S02- Msc); 3.05 (t, 2H, 6-CH2-Arg); 3.41 (t, 
2H, -S0 2 -CH 2 - Msc); 3.75 (d, IH, a-CH-Val); 4.33 (m, 3H, a-CH-Arg/-CH2-0-CO-
Msc); 7.49/8.04 (dd, 4H, arom pNA). 
Msc-Val-X-pNA 
a)X= Lys(Boc): 
Msc-Val-ONSu (109 mg, 0.30 mmol), H-Lys(Boc)-pNA (122 mg, 0.33 mmol, 1.10 eq.) 
were dissolved in DMF (3 mL) and TEA ( 51 μι, 0.37 mmol, 1.23 eq.) was added. After 
stirring overnight at room temperature the reaction mixture was evaporated in vacuo. The 
residue was dissolved in EtOAc and subsequently washed with H20, saturated NaHC03, 2N 
KHSO4 and saturated NaCl. The EtOAc layer was dried on Na2S04, filtered and evaporated to 
dryness. The resulting foam was purified by column chromatography on silica gel with 
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СН2С12/МеОН 95:5 v/v as eluens. Yield: 145 mg (79%), R,<CH2Cl2/MeOH 95:5 v/v): 0.22, 
Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.87, [o]D = -32.8° с = 0.56 МеОН, Ш NMR (CDC13): δ 
= 0.97 (dd, 6H, Y-CH3/y-CH3-Val); 1.43 (m, 13H, Boc(9H)/Y-CH2/6-CH2-Lys); 1.74 (m, 
3H, ß-CH-Val/ß-CH2-Lys); 2.92 (m, 5H, CH3-S02- Msc/e-CH2-Lys); 3.11 (t, 2H, -S02-
CH2- Msc); 4.05 (m, IH, α-CH-Val); 4.60 (m, 3H, a-CH-Lys/~CH2-0-CO~ Msc); 5.54 (d, 
IH, NH); 7.10 (d, IH, NH); 7.76/7.88-8.13/8.22 (dd, 4H, arom pNA); 9.21 (s, IH, arom 
NH). 
b) X = Om(Boc): 
Obtained as described for a). 
Quantities used: Msc-Val-ONSu: 76 mg (0.21 mmol), HCl.H-Orn(Boc)-pNA: 81 mg (0.21 
mmol), TEA: 62 uL (0.45 mmol, 2.14 eq.). Yield: 60 mg (47%), Rf(CH2Cl2/MeOH 95:5 v/v): 
0.22, R[(BuOH/AcOH/H20 4:1:1 v/v/v): 0.84, [ct]D = -43.6° с = 1 МеОН. 
c) X = Nie (2d): 
Obtained as described for a). 
Quantities used: Msc-Val-ONSu: 181 mg (0.50 mmol), HCl.H-Nle-pNA: 142 mg (0.50 
mmol), TEA: 146 μ ι (1.06 mmol, 2.12 eq.). This product was purified by counter current 
distribution with BuOH/AcOH/H20 4:1:5 v/v/v (K = 10.52) as the solvent combination. After 
work-up the pure product was lyophilized from AcOH. Yield: 144 mg (58%), 
Rf(CH2Cl2/MeOH 95:5 v/v): 0.37, Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.87, [a]D = -51.4° с = 
0.25 МеОН, Ή NMR (CD3OD): δ = 0.95 (t, 3H, e-CH3-Nle); 0.99 (dd, 6H, y-CH3/y-CH3-
аі); 1.39 (bm, 4H,
 Y-CH2/5-CH2-NIe); 1.78/1.89 (dm, 2H, ß-CH2-Nle); 2.10 (m, IH, ß-
СН- аІ); 3.05 (s, ЗН, CH3-S02- Msc); 3.48 (t, 2H, ~S02-CH2~ Msc); 3.97 (d, IH, o-CH-
Val); 4.48 (m, IH, a-CH-Nle); 4.56 (m, 2H, ~CH2-0-CO~ Msc); 7.86/8.22 (dd, 4H, arom 
pNA). 
Msc-Val-X-pNA.HCl 
The Boc-protected dipeptidcs were dissolved in AcOH (2 mL) and 3.5 M HCl in EtOAc (2 mL) 
was added. After 2 hrs of stirring, the acid was quenched with terr.-BuOH (10 mL) and the 
reaction mixture was evaporated in vacuo. The residue was coevaporated with feri.-BuOH 
(once 5 mL) and MeOH (twice 10 mL). The residue was dissolved in H 2 0 (15 mL) and 
subsequently washed with CH2C12 (twice 10 mL) and diethyl ether (once 10 mL). The 
aqueous phase was lyophilized. 
a) X = Lys (2b): 
Yield: 95 mg (73%), R,<BuOH/AcOH/H20 4:1:1 v/v/v): 0.49, [a]D = -52.6° с = 0.23 МеОН, 
Ή NMR (D20): δ = 0.81 (dd, 6H, у-СН3/у-СН3- а1); 1.36 (m, 2H, Ô-CH2-Lys); 1.58 (m, 
2H, Y-CH2-Lys); 1.76/1.92 (dm, ЗН, ß-CH-Val/ß-CH2-Lys); 2.86 (t, 2H, e-CH2-Lys); 2.99 
(s, ЗН, CH3-S02- Msc); 3.45 (t, 2H, -S02-CH2~ Msc); 3.79 (d, IH, a-CH-Val); 4.23 (m, 
IH, tx-CH-Lys); 4.37 (t, 2H, ~CH2-0-CO- Msc); 7.51/8.04 (dd, 4H, arom pNA). 
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Ъ) Χ = От (2с): 
Yield: 47 mg (88%), R,{BuOH/AcOH/H20 4:1:1 v/v/v): 0.45, [cefo = -49.3 с = 0.14 MeOH, 
'H NMR (D20): δ = 0.82 (dd, 6H, у-СН3/у-СН3- а1); 1.57-1.84 (bm, 3H Y-CH2-Orn/ß-
CH-Val); 1.84-1.95 (m, 2H, ß-CH2-Orn); 2.92 (t, 2H, 5-CH2-Om); 2.99 (s, 3H, CH3-S02~ 
Msc); 3.46 (t, 2H, -S02-CH2- Msc); 3.81 (d, IH, a-CH-Val); 4.39 (m, 3H, a-CH-Orn/ 
~CH2-0-CO~ Msc); 7.53/8.08 (dd, 4H, arom pNA). 
Boc-Gly-Val-N2H3 : 
Boc-Gly-OH (1.80 g, 10.3 mmol), HCl.H-Val-OMe (1.70 g, 10.1 mmol), HOBt (1.70 g, 
11.1 mmol, 1.10 eq.) were suspended in EtOAc (50 mL). This mixture was cooled on ice and 
the amino component was set free with DIPEA (1.85 mL, 10.6 mmol, 1.05 eq.). Then DCC 
(2.16 g, 10.5 mmol, 1.04 eq.) was added and the suspension was stirred for one hour at 0°C 
and for 16 hrs at room temperature. After this period DCU was filtered off and the clear 
organic solution was subsequently washed with 2N KHS04, H20, saturated NaHC03 and 
saturated NaCl (three times 30 mL each). The EtOAc layer was dried on Na2S04, filtered and 
evaporated in vacuo, yielding an oil which still contained residual DCU; it was therefore 
dissolved in diethyl ether and filtered, and appeared then to be free of DCU (Rf{CH2Cl2/MeOH 
9:1 v/v): 0.60, single spot). The ester was used as such in the hydrazinolysis. 
The obtained oil was dissolved in MeOH (20 mL) and N2H4.H20 (2.5 mL, 51.5 mmol, 5.1 
eq.) was added. This reaction mixture was stirred for three days at room temperature. After this 
period the reaction mixture was evaporated in vacuo and the residue was coevaporated with 
MeOH (three times 20 mL). The residue was recrystallized from diwo-propyl ether. Yield: 2.16 
g (75%), Rf{CH2Cl2/MeOH 9:1 v/v): 0.37, mp: 118-121°C, [afo = -27.0 с = 0.70 MeOH, Ή 
NMR (CDC13): δ = 0.91/0.96 (dd, 6H, 7-СН3/у'-СН3- а1); 1.45 (s, 9H, Вое); 2.11 (m, IH, 
ß-CH- аІ); 3.64 (dd, 2H, CH2-Gly); 3.66 (m, IH, NH); 4.29 (dd, IH, o-CH-Val); 5.73 (m, 
IH, NH); 7.17 (d, <2H, NH2); 8.46 (s, IH, NH). 
Boc-Gly-Val-Arg-pNA.HCl (3'): 
Boc-Gly-Val-N2H3 (1.23 g, 4.26 mmol) was dissolved in DMF (40 mL). This solution was 
cooled on dry ice/aceton to -20°C. To this solution were added: 2.3 M HCl in EtOAc (5.2 mL, 
12.0 mmol, 2.81 eq.) and fer/.-BuONO (0.60 mL, 5.04 mmol, 1.18 eq.). This reaction 
mixture was stirred for 15 min at -20°C (no Barton positive material is present: azide formation 
is complete). The reaction mixture was neutralized by adding DIPEA (2.05 mL, 11.7 mmol) 
and 2HCl.H-Arg-pNA (1.56 g, 4.26 mmol, 1.0 eq.) followed by DIPEA (0.75 mL, 4.31 
mmol, 1.01 eq.) were added. The reaction mixture was kept at 0°C for 16 hrs; at regular time 
intervals the pH was checked and when necessary DIPEA was added to maintain the pH at 7 to 
8. When the reaction was complete, the solvent was evaporated in vacuo and the residue was 
diluted with BuOH. The solution was washed with H 2 0, saturated NaHC03, H 2 0 and 
saturated NaCl respectively. After removal of the solvent the residue was purified by counter 
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current distribution with BuOH/Ac0H/H2O 4 1 5 v/v/v as solvent system The pure fractions 
were collected and evaporated in vacuo The residue was dissolved in AcOH and lyophilized 
Yield 2 22 g (89%), Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 66 (K = 2 96), [a]D = -28 7° с = 
0 57 MeOH, Ή NMR (CD3OD) δ = 0 99 (dd, 6H, ^СН3/у-СН3- а1), 1 40 (s, 9Н, Вое), 
1 65-1 88 (dm, 3H, ^ CH2-Arg/ß-CH-Val), 1 93/2 15 (dm, 2H, ß-CH2-Arg), 3 23 (m, 2H, δ-
CH2-Arg), 3 71/3 84 (dd, 2H, CH2-Gly), 4 18 (d, IH, a-СН- аІ), 4 54 (m, IH, a-CH-Arg), 
7 91/7 93-8 19/8 22 (dd, 4H, arom pNA) 
2HCI H-Gly-Val-Arg-pNA (3) 
Boc-Gly-Val-Arg-pNA HCl (1 2037 g, 2 052 mmol) was dissolved in AcOH (10 mL) and 2 3 
M HCl in EtOAc (10 mL) was added The reaction mixture was stirred for three hrs, the acid 
was quenched with tert -BuOH (20 mL) and evaporated in vacuo The residue was 
coevaporated with tert -BuOH and with MeOH (once 20 mL each) The residue was purified 
by counter current distribution with BuOH/AcOH/H20 4 1 5 v/v/v as solvent combination The 
pure product was dissolved in H 2 0 and lyophilized Yield 0 94 g (88%), 
Rf(BuOH/AcOH/H20 4 1 1 v/v/v) 0 32 (K = 0 37), [a]D = -42 7° с = 0 26 MeOH, >H NMR 
(CDjOD) δ = 0 98-1 03 (dd, 6H, Y-CH3/y'-CH3-Val (J = 6 8 Hz)), 1 61-2 05 (m, 4H, β-
CH2-Arg(lH)/ß-CH-Val/y-CH2-Arg), 2 17 (dm, IH, ß-CH2-Arg(lH)), 3 26 (m, 2H, 6-CH2-
Arg), 3 76-3 87 (dd, 2H, CH2-Gly), 4 28 (d, IH, α-CH-Val (J = 6 4 Hz)), 4 53 (m, IH, o-
CH-Arg), 7 88/7 90-8 20/8 23 (dd, 4H, arom pNA) 
Boc Gh-Val X-pNA 
a)X = Lys(Boc) 
Boc-Gly-Val-N2H3 (0 288 g, 1 0 mmol) was dissolved in DMF (10 mL) and cooled to -20°C 
Subsequently 3 5 M HCl in EtOAc (0 80 mL, 2 75 mmol, 2 75 eq ) and tert -BuONO (0 14 
mL, 1 20 mmol, 1 2 eq ) were added After 15 min the conversion to the corresponding azide 
was complete (negative Barton lest) and the reaction mixture was neutralized by adding DIPEA 
(0 473 mL, 2 75 mmol, 2 75 eq ) H-Lys(Boc)-pNA (0 366 g, 1 0 mmol, 1 0 eq ) was added 
to the azide solution The reaction mixture was kept for 16 hrs at 0°C Then the solvent was 
removed under reduced pressure and the residue was diluted with EtOAc (30 mL) The organic 
solution was subsequently washed with H20, 2N KHS04, H 20, saturated NaHC03, H 2 0 and 
saturated NaCl (three times 10 mL each) After drying on Na 2S0 4, evaporation in vacuo 
resulted in a foam which was purified by column chromatography on sihcagel with 
CH2Cl2/Me0H 95 5 v/v as eluens Yield 0 51 g (81%), Rf(CH2Cl2/MeOH 95 5 v/v) 0 17, 
Rt<CH2Cl2/MeOH 9 1 v/v) 0 60, [a]D = -27 8° с = 0 39 MeOH, Ή NMR (CD3OD) δ = 
0 97/0 99-1 00/1 02 (dd, 6H, y-CH3/y-CH3-Val), 1 39 (s, 9H, Вое), 1 41 (s, 9H, Вое), 
1 48 (m, 4Н, Y-CH2/6-CH2-Lys), 1 80 (m, IH, ß-CH- аІ), 1 93/2 13 (dm, 2H, ß-CH2-Lys), 
3 04 (m, 2H, E-CH2-Lys), 3 74 (dd, 2H, CH2-Gly), 4 21 (d, IH, a-СН- аІ), 4 44 (m, IH, 
a-CH-Lys), 7 91/7 93-8 19/8 21 (dd, 4H, arom pNA) 
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b)X = Om(Boc): 
Obtained as described for a). 
Quantities used: HCl.H-Orn(Boc)-pNA: 0.389 g (0.776 mmol), DIPEA: 0.20 mL (1.16 mmol, 
1.50 eq.). Yield: 0.31 g (66%), Rf(CH2Cl2/MeOH 95:5 v/v): 0.17, Rf(CH2Cl2/MeOH 9:1 
v/v): 0.57, [a] D = -29.2° с = 0.27 MeOH, Ή NMR (CD3OD): δ = 0.97/0.99-0.99/1.01 (dd, 
6H, y-CH3/y-CH3-Val); 1.40 (s, 9H, Вое); 1.42 (s, 9H, Вое); 1.55 (m, 2Н, y-CH2-Orn); 
1.77 (m, IH, ß-CH- аІ); 1.89/2.13 (dm, 2H, ß-CH2-Orn); 3.08 (m, 2H, 6-CH2-Orn); 3.74 
(dd, 2H, CH2-Gly); 4.21 (d, IH, a-СН- аІ); 4.47 (m, IH, a-CH-Orn); 7.90/7.92-8.19/8.22 
(dd, 4H, arom pNA). 
c)X = Me: 
Obtained as described for a). 
Quantities used: HCl.H-Nle-pNA: 0.288 g (1.00 mmol), DIPEA: 0.20 mL (1.16 mmol, 1.16 
eq.). Yield: 0.40 g (79%), Rf<CH2Cl2/MeOH 95:5 v/v): 0.21, R,(CH2Cl2/MeOH 9:1 v/v): 
0.63, [ a ] D = -38.0° с = 0.36 MeOH, 'H NMR (CD3OD): δ = 0.93 (m, 3H, E-CH 3-Nle); 
0.97/0.99-1.00/1.01 (dd, 6H, у-СН3/у'-СН3- а1); 1.38 (s, 9H, Boc); 1.45 (m, 4H, y-CH2/6-
CH2-Nle); 1.79 (m, IH, ß-CH-Val); 1.93/2.14 (dm, 2H, ß-CH2-Nle); 3.73 (dd, 2H, CH2-
Gly); 4.21 (d, IH, a-CH-Val); 4.43 (m, IH, a-CH-Nle); 7.93/7.95-8.19/8.21 (dd, 4H, arom 
pNA). 
nHCl.H-Gly- Val-X-pNA 
a)X = Lys, η = 2 (За): 
Boc-Gly-Val-Lys(Boc)-pNA was dissolved in AcOH (5 mL) and 3.5 M HCl in EtOAc (5 mL) 
was added. After 2 hrs of stirring at room temperature the acid was quenched with iert.-BuOH 
(10 mL) and evaporated in vacuo. The obtained residue was coevaporated with ferf.-BuOH 
(twice 10 mL) and MeOH (10 mL), dissolved in H 2 0 and lyophilized. After purification by 
counter current distribution using the solvent combination BuOH/AcOH/H20 4:1:5 v/v/v the 
pure product was obtained as a fluffy off-white powder. Yield: 0.29 g (72%), 
Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.33 (K = 0.32), [a] D = -56.1° с = 0.36 MeOH, >H NMR 
( D 2 0 ) : δ = 0.78 (dd, 6H, у-СН3/у-СН3- а1); 1.33 (m, 2H, Y-CH2-Lys); 1.53 (m, 2H, δ-
CH2-Lys); 1.74 (m, 2H, ß-CH2-Lys(lH)/ß-CH-Val); 1.92 (m, IH, ß-CH2-Lys(lH)); 2.82 
(m, 2H, e-CH2-Lys); 3.71 (dd, 2H, CH2-Gly); 4.05 (d, IH, a-CH-Val); 4.28 (m, IH, a-CH-
Lys); 7.49/8.05 (dd, 4H, arom pNA). 
b) X = От, η = 2 (3b): 
Obtained as described for a). 
Yield: 0.18 g (73%), Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.33 (K = 0.29), [a] D = -52.7° с = 
0.25 MeOH, 'H NMR (D 2 0) : δ = 0.77 (dd, 6H, у-СН3/у-СН3- а1); 1.54-1.85 (bm, 4H, β-
CH2-Orn(lH)/ß-CH-Val/Y-CH2-Orn); 1.94 (m, IH, ß-CH2-Orn(lH)); 2.86 (m, 2H, 5-CH2-
Om); 3.71 (dd, 2H, CH2-Gly); 4.04 (d, IH, α-CH-Val); 4.23 (m, IH, α-CH-Orn); 7.52/8.06 
(dd, 4H, arom pNA). 
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c)X = Nie, η = 1 (Зс): 
Obtained as described for a). 
Yield: 0.28 g (80%), R,{BuOH/AcOH/H20 4:1:1 v/v/v): 0.68 (K = 2.40), [a]D = -67.2° с = 
0.24 MeOH, Ή NMR (CD3OD): δ = 0.84 (t, 3H, e-CH3-Nle); 0.86/0.90 (dd, 6H, y-CH3/y-
CHj-Val); 1.29 (m, 4H, Y-CH2/6-CH2-Nle); 1.66 (m, IH, ß-CH- аІ); 1.79/2.02 (dm, 2H, β-
CH2-Nle); 3.60 (s, 2H, CH2-Gly); 4.21 (d, IH, a-СН- аІ); 4.35 (m, IH, a-CH-Nle); 
7.75/8.11 (dd, 4H, arom pNA). 
Boc-Glu(0'Bu)-OH: 
H-Glu(0'Bu)-OH (Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.52, [a]D = +9.3° с = 1.05 H 20, mp: 
181°C (dec); lit24: [a]D = +9.8° с = 2 H 20, mp: 182°C) (2.0 g, 9.85 mmol), NaHC03 (1.86 
g, 22.2 mmol, 2.25 eq.) were dissolved in H 2 0 (40 mL) and Вос 20 2 5 (2.36 g, 10.8 mmol, 
1.10 eq.) dissolved in dioxane (20 mL) was added. The reaction mixture became turbid and 
gas evolution started. After 3 hrs of stirring at room temperature, the reaction mixture was 
partially evaporated in vacuo. The aqueous solution was acidified with 10% citric acid and the 
precipitating oil was taken up into EtOAc (three extractions 20 mL). The EtOAc layer was 
subsequently washed with H 2 0 (five times 30 mL), saturated NaCl (three times 30 mL) and 
dried on Na2S04. The residue obtained after evaporation in vacuo was an oil which crystallized 
slowly. Yield: 2.91 g (98%), R,<BuOH/AcOH/H20 4:1:1 v/v/v): 0.87, R,<CH2Cl2/MeOH 9:1 
v/v): 0.17, [a]D = -10.3° с = 0.93 MeOH, mp: 98-99°C (lit26: [a]D = -10.9° с = 1 MeOH, 
mp:101-102°C), Ή NMR (CDC13): δ = 1.44 (s, 18H, Boc/O'Bu (2 χ 9H)); 1.99/2.18 (dm, 
2Н, ß-CH2); 2.38 (m, 2H, у-СН2); 4.34 (m, IH, a-CH); 5.23 (d, IH, NH). 
Boc-Glu(0'Bu)-ONSu: 
Boc-Glu(0'Bu)-ONSu was prepared according to the literature27. 
Quantities used: Boc-Glu(OlBu)-OH: 2.56 g (8.45 mmol), DCC: 1.83 g (8.88 mmol, 1.05 
eq.), HONSu: 1.07 g (9.30 mmol, 1.10 eq.), CH3CN: 30 mL. Yield: 2.98 g (88%), [o]D = 
-26.6° с = 0.64 dioxane, mp: 134-137°C (recrystallized from wo-propyl alcohol). 
Boc-Glu(0'Bu)-Gly-OH: 
H-Gly-OH (0.13 g, 1.73 mmol, 1.16 eq.) and NaHC03 (0.28 g, 3.38 mmol, 2.25 eq.) were 
dissolved in H 2 0 (10 mL) and Boc-Glu(0'Bu)-ONSu (0.60 g, 1.50 mmol), dissolved in 
CH3CN (15 mL), was added dropwise. The resulting turbid reaction mixture was stirred at 
room temperature. After a period of 16 hrs of stirring, the organic solvent was removed in 
vacuo and the aqueous phase was acidified to pH = 3 with 2N KHS04. The precipitated oil 
was extracted into EtOAc (twice 10 mL) and subsequently washed with 2N KHS04 and 
saturated NaCl (once respectively twice 10 mL). The EtOAc layer was dried on Na 2S0 4, 
filtered and evaporated in vacuo. The resulting foam did not crystallize. Yield: 0.51 g (94%), 
Rf(CH2Cl2/MeOH 9:1 v/v): 0.19, R,(CH2Cl2/MeOH 8:2 v/v): 0.22, R,<BuOH/AcOH/H20 
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4:1:1 v/v/v): 0.84, [a]D = -12.6° с = 0.67 MeOH, "H NMR (CDCI3): δ = 1.44 (s, 18H, 
Boc/O'Bu (2 χ 9H)); 1.91/2.10 (dm, 2H, ß-CH2-Glu); 2.36 (m, 2H, y-CH2-Glu); 4.07 (2 χ 
dd, 2H, CH2-Gly); 4.35 (m, IH, a-CH-Glu); 5.68 (d, IH, NH-Glu); 7.35 (m, IH, NH-
Gly). 
Boc-Gly-Gly-OH, Boc-Gly-Pro-OH and Boc-Pro-Gly-OH 
Were obtained as described for Boc-GlulO'BiO-Gly-OH. Due to the good water solubility, 
acidification leads to clear aqueous solutions. The dipeptides were extracted into EtOAc after 
saturation of the aqueous phase with NaCl. The products were recrystallized from wo-propyl 
alcohol/diî'io-propyl ether. 
Quantities used: Boc-Gly-Gly-OH: Boc-Gly-ONSu: 1.36 g (5.0 mmol), H-Gly-OH: 0.41 g 
(5.47 mmol, 1.09 eq.), NaHC03: 0.95 g (11.31 mmol, 2.26 eq.). Yield: 1.13 g (97%), 
R,<CH2Cl2/MeOH 8:2 ν/ν): 0.08, Rf(BuOH/AcOH/H20 4:1:1 ν/ν/ν): 0.66, mp: 123-124°C 
(dec), Ή NMR (DMSO-d6): δ = 1.38 (s, 9H, Вое); 3.57 (d, 2H, CH2-Gly (C-terminal)); 
3.76 (d, 2H, CH2-Gly (N-terminal)); 6.98 (t, IH, NH); 8.04 (t, IH, NH). 
Boc-Gly-Pro-OH: Boc-Gly-ONSu: 1.36 g (5.0 mmol), H-Pro-OH: 0.63 g (5.48 mmol, 1.10 
eq.), NaHC03: 0.95 g (11.31 mmol, 2.26 eq.). Yield: 1.36 g (quant.), R,<CH2Cl2/MeOH 8:2 
v/v): 0.18, R,{BuOH/AcOH/H20 4:1:1 v/v/v): 0.67, [a]D = -70.8° с = 0.98 MeOH, mp: 
123°C, >H NMR (CDCI3): δ = 1.44 (s, 9H, Вое); 2.14 (m, 4H, CH2-Pro (2 χ 2H)); 3.54 (m, 
2H, N-CH2-Pro); 3.98 (dd, 2H, CH2-Gly); 4.50 (m, IH, ot-CH-Pro); 5.82 (m, <1H, NH); 
8.46 (s, IH, COOH). 
Boc-Pro-Gly-OH: Boc-Pro-ONSu: 1.56 g (5.0 mmol), H-GIy-OH: 0.41 g (5.47 mmol, 1.09 
eq.), NaHC03: 0.95 g (11.31 mmol, 2.26 eq.). Yield: 1.36 g (quant.), Rt<CH2Cl2/MeOH 8:2 
v/v): 0.18, R^BuOH/AcOH/H20 4:1:1 v/v/v): 0.73, [a]D = -66.0° с = 0.78 MeOH, mp: 149-
151°C (dec), >H NMR (CDCl3/CD3OD 1:1 v/v): δ = 1.23 (s, 9H, Boc); 1.64-1.96 (bm, 4H, 
CH2-Pro (2 χ 2H)); 3.25 (m, 2H, N-CH2-Pro); 3.76 (s, 2H, CH2-Gly); 4.04 m, IH, a-CH-
Pro). 
Boc-Glu(0'Bu)-Gly-ONSu, Boc-Gly-Gly-ONSu, Boc-Gly-Pro-ONSu and Boc-Pro-Gly-
ONSu 
The protected dipeptide acids were converted to their ONSu-esters following the literature27. 
Quantities used: Boc-Glu(0<Bu)-Gly-ONSu: Boc-Glu(OlBu)-Gly-OH: 0.54 g (1.5 mmol), 
DCC: 0.32 g (1.55 mmol, 1.04 cq.), HONSu: 0.19 g (1.65 mmol, 1.10 eq.), CH3CN: 15 
mL. Yield: 0.569 g (83%), [a]D = -19.6° с = 0.70 dioxane, mp: 79-83°C. 
Boc-Gly-Gly-ONSu: Boc-Gly-Gly-OH: 1.16 g (5.0 mmol), DCC: 1.08 g (5.24 mmol, 1.05 
eq.), HONSu: 0.63 g (5.48 mmol, 1.10 eq.), CH3CN/EtOAc (1:1 v/v): 50 mL. Yield: 1.40 g 
(85%), mp: 143-145°C. 
Boc-Gly-Pro-ONSu: Boc-Gly-Pro-OH: 1.36 g (5.0 mmol), CH3CN: 30 mL. Yield: 1.70 g 
(92%), [oc]D = -65.2° с = 1.12 dioxane, mp: amorphous. 
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Boc-Pro-Gly-ONSu: Boc-Pro-Gly-OH: 1.36 g (5.0 mmol), CH3CN: 30 mL. Yield: 1.80 g 
(97%), [<x]D = -43.7° с = 1.11 dioxane, mp: amorphous. 
Boc-Glu(0'BuHGly)
n
-Val-Arg-pNA.HCl 
a) n = 0: 
Boc-Glu(0'Bu)-ONSu (0.202 g, 0.505 mmol, 1.39 eq.), 2HCl.H-Val-Arg-pNA (0.169 g, 
0.362 mmol) were dissolved in DMF (10 mL) and DIPEA (100 uL, 0.57 mmol, 1.59 eq.) was 
added to start the reaction. The obtained reaction mixture was stirred for 16 hrs at room 
temperature. After this period of stirring, DMF was evaporated under reduced pressure and the 
residue was diluted with BuOH (25 mL). The organic solution was subsequently washed with 
H 20, saturated NaHC03 and H 2 0 (three times 10 mL each) and evaporated in vacuo. The 
obtained residue was purified by counter current distribution with BuOH/AcOH/H20 4:1:5 
v/v/v as solvent combination. The pure product fractions were collected and evaporated in 
vacuo. The residue was lyophilized from AcOH. Yield: 226 mg (87%), R((BuOH/AcOH/H20 
4:1:1 v/v/v): 0.81 (K = 6.81), [a]D = -43.6° с = 0.39 MeOH, Ή NMR (CD3OD): δ = 
0.97/0.99 (d, 6H Y-CHj/y-CHj-Val); 1.43 (s, 18H, Boc(9H)/0'Bu(9H)); 1.51-2.12 (bm, 
7H, ß-CH2-Glu/ß-CH-Val/ß-CH2-Arg/y-CH2-Arg); 2.34 (m, 2H, Y-CH2-GIU); 3.23 (m, 2H, 
5-CH2-Arg); 4.08 (m, IH, α-CH-Glu); 4.16 (m, IH, α-CH-Val); 4.54 (m, IH, α-CH-Arg); 
7.86/7.88-8.21/8.23 (dd, 4H, arom pNA). 
b)n = l: 
Obtained as described for a). 
Quantities used: Boc-Glu(OlBu)-ONSu: 0.205 g (0.511 mmol, 1.01 eq.), 2HC1.H-Gly-Val-
Arg-pNA: 0.265 g (0.506 mmol), DIPEA: 200 μ ι (1.14 mmol, 2.25 eq.) in 10 mL DMF. 
Yield: 352 mg (90%), R,{BuOH/AcOH/H20 4:1:1 v/v/v): 0.78 (K = 10.52), [o]D = -30.0" с = 
0.28 MeOH, 'H NMR (CD3OD): δ = 0.99/1.01 (d, 6H, у-СН3/у-СН3- а1); 1.43 (s, 18H, 
Вос(9Н)/0'Ви(9Н)); 1.69-2.16 (bm, 7H, ß-CH2-Glu/ß-CH-Val/ß-CH2-Arg/"rCH2-Arg); 2.31 
(m, 2H, Y-CH2-G1U); 3.24 (m, 2H, 5-CH2-Arg); 3.90 (dd, 2H, CH2-Gly); 4.04 (m, IH, a-
CH-Glu); 4.16 (d, IH, a-CH-Val); 4.52 (m, IH, a-CH-Arg); 7.89/7.91-8.20/8.22 (dd, 4H, 
arom pNA). 
c) n = 2: 
Obtained as described for a). 
Quantities used: Boc-GluíO'Buí-Gly-ONSu: 0.115 g (0.251 mmol, 1.23 eq.), 2HC1.H-Gly-
Val-Arg-pNA: 0.107 g (0.204 mmol), DIPEA: 86 μ ι (0.50 mmol, 2.45 eq.) in 10 mL DMF. 
Yield: 134 mg (79%), Rt<BuOH/AcOH/H20 4:1:1 v/v/v): 0.74 (K = 6.81), [oc]D = -29.1° с = 
0.17 MeOH, 1H NMR (CD3OD): δ = 0.91 (dd, 6H, r-CH3/y-CH3-Val); 1.33 (m, 20H, 
Boc(9H)/0'Bu(9H)/Y-CH2-Arg); 1.62 (m, IH, ß-CH-Val); 1.76 (m, 2H, ß-CH2-Glu); 
1.93/2.06 (dm, 2H, ß-CH2-Arg); 2.24 (m, 2H, Y-CH2-G1U); 3.14 (m, 2H, 6-CH2-Arg); 3.80 
(dd, 4H, CH2-Gly (2 χ 2H)); 3.92 (m, IH, a-CH-Glu); 4.03 (d, IH, a-CH-Val); 4.46 (m, 
IH, a-CH-Arg); 7.79/8.12 (dd, 4H, arom pNA). 
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Boc-(Gly)
x
-(Pro)y-(Gly)z-Val-Arg-pNA.HCl 
α) χ = 3, y = ζ = 0: 
Boc-Gly-Gly-ONSu (98.4 mg, 0.299 mmol, 1.18 eq.), 2HCl.H-Gly-Val-Arg-pNA (132.1 
mg, 0.253 mmol) were dissolved in DMF (10 mL) and DIPEA (86 uL, 0.49 mmol, 1.94 eq.) 
was added. After stirring for 16 hrs at room temperature, DMF was removed under reduced 
pressure. The residue was purified by counter current extraction with BuOH/AcOH/H20 4:1:5 
v/v/v as the solvent combination. The product fractions were collected and evaporated in vacuo 
and subsequently lyophilized from AcOH. Yield: 148.2 mg (81%), R,{Bu0H/AcOH/H2O 
4:1:1 v/v/v): 0.55 (K = 2.97), [a]D = -30.0° с = 0.28 MeOH, Ή NMR (CD3OD): δ = 0.90 
(dd, 6H, Y-CH3/y-CH3-Val); 1.34 (s, 9H, Boc); 1.61 (m, 2H, y-CH2-Arg); 1.75 (m, IH, β-
CH-Val); 1.84/2.04 (dm, 2H, ß-CH2-Arg); 3.14 (m, 2H, 6-CH2-Arg); 3.66-3.92 (3 χ dd, 6H, 
CH2-Gly (3 χ 2H)); 4.04 (d, IH, α-CH-Val); 4.44 (m, IH, o-CH-Arg); 7.78/8.13 (dd, 4H, 
arom pNA). 
b) x = y = z = l: 
Obtained as described for a). 
Quantities used: Boc-Gly-Pro-ONSu: 110.0 mg (0.298 mmol, 1.17 eq.), 2HC1.H-Gly-Val-
Arg-pNA: 136.0 mg (0.260 mmol), DIPEA: 86 μ ι (0.50 mmol, 1.92 eq.) in 10 mL DMF. 
Yield: 145.8 mg (76%), R^BuOH/AcOH/HjO 4:1:1 v/v/v): 0.50 (K = 3.75), [a]D = -49.4° с 
=•• 0.17 MeOH, "H NMR (CD3OD): δ = 0.90 (dd, 6H, у-СН3/У-СН3- а1); 1.32 (s, 9H, Вое); 
1.63-2.12 (bm, 9Н, ß-CH2-Arg/ß-CH-Val/y-CH2-Arg/CH2-Pro (2 χ 2Η)); 3.14 (m, 2H, δ-
CH2-Arg); 3.52 (m, 2H, N-CH2-Pro); 3.71-3.89 (dd, 4H, CH2-Gly (2 χ 2H)); 4.04 (d, IH, 
a-CH-Val); 4.28 (m, IH, cc-CH-Pro); 4.43 (m, IH, a-CH-Arg); 7.81/8.12 (dd, 4H, arom 
pNA). 
c) x = 0,y = J,z = 2: 
Obtained as described for a). 
Quantities used: Boc-Pro-Gly-ONSu: 101.2 mg (0.274 mmol, 1.05 eq.), 2HC1.H-Gly-Val-
Arg-pNA: 132.7 mg (0.254 mmol), DIPEA: 86 μ ι (0.50 mmol, 1.92 eq.) in 10 mL DMF. 
Yield: 158.9 mg (81%), R,<BuOH/AcOH/H20 4:1:1 v/v/v): 0.65 (К = 4.90), [a]D = -42.1» с 
= 0.24 MeOH, Ш NMR (CD3OD): δ = 0.91 (dd, 6H, у-СН3/у-СН3- а1); 1.36 (s, 9H, Boc); 
1.63-2.12 (bm, 9H, ß-CH2-Arg/ß-CH-Val/Y-CH2-Arg/CH2-Pro (2 χ 2H)); 3.14 (m, 2H, δ-
CH2-Arg); 3.38 (m, 2H, N-CH2-Pro); 3.82 (d, 4H, CH2-Gly (2 χ 2H)); 4.04 (d, IH, a-CH-
Val); 4.09 (m, IH, α-СН-Рго); 4.45 (m, IH, o-CH-Arg); 7.78/8.13 (dd, 4H, arom pNA). 
2HCl.H-(Gly)
x
-(Pro)y-(Gly)z- Val-Α rg-pNA 
a) x = 3,y = z = 0: 
Boc-Gly-Gly-Gly-Val-Arg-pNA.HCl (100.7 mg, 0.140 mmol) was dissolved in AcOH (5 
mL) and 3.5 M HCl in EtOAc (5 mL) was added. After stirring for 2 hrs at room temperature, 
the acid was quenched by the addition of terf.-BuOH (20 mL) and the solution was evaporated 
in vacuo. The residue was coevaporated with tert.-BuOH (once 10 mL) and MeOH (twice 10 
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mL). The foamy residue was dissolved in H 2 0 (25 mL) and subsequently washed with 
CH2C12 (twice 10 mL) and diethyl ether (once 20 mL). The aqueous phase was lyophilized and 
the crude deprotected product was used as obtained. Yield: 90.4 mg (quant.), 
Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.21. 
b)x = y = z = l: 
Obtained as described for a). 
Quantities used: Boc-Gly-Pro-Gly-Val-Arg-pNA.HCl: 110.6 mg (0.146 mmol). Yield: 110.1 
mg (quant.), R,<BuOH/AcOH/H20 4:1:1 v/v/v): 0.15. 
с) x = 0,y = ],z = 2: 
Obtained as described for a). 
Quantities used: Boc-Pro-Gly-Gly-Val-Arg-pNA.HCl: 110.9 mg (0.146 mmol). Yield: 88.1 
mg (87%), R,<BuOH/AcOH/H20 4:1:1 v/v/v): 0.15. 
Boc-Glu(0'Bu)-(Gly)
x
-(Pro)y-(Gly)z-Val-Arg-pNA.HCl 
α) χ = 3, у = ζ = 0: 
Boc-GIu(0'Bu)-ONSu (56.5 mg, 0.142 mmol, 1.03 eq.) and 2HC1.H-Gly-Gly-Gly-Val-Arg-
pNA (90 mg, 0.138 mmol) were dissolved in DMF (10 mL). The reaction was started by the 
addition of DIPEA (50 μL, 0.294 mmol, 2.13 eq.) and kept overnight at room temperature. 
The next day, DMF was removed under reduced pressure and the residue was diluted with 
BuOH (20 mL). The organic solution was subsequently washed with H 2 0, saturated 
NaHC03, H 20, and saturated NaCl (three times 5 mL each). The solvent was removed under 
reduced pressure and the residue was dissolved in AcOH and lyophilized. The product was 
purified by counter current distribution with BuOH/AcOH/H20 4:1:5 v/v/v as the solvent 
system. The pure product fractions were collected, evaporated in vacuo and lyophilized from 
AcOH. Yield: 102.2 mg (82%), Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.60 (K = 5.91), [a]D = 
-26.3° с = 0.24 MeOH, >H NMR (CD3OD): δ = 0.99/1.01 (dd, 6H, у-СН3/у-СН3- а1); 1.45 
(s, 18H, Boc(9H)/0'Bu(9H)); 1.71 (m, 2H,
 Y-CH2-Arg); 1.86 (m, 2H, ß-CH2-Arg); 2.04 (m, 
2H, ß-CH-Val/ß-CH2-Glu(lH)); 2.16 (m, IH, ß-CH2-Glu(lH)); 2.34 (m, 2H, y-CH2-GIu); 
3.24 (m, 2H, 8-CH2-Arg); 3.84/3.87-3.88/3.92//3.87//3.97/3.99-4.03/4.04 (dd/s/dd, 6H, 
CH2-Gly(3 χ 2H)); 4.06 (m, IH, a-CH-Glu); 4.12 (d, IH, a-CH-Val); 4.54 (m, IH, a-CH-
Arg); 7.88/7.90-8.21/8.23 (dd, 4H, arom pNA). 
b)x = y = z = l: 
Obtained as described for a). 
Quantities used: Boc-GlutO'Buí-ONSu: 57.6 mg (0.145 mmol, 1.01 eq.), 2HCl.H-Gly-Pro-
Gly-Val-Arg-pNA: 100.0 mg (0.144 mmol), DIPEA: 50 uL (0.294 mmol, 2.04 eq.) in 10 mL 
DMF. Yield: 123.3 mg (91%), R,<BuOH/AcOH/H20 4:1:1 v/v/v): 0.55, [a]D = -53.2° с = 
0.24 MeOH, IH NMR (CD3OD): δ = 0.99/1.01 (dd, 6H, Y-CH3/y-CH3-Val); 1.45 (s, 18H, 
Boc(9H)/0'Bu(9H)); 1.75 (bm, 4H, ß-CH2-Arg/y-CH2-Arg); 2.03 (bm, 5H, ß-CH-VaI/CH2-
Pro (2 χ 2H)); 2.20 (m, 2H, ß-CH2-Glu); 2.32 (m, 2H, y-CH2-Glu); 3.23 (m, 2H, б-СН2-
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Arg); 3.60 (dm, 2H, N-CH2-Pro); 3.85/3.90-4.00/4.04 (dd, 2H, CH2-Gly(Glu~)); 4.07 (s, 
2H, CH2-Gly(~Val)); 4.12 (m, 2H, a-CH-Val/a-CH-Glu); 4.42 (m, IH, a-CH-Pro); 4.49 
(m, IH, a-CH-Arg); 7.93/7.96-8.18/8.21 (dd, 4H, arom pNA). 
c) x = 0,y= l,z = 2: 
Obtained as described for a). 
Quantities used: Boc-Glu(0'Bu)-ONSu: 50.7 mg (0.132 mmol, 1.04 eq.), 2HCl.H-Pro-Gly-
Gly-Val-Arg-pNA: 88 mg (0.127 mmol), DIPEA: 50 μ ι (0.294 mmol, 2.31 eq.) in 10 mL 
DMF. Yield: 94.6 mg (79%), Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.67 (K = 5.91), [a]D = 
-40.0° с = 0.14 MeOH, Ή NMR (CD3OD): δ = 0.99/1.00-1.01/1.02 (dd, 6H, у-СН3/У-
CH3- Val); 1.46 (s, 18H, Boc(9H)/0'Bu(9H)); 1.73 (m, 2H, y-CH2-Arg); 1.87 (m, IH, β-
CH2-Arg(lH)); 2.00 (m, 5H, ß-CH2-Arg(lH)/CH2-Pro (2 χ 2H)); 2.13 (m, 2Н, ß-CH-Val/ß-
CH2-Glu(lH)); 2.25 (m, IH, ß-CH2-GIu(lH)); 2.34 (m, 2H, Y-CH2-G1U); 3.23 (m, 2H, δ-
CH2-Arg); 3.76 (m, 2Η, N-CH2-Pro); 3.89/3.93-3.97/4.01 (dd, 4H, CH2-Gly(2 χ 2Η)); 4.12 
(d, IH, a-CH-Val); 4.37 (m, IH, a-CH-Glu); 4.43 (m, IH, a-CH-Pro); 4.55 (m, IH, a-CH-
Arg); 7.88/7.90-8.21-8.23 (dd, 4H, arom pNA). 
Deprotection of the N-terminal Boc-Glu(O'Bu)- residue: 
The Boc- and ieri.-Bu function were removed by the method of Sieber et al.21 In general: the 
protected peptide was dissolved in pre-cooled (-5°C) concentrated HCl (37%). After stirring 
for 5 min at 0°C, the reaction mixture was diluted with AcOH (10 volumes) and lyophilized, 
dissolved in H 2 0 and lyophilized again. The crude deprotected product was purified by counter 
current distribution with BuOH/AcOH/H20 4:1:5 v/v/v as the solvent system. The pure 
product fractions were collected, evaporated in vacuo and lyophilized from H20. The fluffy, 
off-white products were further dried in a vacuum desiccator on NaOH-pellets to reduce the 
slightly hygroscopic character of the fresh lyophilisâtes. 
2HCl.H-Glu-Val-Arg-pNA (3d): 
Yield: 69.1 mg (81%), R,<BuOH/AcOH/H20 4:1:1 v/v/v): 0.36 (K = 0.37), [a]D = -43.0° с = 
0.10 MeOH, Ή NMR (D20): δ = 0.78 (dd, 6H, у-СН3/у-СН3- а1); 1.52 (m, 2H, у-СН2-
Arg); 1.72 (m, 2Н, ß-CH2-Arg(lH)/ß-CH-Val); 1.94 (m, 3H, ß-CH2-Arg(lH)/ß-CH2-Glu); 
2.25 (m, 2H, y-CH2-Glu); 3.04 (m, 2H, 5-CH2-Arg); 3.93 (m, IH, a-CH-Glu); 4.00 (d, IH, 
a-CH-Val); 4.28 (m, IH, a-CH-Arg); 7.51/8.07 (dd, 4H, arom pNA). 
2HCl.H-Glu-Gly- Val-Arg-pNA (3e): 
Yield: 71 mg (84%), Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.34 (K = 0.36), [a]D = -40.8° с = 
0.26 MeOH, 'H NMR (CD3OD): δ = 0.98/1.01 (dd, 6H, y-CH3/y-CH3-Val); 1.70 (m, 2H, 
Y-CH2-Arg); 1.84 (m, IH, ß-CH-Val); 1.97/2.13 (dm, 2H, ß-CH2-Arg); 2.13 (m, 2H, ß-CH2-
Glu); 2.56 (m, 2H, v-CH2-Glu); 3.24 (m, 2H, 6-CH2-Arg); 3.97/4.00-4.05/4.09 (dd, 2H, 
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CH2-Gly); 4.02 (m, IH, α-CH-Glu); 4.23 (d, IH, α-CH-Val); 4.53 (m, IH, α-CH-Arg); 
7.86/7.89-8.21/8.23 (dd, 4H, arom pNA). 
2HCl.H-Glu-Gly-Gly- Val-Arg-pNA (3f): 
Yield: 81.3 mg (94%), Rf(BuOH/AcOH/H20 4:1:1 v/v/v): 0.28 (K = 0.34), [a]D = -26.9° с = 
0.13 MeOH, AAA: Glu(l.OO) 1.11; Gly(2.00) 1.97; Val(l.OO) 0.99; Arg(l.OO) 0.93, lH 
NMR (D20): δ = 0.74 (dd, 6H, rCH3/V-CH3-Val); 1.52 (m, 2H, y-CH2-Arg); 1.68 (m, IH, 
ß-CH-Val); 1.77/1.89 (dm, 2H, ß-CH2-Arg); 1.99 (m, 2H, ß-CH2-Glu); 2.37 (m, 2H, rCH2-
Glu); 3.05 (m, 2H, 6-CH2-Arg); 3.84 (m, 4H, CH2-Gly(2 χ 2H)); 3.94 (m, 2H, a-CH-Val/ 
a-CH-Glu); 4.29 (m, IH, a-CH-Arg); 7.52/8.06 (dd, 4H, arom pNA). 
2HCI. H-Glu-Gly-Gly-Gly- Val-Arg-pNA (3g): 
Yield: 71.3 mg (91%), R,{BuOH/AcOH/H20 4:1:1 v/v/v): 0.20 (K = 0.28), [ct]D = -16.4° с = 
0.14 MeOH, AAA: Glu(l.OO) 1.18; Gly(3.00) 2.92; Val(l.OO) 0.99; Arg(l.OO) 0.91, 'H 
NMR (D20): δ = 0.78 (dd, 6H, y-CH3/y-CH3-Val); 1.54 (m, 2H, r-CH2-Arg); 1.73/1.82 
(dm, 2H, ß-CH2-Arg); 1.93 (m, IH, ß-CH-Val); 2.04 (m, 2H, ß-CH2-Glu); 2.42 (dd, 2H, γ-
CH2-Glu); 3.08 (dd, 2H, 6-CH2-Arg); 3.81/3.89 (m, 6H, CH2-Gly(3 χ 2H)); 3.98 (m, 2H, 
a-CH-Val/a-CH-Glu); 4.23 (m, IH, o-CH-Arg); 7.55/8.09 (dd, 4H, arom pNA). 
2HCl.H-Glu-Gly-Pro-Gly-Val-Arg-pNA(3h): 
Yield: 79.6 mg (90%), R,{BuOH/AcOH/H20 4:1:1 v/v/v): 0.17 (K = 0.33), [a]D = -50.8° с = 
0.12 MeOH, AAA: GIu(l.OO) 1.18; Gly(2.00) 1.97; Pro(l.OO) 1.04; Val(l.OO) 0.94; 
Arg(l.OO) 0.87, 'H NMR (D20): δ = 0.78 (dd, 6H, у-СН3/У-СН3- а1); 1.55 (m, 2H, γ-
CH2-Arg); 1.64-2.14 (bm, 9H, ß-CH-Val/ß-CH2-GIu/ß-CH2-Arg/CH2-Pro(2 χ 2H)); 2.43 (m, 
2H,
 V-CH2-Glu); 3.08 (m, 2H, 8-CH2-Arg); 3.46 (m, 2H, N-CH2-Pro); 3.80 (s, 2H, CH2-
Gly); 3.98 (m, 4H, a-CH-Val/a-CH-Glu/CH2-Gly); 4.31 (m, 2H, a-CH-Arg/a-CH-Pro); 
7.55/8.11 (dd, 4H, arom pNA). 
2HCl.H-Glu-Pro-Gly-Gly-Val-Arg-pNA(3i): 
Yield: 40.2 mg (92%), R,(BuOH/AcOH/H20 4:1:1 v/v/v): 0.16 (K = 0.29), [ct]D = -33.3° с = 
0.11 MeOH, AAA: Glu(l.OO) 1.35; Gly(2.00) 1.82; Pro(l.OO) 1.05; Val(l.OO) 0.92; 
Arg(l.OO) 0.85, 'H NMR (D20) δ = 0.79 (dd, 6H, y-CH3/y-CH3-Val); 1.57 (m, 2H, γ-
CH2-Arg); 1.70-2.21 (bm, 9H, ß-CH-Val/ß-CH2-Glu/ß-CH2-Arg/CH2-Pro(2 χ 2H)); 2.42 (m, 
2H, y-CH2-Glu); 3.08 (m, 2H, 6-CH2-Arg); 3.47 (m, 2H, N-CH2-Pro); 3.61 (m, IH, a-CH-
Glu); 3.82 (dd, 4H, CH2-Gly(2 χ 2H)); 3.98 (d, IH, a-CH-Val); 4.32 (m, 2H, ct-CH-Arg/a-
CH-Pro); 7.57/8.12 (dd, 4H, arom pNA). 
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CHAPTER 5 
CONTINUOUS REGISTRATION OF THROMBIN GENERATION 
CURVES USING CHROMOGENIC SUBSTRATES WITH A 
FIBRINOGEN Act -LIKE STRUCTURE 
ABSTRACT 
In this chapter a set of 18 chromogenic substrates from a second design cycle was tested on its 
application in the continuous registration of thrombin formation in plasma The screening and 
selection procedure was the same as described in chapter 3 Two substrates were found to be 
suitable to be used in the continuous assay1 Msc-Val-Arg-pNA HCl and 2HC1 H-Glu-Gly-
Gly-Val-Arg-pNA are promising compounds to replace SQ68 Both compounds have no 
inhibitory activity against the prothrombinase-complex or any other coagulation factor 
Chromogenic substrates of up to six amino acids in length were not sufficiently long to be 
excluded from the active-site of thrombin complexed by a2-macroglobuhn However, we 
found that hydroxylamine is a selective destructive agent of a2-macroglobuhn without affecting 
the coagulation cascade Furthermore, some examples of thrombin generation curves obtained 
from substrate/heparin combinations are given and it was shown that 2HC1 H-D-Phe-Pro-Lys-
pNA can be used to obtain a correct thrombin generation curve in the presence of 5 U/mL 
international standard heparin 
INTRODUCTION 
From our previous experiments we found 2HC1 H-Val-Arg-pNA a suitable chromogenic 
substrate for use in the continuous registration of thrombin formation in plasma (chapter 3) 
Despite the low reaction rate with pure factor Xa and the observation that the hydrolysis of 
CH30-CO-D-Chg-Gly-Arg-pNA AcOH by factor Xa is not affected by the addition of 
2HC1 H-Val-Arg-pNA, the prothrombinase activity is substantially lowered Apart from this, 
the peak of the prothrombinase activity appears at a later time, so this may be due to the 
inhibition of feedback-loop activation by thrombin 
To meet these problems we synthesized chromogenic substrates which are attacked by 
thrombin with a higher selectivity (chapter 4) Knowledge of the structure-activity relationships 
obtained from our earlier experiments (chapter 3) was implemented in the design of these 
substrates Additionally, X-ray studies of fibnnopeptide Aal 16 complexed with bovine a-
thrombin2 and human α-thrombin3 gave information on the structural requirements 
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for an optimal fit into the active-site of thrombin. A second set of substrates was designed in 
which structural elements responsible for interactions with thrombin were gradually omitted to 
obtain the minimal sequence which is capable to interact selectively with thrombin. Fibrinogen 
Act was chosen, in the assumption that this natural substrate represents the optimal set of 
structural elements for selective interaction with thrombin rather than with factor Xa. 
Another obstacle encountered in the determination of the thrombin generation curve is the 
hydrolytic activity of the a2-macrogIobulin-thrombin complex on small chromogenic 
substrates. This complex has no clotting activity but it disturbs the thrombin generation curve 
by its action on substrates which are small enough to be bound by this complex. To reduce the 
contribution of the a2-macroglobulin-thrombin complex to the optical density curve, we 
synthesized chromogenic substrates up to six amino acid residues in length in the assumption 
that these substrates have a decreased access to the active-site of thrombin due to steric 
hindrance caused by its complexation with a2-macroglobulin. 
MATERIALS AND METHODS 
Materiah 
Chromogenic substrates: The syntheses of the substrates are described in chapter 4. The 
substrates were dissolved in distilled water to obtain 10 mM stock solutions. The concentration 
was determined at 316 nm using a molar extinction coefficient of 12,500. Stock solutions 
were stored in the dark at 4°C. Thrombin substrate SQ68 (malonyl-a-amino/sobutyryl-arginine 
p-nitroanilide methyl ester monohydrochloride, CH30-CO-CH2-CO-Aib-Arg-pNA.HCl) was 
obtained from Serbio Laboratories, France. Heparin (4,h international standard heparin) was 
obtained from the National Bureau of Standards and Control (London). Methylamine (40 wt.-
% solution in H2O), Ν,Ν-dii'jopropylethylamine and hydroxylamine hydrochloride were 
purchased from Merck (Darmstadt, Germany). 
Phospholipids: Phospholipids required were 80 mol-% dioleoyl phosphatidyl choline and 20 
mol-% dioleoyl phosphatidyl serine solutions in chloroform; they were obtained from Avanti 
Polar Lipids. They were used to prepare vesicles as described by Rosing et alA 
Buffers: Buffer A: 0.05 M Tris-HCl, 0.1 M NaCl pH = 7.35 containing 0.5 g/L bovine serum 
albumin (Sigma). Buffer B: buffer A containing additional EDTA (20 mM) pH = 7.90. 
Enzyme preparations: Pure human α-thrombin and human factor Xa samples were generous 
gifts of Dr. T. Lindhout (University of Limburg, Maastricht, The Netherlands). The euglobulin 
thrombin fraction was prepared from defibrinated plasma by acid precipitation at low ionic-
strength as described by Josso and Prou-Wartelle5. The precipitate was dissolved in half the 
original volume of buffer A, containing 0.02 M trisodium citrate. 
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Plasma: Plasma was prepared by collecting 9 parts of blood (from 10 healthy donors) on 1 part 
of 0.13 M trisodium citrate. Following centrifugation at 900g (15°C, 15 min) and 10,000g 
(15°C, 15 min) the obtained plasma was pooled and centrifuged at 4°C for 1 hour at 23,000g; 
this plasma was stored at -80°C. Plasma was defibrinated by mixing an aliquot of plasma with 
1/50 volume of repúlase (Laboratories Stago, Asnières, France; the solution was made as 
instructed by the manufacturer), letting a clot form for 10 min at 37°C followed by 10 min on 
ice. The fibrin clot was removed by winding it on a plastic spatula. А1(ОН)з treated plasma: 
lmL defibrinated plasma was incubated with 200 цЬ А1(ОН)з suspension (0.25 g/mL in 0.15 
M NaCl) at 37°C for 5 min. After centrifugation (3 min) the supernatant was used in the 
experiments. А1(ОН)з treatment removes all vitamin К dependent clotting factors (FU, VII, 
IX, X, protein С and protein S). Coagulation factor XI and XII deficient plasmas were 
generous gifts of Dr. G. Tans (University of Limburg, Maastricht, The Netherlands). 
Tissue factor: Recombinant tissue factor (Recomplastin S, Dade, Baxter Diagnostics Inc., 
Deerfield II., USA) was used as a trigger for coagulation. The solution was prepared according 
to the instructions of the manufacturer. The intrinsic pathway was triggered by Actin FS, 
activated PTT reagent from soy phosphatides, containing 1.10"4 M ellagic acid and was 
obtained from Baxter. Contact activation was started by the addition of kaolin (0.5 mg/mL in 
0.15 M NaCl); kaolin (kaolin léger) was provided by B.L.B. Laboratoires du Bois de 
Boulogne (Puteaux, France). 
Methods 
Kinetic parameters: The hydrolysis experiments were run in buffer A at 37°C. The liberation of 
p-nitroaniline was monitored at 405 nm in a dual wavelength (405-546 nm) spectrophotometer 
made in our workshop, using a personal computer for data recording. In a polystyrene 
microcuvette (total volume 500 μι), buffer A and substrate solution were added to obtain a 
final substrate concentration between 200 to 2000 μΜ. After 5 min of incubation at 37°C, 
enzyme solution was added to achieve a final concentration between 0.5 to 50 nM. The 
measurement was carried out at 37°C in a thermostated cuvette-holder. The Michaelis constant 
(K
m
) and the catalytic constant (k
cat) were obtained by measuring the initial reaction velocities 
at different substrate concentrations. The data obtained were fitted by linear regression on the 
Michaelis-Menten equation. 
Continuous registration of the thrombin generation curve: Extrinsic pathway: In a polystyrene 
microcuvette were added: 400 \ib defibrinated plasma, 20 μι of a 45 μΜ phospholipid solution 
(final concentration: 1.5 μΜ) and 140 uL of buffer A which contains the substrate at the desired 
final concentration (500 μΜ). After 4 min of incubation at 37°C, 20 μL tissue factor (undiluted) 
was added. Thrombin generation was started by adding 20 μL of a 0.5 M CaCl2 solution (final 
concentration: 16.67 mM); during the measurement the temperature was kept at 37°C. The 
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optical density was monitored at 405 nm. From the obtained optical density curve, the first 
derivative was calculated giving the enzyme concentration during the measurement. Intrinsic 
pathway: 400 |xL defibrinated plasma, 110 цЬ buffer A (eventually containing the substances to 
be tested) and 40 μ ι Actin FS (undiluted) were added in a plastic microcuvette, intensively 
mixed and incubated at 37°C during 4 min. Then 30 uL of a 10 mM substrate solution (final 
concentration: 500 μΜ), followed by 20 uL of a 0.5 M CaCl2 solution (final concentration: 
16.7 mM) were added (both solutions were prewarmed at 37°C for 4 min). The optical density 
was measured at 37°C at 405 nm during 20 min. Contact activation: 400 \ÍL defibrinated 
plasma, 100 uL buffer A (eventually containing the substances to be tested), 9 μ ι of a 100 μΜ 
phospholipid solution (final concentration: 1.5 μΜ) and 40 uL kaolin (0.5 mg/mL) were added 
in a plastic microcuvette, intensively mixed and incubated at 37°C during 4 min. (It was not 
necessary to remove kaolin by centrifugation.) Then 30 μι of a 10 mM substrate solution (final 
concentration: 500 μΜ), followed by 20 \iL· of a 0.5 M CaCl2 solution (final concentration: 
16.7 mM) were added (both solutions were prewarmed at 37°C for 4 min). The optical density 
was measured at 37°C at 405 nm during 25 min. 
Decay constants of thrombin in plasma: To 120 uL defibrinated plasma was added: 50 \iL of 
buffer A which contained the substances to be tested. To this mixture was added 10 \iL of a 
thrombin preparation to achieve a final concentration of 100 nM. At regular time intervals (5-10 
s) 10 \¡L samples were subsampled into 490 \iL buffer В which contained 200 μΜ of S2238 to 
determine thrombin activity. After 2 min the reaction was stopped by adding 300 μι IM citric 
acid. The moment of sampling and stopping were recorded on a personal computer with 
pushbutton-equipped pipettes. The optical density was read at 405 nm and the obtained 
amidolytic activities were used to calculate the decay constants. The obtained decay constant is 
the sum of the decay constants of the reaction of thrombin with antithrombin III (kt) and ct2-
macroglobulin (k2). 
Manual determination of thrombin generation in plasma: Extrinsic pathway: To 480 μ ι 
defibrinated plasma were added: 172 \ÍL buffer A which contained the substrate at 
concentrations between 0 to 2000 μΜ and 20 μL· of a 54 μΜ phospholipid solution (final 
concentration: 1.5 μΜ). After incubation for 4 min at 37°C, 24 uL tissue factor (undiluted) was 
added. Thrombin formation started at zero time by adding 24 μ ι of a 0.5 M CaCl2 solution 
(final concentration: 16.67 mM). At regular time intervals of 12 s samples of 10 μ ι were 
subsampled as described above. From the amidolytic activities thus obtained, the thrombin 
generation curve can be drawn. The decay constant k2 can be calculated from these data in an 
alternative way, see reference 6 for further details. 
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Influence of the substrate on the prothrombinase-complex: With the obtained decay constants 
and from the curves obtained by the subsampling method we calculated the course of 
prothrombin conversion and the course of prothrombinase concentration. 
RESULTS 
Kinetic parameters: The Km and kcat values for each substrate were determined at an enzyme 
concentration of 0.5-50 nM (thrombin) and 50 nM factor Xa. From the initial reaction 
velocities, measured for at least six substrate concentrations between 200 and 2000 uM, the Km 
and kcat values were calculated by linear regression on the Michaelis-Menten curve. Table 1 
gives an overview of the kinetic parameters of the different substrates hydrolyzed by thrombin 
and by factor Xa in buffer A. 
Continuous registration of the thrombin generation curve: The continuous thrombin generation 
curves of substrates, entries 1, 4 (SQ68), 5, 14-17 and 19 are given in figure 1 (extrinsic 
pathway) respectively figure 2 (intrinsic pathway). All of them show the characteristic thrombin 
generation curve with a good signal to noise ratio. With respect to the kinetic parameters of 
hydrolysis, compounds Msc-Val-Arg-pNA.HCl (entry 5) and 2HC1.H-Glu-Gly-Gly-Val-Arg-
pNA (entry 16) were selected as possible candidates to be used as substrates in the continuous 
assay. In the intrinsic activation by Actin FS some substrates were hydrolyzed before Ca2+ was 
added. To check what the reason is for this hydrolytic activity a control experiment via contact 
activation was carried out with Msc-Val-Arg-pNA.HCl, see figure 3. From this experiment is 
was concluded that kallikrein is responsible for this unwanted substrate hydrolysis. 
Decay constants: The decay constants of thrombin in the presence of Msc-Val-Arg-pNA.HCl 
and 2HCl.H-Glu-Gly-Gly-Val-Arg-pNA are given in table 2. In both cases, inhibition of 
thrombin by AT-III is more efficient than when SQ68 is present. 
Manual determination of thrombin formation and the influence of substrate on the 
prothrombinase-complex: The thrombin generation curves obtained by the subsampling method 
are given in figure 4. From these curves and the decay constants given in table 2, the course of 
the concentration of the prothrombinase complex was calculated and is shown in figure 5. As 
can be seen, both substrates neither influenced the manual thrombin generation curve nor 
showed inhibitory activity on the prothrombinase complex. 
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500 
600 
time (s) 
1200 
MZ-Aib-Aig-pNA — H-Val-Arg-pNA — Msc-Val-Arg-pNA I 
Figure 1A: Continuous optical density curves from extrinsic triggered plasma using the 
substrates MZ-Aib-Arg-pNA.HCl (SQ68), 2HCl.H-Val-Arg-pNA and Msc-Val-Are-
pNA.HCI at 500 μ Μ . 
I — H-EVR-pNA — - H-EGVR-pNA — H-EGGVR-pNA 
| — H-EGGGVR-pNA — - H-EPGGVR-pNA 
Figure IB: Continuous optical density curves from extrinsic triggered plasma using the 
substrates 2HCI.H-Glu-Val-Arg-pNA, 2HCl.H-Glu-Gly-VaI.Arg-pNA, 2HC1.H-Glu-Glv-
Gly-Val-Arg-pNA, 2HCI.H-Glu-Gly-Gly-Gly-Val-Arg-pNA and 2HCl.H-Glu-Pro-Glv-Glv-
Val-Arg-pNA at 500 μ M. 
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800 
-200 
200 400 600 800 1000 
time (s) 
I MZ-Aib-Arg-pNA — - H-Val-Arg-pNA — Msc-Val-Arg-pNA 
Figure 2A: Continuous optical density curves from intrinsic triggered plasma using the 
substrates MZ-Aib-Arg-pNA.HCI (SQ68), 2HCl.H-Val-Arg-pNA and Msc-Val-Arg-
pNA.HCI at 500 μΜ. 
-200 
200 400 600 
time (s) 
800 1000 
H-EVR-pNA H-EGVR-pNA - — H-EGGVR-pNA 
— - H-EGGGVR-pNA — - H-EPGGVR-pNA 
Figure 2B: Continuous optical density curves from extrinsic triggered plasma using the 
substrates 2HCI.H-Glu-Val-Arg-pNA, 2HCI.H-Glu-Gly-Val-Arg-pNA, 2HC1.H-Glu-Gly-
Gly-Val-Arg-pNA, 2HCl.H-Glu-Gly-GIy-Gly-Val-Arg-pNA and 2HCl.H-Glu-Pro-Gly-Gly-
Val-Arg-pNA at 500 μΜ. 
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Table 1: Kinetic parameters of hydrolysis of the substrates by thrombin and factor Xa in 
buffer A at 37°C. 
No 
1 
2 
3 
4 
5 
6 
7 
8 
Substrate 
2HC1 H-Val-Arg-pNAa 
2HC1 H-Val-Lys-pNA 
MZ-Val-Arg-pNA HCla 
MZ-Aib-Arg-pNA HClb 
Msc-Val-Arg-pNA HCl 
Msc-Val-Lys-pNA HCl 
Msc-Val-Om-pNA HCl 
Msc-Val-Nle-pNA 
^m 
1239 
-
1007 
830 
882 
-
-
-
Thrombin 
''cat 
0 23 
NH 
14 4 
0 46 
0 79 
NH 
NH 
NH 
^саг'тп 
1 86E2 
-
143E4 
5 54E2 
8 94E2 
-
-
-
K
m 
-
-
4082 
3940 
9552 
-
-
-
Factor : 
^cat 
NH 
NH 
10 1 
2 9 
4 69 
NH 
NH 
NH 
Ka 
^cat^m 
-
-
2 47E3 
7 38E2 
4 91E2 
-
-
-
9 Boc-Gly-Val-Arg-pNA HCIa 244 112 4 59E4 2679 3 51 1 31E3 
10 2HC1 H-Gly-Val-Arg-pNAa 
11 2HC1 H-Gly-Val-Lys-pNA 
12 2HC1 H-Gly-Val-Om-pNA 
13 HCl H-Gly-Val-Nle-pNA 
14 2HC1 H-Glu-Val-Arg-pNA 
15 2HC1 H-Glu-Gly-Val-Arg-pNA 
16 2HC1 H-EGGVR-pNA* 
17 2HC1 H-EGGGVR-pNA* 
18 2HC1 H-EGPGVR-pNA* 
19 2HC1 H-EPGGVR-pNA* 
20 2HC1 H-D-Phe-Pro-Lys-pNAa 35 90 2 58E6 - NH 
'Amino acyl residues are denoted by their one-letter code, K
m
 in μΜ, k ^ in s"1, k
ca
t/K
m
 in (Ms)"1, NH no 
hydrolysis, afrom chapter 3, bfrom reference 1 
Thrombin generation curves in the presence of high heparin concentrations Some examples of 
thrombin generation curves measured in the presence of different heparin concentrations are 
given in figure 6. The substrates where chosen to cover a continuous range of heparin 
concentrations up to 5 U ISH/mL. 
Thrombin generation curves in the presence of hydroxylamine- Hydroxy lamme was added to 
the plasma sample as a selective denaturating agent of ci2-macroglobulin. The influence of 
3234 
986 
-
-
932 
3274 
1006 
379 
1074 
-
25 4 
0 20 
NH 
NH 
144 
351 
0 55 
0 27 
9 07 
NH 
7 88E3 
198E2 
-
-
154E3 
107E3 
5 42E2 
7 04E2 
8 44E3 
-
4379 
-
-
-
1510 
1433 
2186 
1491 
2192 
961 
2 84 
NH 
NH 
NH 
1 07 
0 93 
0 42 
0 30 
3 41 
0 45 
6 49E2 
-
-
-
7 09E2 
6 38E2 
1 92E2 
2 01E2 
1 56E3 
4 68E2 
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200 400 600 
time (s) 
800 1000 
tissue factor —·— aeon FS — kaolin 
Figure 3: Continuous optical density curves using Msc-Val-Arg-pNA.HCl as substrate at 
500 μΜ in three differently triggered plasmas; extrinsic (tissue factor), intrinsic (Actin 
FS) and contact activation (kaolin). 
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500 
300 400 
time (s) 
I — control —— 200 μΜ 500 μΜ <— 1000 цМІ 
Figure 4A: Thrombin generation curves from extrinsic triggered plasma obtained by the 
subsampling method. The influence of additional Msc-Val-Arg-pNA.HCI on thrombin 
generation. 
500 
300 400 500 600 700 
time (s) 
— control —- 200 μΜ — 500 μΜ -— 1000 μΜ ¡ 
Figure 4B: Thrombin generation curves from extrinsic triggered plasma obtained by tbe 
subsampling method. The influence of additional 2HCI.H-Glu-Gly-Gly-Val-Arg-pNA on 
thrombin generation. 
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300 400 
time (s) 
600 700 
control — 200 μΜ •— 500 μΜ — 1000 μΜ 
Figure 5Α: The influence of Msc-Val-Arg-pNA.HCl on prothrombinase activity in 
extrinsically triggered plasma. 
1200 
200 300 400 
time (s) 
500 600 
— control — - 200 μΜ 500 μΜ — 1000 μΜ 
Figure 5B: The influence of 2HCI.H-Glu-Gly-Gly-VAI-Arg-pNA on prothrombinase 
activity in extrinsically triggered plasma. 
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added hydroxylamine on the thrombin generation curve ,. s measured in the coutinuous assay is 
given in figure 7 Correct thrombin generation curves are obtained at all concentrations of 
hydroxylamine used Already at 25 mM hydroxylamine the residual amidolytic activity of the 
02M-thrombin complex is substantially reduced 
Decay constants and the influence of hydroxylamine on the prothrombinase complex To check 
if hydroxylamine has any inhibitory activity on the coagulation cascade, a thrombin generation 
curve was determined via the subsampling method (figure 8A). The decay constants of 
thrombin in the presence of hydroxylamine (table 3) were determined and were used to 
calculate the course of the prothrombinase concentration (figure 8B) From these experiments it 
was concluded that hydroxylamine did not influence the coagulation cascade 
Continuous registration of thrombin generation curves in non-defibrinated plasma In figure 9 
an example of a thrombin generation curve in non-defibnnated plasma is given Hydroxylamine 
was used to denaturate ct2-macrogIobulin but it also makes the defibrinating step redundant 
because a clear gel is formed, so the measurement is not disturbed by formation of an incipient 
turbidity 
Table 2A: Decay constants of euglothrombin in plasma in the presence of Msc-Val-Arg-
pNA.HCI at different concentrations. 
[S] 
μΜ 
0 
200 
500 
1000 
Ko verall 
min"1 
2 578 
1 958 
1 792 
1 104 
kl 
min"1 
2 262 
1 729 
1 614 
0 980 
k2 
min ' 
0 3 1 6 
0 229 
0 178 
0 124 
4/2 
s 
16 13 
2 1 2 4 
23 22 
37 70 
k2.M 
min ' 
0 225 
0 198 
0 178 
0 144 
к I ,corr 
min ' 
2 183 
1 590 
1 444 
0 790 
(kl.corr) 
min'' 
1508 
1098 
0 998 
0 546 
Table 2B: Decay constants of euglothrombin in plasma in the presence of 2HCI.H-Glu-
Gly-Gly-Val-Arg-pNA at different concentrations. 
[S] ^overall к) кг t i/ 2 k 2 м k i i C o r r (lq - C O r r) 
μΜ min"1 min"1 min ' s min"1 min"1 min"1 
0 2 578 2 262 0 316 16 13 0 225 2 183 1508 
200 2 159 1946 0 213 19 26 0 220 1769 1223 
500 2 024 1733 0 291 2104 0 192 1662 1149 
1000 1766 1594 0 172 23 56 0 169 1427 0 987 
^overall = ^1 + ^2 + 0 170, kj AT-III dependent decay of thrombin, k2 α 2 Μ dependent decay of thrombin, 
^overall· ^1 a n i ' ^2 ш е determined in a decay experiment, k2 M k2 determined by ihe subsampling method, 
k,
 c o r r
 k, after correcting for k2 M and 0 170, k, c o r r c o m r o | / l 508 = 2 183/1 508 = 1 448 μΜ AT-III, 
( Ч с о г г ^ Ч с о г / І Э Э ? 
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200 400 600 
time (s) 
1000 
ι — 0 1 U ISH/mL — 0 25 U ISH/mL 
Figure 6A: Continuous optical density curves from extrinsic triggered plasma in the 
presence of international standard heparin using Msc-Val-Arg-pNA.HCl as substrate at 500 
μΜ. 400 
600 
time (s) 
1200 
1 0 U ISH/mL I 5 U ISH/mL 2 0 U ISH/mL 
Figure 6B: Continuous optical density curves from extrinsic triggered plasma in the 
presence of international standard heparin using Boc-Gly-Val-Arg-pNA.HCI as substrate at 
500 μΜ. 
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2000 
600 
time (s) 
1200 
— Boe-GVR-pNA, 2 U ISH/mL - ^ H-dFPK-pNA, 2U ISH/mL — H-dFPK-pNA, 5 U ISWmL 1 
Figure 6C: Continuous optical density curves from extrinsic triggered plasma in the 
presence of international standard heparin using Boc-Gly-Val-Arg-pNA.HCI and 2HCI.H-D-
Phe-Pro-Lys-pNA as substrates at 500 μ Μ . 
1000 
400 600 
time (s) 
1000 
[ — control — 25 mM -— SO mM —- 100 mM 
Figure 7: Continuous optical density curves from extrinsic triggered plasma in the 
presence of hydroxylamine using Msc-Val-Arg-pNA.HCI as substrate at 500 μΜ. 
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Table 3: Decay constants of euglothrombin in plasma in the presence of hydroxylamine. 
[S] koverall kl k2 t\n k2,M kl.corr (kl.corr) 
mM min"' min"' min"' s min"' min"' min"' 
0 3 240 2 908 0 332 12 84 0 271 2 799 1508 
25 1312 1253 0 059 3170 0 057 1085 0 585 
^overall = kj + k2 + 0 170, kj AT-III dependent decay of thrombin, k2 α 2 Μ dependent decay of thrombin, 
''overall· k l а і и* k 2 a r e determined in a decay experiment, k2 м k 2 determined by the subsampling method, 
k l corr k l a f l e r correcting for k2 M and 0 170, ki c o r r c o n t r o | / l 508 = 2 799/1 508 = 1 856 μΜ AT-III, 
( Ч с о г г ^ Ч с о г / І в З б 
Table 4: Time-point at which the maximum of the amidolytic activity, prothrombinase 
activity and thrombin concentration occur at different substrate concentrations. 
Mic-Val-Arg-pNA HCl 
[S] AA 
0 342 44 
200 388 15 
500 387 15 
1000 456 42 
t 
60 
60 
60 
60 
2HCI H-Glu-Gly-Gly-Val-Arg-pNA 
[S] AA 
0 346 79 
2O0 350 62 
500 376 42 
1000 409 85 
Hydroxylamine 
[S] AA 
0 335 15 
ι 
60 
60 
60 
60 
t 
48 
PT 
1211 
1119 
1090 
1346 
PT 
1046 
1086 
1122 
1149 
PT 
1242 
t 
26 
24 
24 
24 
t 
24 
24 
24 
24 
t 
24 
Τ 
327 04 
37124 
374 80 
443 82 
Τ 
332 89 
335 47 
359 48 
396 23 
Τ 
322 17 
t 
60 
60 
60 
60 
t 
48 
60 
60 
60 
t 
48 
25 383 88 72 1227 36 378 03 72 
AA amidolytic activity (mOD/min), PT prothrombinase concentration (mOD/min), T thrombin concentration 
(mOD/min), t lime point at which maximum of concentration (amidolytic activity) is achieved (s), [S] 
substrate concentration in μΜ, hydroxylamine in mM 
DISCUSSION 
As described in chapter 3, 2HC1 H-Val-Arg-pNA (entry 1, table 1) was found a promising 
compound to be used as substrate in the continuous assay method. To make it more specific for 
thrombin some modifications were introduced starting from 2HC1 H-Val-Arg-pNA as lead 
structure; the results are described in this chapter. 
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300 400 
time (s) 
700 
- · - control —·— 25 mM hydroxylamine j 
Figure 8A: Thrombin generation curves from extrinsic triggered plasma obtained by the 
subsampling method. The influence of hydroxylamine on thrombin generation. 
300 400 
time (s) 
700 
- — control —·— 25 mM hydroxylamine 
Figure 8B: The influence of hydroxylamine on the prothrombinase activity in 
extrinsically triggered plasma. 
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200 400 600 
time (s) 
800 1000 
j —*— control 
— - non-deWS mM HONH2 
—- deC25 mM HONH2 
— - non-def725 mM HONH2/0.05 U ISH/mL 
Figure 9A: Continuous thrombin generation curves triggered by tissue factor with Msc-
Val-Arg-pNA.HCl as substrate at 500 μ M in defibrinated (def) and non-defibrinated (non-
def) plasma. 140 
200 400 600 
time (s) 
800 1000 
— non-def/25 mM HONH2 non-detf25 mM HONH2/0.05 U ISH/mL 
Figure 9B: Continuous thrombin generation curves triggered by tissue factor with Msc-
Val-Arg-pNA.HCl as substrate at 500 μΜ in non defibrinated plasma. Even in the presence 
of hydroxylamine, the influence of heparin (ISH) is measurable. 
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In chapter 3 it was demonstrated that factor Xa hardly hydrolyses substrates with a lysine 
residue at position Pi, in contrast to thrombin When the arginine residue m 2HC1 H-Val-Arg-
pNA is exchanged by lysine, the substrate could not be hydrolyzed by thrombin or factor Xa 
either Evidently, the S2-cavity of thrombin does not recognize the substrate When substrates 
from entry 1 and 3 were mutually compared, the additional hydrophobic interactions from the 
malonyl moiety result in a significant increase of the turnover number 
Therefore, substrates from entries 5-8 were synthesized with the aim to find out if the 
interaction of the Msc-function with the aryl-bindmg pocket would result in hydrolytic cleavage 
of the anihde bond in which the Pi residue is different from arginine Surprisingly, only Msc-
Val-Arg-pNA HCl is susceptible to hydrolysis by thrombin and factor Xa, as can be seen from 
table 1, the other substrates could not be hydrolyzed by thrombin or factor Xa 
The crystal structure of H-D-Phe-Pro-Arg-CH2Cl-inhibited7 thrombin with showed that a D-
configurated Рз residue interacts with the aryl-binding site A substrate or inhibitor m which the 
P3 residue has L-configuration points away from this binding site, whereas the P4 side chain of 
a bound all L-amino acid substrate will interact with this hydrophobic binding cleft As a 
consequence, hydrophobic or aromatic residues should be inserted in P4 position in the 
development of good thrombin substrates8, see table 1, entry 9 
To tune the kinetic parameters of the substrate in a direction in which it is applicable in the 
continuous assay method, the Boc-protection was removed (entry 10) This substrate has not 
the optimal kinetic parameters and was taken as lead structure for the substrates from entries 
11, 12 and 13 in which the arginine residue was replaced by lysyl, omithyl or norleucyl, 
respectively 
As can be seen in table 1 the results are somewhat disappointing, because only entries 10 and 
11 were susceptible to hydrolysis by thrombin This was unexpected since Curragh and 
Elmore9 described already 30 years ago the thrombic hydrolysis of Tos-Lys-OMe and Tos-
Orn-OMe, and it is generally accepted that a single amino acid substrate has a lower 
susceptibility to be hydrolyzed than a peptide substrate Therefore, the resistance to hydrolysis 
of substrates 6, 7 and 11,12 was not expected 
From substrates entries 1-13 it can be concluded that only an arginyl residue in position Pi 
gives access to compounds which can be used as substrates for thrombin In chapter 3 it was 
shown that the H-D-Phe-Pip(Pro)- structural element renders substrates with a residue different 
from arginine in Pi position accessible to thrombin hydrolysis However, these substrates 
showed too low K
m
 values The results in this chapter show that a valyl residue at P2 and other 
substituents in P3 position can not induce the same recognition as a pipecolyl or a D-
phenylalanyl group respectively 
The synthesis of compounds 14-19 was motivated by the next observations (a-e) 
a) The side chain of Glu 192 in thrombin hampers the enzyme to hydrolyze substrates with an 
acidic residue in position Рз 1 0 Protein С is a poor substrate for thrombin due to the presence 
of an aspartic acid residue in that position (primary sequence of protein C1 ' at thrombin 
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cleavage-site: ~VaI(P4)-Asp(P3)-Pro(P2)-Arg(Pl)~); only after complex-formation with 
thrombomodulin, thrombin activates protein C. However, detailed kinetic analysis showed that 
an aspartic acid residue in P3 position affected the kcat value, but had little effect on substrate-
binding (Km value)12. 
b) The natural substrates of thrombin such as the thrombin-receptor, factor VIII and protein S 
have acidic residues (Asp/Glu) in their P3 positions. 
c) Despite the seemingly unfavorable interaction with Glu 192 and an acidic (polar) residue in 
position P3, thrombin can accommodate such a residue in the Michaelis-Menten complex. 
d) Lobo et al.13 who studied the dependence of the thrombic hydrolysis of an Arg-Gly bond on 
the positioning of glutamic acid residues in fibrinopeptides. 
e) By varying the glycine-spacer, the ability of glutamic acid to form a salt-bridge with Argl73 
was changed2·3 (entries 14-17) thereby incorporating a proline residue to mimic a ß-turn14 
(entries 18 and 19). 
Compound 14, 2HCl.H-Glu-Val-Arg-pNA, is indeed hydrolyzed by thrombin, and by factor 
Xa. Factor Xa is known to hydrolyze substrates with a Glu residue at position P315. From 
table 1, it appears that elongation of the peptides leads to more interaction on both enzymes, but 
an unambiguous trend in Km- and kcat values can not be observed. In entry 18 the proline 
residue is at the correct position to form a ß-turn, but the expected significantly lower Km value 
is not observed; a dramatic increase of the kca, is achieved instead. 
In a preliminary experiment, serum was used as enzyme source (thrombin-oç-macroglobulin-
complex) and the substrates did not show a significant reduction of the hydrolysis rate. From 
this it was clear that a substrate of six amino acids is still too small to be excluded from the 
active-site of thrombin complexed with a2-macroglobulin. The most promising compound was 
entry 16, which is predominantly attacked by thrombin; having the lowest susceptibility for 
factor Xa. 
With the reaction kinetics of the hydrolysis as a selection criterion, substrates entries 1, 4, 5, 
14-17 and 19 were tested in the continuous assay method. The thrombin generation curves are 
shown in figure 1 (extrinsic pathway) and figure 2 (intrinsic pathway). 
All the substrates tested showed a characteristic thrombin generation curve with a good signal 
to noise ratio. Substrates 5, 14 and 15 showed a considerable degree of hydrolysis before Ca2+ 
was added to intrinsic triggered plasma. To check which enzymes are responsible for this 
hydrolytic activity a thrombin generation curve via contact activation was measured, see figure 
3. From experiments with plasma deficient in factor XII and factor XI and Al(OH)3-treated 
plasma it was concluded that kallikrein, an unspecific protease, is responsible for this 
hydrolytic activity. 
From these thrombin generation curves, substrates Msc-Val-Arg-pNA.HCl (5) and 2HC1.H-
Glu-Gly-Gly-Val-Arg-pNA (16) were selected as promising compounds. The manual thrombin 
generation curves (figure 4) showed a higher amidolytic activity at higher substrate 
concentration. But more important, each curve showed that the maximum was reached at the 
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same time-point indicating no feedback-loop inhibition1 From the decay constants (table 2) and 
the manual thrombin generation curves the prothrombinase activity could be calculated Again 
no inhibition of the prothrombinase activity or feedback-loop activation was observed, see 
figure 5 (see table 4 for the detailed data-points) From these data it was concluded that Msc-
Val-Arg-pNA HCl and 2HC1 H-Glu-Gly-Gly-Val-Arg-pNA are promising compounds to be 
used as substrates in the continuous registration of thrombin formation m plasma In contrast to 
2HC1 H-Val-Arg-pNA, both compounds showed no inhibitory activity on the activation 
cascade Thus 2HC1 H-Val-Arg-pNA (chapter 3, tables 1, 2) led straightly to the formulation 
of two new compounds with improved applicability 
Thrombin generation curves were recorded using compounds 5, 9 and 20 and hepannized 
plasma, they are represented in figure 6 It must be realized that Boc-Gly-Val-Arg-pNA HCl 
(9) and 2HC1 H-D-Phe-Pro-Lys-pNA (20) cannot be used in the continuous assay method 
without additional heparin The substrate Msc-Val-Arg-pNA HCl (5) can be used in the 
continuous assay at a heparin (ISH) concentration of 0 25 U/mL Boc-Gly-Val-Arg-pNA HCl 
gives a correct thrombin generation curve up to 2U ISH/mL Finally, 2HC1 H D-Phe-Pro-Lys-
pNA was used at a concentration of 5U ISH/mL Incipient turbidities hampered the 
determination of the thrombin generation curve at higher heparin concentrations Generally, 
when heparin is present in plasma, the substrate used should become a better thrombin 
substrate (lower Km, higher kcat) if the heparin concentration increases 
From hydrolysis experiments with serum as enzyme source (thrombin-a2-macroglobulin-
complex) and from the thrombin generation curves derived from them (figures 1-3) it was 
concluded that substrates up to six amino acids showed no slower rates of hydrolysis Most a-
macroglobuhns are tetramere consisting of pairwise disulfide-bndged subunits, wherein an 
internal S-cysteinyl-y-glutamyl thiol ester provides a potential covalent binding site for the 
target protease16 Each thiol ester is reactive toward amines17, aminolysis of this thiol ester 
results in nearly complete loss of protease binding capacity18 In most cases methylamine is 
used as denaturating agent of ot2-macroglobulin19, but this base (pKa = 10 64) can not be used 
in the continuous assay However, hydroxylamine a much weaker base (pKa = 6 03) is known 
as an agent which selectively dénaturâtes thiol ester bonds under neutral conditions without 
affecting the biological activity of enzyme systems20 We included hydroxylamine in the 
continuous assay to denaturate 012-macroglobuIin and found the end level of thrombin-ct2-
macroglobulin significantly reduced, without affecting thrombin generation, already at a 
concentration of 25 mM of hydroxylamine, see figure 7 and 8A 
The effect of hydroxylamine on the prothrombinase activity is presented in figure 8B and the 
decay constants are given in table 3 Figure 8B shows that the maximum of the prothrombinase 
activity is not lowered but a small shift to a later time-point is observed (see table 4) From 
these experiments it was concluded that hydroxylamine is ideally suited to denaturate 012-
macroglobulin without affecting the coagulation cascade 
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This encouraging result prompted us to determine a thrombin generation curve in non-
defibnnated plasma in the presence of hydroxylamine (figure 9). It was expected that thrombin-
cleaved fibrinogen does not polymerize to form insoluble fibrin by the action of factor Xllla in 
the presence of a large excess hydroxylamine Factor Xllla (a transglutaminase), evidently 
incorporates hydroxylamine in fibrin monomers instead of the standard e-amino group of a 
lysyl residue occurring in fibrin monomers Incorporation of hydroxylamine results in the 
formation of a clear gel, permitting the passage of light It is thus possible to measure a 
thrombin generation curve in non-defibrinated plasma with a zero endlevel of thrombin-cç-
macroglobulin In figure 9B it is shown that in this system even the effect of heparin (0 05 U 
ISH/mL) is measurable 
CONCLUSION 
Two compounds Msc-Val-Arg-pNA HCl and 2HC1 H-Glu-Gly-Gly-Val-Arg-pNA were found 
applicable in the continuous registration of thrombin formation in plasma These substrates do 
not affect the coagulation cascade as concluded from the prothrombinase activity Additionally, 
Msc-Val-Arg-pNA HCl (up to 0 25 U ISH/mL), Boc-Gly-Val-Arg-pNA HCl (0 85 to 2 0 U 
ISH/mL) and 2HC1 H-D-Phe-Pro-Lys-pNA (2 0 to 5 0 U ISH/mL) could be used as substrates 
to measure thrombin generation in hepannized plasma (concentration range as given between 
brackets) 
The concept, that longer peptides (up to six units) by their bulk would not fit the reduced cleft 
that gives access to the active centre of thrombin once complexed to a2-macroglobuhn, was not 
tenable The hydrolytic activity of this complex was, however, reduced by the addition of 
hydroxylamine, a selective denaturating agent of a2-macroglobuhn 
It could be shown that hydroxylamine do not affect the prothrombinase-complex and that it 
allows the determination of a thrombin generation curve in non-defibrinated plasma, since there 
are no precipitating reaction products disturbing the optical density recording 
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CHAPTER 6 
THE SYNTHESIS AND BIOCHEMICAL PROPERTIES OF 
CHROMOGENIC SUBSTRATES WITH POST ACTIVE-SITE 
INTERACTION SUBSITES 
THE USE OF 5-AMINO-2-NITROBENZOIC АСШ AS CHROMOPHORE 
ABSTRACT 
Two chromogcnic substrates were synthesized using solid phase- and solution chemistry As 
the chromophonc group, 5-amino-2-nitrobenzoic acid was used, whose carboxylic function 
was coupled to a peptide to give subsite interactions, especially with the fibrinogen recognition 
exosite As the peptide segment, the carboxyl terminal part of hirudin (residues 50-65) was 
chosen to ensure a highly specific thrombin recognition This concept focusses upon 1) 
bridge-binding substrates in which a highly specific substrate-thrombin interaction steers the 
hydrolyzable bond into the active-site, 2) realization of endo-amidase activity of thrombin, 
leading to enhanced selectivity Both substrates are not hydrolysed by factor Xa Hydrolysis 
by thrombin is very slow (low k
cat), and the Michaelis constant (Km) is extremely low as the 
result of the thrombin-hirudin interaction These new qualities are wanted, but with different 
magnitudes The substrates could therefore not yet be used in the continuous determination of 
thrombin formation in plasma but are starting points to arrive at highly specific thrombin 
substrates based on the concept of bridge-binding 
INTRODUCTION 
The most potent thrombin inhibitor currently known is hirudin, a polypeptide isolated from the 
bloodsucking leech Hirudo medicinahs It was isolated for the first time by Markwardt1 and its 
complete amino acid sequence was determined by Dodt et al2 Hirudin is a 
pentahexacontapeptide intramolecularly stabilized by three disulfide bridges, and containing a 
highly acidic carboxyl-terminal segment including a sulfated tyrosine residue (see figure 1) 
Its three-dimensional structure m solution was determined by 2D-NMR spectroscopy3 By 
these experiments it was shown that hirudin is characterized by a compact, well defined amino-
terminal domain (residues 1-39) containing the three disulfide bridges, and a stretched, 
disordered carboxyl-terminal part (residues 50-65) The structure determined by NMR studies 
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was confirmed by X-ray crystallography of the hirudin-thrombin complex4 In this complex, 
the carboxyl terminus attains a well defined shape This could also be corroborated by NMR 
H-VaP-Val-Tyr-Thr-Asp-Cys-Thr-Glu-Ser-Gly^Gln-Asn-Uu-Cys-Leu-
I 1 
-Cys-Glu-Gly-Ser-Asn^-Val-Cys-Gly-Gln-Gly-Asn-Lys-Cys-lle-Leu^-Gly-
-Ser-Asp-Gly-Glu-Lys-Asn-Gln-Cys-VaW-Tbr-Gty-Gb-Giy-Thr-PTO-Lys-
-Pro-Gb-Ser^-His-Asn-Asp-Gly-Asp-Phe-Glu-Glu-Ile-Pro^-Glu-Glu-TyriSOjWLeu-Gln^-OH 
Figure 1: The sequence of hirudin variant 1 as determined by Dodt et al.^ The three 
disulfide bridges are given; the amino acid residues of the hydrophobic core (residues 1-39) 
and of the carboxyl terminal part (50-65) are given in italics. 
using transferred nuclear Overhauser effects on the complex of a C-tenminal fragment of 
hirudin and thrombin5. 
The unique specificity of hirudin towards thrombin stems from a new mechanism of inhibition, 
in which numerous interactions with thrombin are involved Not only the active-site of the 
enzyme thrombin is occupied by hirudin, but also an important recognition exosite of thrombin 
the fibrinogen recognition exosite or anion-binding exosite This unique binding region is 
important for the recognition of the physiological substrates of thrombin and thus for normal 
hemostasis The core region of hirudin interacts with the active-site of thrombin and shuts it off 
for interaction with active-site directed compounds The highly acidic C-terminus of hirudin 
interacts with the fibrinogen recognition exosite of thrombin, a basic and positively charged 
region on the thrombin surface, and thus many electrostatic interactions can be made 
Additionally to these electrostatic interactions, important hydrophobic contacts are formed 
between the two interacting regions of hirudin and thrombin This large number of binding 
interactions is the basis of the high specificity of hirudin towards thrombin6 
Hirudin inhibits the hydrolysis of small active-site directed tnpeptidep-nitroanilides7 and the 
cleavage of fibrinopeptide A8 in a competitive way This is caused by the occupation of the 
fibrinogen recognition exosite of thrombin by the C-terminal part of hirudin This observation 
induced the development of thrombin inhibitors derived from the C-terminal tail of hirudin9 
These inhibitors leave the catalytic-site of thrombin free, thus the amidolytic activity on small 
peptide p-nitroanihdes is not affected 
The fibrinogen recognition exosite is an important structural element for recognition and 
binding of thrombin-cleaved proteins Hirudin, C-terminal fragments of hirudin and their 
analogues, inhibit thrombm-functions related to the interaction with the fibrinogen recognition 
exosite The activation of factor XIII by thrombin10, the thrombin-induced platelet activities1 ', 
the binding of fibrin II to thrombin8 and the binding of thrombomodulin to thrombin12 are all 
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inhibited by C-terminal fragments of hirudin Contranly, the activation of factor V by 
thrombin13 and the thrombin-catalyzed activation of protein C 1 4 are only partially inhibited by 
hirudin C-terminal fragments The inactivation of thrombin by АТ-Ш is not at all affected by 
hirudin C-terminal peptides Recently, it was shown that thrombin-induced platelet activation 
by receptor proteolysis, functions by binding of a receptor domain to the fibrinogen recognition 
exosite15 
The binding of hirudin to thrombin proceeds via a two step mechanism73 The first step, which 
depends on the ionic strength, involves the association of hirudin and thrombin by interaction 
of the C-terminal segment of hirudin and the fibrinogen recognition exosite This binding 
interaction induces a conformational change in thrombin м 1 6 which results in a higher active-
site susceptibility, resulting in a decrease of the K
m
 value for hydrolysis of tripeptide 
(chromogenic and fluorogenic) amines17 This change of the active-site region enables rapid 
interaction of the N-terminal core region of hirudin and thrombin which is the second step of 
binding The amount of cooperati vity in binding is, however, small 
Augmentation of cooperativity of the binding provided a new aim of research to arrive at 
bivalent thrombin inhibitors18, called hirulogs Such inhibitors consist of the following 
structural elements 1) an active-site directed part, which inhibits the active-site, the sequence 
H-D-Phe-Pro-Arg-Pro being used most frequently, 2) a segment of hirudin, capable to interact 
with the fibrinogen recognition exosite, usually the chain comprising the residues 53 to 64 
being used and 3) a peptide segment which spans the distance between the C-terminus of the 
active-site directed part and the N-terminus of the hirudin fragment From X-ray studies the 
length of this spacermolecule could be obtained and was determined at 18 7À, which 
corresponds to a minimum of four amino acid residues 
The crystal structure of hirulog-inhibited thrombin shows an important difference of the 
binding mode compared to hirudin19 The active-site directed part of the inhibitor binds in a 
substrate-like manner As a consequence, these inhibitors will be cleaved by thrombin at the 
Arg-Pro bond albeit at a slow rate Proteolytically stable inhibitors were obtainçd when the 
Arg-Pro sequence was replaced by ß-homoarginine20 (ß-amino-e-guanidino-L-caproic acid) or 
ketomethylene arginyl pseudopeptides21 The spacer can contribute to optimal inhibitor 
properties if it is forced onto the thrombin surface From structure-activity relationship-
studies22 it was found that the optimal length of the spacer will be a peptide-like segment of 13 
atoms 
This type of thrombin inhibition prompted us to synthesize a chromogenic substrate which has 
a hirudin segment for selective recognition, a poor thrombin-substrate-hke sequence as the 
active-site directed part, connected by a chromophore and a linker segment, see figure 2 As 
the chromophore, 5-amino-2-mtroben7oic acid (ANBA) was used23 This chromophoric group 
has the same spectroscopic properties as p-nitroaniline Its carboxyl group enables coupling to 
an amino component which interacts with thrombin's S'subsites (post active-site interactions) 
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In a first approach we chose a hirudin segment since it was known from X-ray studies what 
the optimal length should be between the active-site directed part and the fibrinogen recognition 
exosite to fit. The recently resolved X-ray structure of factor Xa showed that a positively 
charged binding region like the fibrinogen recognition exosite is absent on factor Xa24. 
/ ~ \ H-Val-Arg- NH—Г y—N02 
active-site ' С 
interactions *-w Gly-Ser-His-Asn-Asp-Gly-Asp-Phe-G\u-G\u-
-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH 
fibrinogen recognition exosite 
interactions 
Figure 2: Structure of a bifunctional substrate which interacts with the active-site and 
fibrinogen recognition exosite. The residues in italics constitute the spacer-segment 
between both interaction sites. 
Furthermore, site-directed mutagenesis with recombinant hirudin showed which amino acids 
in the carboxyl-terminal part are important to achieve high affinity for thrombin and how the 
specificity of thrombin could be met25. These insights were exploited as tools in a study to 
obtain selective thrombin substrates in which ANBA functions as a chromophore and a hirudin 
fragment as the recognition site. 
In chapter 5 it was shown that the chain-length of a substrate containing six amino acids was 
not yet long enough to be excluded from the partially covered active-site of thrombin 
complexed with ot2-macroglobulin. This means that we need substrates with post active-site 
interactions. The common substrates are hydrolysed by thrombin in such a way that thrombin 
acts as an exo-amidase. To gain more selectivity it would be desirable to hydrolyse a substrate 
in an endo-amidase-like fashion. Therefore we synthesized a substrate with a tripeptide 
(2HCl.H-Gly-Phe-Lys-OH) coupled to the ANBA carboxyl function. This tripeptide was 
based on modeling experiments of factor Xa26 in which S'3 has to be a residue with an acidic 
side chain for optimal fit. We chose a basic side chain to minimize interactions of the substrate 
with factor Xa. 
METHODS OF SYNTHESIS 
The substrates described in this chapter were synthesized by a combination of solid phase- and 
solution chemistry. 
The syntheses were started with the synthesis of the tripeptide 2HCl.H-GIy-Phc-Lys-OH and 
of the pseudo-peptide derivative Fmoc-Arg-ANBA-Gly-OH.HCl (scheme 1A respectively IB) 
which was used as a building block in the solid phase synthesis of H-Val-Arg-ANBA-Gly-
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Ser-His-Asn-Asp-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH(H-VR-ANBA-
Gly[Hir50-65]-OH) and H-Glu-Gly-Gly-Val-Arg-ANBA-Gly-Phe-Lys-OH (H-EGGVR-
ANBA-GFK-OH). 
Z-Lys(Boc)-OH -i-> Z-Lys(Boc)-0'Bu -н-> AcOH H-Lys(Boc)-0'Bu -ш-> 
Z-Phe-Lys(Boc)-0'Bu -ii-> AcOH.H-Phe-Lys(Boc)-OlBu -ÍV-> 
Boc-Gly-Phe-Lys(Boc)-0'Bu -v-> 2HC1 H-Gly-Phe-Lys-OH 
Scheme 1A: ¡) РОСІз/íerí.-BuOH in pyridine at -5°C; ii) H2/Pd/C, 1 eq. AcOH in 
MeOH; iii) Z-Phe-ONSu/DIPEA in EtOAc; iv) Boc-Gly-ONSu/DIPEA in EtOAc; v) 37% 
HCl at 0°C. 
H-ANBA-OH -i-> H-ANBA-Gly-OAll -ii-> Fmoc-Arg-ANBA-Gly-OAll HCl -ш-> 
Fmoc-Arg-ANBA-Gly-OH HCl 
Scheme IB: i) 1. SOCI2, 2. pTSZ.H-Gly-OAll/TEA in pyridine; ii) Fmoc-Arg-
OH.HCI/POCI3 in pyridine at -15°C; iii) Pd°(Ph3P)4 in DMF/AcOH/NMM 5:1:0.1 
v/v/v. 
Starting from Z-Lys(Boc)-OH, Z-Lys(Boc)-0'Bu was synthesized under very mild conditions 
as described by Taschner et al2Ί Phosphorus oxychlonde in pyridine was used as the 
condensing agent m the coupling reaction with the weak nucleophile tert -butanol. The 
product, Z-Lys(Boc)-0'Bu was purified by column chromatography on silica gel and was 
obtained as a colourless oil in 76% yield The Z-protection was removed by hydrogénation 
with Pd on activated carbon in MeOH in the presence of acetic acid. The acetate of H-
Lys(Boc)-0'Bu was obtained as a white solid in nearly quantitative yield. Z-Phe-ONSu was 
used to prepare the dipeptide ester Z-Phe-Lys(Boc)-0'Bu. The product, Z-Phe-Lys(Boc)-0'Bu 
was purified by crystallization from diiio-propyl ether and was obtained as white crystals in 
78% yield Upon catalytic hydrogenolysis, AcOH H-Phe-Lys(Boc)-0'Bu, which crystallized 
from duso-propyl ether, was acylated with Boc-Gly-ONSu in EtOAc to give Boc-Gly-Phe-
Lys(Boc)-0'Bu The protected tnpeptide was crystallized from pet. ether 60-80 as a white 
solid in 98% yield The fully deprotected tnpeptide 2HC1 H-Gly-Phe-Lys-OH was obtained as 
a fluffy powder in high yield, following the deprotection with concentrated HCl as described 
by Sieber et al28 
The acid H-ANBA-OH was converted to its acid chloride H-ANBA-C1 by refluxing it with 
SOCI2 containing one drop of DMF as a catalyst The amino function does not need 
protection, since it is a poor nucleophile due to the strong electron withdrawal by the nitro- and 
the carboxyl functions The acid chloride was coupled under Schotten-Baumann conditions to 
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pTSZ H-Gly-OAIl in the presence of 2 25 eq TEA in dry pyridine as the solvent The ensuing 
crude H-ANBA-Gly-OAH was purified by column chromatography on silica gel in a very low 
yield 13%, and was acylated with Fmoc-Arg-OH HCl using POCI3 in dry pyridine as 
described for the synthesis of protected ammo acidp-nitroanihdes (see chapter 1) Despite the 
presence of a second electron withdrawing function, the phosphorus oxychlonde/pyndine 
activation appeared sufficiently strong to couple Fmoc-Arg-OH to H-ANBA-Gly-OAll in high 
yield Fmoc-Arg-ANBA-Gly-OAll HCl was purified by counter current distribution with 
ВиОН/АсОН/НгО 4 1 5 v/v/v as the solvent system and was obtained as a pale yellow powder 
in 92% yield The allyl function was removed by Pd-catalyzed nucleophilic transfer using 
Pd°(Ph3P)4 as catalyst and DMF/AcOH/NMM 5 10 1 v/v/v as solvent as described by 
Albencio et al29 Pd°(Ph3P)4 was used in 0 045 eq with regard to Fmoc-Arg-ANBA-Gly-
OAll HCl, which contrasts with the large excess used by the authors in the solid phase 
synthesis of cyclic lactam peptides As a consequence, the deprotection lasted some 30 hrs at 
room temperature The pseudo-peptide, Fmoc-Arg-ANBA-GIy-OH HCl was purified by 
counter current distribution with ВиОН/АсОН/НгО 4 1 5 v/v/v as the solvent system and was 
obtained as a fluffy off-white material in high yield Although the side chain of arginine is only 
protected by protonation, Fmoc-Arg-ANBA-Gly-OH HCl could be used as a building block in 
solid phase peptide synthesis It can be activated with DCC/HOBt without racemization, and 
the guamdino function cannot be deprotonated by the treatment with piperidme for removal of 
the Fmoc-function 
The peptides H-Val-Arg-ANBA-Gly-Ser-His-Asn-Asp-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-
Glu-Tyr-Leu-Gln-OH (H-VR-ANBA-Gly[Hir50-65]-OH) and H-Glu-Gly-Gly-Val-Arg-
ANBA-Gly-Phe-Lys-OH (H-EGGVR-ANBA-GFK-OH) were synthesized using the 
Fmoc/tert -Bu protocol30, see scheme 2 
The peptides were synthesized on a p-alkoxybenzyl alcohol resin (Wang-resin)31 During the 
solid phase peptide synthesis the side chains were protected by acid labile functions Trt for 
Gin, Asn and His, Boc for Lys, *Bu for Glu, Asp, Ser and Tyr, arginine was protected by 
protonation Fmoc-amino acids were coupled by DIPCDI/HOBt in DMF Removal of the 
Fmoc-protection was performed with 25% pipendine in DMF After each coupling step, the 
absence of free amino groups was checked with ninhydnn (Kaiser-test)32, nevertheless, any 
remaining free amino functions were acylated by AC2O/DIPEA 2 1 v/v in DMF The peptides 
were detached from the resin and deprotected by treatment with TFA/EDT/H2O 95 2 5 2 5 
v/v/v and precipitated with diethyl ether The crude peptides were eluted over a weakly basic 
ion-exchange column to remove TFA After purification by counter current distribution in 
which ВиОН/АсОН/НгО 4 1 5 v/v/v was used as the solvent system the peptides were 
obtained as off-white materials in 20 respectively 38% yield The purity and identity of the 
peptides was determined by TLC, HPLC, AAA and NMR 
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Fmoc-Gln-(Trt)-0-Resin-i->H-Scr(IBu)-His(Trt)-Asn(Trt)-Asp(0,Bu)-Gly-Asp(0,Bu)-Phe-
Glu(01Bu)-Glu(01Bu)-He-Pro-Glu(OtBu)-Glu(OtBu)-Tyr(,Bu)-Leu-Gln(Trt)-0-Resin-ii-> 
Fmoc-Arg(H+)-ANBA-Gly-[Hir50-65]-0-Resin -ш-> H-Val-Arg(H+)-ANBA-Gly-[Hir50-
65]-0-Resin-(v->H-Val-Arg-ANBA-Gly-Ser-His-Asn-Asp-Gly-Asp-Phe-Glu-Glu-Ile-Pro-
Glu-Glu-Tyr-Leu-Gln-OH 
Fmoc-Lys(Boc)-0-Resin -v-> H-Phe-Lys(Boc)-0-Resin -»-> Fmoc-Arg(H+)-ANBA-Gly-
Phe-Lys(Boc)-0-Resin -vi-> H-Glu(0'Bu)-Gly-Gly-Val-Arg(H+)-ANBA-Gly-Phe-Lys-0-
Resin -iv-> H-Glu-Gly-Gly-Val-Arg-ANBA-Gly-Phe-Lys-OH 
Scheme 2: i) la. 25% piperidine ¡η DMF, b. Fmoc-Leu-OH/DIPCDI/HOBt in DMF; 2a. 
25% piperidine in DMF, b. Fmoc-Tyr^BubOH/DIPCDI/HOBt in DMF; 3a. 25% 
piperidine in DMF, b. Fmoc-Glu(0'Bu)-OH/DIPCDI/HOBt in DMF; 4a. 25% piperidine in 
DMF, b. Fmoc-GlutO'BubOH/DIPCDI/HOBt in DMF; 5a. 25% piperidine in DMF, b. 
Fmoc-Pro-OH/DIPCDI/HOBt in DMF; 6a. 25% piperidine in DMF, b. Fmoc-Ile-
OH/DIPCDI/HOBt in DMF; 7a. 25% piperidine in DMF, b. Fmoc-Glu(0'Bu )-
OH/DIPCDI/HOBt in DMF; 8a. 25% piperidine in DMF, b. Fmoc-Glu(O'Bu)-
OH/DIPCDI/HOBt in DMF; 9a. 25% piperidine in DMF, b. Fmoc-Phe-OH/DIPCDI/HOBt 
in DMF; 10a. 25% piperidine in DMF, b. Fmoc-AspiO'BubOH/DIPCDI/HOBt in DMF; 
IIa. 25% piperidine in DMF, b. Fmoc-Gly-OH/DIPCDI/HOBt in DMF; 12a. 25% 
piperidine in DMF, b. Fmoc-Asp(OlBu)-OH/DIPCDI/HOBt in DMF; 13a. 25% piperidine 
in DMF, b. Fmoc-Asn(Trt)-OH/DIPCDI/HOBt in DMF; 14a. 25% piperidine in DMF, b. 
Fmoc-His(Trt)-OH/DIPCDI/HOBt in DMF; 15a. 25% piperidine in DMF, b. Fmoc-
Ser('Bu)-OH/DIPCDI/HOBt in DMF; 16. 25% piperidine in DMF; ii) Fmoc-Arg(H+)-
ANBA-GIy-OH/DIPCDI/HOBt in DMF 24 hrs at room temperature; iii) la. 25% 
piperidine in DMF, b. Fmoc-Val-OH/DIPCDI/HOBt in DMF; 2a. 25% piperidine in DMF; 
iv) 1. TFA/EDT/H2O 95.2.5:2.5 v/v/v 4 hrs at room temperature; 2. Merck II ion-
exchange resin acetate-form; v) la. 25% piperidine in DMF, b. Fmoc-Phe-
OH/DIPCDI/HOBt in DMF; 2. 25% piperidine in DMF; vi) la. 25% piperidine in DMF, 
b. Fmoc-Val-OH/DIPCDI/HOBt in DMF; 2a. 25% piperidine in DMF, b. Fmoc-Gly-
OH/DIPCDI/HOBt in DMF; 3a. 25% piperidine in DMF, b. Fmoc-Gly-OH/DIPCDI/HOBt 
in DMF; 4a. 25% piperidine in DMF, b. Fmoc-GlufO'BuJ-OH/DIPCDI/HOBt in DMF; 5a. 
25% piperidine in DMF. 
EXPERIMENTAL PROCEDURES 
General 
1H NMR spectra were recorded on Bruker AM 100 and AM 400 spectrometers As an internal 
standard the residual solvent peak was used Chemical shifts are given in part per million 
(ppm) Optical rotations were measured on a Perkin Elmer 241 Polarimeter in a 10 cm cuvette 
at room temperature Melting points were determined with a Buchi melting point apparatus 
(Tottoli) Peptides were prepared by SPPS using a Labortec SP 640 semi-automatic peptide 
synthesizer Peptides (1 μιτιοί) were hydrolysed in 5 7 M HCl (Merck Suprapur 30% HCl) for 
24 hrs at 120°C The hydrolysates were coevaporated with H2O (three times), dried over 
NaOH pellets and analysed on a Vanan Star 9095 amino acid analyser Analytical reverse-
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phase HPLC experiments were performed on a Vanan LC equipped with a 9010 solvent 
delivery system, 9050 variable wavelength UV-VIS detector and a CI8 column (4 0 χ 150 
mm) using a gradient of 10-100% buffer В (0 08% TFA/10% H 2 0 v/v in CH3CN) in buffer A 
(0 1 % TFA in H2O) as mobile phases at a flow rate of 0 2 mL/min 
TLC was performed on Merck Silicagel 60 F254 plates, and column chromatography on Merck 
Kieselgel 60 70-230 Mesh ASTM Spots were visualized by UV-fluorescence quenching, 
ninhydnne (free amino functions), chlorine/TDM (NH groups), Barton's- (tyrosine residues), 
Pauly's- (histidine residues) and Sakaguchi's (arginine residues) reagent 
Pyridine was distilled over KOH and stored on 4Â molsieves, dioxane was stored on 3Â 
molsieves 
Z-amino acids were synthesized with benzyloxycarbonyl chloride (Z-Cl)33 Boc-amino acids 
were prepared by the method of Schnabel34 Hydroxysuccinimide active esters were 
synthesized following the method of Anderson et al35 
Fmoc-amino acids for solid phase peptide synthesis were purchased from Bachern, and 
included Fmoc-Gln(Trt)-0-resin, Fmoc-Lys(Boc)-0-resin, Fmoc-Gly-OH, Fmoc-Val-OH, 
Fmoc-Phe-OH, Fmoc-Рго-ОН, Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-GlutO'BuVOH, Fmoc-
Asp(0'Bu)-OH, Fmoc-Ser('Bu)-OH, Fmoc-Tyr('Bu)-OH, Fmoc-Asn(Trt)-OH and Fmoc-
His(Trt)-OH Z-Lys(Boc)-OH was from Bachern All other chemicals were of reagent grade 
Materials 
Chromogenic substrates The substrates were dissolved in dimethyl sulfoxide to obtain 10 mM 
stock solutions The concentration was determined at 316 nm using a molar extinction 
coefficient of 12,500 Stock solutions were stored in the dark at 4°C Factor Xa substrate 
methyloxycarbonyl-D-cyclohexylglycyl-glycyl-arginine p-nitroanilide acetate (CH3O-CO-D-
Chg-Gly-Arg-pNA AcOH) was obtained from Pentapharm (Basel, Switzerland) 
Phospholipids Phospholipids required were 80 mol-% dioleoyl phosphatidyl choline and 20 
mol-% dioleoyl phosphatidyl serine solutions in chloroform, they were obtained from Avanti 
Polar Lipids They were used to prepare vesicles as described by Rosing et alзб 
Enzyme preparations Pure human α-thrombin and human factor Xa samples were generous 
gifts of Dr Τ Lindhout (University of Limburg, Maastricht, The Netherlands) 
Buffers Buffer A 0 05 M Tris-HCl, 0 1 M NaCl pH = 7 35 containing 0 5 g/L bovine serum 
albumin (Sigma) Buffer В buffer A containing additional EDTA (20 mM) pH = 7 90 
Plasma Plasma was prepared by collecting 9 parts of blood (from 10 healthy donors) on 1 part 
of 0 13 M tnsodium citrate Following centnfugation at 900g (15°C, 15 mm) and 10,000g 
(15°C, 15 mm) the obtained plasma was pooled and centnfuged at 4°C for 1 hour at 23,OO0g, 
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this plasma was stored at -80°C Plasma was defibnnated by mixing an aliquot of plasma with 
1/50 volume of reptilase (Laboratories Stago, Asnières, France, the solution was made as 
instructed by the manufacturer), letting a clot form for 10 min at 37°C followed by 10 mm on 
ice The fibrin clot was removed by winding it on a plastic spatula 
Tissue factor Recombinant tissue factor (Recomplastin S, Dade, Baxter Diagnostics Ine , 
Deerfield И , USA) was used as a trigger for coagulation The solution was prepared according 
to the instructions of the manufacturer 
Methods 
Kinetic parameters The hydrolysis experiments were run in buffer A at 37°C The liberation of 
p-nitroaniline was monitored at 405 nm in a dual wavelength (405-546 nm) spectrophotometer 
made in our workshop, using a personal computer for data recording In a polystyrene 
microcuvette (total volume 500 μι), buffer A and substrate-solution were added to obtain a 
final substrate concentration between 1 to 50 μΜ After 5 min of incubation at 37°C, enzyme 
solution was added to achieve a final concentration of 25 nM The measurement was carried 
out at 37°C in a thermostated cuvette-holder The Michaelis constant (K
m
) and the catalytic 
constant (k
cat) were obtained by measuring the initial reaction velocities at different substrate 
concentrations The data obtained were fitted by linear regression on the Michaehs-Menten 
equation 
Factor Xa inhibition experiments37 In a polystyrene microcuvette were added buffer A (the 
substrate to be tested on inhibitory effects on factor Xa in the concentration range between 0 to 
1000 μΜ), the chromogenic substrate CH30-CO-D-Chg-Gly-Arg-pNA AcOH at a 
concentration of 100 μΜ and factor Xa at a concentration of 1 0 nM The measurement was 
carried out in a total volume of 500 uL at 37°C Optical density was measured as above 
Continuous registration of the thrombin generation curve Extrinsic pathway In a polystyrene 
microcuvette were added 400 \iL defibnnated plasma, 20 \iL· of a 45 μΜ phospholipid solution 
(final concentration 1 5 μΜ) and 140 uL of buffer A which contains the substrate at the desired 
final concentration (500 μΜ) After 4 mm of incubation at 37°C, 20 uL tissue factor (undiluted) 
was added Thrombin generation was started by adding 20 uL of a 0 5 M CaCl2 solution (final 
concentration 16 67 mM), during the measurement the temperature was kept at 37°C The 
optical density was monitored at 405 nm From the obtained optical density curve, the first 
derivative was calculated This gives the enzyme concentration during the measurement 
Syntheses 
Ζ Lys(Boc)-0'Bu38 
This compound was synthesized according to the method of Taschner et al27 
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Z-Lys(Boc)-OH (3 80 g, 10 mmol) was dissolved in dry pyridine (15 mL) and tert -BuOH 
(25 mL, 19.7 g, 0 265 mmol, 26 5 eq ), the obtained solution was cooled to -5°C and POCl3 
(110 mL, 11 mmol, 1 10 eq ) was added dropwise The reaction mixture was stirred for 15 
mm at -5°C and 4 5 hrs at room temperature During this period of stirring the clear solution 
became turbid The reaction mixture was poured into H 20 (100 mL) and extracted with EtOAc 
(three times 25 mL) The combined EtOAc layers were subsequently washed with H 2 0, 
saturated NaHC03, H 2 0, 2N KHS04 and saturated NaCl (three times 30 mL each) The 
EtOAc solution was dried on Na2S04, filtered and evaporated in vacuo The resulting oil was 
purified by column chromatography on silica gel with CH2Cl2/MeOH 97 3 v/v as eluens 
Yield 3 32 g (76%) colourless oil (Lit38 77%), Rf(CH2Cl2/MeOH 95 5 v/v) 0 57, 
Rf(CHCl3/MeOH/AcOH 95 20 3 v/v/v) 0 86, [a]D = -15 4° с = 0 89 MeOH, Ή NMR 
(CDCI3) δ = 1 36 (m, 4H, Y-CH2/6-CH2), 1 42 (s, 9H, O'Bu), 1 46 (s, 9H, Boc), 1 65/1 79 
(dm, 2H, ß-CH2), 3 10 (m, 2H, e-CH2), 4 25 (m, IH, a-CH), 4 60 (bs, IH, NH), 5 11 (s, 
2H, CH2-benzyl), 5 38 (d, IH, NH), 7 29-7 38 (m, 5H, arom benzyl) 
Z-Phe-Lys(Boc)-0'Bu 
Z-Lys(Boc)-0'Bu (3 32 g, 7 6 mmol) was hydrogenated in MeOH (50 mL) m the presence of 
AcOH (0 60 mL, 1 0 eq ) with Pd on activated carbon (Pd content 10%) When Z-removal 
was complete, the solution was filtered and evaporated to dryness AcOH H-Lys(Boc)-OlBu 
was obtained as white crystals Yield 2 68 g (97%), Rf(CHCl3/MeOH/AcOH 95 20 3 v/v/v) 
0 42, R,(BuOH/AcOH/H20 4 1 1 v/v/v) 0 67, [a]D = +101°c = 0 84 MeOH, mp 84-86°C, 
>H NMR (CD3OD) δ = 1 45 (s, 9H, O'Bu), 1 48 (m, 4H, у-СН2/6-СН2), 1 54 (s, 9Н, Вое), 
1 84 (m, 2Н, ß-CH2), 1 95 (s, ЗН, СН3 acetic acid), 3 06 (m, 2H, E-CH 2 ), 3 79 (m, IH, α-
CH) 
AcOH H-Lys(Boc)-0'Bu (1 81 g, 5 0 mmol) and Z-Phe-ONSu (1 98 g, 5 0 mmol, 1 0 eq ) 
were dissolved in EtOAc (50 mL) DIPEA (171 mL, 10 mmol, 2 0 eq ) was added to start the 
reaction After 16 hrs of stirring at room temperature, the EtOAc solution was washed with 
H 2 0, saturated NaHC03, H 20, 2N KHS04, H 2 0 and saturated NaCl (two times 20 mL 
each) After drying on Na 2S0 4, the solvent was removed under reduced pressure which 
results in a white foam, which was crystallized from pet ether 60-80 The crystals were 
recrystalhzed from diiio-propyl ether Yield 2 28 g (78%), R,<CH2Cl2/MeOH 95 5 v/v) 
0 62, R[<CHCl3/MeOH/AcOH 95 20 3 v/v/v) 0 87, [a]D = -12 9° с = 0 75 MeOH, mp 77-80 
°C, Ή NMR (CDC13) δ = 1 22 (m, 4H, Y-CH2/6-CH2-Lys), 1 44 (s, 18H, Boc/O'Bu (2 χ 
9H)), 1 60/1 78 (dm, 2H, ß-CH2-Lys), 3 06 (m, 2H, e-CH2-Lys), 3 09 (d, 2H, ß-CH2-Phe), 
4 41 (m, IH, a-CH-Lys), 4 46 (m, IH, a-CH-Phe), 4 71 (bs, IH, NH), 5 09 (s, 2H, CH2-
benzyl), 5 42 (d, IH, NH), 6 45 (d, IH, NH), 7 11-7 41 (m, 10H, arom Phe/arom benzyl) 
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Boc-Gly-Phe-Lys(Boc)-0'Bu: 
Z-Phe-Lys(Boc)-OBu (1.25 g, 2.14 mmol) was hydrogenated in MeOH (30 mL) as described 
above. AcOH.H-Phe-LystBocVO'Bu was crystallized from pet. ether 60-80 and recrystallized 
from diiso-propyl ether. Yield: 0.92 g (84%), Rf(CHCl3/MeOH/AcOH 95:20:3 v/v/v): 0.54, 
Rf(Bu0H/AcOH/H2O 4:1:1 v/v/v): 0.80, [a]D = -8.9° с = 0.90 MeOH, mp: 79-81°C, 'H 
NMR (CD3OD): δ = 1.39-1.47 (m, 4H, Y-CH2/5-CH2-Lys); 1.45 (s, 9H, 0»Bu); 1.50 (s, 9H, 
Вое); 1.70/1.84 (dm, 2H, ß-CH2-Lys); 1.96 (s, 3H, CH3 acetic acid); 2.94/3.21 (2 χ dd, 2H, 
ß-CH2-Phe); 3.04 (m, 2H, e-CH2-Lys); 3.92 (dd, IH, α-CH-Lys); 4.29 (dd, IH, α-CH-
Phe); 7.25-7.38 (m, 5H, arom Phe). 
Ac0H.H-Phe-Lys(Boc)-O'Bu (0.50 g, 0.98 mmol) and Boc-Gly-ONSu (0.267 g, 0.98 mmol, 
1.0 eq.) were dissolved in EtOAc (20 mL) and DIPEA (0.34 mL, 1.96 mmol, 2.0 eq.) was 
added. After 16 hrs of stirring at room temperature, the EtOAc solution was subsequently 
washed with H 2 0, saturated NaHC03, H 20, 2N KHSO4, H 2 0 and saturated NaCl (three 
times 10 mL each). The EtOAc solution was dried on Na 2S0 4, filtered and evaporated in 
vacuo, the residue was crystallized from pet. ether 60-80. Yield: 0.58 g (98%), 
Rf{CH2Cl2/MeOH 95:5 v/v): 0.31, Rf(CHCl3/MeOH/AcOH 95:20:3 v/v/v): 0.81, [a]D = 
-14.2 с = 0.64 MeOH, mp: 71°C, lH NMR (CD3OD): δ = 1.38 (m, 4H, y-CH2/5-CH2-Lys); 
1.43 (s, 18H, Boc(2 χ 9H)); 1.46 (s, 9H, O'Bu); 1.67/1.83 (dm, 2H, ß-CH2-Lys); 2.94/3.14 
(2 χ dd, 2H, ß-CH2-Phe); 3.04 (m, 2H, E-CH2-Lys); 3.58/3.62-3.66/3.70 (dd, 2H, CH2-
Gly); 4.24 (m, IH, a-CH-Lys); 4.68 (m, IH, a-CH-Phe); 7.18-7.28 (m, 5H, arom Phe). 
2HCl.H-Gly-Phe-Lys-OH: 
The deprotection was carried out following the method of Sieber et α/.28 
Boc-Gly-Phe-Lys(Boc)-0'Bu (273.8 mg, 0.452 mmol) was stirred in ice-cold concentrated 
HCl (11 mL) for 6 min at 0°C. Then AcOH (120 mL) was added and the product was 
lyophilized. The residue was dissolved in H 2 0 and lyophilized again. Yield: 165.3 mg (87%), 
Rf(Bu0H/AcOH/H2O 4:1:1 v/v/v): 0.16, [a]D = +10.4° с = 0.43 MeOH, mp: 201°C (dec), 
•H NMR (D20): δ= 1.32 (m, 2H, 7-CH2-Lys); 1.61 (m, 2H, 6-CH2-Lys); 1.68/1.81 (dm, 
2H, ß-CH2-Lys); 2.92 (m, 2H, E-CH2-Lys); 2.98/3.08 (2 χ dd, 2Η, ß-CH2-Phe); 3.68/3.72-
3.75/3.79 (dd, 2H, CH2-Gly); 4.23 (m, IH, a-CH-Lys); 4.63 (m, IH, a-CH-Phe); 7.23-
7.34 (m, 5H, arom Phe). 
pTSZ.H-Gly-OAll: 
This compound was synthesized as described by Waldmann et α/.39 
Yield: 97% (lit39: 84%), R,<BuOH/AcOH/H20 4:1:1 v/v/v): 0.51, mp: 73-74°C (lit39: 57-
58°C), Ή NMR (CDC13): δ = 2.32 (s, ЗН, СН3); 3.67 (s, 2Н, СН2); 4.46 (d, 2Н, ~СН2-0-
СО- allyl (J = 5.6 Hz)); 5.20 (m, 2H, CH2=C- allyl ); 5.69 (m, IH, =CH- allyl); 7.03/7.11-
7.64/7.73 (dd, 4H, arom tosyl); 8.02 (s, ЗН, NH3+). 
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H-ANBA-Gly-OAll 
H-ANBA-OH (2 0 g, 11 mmol) was refluxed in S0C12 (20 mL) with one drop of DMF, the 
suspension became clear after 10 mm of refluxmg After 2 hrs, excess SOCl2 was removed 
under reduced pressure and the residue was diluted with dry dioxane (10 mL) The acid 
chloride was added dropwise to a solution of pTSZ H-Gly-OAll (3 16 g, 11 mmol, 1 0 eq ) in 
dry pyridine (40 mL) in the presence of TEA (3 43 mL, 24 8 mmol, 2 25 eq ) After 1 hr of 
stimng at room temperature, the reaction mixture was evaporated in vacuo The residue was 
dissolved m EtOAc (100 mL) and subsequently washed with H 20, saturated NaHC03, H 20, 
2N KHSO4 and saturated NaCl (three times 30 mL each) After drying on Na2S04, the solvent 
was removed under reduced pressure (Yield 1 18 g (38%), Rj(BuOH/AcOH/H20 4 1 1 v/v/v) 
0 82) The residue was purified by column chromatography on silica gel with CH2Cl2/MeOH 
98 2 v/v as eluens Yield 0 40 g (13%) dark yellow foam, Rf(CH2Cl2/MeOH 95 5 v/v) 0 24, 
R^CHClj/MeOH/AcOH 95 20 3 v/v/v) 0 62, Ш NMR (CDCI3) δ = 4 26 (d, 2H, CH2), 4 66 
(m, 2H, ~CH2-0-CO~ allyl), 5 34 (m, 2H, CH2=C~ allyl), 5 85 (m, IH, =CH~ allyl), 6 32 
(m, <1H, NH), 6 59-6 68 (m, 2H, arom ANBA H4/H6), 7 95/8 05 (d, IH, arom ANBA H3) 
Fmoc-Arg-ANBA-Gly OAll HCl 
Fmoc-Arg-OH HCl (0 62 g, 1 43 mmol) and H-ANBA-Gly-OAll (0 40 g, 1 43 mmol) were 
coupled by POCI3 in pyridine as described by us4 0 After purification by counter current 
distribution with the solvent system BuOH/AcOH/H20 4 1 5 v/v/v (K = 5 12), the product 
was lyophihzed from AcOH and obtained as a fluffy pale yellow powder Yield 0 91 g (92%), 
RfíCHC^/MeOH/AcOH 95 20 3 v/v/v) 0 20, R,(BuOH/AcOH/H20 4 1 1 v/v/v) 0 74, [a]D = 
-22 6° с = 0 24 MeOH, Ή NMR (DMSO-d6) δ = 1 50-1 75 (dm, 4H, Y-CH2/ß-CH2-Arg), 
3 08 (m, 2H, 6-CH2-Arg), 4 04 (d, 2H, CH2-Gly), 4 16 (t, IH, CH-Fmoc), 4 21 (m, IH, a-
CH-Arg), 4 28 (d, 2H, CH2-Fmoc), 4 63 (d, 2H, ~CH2-0-CO- allyl), 5 22/5 37 (2 χ dd, 2H, 
CH2=C- allyl), 5 93 (m, IH, =CH~ allyl), 7 32/7 41 (m, 4H, arom Fmoc), 7 73 (m, 2H, 
arom ANBA H4/H6), 7 89 (m, 4H, arom Fmoc), 8 11 (d, IH, arom ANBA H3) 
Fmoc-Arg-ANBA-Gly-OH HCl 
The removal of the allyl function was accomplished under the conditions described by 
Albencio et al29 
Fmoc-Arg-ANBA-Gly-OAll HCl (398 mg, 0 574 mmol) was dissolved in 25 mL 
DMF/AcOH/NMM ( 5 1 0 1 v/v/v), argon was bubbled through the solution during 10 mm and 
Pd°(Pli3P)4 (30 mg, 0 026 mmol, 0 045 eq ) was added The obtained reaction mixture was 
stirred for 30 hrs at room temperature After this period of stimng, solvent was removed under 
reduced pressure and the oily residue was purified by counter current distribution with the 
solvent combination BuOH/AcOH/H20 4 1 5 v/v/v (K = 4 18) Pure product was lyophihzed 
from AcOH and obtained as a fluffy off-white material Yield 306 mg (82%), 
R(<BuOH/AcOH/H20 4 1 1 v/v/v) 0 53, [a]D = -66 4° с = 0 11 DMF, Ή NMR (DMSO-de) 
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δ = 1 23-1 75 (dm, 4H, Y-CH2/ß-CH2-Arg), 3 09 (m, 2H, 8-CH2-Arg), 3 64 (m, 2H, СН2-
Gly), 4 15-4 29 (m, 4Н, a-CH-Arg/CH-Fmoc/CH2-Fmoc), 7 31/7 40 (m, 4H, arom Fmoc), 
7 71-7 77 (m, 2H, arom ANBA H4/H6), 7 88/7 95 (m, 4H, arom Fmoc), 8 14 (d, IH, arom 
ANBAH3) 
Solid Phase Peptide Synthesis 
The peptides were synthesized by solid phase techniques following the Fmoc/tert -Bu protocol 
on a Wang-resin The Na-Fmoc amino acids (3 eq over substitution level of the resin) were 
coupled with DIPCDI (3 eq ) and HOBt (3 eq ) at room temperature for 1 hr using DMF as the 
solvent The side chain protection was chosen as follows Gln(Trt), Asn(Trt), His(Trt), 
Lys(Boc), Glu(O'Bu), Asp(O'Bu), Ser('Bu) and Tyr('Bu) Fmoc protection was removed by 
treatment with 25% pipendine in DMF (three times for 6 min each) The peptides were 
detached from the resin and deprotected by treatment with TFA/H2O/EDT 95 2 5 2 5 v/v/v at 
room temperature for 4 hrs The peptides were precipitated with diethyl ether The precipitate 
was decanted and subsequently washed with diethyl ether and finally dried over NaOH-pellets 
The crude deprotection product was eluted over a Merck II (weakly basic ion-exchanger, 
acetate form) ion-exchange column with H20/AcOH 95 5 v/v as eluens After lyophilization of 
the effluent, the crude peptides were purified by counter current distribution with 
BuOH/AcOH/H20 4 1 5 v/v/v as solvent system The purity and identity of the peptides was 
assessed by TLC, analytical HPLC, amino acid analysis and NMR 
H-VR-ANBA Gly[Hir50-65]-OH, H Val Arg-ANBA-Gly Ser-His-Asn-Asp-Gly-Asp Phe-
Glu Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln OH 
Quantities used Fmoc-Gln(Trt)-0-Resin 0 50 g (0 25 mmol), crude yield 370 9 mg (59%), 
yield after purification 126 1 mg (20%), R f(BuOH/AcOH/H20 4 1 1 v/v/v) 0 02, 
RKBuOH/Pyr/AcOH/H20 4 112 v/v/v/v) 0 28, К = 0 14, HPLC Rt = 26 7 min, [a]D = 
-38 2° с = 0 11 AcOH, -42 I o с = 0 19 DMF/H20 1 1 v/v, AAA Glu/Gln(5 00) 4 66, 
Leu(l 00) 0 86, Tyr(l 00) -, Pro(l 00) 0 86, Ile(l 00) 0 77, Phe(l 00) 1 22, Asp/Asn(3 00) 
3 17, Gly(2 00) 2 47, His(l 00) 0 87, Ser(l 00) -, Arg(l 00) 1 04, Val(l 00) 1 06, Ή NMR 
(aromatic part, DMSO-d6) 6 = 6 60/6 62-6 99/7 01 (dd, 4H, arom Туг), 7 13-7 30 (m, 5H, 
arom Phe), 7 30 (s, IH, arom His (Hs)), 7 69 (m, 2H, arom ANBA), 8 08 (d, IH, arom 
ANBA), 8 24 (bs, IH, arom His (H2)) 
H-EGGVR-ANBA-GFK OH, H-Glu-Gly-Gly-Val-Arg-ANBA-Gly-Phe-Lys-OH 
Quantities used Fmoc-Lys(Boc)-0-Resin 0 30 g (0 165 mmol), crude yield 128 4 mg 
(72%), yield after purification 67 9 mg (38%), Rf{BuOH/AcOH/H20 4 1 1 v/v/v) 0 02, 
RKBuOH/Pyr/AcOH/H20 4 112 v/v/v/v) 0 32, K(BuOH/AcOH/H20 4 1 5 v/v/v) = 0 53, 
K(BuOH/H20 1 1 v/v) 0 05, HPLC Rt = 24 8 min, [a]D = -5 0° с = 0 10 AcOH, -3 6° с = 
0 11 DMF/H20 1 1 v/v, AAA Glu(l 00) 1 45, Gly(3 00) 2 97, Val(l 00) 1 00, Arg(l 00) 
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0.91; Phe(l.OO) -; Lys(l.OO) -, Ή NMR (DMSO-d6/D20 9:1 ν/ν): δ = 0.79 (dd, 6H, γ-
CH3/y-CH3-Val); 1.22 (m, 4H, y-CH2/6-CH2-Lys); 1.51 (m, 4H, p-CH2/Y-CH2-Arg); 
1.76/2.00 (dm, 2H, ß-CH2-Lys); 2.00 (m, 3H, ß-CH-Val/ß-CH2-Glu); 2.23 (dd, 2H, γ-(ΖΗ2-
Glu); 2.84 (m, 2H, e-CH2-Lys); 3.03 (m, 2H, 6-CH2-Arg); 3.08/3.26 (dm, CH2-Phe); 3.74 
(m, 6H, CH2-Gly (3 χ 2H)); 3.88 (d, IH, a-CH-Val); 3.99 (m, IH, a-CH-Glu); 4.14 (m, 
IH, a-CH-Lys); 4.31 (m, IH, a-CH-Arg); 4.48 (m, IH, a-CH-Phe); 7.13-7.27 (m, 5H, 
arom Phe); 7.76/8.06 (dm, 3H, arom ANBA). 
RESULTS AND DISCUSSION 
The substrates were not very soluble in water. Therefore we chose dimethyl sulfoxide as the 
solvent. From preliminary experiments it was concluded that DMSO has a minimal effect on 
the hydrolysis rate of S2238 and CH30-CO-D-Chg-Gly-Arg-pNA.AcOH by thrombin, 
respectively factor Xa. However, up to a 20% lower initial hydrolysis rate was observed in the 
presence of the quantity of DMSO corresponding to high substrate concentration; this amount 
of DMSO being present in each measurement. 
Both substrates were not hydrolyzed by factor Xa. This was as expected. From X-ray 
crystallography24 it was concluded that the factor Xa molecule lacks a positively charged 
binding cleft. So recognition of H-VR-ANBA-Gly[Hir50-65]-OH via the exosite is excluded. 
When factor Xa would be able to recognize the substrate in an exosite-like manner41 it is 
reasonable that a change in the conformation of the active-site can occur, resulting in better 
substrate (СНзО-CO-D-Chg-Gly-Arg-pNA.AcOH) recognition as seen in the case of 
thrombin. This, however is not observed. H-EGGVR-ANBA-GFK-OH is not hydrolyzed by 
factor Xa in contrast to H-EGGVR-pNA which showed a considerable hydrolysis rate. The 
addition of the ANBA-substrates did not affect the hydrolysis of the pNA-substrate, 
confirming the absence of any competition by the ANBA-substrate. 
When H-EGGVR-ANBA-GFK-OH was exposed to thrombin, no hydrolytic activity was 
observed either. This is somewhat disappointing because H-EGGVR-pNA was at a 
considerable rate hydrolyzed by thrombin. The amino acid residues of fibrinogen interacting 
with the primed subsites (C-terminal to the cleavage site) are Gly-Pro-Arg. The S'l pocket of 
thrombin is limited in size due to the Lys60F side chain42, and therefore only accessible for 
small P'l residues as glycine. The P'2 residue is bound by thrombin in a hydrophobic pocket 
formed by residues Leu41, Cys42, Cys58 and Lys60F. When a proline residue occupies 
position P'2, the e-NH2-function of Lys60F forms a hydrogen bond to the carbonyl group of 
the prolyl residue. This results in an optimal position of the arginine residue side chain at 
position P'3 to form salt bridges with Glu 192 or Glu39. When the sequence Pro-Arg is 
changed to Phe-Lys, the aromatic side chain might be too bulky for optimal fit into the S'2 
pocket, thereby preventing electrostatic interactions between the side chains of Lys at P'3 and 
Glu 192 or Glu39 of the thrombin molecule. It must be realized that an exact picture of the S'l -
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S'3 subsites cannot be given because hirudin and small serine protease inhibitors show a 
fundamental different mode of binding than the modeled structure of fibrinogen Act residues 
17.3443 it has b
e e n
 shown that the selectivity towards thrombin can be switched to factor Xa 
by introducing acidic side chains at position S'344, motivating the design of H-EGGVR-
ANBA-GFK-OH, with a basic amino acid in that position 
In table 1 the kinetic data of hydrolysis by thrombin (factor Xa) are given. 
Table 1: Kinetic data of hydrolysis by human α-thrombin and human factor Xa of the 
ANBA chromogenic substrates in buffer A at 37°C. 
Substrate Thrombin Factor Xa 
Km kcat ^cat/Km K
m
 k^t kcat/Km 
H-VR-ANBA-Gly[Hir50-65]-OH 4 6 0 43 9 29E4 - NH 
H-EGGVR-ANBA-GFK-OH NH NH -
H-VR-pNA 1239 0 23 1 86E2 - NH 
H-EGGVR-pNA 1006 0 55 5 42E2 2186 0 42 1 92E2 
kLat in s
-1
, K
m
 in μΜ, k
c a t/Km in (Ms) ', NH no hydrolysis H-VR-pNA and H-EGGVR-pNA are references 
(see chapter 3 respectively 5) 
From table 1 it appears that the Michaelis constant of H-VR-ANBA-Gly[Hir50-65]-OH is 
enormously decreased, while the turnover number is hardly affected This decrease of the K
m 
and the apparent independency of the k
cat are surprising findings and allow an interesting 
conclusion The surprising aspect concerns the magnitude of the measured K
m
 value, since the 
addition of C-terminal fragments of hirudin to the reaction mixture of thrombin and a substrate 
causes a decrease of K
m
 value of only 25%17 The interesting conclusion concerns a promising 
opening the substrate contains a fragment which is hydrolyzed with the wanted low kc
at and 
the wanted high K
m
 value, the other part represents a hirudin fragment This part is evidently 
very tightly bound to thrombin endowing the adduct with a K
m
 of very low value Substrates 
consisting of the same hydrolyzable part but connected to smaller C-terminal hirudin fragments 
or analogues thereof, should thus necessarily contain the proper sequence of the optimal 
substrate 
The binding of the substrate to thrombin should be considered as a two step process in which 
binding of the acidic side chain steers the cleavable site of the substrate into the active-site 
cleft15 This phenomenon is known as electrostatic steering45 and is an important recognition 
mechanism The concept of bridge-binding46 originates from the binding of hirudin and results 
into higher affinity caused by chemical compensation47 The C-terminal acidic part of hirudin 
binds to the fibrinogen recognition exosite displacing one Cl'-ion from the thrombin surface. 
The higher accessibility of the catalytic pocket as a result of the concomitant conformational 
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transition gives rise, at the same moment, to the uptake of Na+ and induces a slow -* fast 
transition48 of the thrombin molecule. 
Although the compound has not the required kinetic parameters it was subjected as substrate in 
the continuous assay49; see figure 3. From previous experiments50 it is known that hirudin is 
not able to prevent thrombin generation, it only prolongates the lag-phase of thrombin 
generation. 
200 400 600 
time (s) 
1000 
— ANBA — pNA [ 
Figure 3: Continuous optical density curves from extrinsic triggered plasma using 
2HCl.H-Val-Arg-pNA and H-VR-ANBA-Gly[Hir50-65]-OH as substrate at a concentration 
of 500 μΜ. 
Figure 3, reveals indeed an increased lag-phase in comparison to H-VR-pNA and the substrate 
is almost completely hydrolyzed; intact substrate is able to displace the hirudin residues 50-65 
from the thrombin molecule90. Thrombin inhibition is delayed as the result of competitive 
inhibition of AT-III by the substrate. In fact, thrombin can be displaced from the аг-
macroglobulin-thrombin complex by hirudin as described by Pochon and Steinbuch51. 
Specific ions5-, changes in ionic-strength53, pH54 and temperature55 are described to modulate 
fibrinogen recognition exosite-mediated binding processes and thrombin amidase activity. 
These conditions however, are not relevant under physiological conditions. To use the concept 
of bridge-binding in the development of selective thrombin substrates, changes of amino acid 
residues in the hirudin carboxyl-terminal part is the only practicable route. 
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CONCLUSION 
The substrates described in this chapter were synthesized by a combination of solution- and 
solid phase chemistry and were obtained in an acceptable yield Phosphorus oxychlonde in 
pyridine is an efficient coupling reagent even for aniline derivatives with more than one 
electron-withdrawing function The isolated yield of the key-intermediate H-ANB A-Gly-OAU 
is low and its synthesis has to be improved to start a structure-activity relationship-study with 
the described afunctional substrates 
Both substrates were not hydrolyzed by factor Xa as expected. With respect to thrombin, it 
was shown that the principle of bridge-binding leads to high affinity substrates. This however, 
resulted in a dramatical lowering of the K
m
 value of H-VR-ANB A-Gly[Hir50-65]-OH which 
prohibits application in the continuous registration of thrombin formation in plasma. 
Notwithstanding the observed negative results, the concept of bridge-binding can be expected 
to result in the definition of highly selective thrombin substrates once the optimal amino acid 
sequence conforming the fibrinogen recognition exosite has been found; in this manner the full 
selectivity from subsite interactions, is exploited 
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GENERAL DISCUSSION AND CONCLUSIONS 
This thesis describes a study to arrive at chromogenic substrates which can be used in the 
determination of thrombin in a mixture of serine proteases with the same primary specificity 
To discriminate between the several senne proteases involved m the coagulation cascade, the 
enormous variation in structure of amino acids was used to synthesize a peptide which is 
selectively recognized by its target enzyme Peptide p-nitroanihdes were used for their ease of 
detection, sensitivity and their favourable physicochemical properties 
A restraint is however, the low nucleophilicity of p-nitroanihne The common coupling 
methods used in peptide chemistry are insufficient to obtain acceptable yields Strong activation 
seems to be needed, but this introduces the risk of racemization and requires the use of less 
sensitive semi-permanent protective functions which are removable only with strong acids 
We developed a method in which protected amino acid p-nitroanilides are obtained in high yield 
when phosphorus oxychlonde is used as the coupling reagent This reagent has been described 
by Wieland et al ' for the first time and it proved to be an efficient coupling reagent for poor 
nucleophiles such as tert -butanol2 Dry pyridine is used as the solvent and functions also as a 
base and a catalyst in the synthesis of p-nitroanilides When applied to the synthesis of 
protected amino acid p-nitroanilides, mildly acid-labile protections were sufficient to ensure 
correct coupling Since the Fmoc-group, although sensitive to bases, resists the action of 
pyridine, Na-Fmoc-protected amino acid p-nitroanilides became available by this method The 
nitroanilide bond was found to be stable to pipendine (as used in the removal of the Fmoc-
group), which gives access to virtually all orthogonally protected tnfunctional amino acid p-
nitroanihdes These compounds made a new strategy for the synthesis of peptide p-
nitroanilides possible following the synthesis of a complicated peptide nitroanilide, all 
protective functions can be removed in one single deprotection step under mild acidic 
conditions, when the protections were chosen properly 
The synthesis of the anilides proceeds without racemization3, comparison with anilides cited in 
the literature and synthesized via well known methods gave good correlations with those 
synthesized by us Thus it can be concluded that phosphorus oxychlonde in pyridine is a very 
powerful condensing agent to synthesize all types of protected amino acid p-nitroanilides 
The anilides bearing mild acid removable protections give access to a convenient strategy of 
substrate synthesis A convergent synthesis from a peptide fragment and an amino acid anilide 
is preferred to a stepwise elongation of the peptide fragment starting from the anilide As a 
consequence of the convergent synthesis approach, the coupling of the peptide fragment to the 
anilide must proceed via a method with a minimal degree of racemization The azide procedure 
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of Curtius4 or DCC/HOBt-mediated couplings at C-terminal glycyl- or prolyl residues warrant 
minimal racemization This approach was preferred to the repetitive acid treatments of the 
anilide when a stepwise synthesis is used 
Most peptide p-nitroanilides synthesized thus far were designed from structure-activity 
relationships or trial and error procedures Most of them were used to determine the activity of 
purified enzymes In enzyme mixtures a compromise has to be made about the optimal structure 
of the substrate The combination of the kinetic parameters together with the concentration of 
the pertinent enzyme leads to justification of the choice of a particular substrate 
The crystal structures of chymotrypsin and trypsin formed a basis for a more rational design of 
substrates and inhibitors Homology model-building5, compantive model-building6 and 
molecular modeling-studies7 on the trypsin-like serine proteases of the blood coagulation 
system have been performed to obtain insight into their three dimensional structure 
Recently, X-ray diffraction studies of thrombin8, thrombin-inhibitor complexes8*11 and factor 
Xa12 became available The understanding of the molecular interactions of substrates/inhibitors 
and thrombin gave access to the design of substrates wanted in the continuous assay 
To measure the thrombin concentration in plasma, a method11 was developed in which plasma 
was subsampled into a substrate solution as a function of time A disadvantage of this method 
is its laborious way of obtaining the data In an effort to obtain the same information more 
conveniently, a method14 was developed in which the increasing optical density was measured 
continuously as a result of the changing thrombin concentration This assay requires the design 
of modified chromogenic substrates with not optimal kinetic parameters Structural elements, 
predicted by X-ray analysis were taken into account to enhance recognition by thrombin 
exclusively From the first design cycle, one compound was selected to be used as substrate in 
the continuous assay method 
Although the structures were derived from highly selective thrombin substrates/inhibitors, they 
are not exclusively recognized The hydrolysis of the substrates by factor Xa, the inhibition of 
factor Xa by thrombin substrates15, the action of tissue factor-complexed factor Vila on 
thrombin substrates16, the inhibition of feedback-loop activation by thrombin and the residual 
amidolytic activity of the thrombin-02-macroglobulin complex are disturbing factors in the 
determination of a correct thrombin generation curve 
The second approach started with the elongation of the peptide up to hexapeptide p-
nitroanilides, as concluded from the structure-activity relationships obtained from the first 
design-cycle and the recently resolved crystal structures of thrombin and fibnnopeptide A17 
Unfortunately, a longer peptide sequence resulted in more interaction possibilities and thus a 
lower degree of selectivity Furthermore, a substantial decreased activity on thrombin-a2-
macroglobuhn was not observed Nevertheless, Msc-Val-Arg-pNA HCl and 2HC1 H-Glu-
Gly-Gly-Val-Arg-pNA were found as new compounds which show optimal behaviour at the 
first sight The problem of the residual amidolytic activity of thrombin-oç-macroglobulin was 
circumvented by a selective denaturation of a2-macroglobulin with hydroxylamine 
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Furthermore, hydroxylamine showed to be a reagent with minimal effect on the coagulation 
cascade, it also made the defibrination of plasma superfluous It was not expected that the mere 
addition of hydroxylamine gives nse to such an important simplification of the measurement 
α-Thrombin possesses at least three independent binding sites for substrates and inhibitors 
The primary specificity pocket prefers the binding of the side chain of an arginine residue as do 
the other coagulation factors A second criterion of discrimination is selective interaction with 
the S2 binding pocket, a secondary specificity pocket In contrast to other blood coagulation 
enzymes, thrombin possesses an additional binding site the fibrinogen recognition exosite or 
anion-binding site This tertiary specificity apparatus18 binds negatively charged molecules in a 
highly specific manner The exosite is normally used in the correct positioning of physiological 
substrates or inhibitors, the structural requirements of the binding pocket can be used in the 
design of selective thrombin substrates Incorporation of a hirudin-hke fragment (50-65) in 
such a substrate appeared not yet the fruitful approach Hirudin is a highly potent thrombin 
inhibitor and therefore shows a strong binding towards thrombin When part of a substrate, 
binding of the chosen hirudin fragment to thrombin lowered the Michaelis constant to a value at 
which the substrate could not longer be used in the continuous assay The process of selective 
recognition however, has been demonstrated Modification of another hirudin fragment which 
still binds to thrombin but with lower affinity would give nse to unique thrombin substrates 
Probably unspecific interactions of negatively charged molecules would lead to selective 
thrombin recognition Recently, crystal structures of thrombin with a single stranded DNA 
aptamer19 were resolved, and antithrombotic properties of nucleotide-based thrombin 
inhibitors20 showed that negatively charged non-physiological effector-molecules interact also 
with the fibrinogen recognition exosite21 This demonstrates that utilizing the fibrinogen 
recognition exosite for binding of inhibitors would induce more selectivity towards thrombin 
than if only interaction with the Si, S2 and S3 binding sites are taken into account This has 
been predicted already by Naski et al22, who found that if the major mode of macti vation of a-
thrombin occurs via reaction with AT-III and other serpins, the competitive exosite inhibition is 
more effective than competitive active-site inhibition These conditions are most important in 
the registration of thrombin generation by means of the continuous assay 
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SUMMARY 
Thrombin is the pivotal enzyme of thrombosis and hemostasis. 
The function of the blood coagulation cascade is reflected in the transient amount of thrombin 
which is formed. For this reason there is great interest for a rapid and unambiguous 
measurement of this thrombin quantity. 
Some years ago, a method was developed which measures the thrombin concentration during 
regular time intervals and assayed on the basis of chromogenic substrates. This subsampling 
method is very laborious and not suited for routine use. Recently, a method was developed in 
which continuously the optical density was measured; the thrombin concentration was 
calculated from this curve. The obtained thrombin generation curves contain valuable 
information about the process of blood coagulation. In this technique however, the common 
chromogenic substrates can not be used, so new substrates have to be developed. This thesis 
describes the design, the synthesis and the biochemical evaluation of such chromogenic 
substrates. 
A chromogenic substrate consists of an amino acid sequence, a peptide, and a chromophoric 
leaving-group: para-nitroaniline (pNA). The peptide should meet the specificity of thrombin. 
In chapter 1 an efficient method is described to synthesize protected amino acid p-nitroanilides. 
When phosphorus oxychloride in pyridine is used as the condensing agent, high yields (70-
90%) of the anilide are achieved. By using this coupling method all protective functions can be 
used, and Na-Fmoc-protected amino acidp-nitroanilides became available for the first time. 
These compounds are important building-blocks for the synthesis of chromogenic substrates; 
they allow semi-permanent side chain protections which can be removed under mild acidic 
conditions in one single deprotection step. As examples, the syntheses of a thrombin substrate 
(S2238, 2HCl.H-D-Phe-Pip-Arg-pNA) and two factor Xa substrates (S2222, Bz-Ile-Glu-Gly-
Arg-pNA.HCl and S2337, Bz-Ile-Glu(yPi)-GIy-Arg-pNA.HCl) were described. 
Chapter 2 describes the design and synthesis of 25 chromogenic substrates. As lead-structures, 
two substrates were chosen which are hydrolyzed by thrombin with high selectivity (S2238, 
and SQ68, CH30-CO-CH2-CO-Aib-Arg-pNA.HCl). With knowledge of the three dimensional 
structure of the active-site of thrombin, obtained from X-ray structure analysis, the kinetic data 
of the substrates were tuned by structural modifications to arrive at peptide p-nitroanilides for 
use in the continuous assay. 
Chapter 3 describes the biochemical selection procedures used to arrive at substrates which can 
be used in the continuous assay. The selection indicated: 2HCl.H-Val-Arg-pNA, as the 
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substrate with the best, although not optimal biological properties The biochemical 
experiments gave access to structure-activity relationships with respect to the requirements of 
thrombin to effect hydrolysis, and gave indications for the development of a new series of 
chromogenic substrates 
The design process and synthesis of these substrates are described in chapter 4 Crystal 
structures of complexes between thrombin and fibnnopeptide A were used as another lead 
structure Ultimately, a series of 18 chromogenic substrates was synthesized and their 
biochemical properties are described in chapter 5 
This chapter describes the same selection procedures as used in chapter 3 This resulted in two 
substrates with optimal biological properties Msc-Val-Arg-pNA HCl and 2HC1 H-Glu-Gly-
Gly-Val-Arg-pNA respectively 
This chapter describes also examples of thrombin generation curves obtained with heparinized 
plasma By using hydroxylamine, the residual amidolytic activity of the thrombin-ot2-
macroglobulin complex is substantially decreased In addition, hydroxylamine makes 
defibrination of plasma redundant All three applications are steps forward to the clinical 
implementation of the continuous assay 
Chapter 6 describes a new approach to the development of highly selective thrombin substrates 
By using a bifunctional chromophonc group 5-amino-2-nitrobenzoic acid (ANBA), 
simultaneous interaction with active-site respectively fibrinogen recognition exosite and 
substrate was achieved As lead structure, the C-terminal pentadecapeptide of hirudin was 
used The application of this kind of substrate in the continuous assay however, is not yet 
realized, on the other hand, the principle of recognition through two sites is demonstrated 
The chapter describes the synthesis, a combination of solid phase- and solution chemistry, and 
the biochemical properties of the substrates The structure-activity relationships should be 
studied to determine if this approach will be successful in the development of substrates, which 
find their application in the continuous assay 
Chapter 7 describes the general conclusions which can be drawn from the investigations 
presented in this thesis 
SAMENVATTING 
Synthetische substraten voor trombine, Peptide p-nitroanihden voor het continu volgen van 
trombine-vorming in bloedplasma 
Trombine is het centrale enzym binnen de trombose en hémostase 
Het functioneren van de bloedstollingscascade weerspiegelt zich in de variabele hoeveelheid 
trombine die gevormd wordt Er bestaat daarom dan ook grote behoefte om deze hoeveelheid 
trombine snel en eenduidig te meten 
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In het verleden is hiervoor een analyse-techniek ontwikkeld, waarbij de trombineconcentratie 
op regelmatige tijdsstippen gemeten wordt met behulp van chromogene substraten Deze 
techniek is echter zeer arbeidsintensief en leent zich niet voor automatisering Recent is een 
techniek ontwikkeld die continu de optische dichtheid meet, waaruit de trombineconcentratie 
berekend kan worden De hieruit verkregen continue trombine generatie curven geven 
waardevolle informatie over de conditie van het bloedstollingsmechanisme Deze techniek stelt 
echter speciale eisen aan de toegepaste chromogene substraten Dit proefschrift beschrijft het 
ontwerp, de synthese en de biochemische evaluatie van zulke chromogene substraten 
Een chromogeen substraat bestaat uit een peptide en een chromofore groep para-nitroaniline 
(pNA) Het peptide moet aangepast zijn aan de specificiteit van trombine In hoofdstuk 1 wordt 
een efficiente synthese methode beschreven voor beschermde aminozuurp-nitroaniliden 
Door fosforoxychlonde in pyridine als koppehngsreagens toe te passen worden hoge 
opbrengsten (70-90%) van het anilide gerealiseerd Met deze methode zijn alle 
beschermgroepen te gebruiken en zijn Na-Fmoc-beschermde aminozuur p-nitroaniliden voor 
het eerst gesynthetiseerd Deze verbindingen vormen belangrijke uitgangsstoffen voor de 
synthese van chromogene substraten, daar alle semi-permanente beschermgroepen onder mild 
zure condities in één ontschermingsstap te verwijderen zijn Als voorbeeld wordt de synthese 
van een trombine substraat (S2238, 2HCI H-D-Phe-Pip-Arg-pNA) en twee factor Xa 
substraten (S2222, Bz-Ile-Glu-Gly-Arg-pNA HCl en S2337, Bz-Ile-Glu(YPi)-Gly-Arg-
pNA HCl) beschreven 
Hoofdstuk 2 beschrijft het ontwerp en de synthese van 25 chromogene substraten Hiervoor 
hebben twee selectieve trombine substraten als voorbeeldstructuur gediend (S2238, en SQ68, 
CH30-CO-CH2-CO-Aib-Arg-pNA HCl) Met kennis van de drie-dimensionale structuur van 
het actieve centrum van trombine, verkregen uit rontgen-structuuranalyse, is door middel van 
gerichte structuurvariaties van het substraat, getracht de kinetische parameters zodanig te 
wijzigen dat het substraat toepassing kan vinden in de continue assay methode 
Hoofdstuk 3 beschrijft de biochemische procedure die een substraat selecteert dat gebruikt kan 
worden in de continue assay methode Dit heeft geresulteerd in één substraat 2HC1 H-Val-Arg-
pNA, zij het met nog niet optimale biologische eigenschappen De biochemische experimenten 
hebben geleid tot inzicht in de structuur-activiteits relaties met betrekking tot selectieve 
hydrolyse door trombine, waarmee een nieuwe serie chromogene substraten ontwikkeld is 
De ontwikkeling en synthese van deze substraten worden in hoofdstuk 4 beschreven Tevens is 
hierbij gebruik gemaakt van kristalstructuren van trombine gecomplexeerd met fibrinopeptide 
A Uiteindelijk zijn 18 chromogene substraten gesynthetiseerd en hun biochemische 
eigenschappen worden in hoofdstuk 5 beschreven 
Dit hoofdstuk beschrijft dezelfde selectie procedure als gebruikt in hoofdstuk 3 Hieruit zijn 
twee substraten naar voren gekomen met optimale biologische eigenschappen Msc-Val-Arg-
pNA HCl respectievelijk 2HC1 H-Glu-Gly-Gly-Val-Arg-pNA 
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Verder worden in dit hoofstuk voorbeelden gegeven van continue trombine generatie curven 
gemeten in gehepariniseerd plasma Door toepassing van hydroxylamine is de Testactiviteit van 
trombine gecomplexeerd met oç-macroglobuhne aanzienlijk te reduceren Bovendien is met 
hydroxylamine het defibrineren van plasma overbodig geworden Alle dne de toepassingen zijn 
stappen voorwaarts in de klinische toepassing van de continue assay methode 
Hoofdstuk 6 beschrijft een nieuwe benadering voor de ontwikkeling van zeer specifieke 
trombine substraten Door gebruik te maken van een bifunctionele chromofore groep. 5-amino-
2-nitrobenzoezuur (ANBA) is een gelijktijdige interactie van substraat met het actieve centrum 
en fibnnogeen bindings plaats gerealiseerd Als voorbeeldstructuur is het C-terminale 
pentadecapeptide van hirudine gebruikt De toepassing van deze substraten in de continue assay 
methode is nog niet gerealiseerd, het principe van selectieve herkenning via twee 
bindingsplaatsen is echter aangetoond 
Het hoofdstuk beschrijft de synthese, een combinatie van vaste drager- en oplossingssynthese, 
en de biochemische eigenschappen van het substraat Een studie naar de structuur-activiteits 
relaties zal moeten bepalen of deze benadering succesvol zal zijn in de ontwikkeling van 
substraten die hun toepassing vinden in de continue assay methode 
Hoofdstuk 7 bediscussieert de algemene conclusies die ontleend kunnen worden aan het 
onderzoek gepresenteerd in dit proefschrift 
180 
LIST OF PUBLICATIONS 
1 Rijkers, D T S , Hemker, H C , Nefkens, G H L and Tesser, G l (1991) The Use of Phosphorus 
Oxychlonde in the Synthesis of Amino Acid p-Nitroanihdes, Reel Trav Chim Pays-Bas 110, 347-348 
2 Rijkers, D T S , Hemker, H C , Nefkens, G H L and Tesser, G l (1993) A Generally Applicable 
Synthesis of Amino Acid p-Nitroanilides as Synthons, In Peptides 1992, Proceedings of the 22nd 
European Peptide Symposium, Schneider, С H and Eberie, A N (Eds), 175-176, ESCOM Science 
Publishers В V , Leiden, The Netherlands 
3 van Vhet, A , Smulders, R Η Ρ Η , Rietman, Β Η , Klink, Α -Μ Ε , Rijkers, D T S , Eggen, I F , van 
de Werken, G and Tesser, G I (1993) Protected Peptide Intermediates using a Trityllinker on a Solid 
Support, In Peptides ¡992 Proceedings of the 22nd European Peptide Symposium, Schneider, С H and 
Eberle, A N (Eds ), 279-280, ESCOM Science Publishers В V , Leiden, The Netherlands 
4 Rijkers, D T S , Adams, Η Ρ Η M , Hemker, H С and Tesser, G I A Convenient Synthesis of Amino 
Acidp-Nitroanilides, Synthons in the Synthesis of Protease Substrates, in preparation 
5 Rijkers, D T S , Hemker, H С and Tesser, G I (1995) Peptide p-Nitroanilides, Chromogenic Substrates 
for the Determination of the Thrombin Generation Curve, In, Peptides ¡994, Proceedings of the 23rd 
European Peptide Symposium, Maia, H L S (Ed ) ESCOM Science Publishers В V , Leiden, The 
Netherlands, in press 
6 van Vhet, A Rijkers, D T S and Tesser, G I (1995) Protected Peptide Intermediates Using a Trityl 
Linker on a Solid Support III, In, Peptides ¡994, Proceedings of the 23rd European Peptide Symposium, 
Maia, H L S (Ed ) ESCOM Science Publishers В V , Leiden, The Netherlands, m press 
7 Rijkers, D T S , Wielders, S J H , Tesser, G I and Hemker, H С Design and Synthesis of Thrombin 
Substrates with Modified Kinetic Parameters, in preparation 
8 Rijkers, D T S , Wielders, S J H , Tesser G I , Béguin, S and Hemker, H С Biochemical Evaluation of 
Slow Reacting Thrombin Substrates in a Continuous Thrombin Assay, in preparation 
9 Rijkers, D T S , Tesser, G I and Hemker, H С Msc-Protected Dipeplides as Chromogenic Substrates in 
the Continuous Thrombin Generation Assay, in preparation 
181 
CURRICULUM VITAE 
Dirk Rijkers werd geboren op 31 juli 1966 te Eindhoven In juni 1982 werd het MAVO-4 
diploma aan de Dr Edith Stein Mavo te Eindhoven behaald De middelbare school studie werd 
voortgezet aan het Eckart College te Eindhoven alwaar in juni 1985 het VWO diploma behaald 
werd In september van dat jaar werd met de studie Scheikundige Technologie aan de 
Technische Universiteit Eindhoven begonnen Het propaedeutisch examen werd op 19 
september 1986 afgelegd De bednjfsstage werd uitgevoerd bij DSM Research te Geleen 
binnen de sectie Bio-organische Chemie (Prof Dr E M Meijer/Dr J Kamphuis) gedurende 
de periode mei-november 1989 Onder begeleiding van Dr M Kloosterman werd aan 
enzymatische en microbiele racemaatsphtsingen gewerkt In november 1989 werd in het 
laboratorium Organische Chemie van Prof Dr H M Buck met het afstudeeronderzoek, onder 
begeleiding van Dr Ir Ρ J L M Quaedflieg, begonnen Dit onderzoek omvatte de synthese 
van enkele fosfaat-gemethyleerde DNA-fragmenten ter bestudering van de B-» Ζ overgang in 
natuurlijk DNA Het ingenieursexamen werd op 28 augustus 1990 afgelegd Van 1 oktober 
1990 tot 1 oktober 1994 was hij Assistent m Opleiding aan de Rijksuniversiteit Limburg te 
Maastricht, Faculteit der Geneeskunde vakgroep Biochemie en werd hij gedetacheerd bij de 
Katholieke Universiteit Nijmegen, Faculteit der Natuurwetenschappen vakgroep Organische 
Chemie Het onderzoek beschreven in dit proefschrift werd uitgevoerd aan beide universiteiten 
onder begeleiding van Prof Dr G I Tesser (KUN) en Prof Dr H С Hemker (RL) 
Gedeelten van het onderzoek beschreven in dit proefschrift werden gepresenteerd op 
internationale congressen september 1992, 22nd European Peptide Symposium te Interlaken, 
Zwitserland, juni 1993, 13th American Peptide Symposium te Edmonton, Canada en september 
1994, 23rd European Peptide Symposium te Braga, Portugal Daarnaast werd hij in de 
gelegenheid gesteld deel te nemen aan het 14th Congress of the International Society on 
Thrombosis and Haemostasis, juli 1993 te New York, USA Vanaf 1 oktober 1994 is hij 
werkzaam als post-doc in het laboratorium van Prof Dr H С Hemker 
182 
NAWOORD 
Het uitvoeren van een promotie-onderzoek gaat niet zonder de hulp van collega's Dit geldt in 
het bijzonder wanneer het onderzoek uitgevoerd wordt op twee laboratoria met een 
verschillende wetenschapsdiscipline Al deze collega's dank ik hartelijk voor hun 
hulpvaardigheid' Een aantal wil ik echter met naam noemen 
Mijn promotores, Prof Dr G I Tesser en Prof Dr H С Hemker, U heeft mij de gelegenheid 
geboden zelfstandig wetenschappelijk onderzoek te beoefenen en het vertrouwen gegeven de 
voorgaande vier jaar succesvol af te sluiten 
Suzette Béguin en Leo Koole, bedankt voor jullie interesse en de geboden hulp bij het 
gereedkomen van het manuscript 
Een bijzonder woord van dank geldt Hans Adams en Simone Wielders, jullie zorgden ervoor 
dat ik werd ingewijd in de praktische geheimen van de peptide chemie respectievelijk de 
biochemische werkwijzen Voor praktische vragen kon ik altijd bij jullie terecht en bovendien 
zorgden jullie ervoor dat altijd alles voorradig was op het lab 
De sfeer op het lab werd bepaald door mijn Nijmeegse collega's Bert Rietman, Rob Rutten, 
Wim Schielen en Alexandra van Vliet, hetzelfde geldt voor Didier Billy, Paul Devilée, Marion 
Feijge, Hu Kai, Han Kessels, Rachana Kumar, Khaled Maroofi en Vincent Peyrou, jullie 
zorgden ervoor dat ik me thuisvoelde in het Maastrichtse 
De hulp die Arthur van der Heijden geboden heeft bij het vele NMR-werk heb ik bijzonder 
gewaardeerd Zjak van Eupen dank ik voor het gebruik van de apparatuur op het LGSS 
In mijn verbruik aan gezuiverd humaan trombine en factor Xa werd ik voorzien door Jo 
Franssen en Theo Lindhout, factor XI en factor ХП deficiente plasmas werden mij bereidwillig 
door Guido Tans ter beschikking gesteld 
Mijn analysemonsters werden snel en vakkundig uitgevoerd door Helene Amatdjais-Groenen 
(element analyse), Rien van der Gaag (aminozuur analyse) en Ad Swolfs (NMR analyse) 
Ruud Zwijnen, Chris Kroon en Wim van Luyn stonden borg voor een betrouwbare aflevering 
van de diverse (magazijn)bestelhngen 
Johan Kamphuis en Bernard Kaptein (DSM Research) dank ik voor hun gastvrijheid en de 
levering van onnatuurlijke aminozuurdenvaten 
Trees Camphuisen, Manet Molenaar, Sandra Tijdink en Gertie Wijckmans stonden klaar voor 
allerlei karweitjes van secretariële aard 
Beste Alexandra, ik wil je speciaal bedanken voor het nauwkeurig doorlezen van het 
manuscript De reis naar Canada heeft ons geleerd dat veel afstanden overbrugbaar zijn' 
Tenslotte mijn ouders, zij hebben mij de gelegenheid gegeven te studeren en hebben de laatste 
vier jaar mijn doen en laten altijd vol enthousiasme en welgemeende zorg gevolgd 
183 

STELLINGEN 
behorende bij het proefschrift 
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